En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies. Ces derniers assurent le bon fonctionnement de nos services. En savoir plus.
Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.
https://www.ncbi.nlm.nih.gov/pubmed/32046815
Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers.
Chantal B E M Reusken;Eeva K Broberg;Bart Haagmans;Adam Meijer;Victor M Corman;Anna Papa;Remi Charrel;Christian Drosten;Marion Koopmans;Katrin Leitmeyer;On Behalf Of Evd-LabNet And Erli-Net
Viroscience department, Erasmus MC, Rotterdam, the Netherlands.;Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.;European Centre for Disease Prevention and Control, Solna, Sweden.;German Centre for Infection Research (DZIF), Berlin, Germany.;Charité - Universitätsmedizin Berlin Institute of Virology, Berlin, Germany.;Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.;Unité des Virus Emergents (Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.;The participating members of EVD-LabNet and ERLI-Net are acknowledged at the end of the article.
7
Editorial;Comment
en
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.;Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: didier.raoult@gmail.com.
8
10.1016/j.joim.2020.02.005
Journal Article;Research Support, Non-U.S. Gov't
en
In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.
https://www.ncbi.nlm.nih.gov/pubmed/32113846
In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia.
Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China. Electronic address: shanghai_zhang@hotmail.com.;Department of Traditional Chinese Medicine, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China.;Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China.;Department of Research Affair Management, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China.
10
10.2807/1560-7917.es.2020.25.6.2000094
Case Reports;Journal Article
en
First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020.
https://www.ncbi.nlm.nih.gov/pubmed/32070465
A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) causing a cluster of respiratory infections (coronavirus disease 2019, COVID-19) in Wuhan, China, was identified on 7 January 2020. The epidemic quickly disseminated from Wuhan and as at 12 February 2020, 45,179 cases have been confirmed in 25 countries, including 1,116 deaths. Strengthened surveillance was implemented in France on 10 January 2020 in order to identify imported cases early and prevent secondary transmission. Three categories of risk exposure and follow-up procedure were defined for contacts. Three cases of COVID-19 were confirmed on 24 January, the first cases in Europe. Contact tracing was immediately initiated. Five contacts were evaluated as at low risk of exposure and 18 at moderate/high risk. As at 12 February 2020, two cases have been discharged and the third one remains symptomatic with a persistent cough, and no secondary transmission has been identified. Effective collaboration between all parties involved in the surveillance and response to emerging threats is required to detect imported cases early and to implement adequate control measures.
Santé publique France, Direction des maladies infectieuses, Saint-Maurice, France.;Santé publique France, Direction des régions, Saint-Maurice, France.;Santé publique France, Direction des régions, Cellule Régionale Ile-de-France, Paris, France.;Agence Régionale de Santé Ile-de-France, Paris, France.;Agence Régionale de Santé Nouvelle-Aquitaine, Bordeaux, France.;Santé publique France, Direction des régions, Cellule Régionale Nouvelle-Aquitaine, Bordeaux, France.;Centre National de Référence des virus des infections respiratoires, dont la grippe, Institut Pasteur, Paris, France.;AP-HP, Hôpital Bichat, Service des maladies infectieuses et tropicales, Paris, France.;Centre Hospitalier Universitaire de Bordeaux, Service des maladies infectieuses et tropicales, Bordeaux GeoSentinel Site, Bordeaux, France.;UMR 1219, Université de Bordeaux, Bordeaux, France.;Université de Paris, IAME, INSERM, Paris, France.;Direction Générale de la Santé, Ministère des solidarités et de la santé, Centre opérationnel de réception et de régulation des urgences sanitaires et sociales, Paris, France.;Santé publique France, Direction alerte et crise, Saint-Maurice, France.;The members of the investigation team are listed at the end of the article.
13
Editorial;Comment
en
Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future.
Zambia National Public Health Institute, Minsitry of Health, Lusaka, Zambia. Electronic address: nkapata@gmail.com.;Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria. Electronic address: chikwe.ihekweazu@ncdc.gov.ng.;University Marien NGouabi, Brazzaville, Congo, Institute for Tropical Medicine/University of Tübingen, Germany. Electronic address: fntoumi@fcrm-congo.com.;Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia. Electronic address: TajudeenR@africa-union.org.;Ministry of Health, Lusaka, Zambia. Electronic address: pascykapata@gmail.com.;Lusaka Apex Medical University, Lusaka, Zambia. Electronic address: pbmwaba2000@gmail.com.;National Public Health Institute, Ministry of Health, Lusaka, Zambia. Electronic address: vmukonka@gmail.com.;School of Life Sciences, University of Lincoln, Lincoln, United Kingdom. Electronic address: mbates@lincoln.ac.uk.;HerpeZ and UNZA-UCLMS Project, University Teaching Hospital, Lusaka, Zambia. Electronic address: john.tembo@gmail.com.;Charité - Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany, German Centre for Infection Research (DZIF), Berlin, Germany. Electronic address: victor.corman@charite.de.;National Institute of Medical Research, Dar es Salaam, Tanzania. Electronic address: gsmfinanga@yahoo.com.;Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria. Electronic address: asogun2001@yahoo.com.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: linzy.elton@ucl.ac.uk.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: l.arruda@ucl.ac.uk.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: m.thomason@ucl.ac.uk.;SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, Tanzania. Electronic address: leonard.mboera@sacids.org.;Institute of Health Informatics, Faculty of Pop Health Sciences, UCL, London, United Kingdom. Electronic address: a.yavlinsky@ucl.ac.uk.;The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom. Electronic address: nhaider@rvc.ac.uk.;The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom. Electronic address: dsimons19@rvc.ac.uk.;Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, United Kingdom. Electronic address: LHollmann@chathamhouse.org.;Institute for Global Health, University College London, London, United Kingdom. Electronic address: swaiblule@gmail.com.;Faculty of Pharmacy, Montpellier University, IRD UMR5569, Montpellier, France. Electronic address: francisco.veas@ird.fr.;Dept of Parasitology and Medical Entomology, Institute of Endemic Diseases, University of Khartoum, Sudan. Electronic address: mahdi@iend.org.;Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, United Kingdom. Electronic address: Osman.Dar@phe.gov.uk.;Ethics and Governance, University College London, London, United Kingdom. Electronic address: sarah.edwards@ucl.ac.uk.;National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: francesco.vairo@inmi.it.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: t.mchugh@ucl.ac.uk.;Charité - Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany, German Centre for Infection Research (DZIF), Berlin, Germany. Electronic address: christian.drosten@charite.de.;The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom. Electronic address: rkock@rvc.ac.uk.;National Institute for Infectious Diseases - Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom, Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.
14
Letter
en
Coronavirus outbreak: the role of companies in preparedness and responses.
University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, INSERM, School of Public Health, Institut de recherche en santé, environnement et travail-UMR_S1085, CAPTV-CDC, F49000 Angers, France, Paris Hospital (AP-HP) Occupational Health Unit, Poincaré University Hospital, Paris, France.;Versailles Saint Quentin-en-Yvelines University, INSERM, UMR 1181, Institut Pasteur, Paris, France, AP-HP, Department of Acute Medicine, CHU PIFO, Poincaré Hospital, Paris, France, General Director for Health, Ministry of Solidarities and Health, Paris, France.;University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, INSERM, School of Public Health, Institut de recherche en santé, environnement et travail-UMR_S1085, CAPTV-CDC, F49000 Angers, France, Paris Hospital (AP-HP) Occupational Health Unit, Poincaré University Hospital, Paris, France. Electronic address: alexis.descatha@inserm.fr.
15
10.2807/1560-7917.es.2020.25.8.2000171
Journal Article
en
Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2.
Aix-Marseille University, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), France.;Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France.;Unité des Virus Emergents (UVE), Aix-Marseille University, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.;Service de l'Information Médicale, Hôpital de la Timone, Marseille, France.;French Armed Forces Center for Epidemiology and Public Health (CESPA), Service de Santé des Armées (SSA), Marseille, France.;Aix-Marseille University, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), Marseille, France.
17
Letter
en
Guidelines for pregnant women with suspected SARS-CoV-2 infection.
Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland.;CHESS Center, The First Hospital of Lanzhou University, Lanzhou, China.;Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.;Aix Marseille Université, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée infection, Marseille, France, Laboratoire Eurofins Labazur Guyane, French Guiana, France.;Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: david.baud@chuv.ch.
27
10.1016/j.ijantimicag.2020.105933
Editorial
en
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.;Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance 7 Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 8 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.;Department of Infectious Diseases, Chang Gung Memorial Hospital, Taoyuan, Taiwan.;Department of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.;Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw.
30
10.1684/vir.2020.0826
Journal Article
en
Facing challenges with the novel coronavirus SARS-CoV-2 outbreak
National Reference Center for Respiratory Viruses, WHO National Influenza Center, Institut Pasteur, Paris, France, Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris, Institut Pasteur, Paris, France.;Incentive Scientific Programs Department, Institut Pasteur, Paris, France.
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.
https://www.ncbi.nlm.nih.gov/pubmed/32511329
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity- purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.
2020-03-22 01:00:00+01:00
pubmed
David E Gordon;Gwendolyn M Jang;Mehdi Bouhaddou;Jiewei Xu;Kirsten Obernier;Matthew J O'Meara;Jeffrey Z Guo;Danielle L Swaney;Tia A Tummino;Ruth Hüttenhain;Robyn M Kaake;Alicia L Richards;Beril Tutuncuoglu;Helene Foussard;Jyoti Batra;Kelsey Haas;Maya Modak;Minkyu Kim;Paige Haas;Benjamin J Polacco;Hannes Braberg;Jacqueline M Fabius;Manon Eckhardt;Margaret Soucheray;Melanie J Bennett;Merve Cakir;Michael J McGregor;Qiongyu Li;Zun Zar Chi Naing;Yuan Zhou;Shiming Peng;Ilsa T Kirby;James E Melnyk;John S Chorba;Kevin Lou;Shizhong A Dai;Wenqi Shen;Ying Shi;Ziyang Zhang;Inigo Barrio-Hernandez;Danish Memon;Claudia Hernandez-Armenta;Christopher J P Mathy;Tina Perica;Kala B Pilla;Sai J Ganesan;Daniel J Saltzberg;Rakesh Ramachandran;Xi Liu;Sara B Rosenthal;Lorenzo Calviello;Srivats Venkataramanan;Yizhu Lin;Stephanie A Wankowicz;Markus Bohn;Raphael Trenker;Janet M Young;Devin Cavero;Joe Hiatt;Theo Roth;Ujjwal Rathore;Advait Subramanian;Julia Noack;Mathieu Hubert;Ferdinand Roesch;Thomas Vallet;Björn Meyer;Kris M White;Lisa Miorin;David Agard;Michael Emerman;Davide Ruggero;Adolfo García-Sastre;Natalia Jura;Mark von Zastrow;Jack Taunton;Olivier Schwartz;Marco Vignuzzi;Christophe d'Enfert;Shaeri Mukherjee;Matt Jacobson;Harmit S Malik;Danica G Fujimori;Trey Ideker;Charles S Craik;Stephen Floor;James S Fraser;John Gross;Andrej Sali;Tanja Kortemme;Pedro Beltrao;Kevan Shokat;Brian K Shoichet;Nevan J Krogan
QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.;University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.;J. David Gladstone Institutes, San Francisco, CA 94158, USA.;University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.;Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.;Department of Pharmaceutical Chemistry, University of California, San Francisco.;Howard Hughes Medical Institute.;European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.;Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco.;The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.;Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego.;Department of Cell and Tissue Biology, University of California, San Francisco.;Biophysics Graduate Program, University of California, San Francisco.;Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94158, USA.;Division of Basic Sciences, Fred Hutchinson Cancer Research Center.;Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA.;George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco.;Virus and Immunity Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France.;Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France.;Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.;Biochemistry & Biophysics and Quantitative Biosciences Institute UCSF 600 16th St San Francisco, CA 94143.;Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98103.;Department of Urology, University of California, San Francisco, San Francisco, CA, USA.;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA.;University of California San Francisco, Department of Psychiatry, San Francisco, CA, 94158, USA.;Direction Scientifique, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France.;Division of Genetics, Department of Medicine, University of California San Diego.
45
10.1016/j.ijantimicag.2020.105947
Journal Article
en
SARS-CoV-2: fear versus data.
https://www.ncbi.nlm.nih.gov/pubmed/32201354
SARS-CoV-2, the novel coronavirus from China, is spreading around the world, causing a huge reaction despite its current low incidence outside China and the Far East. Four common coronaviruses are in current circulation and cause millions of cases worldwide. This article compares the incidence and mortality rates of these four common coronaviruses with those of SARS-CoV-2 in Organisation for Economic Co-operation and Development countries. It is concluded that the problem of SARS-CoV-2 is probably being overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.
Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France.;Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs - Infections Tropicales et Méditerranéennes, Marseille, France, Centre d'Epidémiologie et de Santé Publique des Armées, Marseille, France, Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France. Electronic address: didier.raoult@gmail.com.
50
10.1016/s2468-1253(20)30082-0
Journal Article
en
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel.
Gianluca Ianiro;Benjamin H Mullish;Colleen R Kelly;Harry Sokol;Zain Kassam;Siew C Ng;Monika Fischer;Jessica R Allegretti;Luca Masucci;Faming Zhang;Josbert Keller;Maurizio Sanguinetti;Samuel P Costello;Herbert Tilg;Antonio Gasbarrini;Giovanni Cammarota
2020-03-17 01:00:00+01:00
32192627
FR;CN;GB;US;HK;IT;AU;NL;AT
Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. Electronic address: gianluca.ianiro@unicatt.it.;Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.;Division of Gastroenterology, Alpert Medical School of Brown University, Providence, RI, USA.;Service de Gastroenterologie, Hôpital Saint Antoine, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Paris, France, French Group of Fecal Microbiota Transplantation, Paris, France, INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.;Finch Therapeutics Group, Somerville, MA, USA.;Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.;Department of Medicine, Indiana University, Indianapolis, IN, USA.;Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;Microbiology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.;Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.;Department of Gastroenterology, Haaglanden Medical Center, The Hague, Netherlands, Netherlands Donor Feces Bank, Leiden University Medical Center, Leiden, Netherlands.;Department of Gastroenterology, The Queen Elizabeth Hospital, University of Adelaide, Adelaide, SA, Australia.;Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Innsbruck Medical University, Innsbruck, Austria.;Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
51
10.1128/mbio.00398-20
Journal Article
en
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32198163
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
2150-7511
2020-03-22 01:00:00+01:00
pubmed
Angiotensin II Type 2 Receptor Blockers__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors__therapeutic use;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__metabolism;Receptor, Angiotensin, Type 2__biosynthesis;Receptors, Virus__biosynthesis;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2
57, chemin du Lavoir, Sergy Haut, France davidsfedson@gmail.com.;Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.;Fyordgata 59, Trondheim, Norway.
Institut Pasteur, Biology of Infection Unit, 75015 Paris, France, Inserm U1117, 75015 Paris, France, Université de Paris, Necker-Enfants Malades University Hospital, Division of Infectious Diseases and Tropical Medicine, Institut Imagine, APHP, 75006 Paris, France. Electronic address: marc.lecuit@pasteur.fr.
63
Letter
fr
[SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals].
Thomas Grellety;Alain Ravaud;Anne Canivet;Gérard Ganem;Philippe Giraud;Rosine Guimbaud;Laure Kaluzinski;Ivan Krakowski;Didier Mayeur;Jean-Pierre Lotz;Benoit You
2020-03-27 01:00:00+01:00
32229048
FR
Service d'oncologie médicale, centre hospitalier de la Côte Basque, 13, avenue de l'Interne-Jacques-Loeb, 64100 Bayonne, France. Electronic address: tgrellety@ch-cotebasque.fr.;CHU de Bordeaux, service d'oncologie médicale, Bordeaux, France.;Centre Francois-Baclesse, service d'hygiène, Caen, France.;Clinique Victor Hugo-Centre Jean-Bernard, Le Mans, France.;Radiotherapy Department, hôpital Européen Georges-Pompidou, Société Française de Radiothérapie Oncologique, France.;CHU de Toulouse, oncologie médicale digestive, Toulouse, France.;Centre hospitalier public du Cotentin, service d'oncologie médicale, Cherbourg-en-Cotentin, France.;AFSOS, centre de lutte contre le cancer institut Bergonié, Bordeaux, France.;Centre Georges-François-Leclerc, service d'oncologie médicale, Dijon, France.;AP-HP, hôpital de Tenon, Paris, France.;Institut de cancérologie des hospices civils de Lyon (IC-HCL), service d'oncologie médicale, Lyon, France.
65
10.1016/j.kint.2020.03.010
Editorial
en
Kidney International and the COVID-19 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32284224
0085-2538
2020-03-29 01:00:00+01:00
pubmed
Kidney International
Brad H Rovin;Pierre Ronco
education;microbiology
2020-03-26 01:00:00+01:00
32284224
FR;US
Internal Medicine-Nephrology, The Ohio State University, Columbus, Ohio, USA. Electronic address: Brad.rovin@osumc.edu.;Sorbonne Université, Paris, France, Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche S1155, Paris, France, Hôpital de jour - Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France.
68
10.1001/jama.2020.5110
Journal Article
en
Toward Universal Deployable Guidelines for the Care of Patients With COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32215641
0098-7484
2020-03-29 01:00:00+01:00
pubmed
JAMA
Francois Lamontagne;Derek C Angus
2020-03-26 01:00:00+01:00
32215641
FR;CA;US;UNK
Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.;Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.;Associate Editor.
73
10.1016/j.bulcan.2020.03.003
Practice Guideline
fr
[Therapeutic options for genitourinary cancers during the epidemic period of COVID-19].
Institut Gustave-Roussy, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France. Electronic address: Karim.Fizazi@gustaveroussy.fr.;Institut Gustave-Roussy, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
75
10.12890/2020_001641
Journal Article
en
Anosmia and Dysgeusia in the Absence of Other Respiratory Diseases: Should COVID-19 Infection Be Considered?
https://www.ncbi.nlm.nih.gov/pubmed/32309267
We describe two elderly patients evaluated at emergency departments for anosmia/dysgeusia in the absence of any other respiratory symptoms prior to or upon admission. In the current epidemiological context, clinical and biological work-up led to a diagnosis of COVID-19 infection. Unfortunately, one of the patients died during hospitalization, but the other recovered and was discharged.
2020-04-05 02:00:00+02:00
pubmed
Noel Lorenzo Villalba;Yasmine Maouche;Maria Belen Alonso Ortiz;Zaida Cordoba Sosa;Jean Baptiste Chahbazian;Aneska Syrovatkova;Pierre Pertoldi;Emmanuel Andres;Abrar-Ahmad Zulfiqar
2019-nCoV;COVID-19;SARS-CoV-2;anosmia;dysgeusia
2020-04-03 02:00:00+02:00
32309267
FR;ES
Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, France.;Internal Medicine Department, Dr Negrin University Hospital, Gran Canaria, Spain.;Internal Medicine Department, Fuerteventura General Hospital, Fuerteventura, Spain.
78
10.1097/mej.0000000000000701
Journal Article
en
European Society For Emergency Medicine position paper on emergency medical systems' response to COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32243317
The 2019 novel coronavirus acute respiratory epidemic is creating a stressed situation in all the health systems of the affected countries. Emergency medical systems and specifically the emergency departments as the front line of the health systems are suffering from overload and severe working conditions, the risk of contagion and transmission of the health professionals adds a substantial burden to their daily work. Under the perspective of European Society For Emergency Medicine, the recommendations provided by the health authorities are reviewed focus on the emergency department's activity.
Luis Garcia-Castrillo;Roberta Petrino;Robert Leach;Christoph Dodt;Wilhelm Behringer;Abdo Khoury;Marc Sabbe
2020-04-04 02:00:00+02:00
32243317
FR;IT;ES;BE;DE
Emergency Department, Hospital Marqués de Valdecilla, Santander, Spain.;Emergency Department, S. Andrea Hospital, Vercelli, Italy.;Department of Emergency Medicine, Centre Hospitalier de Wallonie picarde, Tournai, Belgium.;Emergency Department, Städtisches Klinikum München Bogenhausen, München.;Emergency Department, Center for Emergency Medicine, University Hospital Jena, Friedrich Schiller University, Am Klinikum 1, Jena, Germany.;Department of Emergency Medicine and Critical Care, Besançon University Hospital, Besançon, France.;Department of Emergency Medicine, University Hospitals Leuven, Leuven, Belgium.
91
10.1016/s0262-4079(20)30683-7
Journal Article
en
Tackling two crises at once.
https://www.ncbi.nlm.nih.gov/pubmed/32372791
We can't lose sight of the climate emergency when dealing with the covid-19 pandemic, say Christiana Figueres and Tom Rivett-Carnac.
0262-4079
2020-04-05 02:00:00+02:00
pubmed
New Scientist
Christiana Figueres;Tom Rivett-Carnac
2020-04-03 02:00:00+02:00
32372791
FR
Christiana Figueres and Tom Rivett-Carnac played key roles in the Paris climate agreement. Their new book is The Future We Choose: Surviving the climate crisis.
97
Letter
en
Will the Quality of Research Remain the Same During the COVID-19 Pandemic?
Inserm Nutrition - génétique et exposition aux risques environnementaux, Lorraine University, Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-les-Nancy, France.
100
Letter
en
COVID-19 therapeutic options for patients with kidney disease.
Department of Nephrology, Peupliers Private Hospital, Ramsay Générale de Santé, Paris, France. Electronic address: h.izzedine@ramsaygds.fr.;Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.;Yale University School of Medicine, New Haven, Connecticut, USA.
104
10.1016/j.jchirv.2020.03.007
English Abstract;Journal Article
fr
[Strategy for the practice of digestive and oncologic surgery in COVID-19 epidemic situation].
https://www.ncbi.nlm.nih.gov/pubmed/32834885
The COVID-19 pandemic is changing the organization of healthcare and has a direct impact on digestive surgery. Healthcare priorities and circuits are being modified. Emergency surgery is still a priority. Functional surgery is to be deferred. Laparoscopic surgery must follow strict rules so as not to expose healthcare professionals (HCPs) to added risk. The question looms large in cancer surgery - go ahead or defer? There is probably an added risk due to the pandemic that must be balanced against the risk incurred by deferring surgery. For each type of cancer - colon, pancreas, oesogastric, hepatocellular carcinoma - morbidity and mortality rates are stated and compared with the oncological risk incurred by deferring surgery and/or the tumour doubling time. Strategies can be proposed based on this comparison. For colonic cancers T1-2, N0, it is advisable to defer surgery. For advanced colonic lesions, it seems judicious to undertake neoadjuvant chemotherapy and then wait. For rectal cancers T3-4 and /or N+, chemoradiotherapy is indicated, short radiotherapy must be discussed (followed by a waiting period) to reduce time of exposure in the hospital and to prevent infections. Most complex surgery with high morbidity and mortality - oesogastric, hepatic or pancreatic - is most often best deferred.
1878-786X
2020-04-05 02:00:00+02:00
pubmed
Journal de Chirurgie Viscérale
J-J Tuech;A Gangloff;F Di Fiore;P Michel;C Brigand;K Slim;M Pocard;L Schwarz
Department of Digestive Surgery, Rouen University Hospital, 1, rue de Germont, 76031 Rouen cedex, France.;UMR 1245 Inserm, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, UNIROUEN, Rouen University Hospital, Normandie Université, 76000 Rouen, France.;Department of Digestive Oncology, Rouen University Hospital, 1, rue de Germont, 76031 Rouen cedex, France.;Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, 67200 Strasbourg, France.;Department of digestive surgery, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France.;UMR 1275 CAP Paris-Tech, université de Paris, 75010 Paris, France.;Service de chirurgie digestive et cancérologique, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France.
108
10.1016/j.reval.2020.03.003
Journal Article
fr
[Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan].
https://www.ncbi.nlm.nih.gov/pubmed/32292530
1877-0320
2020-04-05 02:00:00+02:00
pubmed
Revue Française d'Allergologie
G Kanny
2020-04-01 02:00:00+02:00
32292530
FR
Médecine Interne, Immunologie Clinique et Allergologie, CHRU de Nancy, Laboratoire d'Hydrologie et Climatologie Médicales, Faculté de Médecine, 9 rue de la Forêt de Haye, 54505 Vandœuvre-lès-Nancy, France.
119
10.1016/j.encep.2020.03.001
Journal Article;Review
fr
[Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review].
https://www.ncbi.nlm.nih.gov/pubmed/32312567
The lack of ressources and coordination to face the epidemic of coronavirus raises concerns for the health of patients with mental disorders in a country where we keep in memory the dramatic experience of famine in psychiatric hospitals during the Second World War. This article aims at proposing guidance to ensure mental health care during the SARS-CoV epidemy in France.
Université de Paris, CRESS, Inserm, INRA, 75004 Paris, France. Electronic address: astrid.chevance@gmail.com.;HEC Paris (Jouy-en-Josas), Paris, France.;Centre ressource régional de psychiatrie du sujet âgé (CRRPSA), service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, DMU psychiatrie et addictologie, Inserm U1266, institut de psychiatrie et neurosciences de Paris, centre université de Paris, AP-HP, Paris, France.;Université Clermont-Auvergne, CHU de Clermont-Ferrand, Clermont-Ferrand, France.;Laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), université de Lille, CNRS UMR 9193, CHU de Lille, Lille, France.;CHU de Nantes, Nantes, France.;Université de Paris, collège national des universitaires de psychiatrie (CNUP), Inserm, CESP, Paris, France.;Pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie du Grand-Nancy, centre psychothérapique de Nancy, Laxou, France, Faculté de médecine, université de Lorraine, Nancy, France.;Département de psychiatrie et d'addictologie, hôpital Paul-Brousse, AP-HP, 94800 Villejuif, France, Unité psychiatrie-comorbidités-addictions-unité de recherche, PSYCOMADD université Paris Sud, université Paris Saclay, AP-HP, Paris, France.;Service de psychiatrie adultes, Sorbonne université, groupe hospitalier Pitié-Salpêtrière, ICM, Inserm U1127, AP-HP, Paris, France.;SHU, GHU psychiatrie et neurosciences, Nightingale Hospitals-Paris, clinique du Château-de-Garches, Paris, France.;Centre hospitalier Le Vinatier, Bron, France, Université Lyon, Lyon, France.;Université Paris Est Créteil, Inserm, Fondation FondaMental, AP-HP, Paris, France.;Université de Paris, GHU psychiatrie et neurosciences, Paris, France.
120
Letter
en
Challenges with the management of older patients with cancer during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32273247
2020-04-05 02:00:00+02:00
pubmed
Age Factors;Aged;Betacoronavirus;Coronavirus Infections__diagnosis;Humans;Incidence;Neoplasms__complications;Pandemics;Pneumonia, Viral__diagnosis;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2
Claire Falandry;Cynthia Filteau;Christine Ravot;Olivia Le Saux
2020-04-02 02:00:00+02:00
32273247
FR
Geriatric Unit, Lyon-Sud University Hospital, Lyon 1 University, France, CarMEN Laboratory of Lyon University INSERM U.1060/Université Lyon1/INRA U. 1397/INSA Lyon/Hospices Civils Lyon, France. Electronic address: claire.falandry@chu-lyon.fr.;Geriatric Unit, Lyon-Sud University Hospital, Lyon 1 University, France.;Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052 CNRS 5286, France.
122
10.1016/j.bulcan.2020.03.008
Practice Guideline
fr
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)].
Department of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy.;Editor, European Psychiatry.;GHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, 75014 Paris, France.;Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, 75014 Paris, France.
127
10.1016/j.eururo.2020.03.033
Editorial
en
The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is "Safe Better than Sorry"?
Benjamin Pradère;Guillaume Ploussard;James W F Catto;Morgan Rouprêt;Vincent Misrai
2020-04-10 02:00:00+02:00
32284245
FR;GB;AT
Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria, Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.;Department of Urology, Ramsay Santé, Clinique La Croix du Sud, Quint Fonsegrives, France.;Academic Urology Unit, University of Sheffield, Sheffield, UK.;Department of Urology, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.;Department of Urology, Clinique Pasteur, Toulouse, France. Electronic address: v.misrai@clinique-pasteur.com.
139
10.1016/j.tmaid.2020.101663
Journal Article;Observational Study
en
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.
https://www.ncbi.nlm.nih.gov/pubmed/32289548
We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration.
IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam.;IHU-Méditerranée Infection, Marseille, France.;Assistance Publique de Marseille, Hôpital Nord, Explorations Fonctionnelles Respiratories, Aix Marseille Université, France.;Service de Pharmacie, Hôpital Timone, AP-HM, Marseille, France, Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.;Assistance Publique de Marseille, Médecine Interne, Unité de Médecine Aigue Polyvalente (UMAP), France.;Department of Radiology and Cardiovascular Imaging, Aix-Marseille Université, UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale-Centre d'Exploration Métaboliques par Résonance Magnétique), France.;Assistance Publique de Marseille, Hôpital Timone, Cardiologie, Rythomologie, Aix Marseille Université, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com.
140
Comparative Study;Letter
en
Collateral consequences of COVID-19 epidemic in Greater Paris.
https://www.ncbi.nlm.nih.gov/pubmed/32283116
2020-04-12 02:00:00+02:00
pubmed
Aged;Aged, 80 and over;Betacoronavirus;Cardiopulmonary Resuscitation__methods;Cohort Studies;Coronavirus Infections__epidemiology;Disease Outbreaks;Emergency Medical Services__organization & administration;Female;Heart Arrest__epidemiology;Humans;Intensive Care Units__statistics & numerical data;Male;Middle Aged;Outcome Assessment, Health Care;Pandemics;Paris;Pneumonia, Viral__epidemiology;Risk Assessment;Survival Analysis;COVID-19;severe acute respiratory syndrome coronavirus 2
F Lapostolle;J M Agostinucci;A Alhéritière;T Petrovic;F Adnet
2020-04-10 02:00:00+02:00
32283116
FR
SAMU 93, hôpital Avicenne, APHP, 125, rue de Stalingrad, Université Paris 13, Bobigny, France.
152
10.1093/eurheartj/ehaa282
Journal Article
en
Denominator matters in estimating COVID-19 mortality rates.
https://www.ncbi.nlm.nih.gov/pubmed/32255475
0195-668X,1522-9645
2020-04-12 02:00:00+02:00
pubmed
European Heart Journal
Bamba Gaye;Anouar Fanidi;Xavier Jouven
2020-04-07 02:00:00+02:00
32255475
FR;GB;UNK
The African Research Network.;Université de Paris, PARCC, INSERM, F-75015 Paris, France.;MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.;Cardiology Department, Georges-Pompidou European Hospital, Paris, France.
156
10.1007/s12204-020-2168-1
Journal Article
en
CIRD-F: Spread and Influence of COVID-19 in China.
https://www.ncbi.nlm.nih.gov/pubmed/32288416
The outbreak of coronavirus disease 2019 (COVID-19) has been spreading rapidly in China and the Chinese government took a series of policies to control the epidemic. Therefore, it will be helpful to predict the tendency of the epidemic and analyze the influence of official policies. Existing models for prediction, such as cabin models and individual-based models, are either oversimplified or too meticulous, and the influence of the epidemic was studied much more than that of official policies. To predict the epidemic tendency, we consider four groups of people, and establish a propagation dynamics model. We also create a negative feedback to quantify the public vigilance to the epidemic. We evaluate the tendency of epidemic in Hubei and China except Hubei separately to predict the situation of the whole country. Experiments show that the epidemic will terminate around 17 March 2020 and the final number of cumulative infections will be about 78 191 (prediction interval, 74 872 to 82 474). By changing the parameters of the model accordingly, we demonstrate the control effect of the policies of the government on the epidemic situation, which can reduce about 68% possible infections. At the same time, we use the capital asset pricing model with dummy variable to evaluate the effects of the epidemic and official policies on the revenue of multiple industries.
1Antai College of Economics and Management, Shanghai Jiao Tong University, Shanghai, 200240 China.;2SJTU-ParisTech Elite Institute of Technology, Shanghai Jiao Tong University, Shanghai, 200240 China.;3School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240 China.
168
Letter;Comment
en
Nutritional management in hospital setting during SARS-CoV-2 pandemic: a real-life experience.
Marco Cintoni;Emanuele Rinninella;Maria Giuseppina Annetta;Maria Cristina Mele
2020-04-06 02:00:00+02:00
32253375
FR;IT
Scuola di Specializzazione in Scienza dell'Alimentazione, Università di Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. marco.cintoni@gmail.com.;UOC di Nutrizione Clinica, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.;UOC di Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica, Dipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.;UOSA di Nutrizione Avanzata in Oncologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.
179
10.1016/j.accpm.2020.04.001
Journal Article
en
SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
https://www.ncbi.nlm.nih.gov/pubmed/32278670
Community transmission of SARS-CoV-2 was detected in Spain in February 2020, with 216% intensive care unit (ICU) capacity expanded in Vitoria by March 18th, 2020.
2352-5568
2020-04-12 02:00:00+02:00
pubmed
Anaesthesia Critical Care & Pain Medicine
Helena Barrasa;Jordi Rello;Sofia Tejada;Alejandro Martín;Goiatz Balziskueta;Cristina Vinuesa;Borja Fernández-Miret;Ana Villagra;Ana Vallejo;Ana San Sebastián;Sara Cabañes;Sebastián Iribarren;Fernando Fonseca;Javier Maynar
ARDS;COVID-19;Pneumonia;Procalcitonin
2020-04-09 02:00:00+02:00
32278670
FR;ES;PS
Critical Care Department, Hospital Universitario de Alava, Spain.;Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos II, Madrid, Spain, Clinical Research in Pneumonia & Sepsis (CRIPS), Vall d'Hebron Institute of Research, Barcelona, Spain, Clinical Research, CHU Nîmes, University Montpellier - Nîmes, Nîmes, France.;Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos II, Madrid, Spain, Clinical Research in Pneumonia & Sepsis (CRIPS), Vall d'Hebron Institute of Research, Barcelona, Spain. Electronic address: stmagraner@gmail.com.
186
Letter;Research Support, Non-U.S. Gov't
en
French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak.
N Penel;S Bonvalot;V Minard;D Orbach;F Gouin;N Corradini;M Brahmi;P Marec-Bérard;S Briand;N Gaspar;C Llacer;S Carrère;A Dufresne;A Le Cesne;J Y Blay
2020-04-09 02:00:00+02:00
32278878
FR;UNK
Medical Oncology Department, Oscar Lambret Cancer Centre, Lille University, Lille, France.;Surgical Oncology Department, Institut Curie, Paris, France.;Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.;Department of Pediatric Oncology, Institut Curie, Paris, France.;Departments of Surgical Oncology.;Pediatric Oncology.;Medical Oncology, Centre Léon Bérard, Lyon, France.;Surgical Oncology Department, CHU Kremlin-Bicêtre, Paris, France.;Departments of Radiotherapy.;Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France.;Medical Oncology, Centre Léon Bérard, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.
191
Letter
en
Intrapartum care of women with COVID-19: A practical approach.
Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A position paper.
https://www.ncbi.nlm.nih.gov/pubmed/32311380
Antimicrobial resistance (AMR) continues to threaten global health. Although global and national AMR action plans are in place, infection prevention and control is primarily discussed in the context of health care facilities with home and everyday life settings barely addressed. As seen with the recent global SARS-CoV-2 pandemic, everyday hygiene measures can play an important role in containing the threat from infectious microorganisms. This position paper has been developed following a meeting of global experts in London, 2019. It presents evidence that home and community settings are important for infection transmission and also the acquisition and spread of AMR. It also demonstrates that the targeted hygiene approach offers a framework for maximizing protection against colonization and infections, thereby reducing antibiotic prescribing and minimizing selection pressure for the development of antibiotic resistance. If combined with the provision of clean water and sanitation, targeted hygiene can reduce the circulation of resistant bacteria in homes and communities, regardless of a country's Human Development Index (overall social and economic development). Achieving a reduction of AMR strains in health care settings requires a mirrored reduction in the community. The authors call upon national and international policy makers, health agencies, and health care professionals to further recognize the importance of targeted hygiene in the home and everyday life settings for preventing and controlling infection, in a unified quest to tackle AMR.
0196-6553
2020-04-19 02:00:00+02:00
pubmed
American Journal of Infection Control
Jean-Yves Maillard;Sally F Bloomfield;Patrice Courvalin;Sabiha Y Essack;Sumanth Gandra;Charles P Gerba;Joseph R Rubino;Elizabeth A Scott
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK, International Scientific Forum on Home Hygiene, Somerset, UK. Electronic address: maillardj@cardiff.ac.uk.;London School of Hygiene and Tropical Medicine, London, UK.;Department of Microbiology, Institut Pasteur, Paris, France.;Antimicrobial Research Unit, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.;Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.;Departments of Soil, Water and Environmental Science and Environmental Health, University of Arizona, Tucson, AZ, USA.;Research & Development, Home Hygiene, Lysol/Harpic, Reckitt Benckiser LLC., One Philips Parkway, Montvale, NJ, USA.;College of Natural, Behavioral and Health Sciences, Simmons University, Boston, MA, USA.
201
10.1530/eje-20-0386
Editorial;Introductory Journal Article
en
Endocrinology in the time of COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32302976
0804-4643,1479-683X
2020-04-19 02:00:00+02:00
pubmed
Coronavirus Infections;Delivery of Health Care;Endocrinology;Pandemics;Pneumonia, Viral;COVID-19
European Journal of Endocrinology
Wiebke Arlt;Olaf M Dekkers;Juliane Léger;Robert K Semple
2020-04-18 02:00:00+02:00
32302976
FR;NL;GB
Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.;Department of Clinical Epidemiology, Leids Universitair Medisch Centrum, Centrum voor Humane en Klinische Genetica, Leiden, the Netherlands.;Department of Paediatric Endocrinology and Diabetes, Head, Reference Center for Rare Endocrine Growth Diseases, Robert Debré University Hospital, Paris, France.;Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
211
10.1016/j.neurol.2020.03.002
Editorial
en
Covid-19, the pandemic war: Implication for neurologists.
MS Clinic, CHU Strasbourg, 1 Avenue Molière, 67200 Strasbourg, France.;MS Clinic, MS Unit research Nice Cote D'Azur University (UR2CA), Pasteur2 University Hospital, 30 Voie Romaine, 06002 Nice, France. Electronic address: lebrun-frenay.c@chu-nice.fr.
213
Editorial;Comment
en
Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists.
Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Firenze, Italy icro.meattini@unifi.it.;Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.;Department of Oncology, Radiation Oncology, University of Turin, Torino, Italy.;Health Science Department (DISSAL), University of Genoa, Genova, Italy.;Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Roma, Italy.;Department of Radiation Oncology, Institut d'Oncologie Thoracique (IOT), Villejuif, France.;Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Division of Radiation Oncology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.;Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.;Radiation Oncology Unit, Santa Maria della Misericordia Hospital, Rovigo, Italy.;Radiation Oncology Unit - Department of Biomedical, Dental Science, and Morphological and Funcitional Images, University of Messina, Messina, Italy.;Department of Radiation Oncology, University of Brescia and Spedali Civili Hospital, Brescia, Italy.;Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genova, Italy.;Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Firenze, Italy.
Department of Dermatology, CHR Orléans, Orléans, France.
219
10.1093/cvr/cvaa097
Journal Article;Research Support, Non-U.S. Gov't
en
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32293003
Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic.
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.;Université Paris-Descartes, AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, INSERM, CIC1418, Paris, France.;Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.;Institute of Cardiovascular & Medical Sciences BHF Glasgow Cardiovascular Research Centre, Glasgow, UK and Jagiellonian University, Collegium Medicum, Krakow, Poland.;Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.;The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.;Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
220
10.1016/j.jchirv.2020.04.009
English Abstract;Journal Article
fr
[Management of the COVID-19 epidemic by public health establishments - Analysis by the Fédération hospitalière de France].
https://www.ncbi.nlm.nih.gov/pubmed/32313587
The objective of this article is to detail the measures taken in public institutions to cope with the COVID-19 epidemic. It details the initial strategy, organizational evolution towards "all-COVID", coordination between the various stakeholders and the strategy for maintaining continuity of care. The Quebec experience is also used as an example. Finally, an exit strategy must be anticipated at this phase of the epidemic.
1878-786X
2020-04-19 02:00:00+02:00
pubmed
Journal de Chirurgie Viscérale
K Barro;A Malone;A Mokede;C Chevance
COVID-19;Coronavirus;Pandemic
2020-04-18 02:00:00+02:00
32313587
FR
CS 41402, pôle offre de soins, Fédération hospitalière de France, 1 bis, rue Cabanis, 75993 Paris cedex 14, France.;CS 41402, pôle prospective, Europe, International Fédération hospitalière de France, 1 bis, rue Cabanis, 75993 Paris cedex 14, France.;Pôle finance, Fédération hospitalière de France, 1 bis, rue Cabanis, 75993 Paris cedex 14, France.
228
Letter
fr
[Gynecological surgery during the COVID-19 pandemic: Take home messages].
Service de gynécologie-obstétrique, hôpital Femme-Mère-Enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69120 Lyon-Bron, France. Electronic address: erdogan.nohuz@chu-lyon.fr.;Service de gynécologie-obstétrique, hôpital de la Croix-Rousse, hospices civils de Lyon, 103, Grande Rue de la Croix-Rousse, 69004 Lyon, France.;Service de gynécologie-obstétrique, hôpital Femme-Mère-Enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69120 Lyon-Bron, France.;Service de gynécologie-obstétrique, hôpital Femme-Mère-Enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69120 Lyon-Bron, France, EMR 3738, université Claude-Bernard Lyon 1, 69000 Lyon, France.
229
Letter;Comment
en
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
https://www.ncbi.nlm.nih.gov/pubmed/32331979
2020-04-19 02:00:00+02:00
pubmed
Azithromycin;Betacoronavirus;Cardiovascular Diseases;Chloroquine;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine;Pandemics;Pneumonia, Viral;Torsades de Pointes;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2
Christian Funck-Brentano;Joe-Elie Salem;Lee S Nguyen;Milou-Daniel Drici;Dan M Roden
Azithromycin;Azithromycine;Chloroquine;Hydroxychloroquine;Long QT syndrome;Syndrome du QT long;Torsade de Pointes
2020-04-15 02:00:00+02:00
32331979
FR;US
Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France. Electronic address: christian.funck-brentano@aphp.fr.;Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France.;Intensive Care Medicine department, Cochin University Hospital, AP-HP Centre, 75014 Paris, France.;Department of Pharmacology and Toxicology, PharmacoVigilance Centre, Hôpital de Cimiez, University of Nice Côte d'Azur Medical Centre, 06003, Nice, France.;Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA.
231
Case Reports;Letter
en
Immune Thrombocytopenic Purpura in a Patient with Covid-19.
Hôpitaux Universitaires de Strasbourg, Strasbourg, France abzulfiqar@gmail.com.;Centre Hospitalier de Haguenau, Haguenau, France.;Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
236
Letter
en
Smell and taste dysfunction in patients with COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32304629
2020-04-19 02:00:00+02:00
pubmed
Michael S Xydakis;Puya Dehgani-Mobaraki;Eric H Holbrook;Urban W Geisthoff;Christian Bauer;Charlotte Hautefort;Philippe Herman;Geoffrey T Manley;Dina M Lyon;Claire Hopkins
2020-04-15 02:00:00+02:00
32304629
FR;GB;US;IT;DE
Department of Defense, United States Air Force Medical Corp, Wright-Patterson Air Force Base, OH 45433, USA. Electronic address: michael.xydakis@us.af.mil.;Associazione Naso Sano, Umbria Regional Registry of Volunteer Activities, Corciano, Italy.;Harvard University, Massachusetts Eye and Ear, Boston, MA, USA.;Philipps University Marburg, Marburg, Germany.;Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, INSERM U1141, Université of Paris, Paris, France.;University of California, San Francisco, CA, USA.;Air Force Research Lab, Wright-Patterson Air Force Base, OH 45433, USA.;Guy's and St Thomas' Hospital, London Bridge Hospital, London, UK.
238
10.1016/j.medin.2020.04.006
Journal Article
en
Ethical recommendations for a difficult decision-making in intensive care units due to the exceptional situation of crisis by the COVID-19 pandemia: A rapid review & consensus of experts.
https://www.ncbi.nlm.nih.gov/pubmed/32402532
In view of the exceptional public health situation caused by the COVID-19 pandemic, a consensus work has been promoted from the ethics group of the Spanish Society of Intensive, Critical Medicine and Coronary Units (SEMICYUC), with the objective of finding some answers from ethics to the crossroads between the increase of people with intensive care needs and the effective availability of means. In a very short period, the medical practice framework has been changed to a 'catastrophe medicine' scenario, with the consequent change in the decision-making parameters. In this context, the allocation of resources or the prioritization of treatment become crucial elements, and it is important to have an ethical reference framework to be able to make the necessary clinical decisions. For this, a process of narrative review of the evidence has been carried out, followed by a unsystematic consensus of experts, which has resulted in both the publication of a position paper and recommendations from SEMICYUC itself, and the consensus between 18 scientific societies and 5 institutes/chairs of bioethics and palliative care of a framework document of reference for general ethical recommendations in this context of crisis.
0210-5691
2020-04-19 02:00:00+02:00
pubmed
Medicina Intensiva
O Rubio;A Estella;L Cabre;I Saralegui-Reta;M C Martin;L Zapata;M Esquerda;R Ferrer;A Castellanos;J Trenado;J Amblas
Atención de crisis;Catastrophe;Catástrofe;Crisis care;Ethics;ICU;Pandemia;Pandemic;UCI;Ética
2020-04-15 02:00:00+02:00
32402532
FR;ES;PS
Cuidados Intensivos, Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, España. Electronic address: orubio@althaia.cat.;Cuidados Intensivos, Hospital Universitario de Jerez, Jerez de la Frontera, Cádiz, España.;Cuidados Intensivos, Comité de Bioética de Cataluña, Catalunya, España.;Cuidados Intensivos, Hospital Universitario de Áraba, Osakidetza Araba, Vitoria-Gasteiz, España.;Servicio de Medicina Intensiva, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, España.;Cuidados Intensivos, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Instituto Borja de Bioética, Esplugues de Llobregat, Barcelona, España.;Servicio de Medicina Intensiva, Hospital Universitario Vall de Hebron, Barcelona, España.;Área de Medicina Crítica, Hospital Universitario y Politécnico La Fe, Valencia, España.;Servicio de Medicina Intensiva, Hospital Universitario Mútua de Terrassa, Terrassa, Barcelona, España.;Geriatría y Cuidados paliativos, Hospital Universitario de la Santa Creu de Vic, Central Catalonia Chronicity Research Group (C3RG), Universitat de Vic-UCC, Vic, Barcelona, España.
244
10.1002/hed.26164
Journal Article
en
COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice.
https://www.ncbi.nlm.nih.gov/pubmed/32270581
The 2019 novel coronavirus disease (COVID-19) is a highly contagious zoonosis produced by SARS-CoV-2 that is spread human-to-human by respiratory secretions. It was declared by the WHO as a public health emergency. The most susceptible populations, needing mechanical ventilation, are the elderly and people with associated comorbidities. There is an important risk of contagion for anesthetists, dentists, head and neck surgeons, maxillofacial surgeons, ophthalmologists, and otolaryngologists. Health workers represent between 3.8% and 20% of the infected population; some 15% will develop severe complaints and among them, many will lose their lives. A large number of patients do not have overt signs and symptoms (fever/respiratory), yet pose a real risk to surgeons (who should know this fact and must therefore apply respiratory protective strategies for all patients they encounter). All interventions that have the potential to aerosolize aerodigestive secretions should be avoided or used only when mandatory. Health workers who are: pregnant, over 55 to 65 years of age, with a history of chronic diseases (uncontrolled hypertension, diabetes mellitus, chronic obstructive pulmonary diseases, and all clinical scenarios where immunosuppression is feasible, including that induced to treat chronic inflammatory conditions and organ transplants) should avoid the clinical attention of a potentially infected patient. Health care facilities should prioritize urgent and emergency visits and procedures until the present condition stabilizes; truly elective care should cease and discussed on a case-by-case basis for patients with cancer. For those who are working with COVID-19 infected patients' isolation is compulsory in the following settings: (a) unprotected close contact with COVID-19 pneumonia patients; (b) onset of fever, cough, shortness of breath, and other symptoms (gastrointestinal complaints, anosmia, and dysgeusia have been reported in a minority of cases). For any care or intervention in the upper aerodigestive tract region, irrespective of the setting and a confirmed diagnosis (eg, rhinoscopy or flexible laryngoscopy in the outpatient setting and tracheostomy or rigid endoscopy under anesthesia), it is strongly recommended that all health care personnel wear personal protective equipment such as N95, gown, cap, eye protection, and gloves. The procedures described are essential in trying to maintain safety of health care workers during COVID-19 pandemic. In particular, otolaryngologists, head and neck, and maxillofacial surgeons are per se exposed to the greatest risk of infection while caring for COVID-19 positive subjects, and their protection should be considered a priority in the present circumstances.
Luiz P Kowalski;Alvaro Sanabria;John A Ridge;Wai Tong Ng;Remco de Bree;Alessandra Rinaldo;Robert P Takes;Antti A Mäkitie;Andre L Carvalho;Carol R Bradford;Vinidh Paleri;Dana M Hartl;Vincent Vander Poorten;Iain J Nixon;Cesare Piazza;Peter D Lacy;Juan P Rodrigo;Orlando Guntinas-Lichius;William M Mendenhall;Anil D'Cruz;Anne W M Lee;Alfio Ferlito
COVID-19;contamination;head neck;otolaryngology;risk of contamination;surgery
2020-04-15 02:00:00+02:00
32270581
SE;FR;IE;CO;FI;CN;GB;US;HK;BR;IT;NL;ES;IN;BE;DE
Head and Neck Surgery Department, University of Sao Paulo Medical School, Sao Paulo, Brazil.;Department of Head and Neck Surgery and Otorhinolaryngology, A C Camargo Cancer Center, Sao Paulo, Brazil.;Department of Surgery, School of Medicine, Universidad de Antioquia, Centro de Excelencia en Cirugia de Cabeza y Cuello-CEXCA, Medellin, Colombia.;Head and Neck Surgery Section, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.;Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.;Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.;University of Udine School of Medicine, Udine, Italy.;Department of Otolaryngology-Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.;Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.;Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, Sweden.;Screening Group, International Agency for Research in Cancer. IARC, Lyon, France.;Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.;Head and Neck Unit, The Royal Marsden Hospital, London, UK.;Department of Otolaryngology Head and Neck Surgery, Institut Gustave Roussy and University Paris-Sud, Villejuif Cedex, France.;Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven, Belgium.;Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.;Department of Otolaryngology, Head and Neck Surgery, NHS Lothian, University of Edinburgh, Edinburgh, UK.;Department of Otorhinolaryngology, Maxillofacial, and Thyroid Surgery, Fondazione IRCCS, National Cancer Institute of Milan, University of Milan, Milan, Italy.;Department of Otolaryngology, Beaumont Hospital, Dublin, Ireland.;Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.;Department of Otorhinolaryngology, Institute of Phoniatry/Pedaudiology, Jena University Hospital, Jena, Germany.;Department of Radiation Oncology, University of Florida, Gainesville, Florida, USA.;Head Neck Services, Tata Memorial Hospital, Mumbai, Maharashtra, India.;Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.;International Head and Neck Scientific Group, Udine, Italy.
Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review.
https://www.ncbi.nlm.nih.gov/pubmed/32282894
Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions.
Matthew P Cheng;Jesse Papenburg;Michaël Desjardins;Sanjat Kanjilal;Caroline Quach;Michael Libman;Sabine Dittrich;Cedric P Yansouni
Antibodies;Antigens;COVID-19;Cells;Infectious disease immunology;Nucleic acids;Prevention, policy, and public health;Pulmonary diseases;Research laboratories;Upper respiratory tract infections
2020-04-13 02:00:00+02:00
32282894
FR;CA;CH;GB;US
McGill University Health Centre and McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada (M.P.C.).;McGill Interdisciplinary Initiative in Infection and Immunity and Montreal Children's Hospital, Montreal, Quebec, Canada (J.P.).;Brigham and Women's Hospital, Boston, Massachusetts, and Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada (M.D.).;Brigham and Women's Hospital, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (S.K.).;CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada (C.Q.).;McGill University Health Centre, McGill Interdisciplinary Initiative in Infection and Immunity, and McGill University, Montreal, Quebec, Canada (M.L., C.P.Y.).;Foundation of Innovative New Diagnostics, Malaria and Fever Program, Geneva, Switzerland, and University of Oxford, Oxford, United Kingdom (S.D.).
257
10.1136/neurintsurg-2020-016137
Journal Article;Review
en
European Society of Minimally Invasive Neurological Therapy (ESMINT) recommendations for optimal interventional neurovascular management in the COVID-19 era.
Saint Etienne, Rhone-Alpes, France aggour.mohamed@gmail.com.;Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK.;Neuroradiology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.;Neuroradiology, Zurich University Hospital, Zurich, Switzerland.;Department of Neuroradiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany.;Neuroradiology, Karolinska Universitetssjukhuset, Stockholm, Sweden.;University NeuroVascular Center - UNVC, LUMC Leiden / HMC The Hague, Netherlands.
268
Letter;Comment
en
PET imaging of COVID-19: the target and the number.
Aix-Marseille Université, CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, Marseille, France. eric.guedj@ap-hm.fr.;Department of Nuclear Medicine, Assistance Publique des Hôpitaux de Marseille, Timone University Hospital, Marseille, France. eric.guedj@ap-hm.fr.;CERIMED, Aix-Marseille Université, Marseille, France. eric.guedj@ap-hm.fr.;Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, F-54000, Nancy, France.;IADI, Université de Lorraine, INSERM U1254, F-54000, Nancy, France.;Aix-Marseille Université, CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, Marseille, France.;Department of Nuclear Medicine, Assistance Publique des Hôpitaux de Marseille, Timone University Hospital, Marseille, France.;CERIMED, Aix-Marseille Université, Marseille, France.
273
10.1016/j.jfo.2020.04.002
Case Reports;Journal Article
en
Ocular manifestation as first sign of Coronavirus Disease 2019 (COVID-19): Interest of telemedicine during the pandemic context.
https://www.ncbi.nlm.nih.gov/pubmed/32334847
We report here the case of a 27-year-old man who consulted by telemedicine during the Coronavirus disease 2019 (COVID-19) pandemic, due to foreign body sensation and left eye redness. Examination revealed unilateral eyelid edema and moderate conjunctival hyperemia. A few hours later, the patient experienced intense headache and developed fever, cough and severe dyspnea. A nasopharyngeal swab proved positive for SARS-CoV-2. This case demonstrates that conjunctivitis can be the inaugural manifestation of the COVID-19 infection. It illustrates the interest of telemedicine in ophthalmology during the COVID-19 pandemic, since moderate conjunctival hyperemia can be the first sign of a severe respiratory distress.
Ophthalmology department, hôpital universitaire Necker-Enfants Malades, AP-HP université de Paris, 149, rue de Sèvres, 75015 Paris, France, INSERM, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, université Sorbonne Paris Cité, Centre de recherche des cordeliers, 15, rue de l'école de médecine, Paris, France.;Instituto de ojos y oídos, avenida Belgrano 647, Resistencia, Chaco, Argentina.;Ophthalmology department, hôpital universitaire Necker-Enfants Malades, AP-HP université de Paris, 149, rue de Sèvres, 75015 Paris, France, INSERM, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, université Sorbonne Paris Cité, Centre de recherche des cordeliers, 15, rue de l'école de médecine, Paris, France. Electronic address: dominique.bremond@aphp.fr.
275
10.1055/a-1154-8768
Editorial
en
COVID-19: How to select patients for endoscopy and how to reschedule the procedures?
Mental health;novel coronavirus;pandemic;psychological support
2020-04-16 02:00:00+02:00
32528618
FR;BE;CM
Psychiatry Internship Program, University of Bourgogne, 21000 Dijon, France.;Bertoua Regional Hospital, Bertoua, Cameroon.;Epidemiology and Biostatistics Unit, Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium.
281
10.1053/j.gastro.2020.04.032
Journal Article
en
Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Biomedical Sciences, Humanitas University, IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center (IRCCS), Milan, Italy.
287
10.1016/j.cjca.2020.04.029
Editorial;Research Support, Non-U.S. Gov't
en
A Focus on COVID-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients.
https://www.ncbi.nlm.nih.gov/pubmed/32343999
0828-282X
2020-04-26 02:00:00+02:00
pubmed
Betacoronavirus__isolation & purification;Canada;Cardiovascular Diseases__epidemiology;Coronavirus Infections__epidemiology;Health Information Management;Hospital Rapid Response Team__organization & administration;Humans;Pandemics;Patient Care Management__methods;Pneumonia, Viral__epidemiology;Societies, Medical;Translational Medical Research;COVID-19;severe acute respiratory syndrome coronavirus 2
Canadian Journal of Cardiology
Stanley Nattel;Michelle Graham;Andrew Krahn
2020-04-25 02:00:00+02:00
32343999
FR;CA;GB;US;DE
Department of Medicine, Montreal Heart Institute and Université de Montréal, and Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada, IHU Liryc and Fondation Bordeaux Université, Bordeaux, France, and Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany. Electronic address: stanley.nattel@icm-mhi.org.;Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.;Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
293
10.1016/j.jaci.2020.04.026
Editorial
en
Will environmental impacts of social distancing due to the pandemic caused by SARS-CoV-2 decrease allergic disease?
Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, Clermont-Ferrand, France. Electronic address: valentin.navel@hotmail.fr.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, Clermont-Ferrand, France.
300
10.1016/j.jbspin.2020.03.011
Editorial;Research Support, Non-U.S. Gov't
en
Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Luca Quartuccio;Luca Semerano;Maurizio Benucci;Marie-Christophe Boissier;Salvatore De Vita
COVID-19;Coronavirus;Cytokine;IL-6;SARS
2020-04-24 02:00:00+02:00
32321634
FR;IT
Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy. Electronic address: luca.quartuccio@asufc.sanita.fvg.it.;Université Sorbonne Paris Nord, Li2P, Bobigny, France, Inserm U1125, Bobigny, France, Assistance Publique-Hôpitaux de Paris, GH HUPSSD, Rheumatology Department, Bobigny, France.;Rheumatology Unit, S. Giovanni di Dio Hospital, Florence, Italy.;Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy.
301
10.1093/jtm/taaa063
Journal Article
en
Pulmonary embolism in a returning traveller with COVID-19 pneumonia.
Pneumologie, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.;Radiologie, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.;Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.;Département d'Informatique Clinique, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.
303
Letter;Comment
en
Comment on 'Cutaneous manifestations in COVID-19: a first perspective' by Recalcati S.
M Hedou;F Carsuzaa;E Chary;E Hainaut;F Cazenave-Roblot;M Masson Regnault
2020-04-22 02:00:00+02:00
32314436
FR
Dermatologie, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.;ORL, Chirurgie Cervico-Maxillo-Faciale et Audiophonologie, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.;Médecine interne et Maladie infectieuse, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.;Unité Inserm U1070, Faculté de Médecine et Pharmacie, Poitiers, France.
308
10.1701/3347.33181
Journal Article
it
[Post-Normal Pandemics: why CoViD-19 requires a new approach to science.]
https://www.ncbi.nlm.nih.gov/pubmed/32319440
In addressing pandemics, science has never seemed more needed and useful, while at the same time limited and powerless. The existing contract between science and society is falling apart. A new covenant is urgently needed to navigate the days ahead.
David Waltner-Toews;Annibale Biggeri;Bruna De Marchi;Silvio Funtowicz;Mario Giampietro;Martin O'Connor;Jerome R Ravetz;Andrea Saltelli;Jeroen P van der Sluijs
2020-04-23 02:00:00+02:00
32319440
FR;SE;CA;GB;IT;NL;ES
University of Guelph (Canada).;Università di Firenze (Italia).;Universitetet i Bergen (Norvegia).;Universitat Autònoma de Barcelona (Spagna) - Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona (Spagna).;L'Association ePLANETe Blue (Francia) - Université de Paris Saclay (Francia).;University of Oxford (Regno Unito).;Universitetet i Bergen (Norvegia) - Universitat Oberta de Catalunya (Spagna).;Universitetet i Bergen (Norvegia) - Universiteit Utrecht (Paesi Bassi).
311
Letter;Comment
en
Does nasal screening for Staphylococcus aureus before surgery compromise health care professional safety in the COVID-19 era?
Nicolas Mayeur;Pierre Berthoumieu;Hélène Charbonneau
2020-04-22 02:00:00+02:00
32448698
FR
Department of Anesthesiology and Intensive Care Unit, Clinique Pasteur, Toulouse Cedex 03, France.;Department of Cardiothoracic and Vascular Surgery, Clinique Pasteur, Toulouse Cedex 03, France.
322
10.1136/bmjgh-2020-002622
Journal Article
en
COVID-19: time for paradigm shift in the nexus between local, national and global health.
health policy;health systems;prevention strategies;public health
2020-04-20 02:00:00+02:00
32399261
FR;BE;GB
School of Public Health, Université Libre de Bruxelles, Bruxelles, Belgium.;Tax Institute, Liege University, Liege, Belgium.;Global Health Theme, POLIS, University of Leeds, Leeds, West Yorkshire, UK.;CEPED (IRD-Universités de Paris), INSERM, Institut de recherche pour le developpement, Paris, France.
340
Letter;Comment
en
CORONA-steps for tracheotomy in COVID-19 patients: A staff-safe method for airway management.
Department of Maxillofacial Surgery, Laveran Military Teaching Hospital, Laveran Boulevard, 13013 Marseille, France. Electronic address: pierre.haen@yahoo.fr.;Department of Head and Neck Surgery and Maxillofacial Surgery, Percy Military Teaching Hospital, 1 Lieutenant Raoul Batany Street, 92140 Clamart, France.;Department of Maxillofacial Surgery, Laveran Military Teaching Hospital, Laveran Boulevard, 13013 Marseille, France.;Intensive Care Unit, Laveran Military Teaching Hospital, Laveran Boulevard, 13013 Marseille, France.
343
10.1016/j.jviscsurg.2020.04.013
Journal Article;Review
en
Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups.
https://www.ncbi.nlm.nih.gov/pubmed/32387058
The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care.
Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France, EA 3738, Université Lyon 1, Lyon, France. Electronic address: olivier.glehen@chu-lyon.fr.;Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France, EA 3738, Université Lyon 1, Lyon, France.;Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims, France.;Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse, France.;Département de chirurgie, institut Gustave-Roussy, Villejuif, France.
355
10.1017/s0033291720001336
Journal Article
en
PTSD as the second tsunami of the SARS-Cov-2 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32326997
Since the first cases, the coronavirus disease (COVID-19) rapidly spread around the world, with hundred-thousand cases and thousands of deaths. Post-traumatic stress disorder (PTSD) is a common consequence of major disasters. Exceptional epidemic situations also promoted PTSD in the past. Considering that humanity is undergoing the most severe pandemic since Spanish Influenza, the actual pandemic of COVID-19 is very likely to promote PTSD. Moreover, COVID-19 was renamed severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). With a poor understanding of viruses and spreading mechanisms, the evocation of SARS is generating a great anxiety contributing to promote PTSD. Quarantine of infected patients evolved to quarantine of 'infected' towns or popular districts, and then of entire countries. In the families of cases, the brutal death of family members involved a spread of fear and a loss of certainty, promoting PTSD. In the context of disaster medicine with a lack of human and technical resources, healthcare workers could also develop acute stress disorders, potentially degenerating into chronic PTSD. Globally, WHO estimates 30-50% of the population affected by a disaster suffered from diverse psychological distress. PTSD individuals are more at-risk of suicidal ideation, suicide attempt, and deaths by suicide - considering that healthcare workers are already at-risk occupations. We draw attention towards PTSD as a secondary effect of the SARS-Cov-2 pandemic, both for general population, patients, and healthcare workers. Healthcare policies need to take into account preventive strategy of PTSD, and the related risk of suicide, in forthcoming months.
0033-2917,1469-8978
2020-04-26 02:00:00+02:00
pubmed
Psychological Medicine
Frédéric Dutheil;Laurie Mondillon;Valentin Navel
2020-04-24 02:00:00+02:00
32326997
FR
Preventive and Occupational Medicine, Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Witty Fit, F-63000Clermont-Ferrand, France.;Physiological and Psychosocial Stress, Université Clermont Auvergne, CNRS, LaPSCo, F-63000Clermont-Ferrand, France.;Ophthalmology, Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, F-63000Clermont-Ferrand, France.
358
10.1016/j.eururo.2020.04.039
Editorial
en
Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32349928
Non-muscle-invasive bladder cancer patients with COVID-19 are more likely to develop acute respiratory distress syndrome. Thus, several adjustments to the use of intravesical instillations of bacillus Calmette-Guérin should be made during the current pandemic to limit the risk of contamination.
Louis Lenfant;Thomas Seisen;Yohann Loriot;Morgan Rouprêt
2020-04-24 02:00:00+02:00
32349928
FR
Sorbonne University, GRC 5 Predictive onco-uro, APHP, Urology, Pitié-Salpétrière Hospital, 75013 Paris, France.;Department of Cancer Medicine, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.;Sorbonne University, GRC 5 Predictive onco-uro, APHP, Urology, Pitié-Salpétrière Hospital, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr.
368
Letter
en
Myositis as a manifestation of SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32327427
2020-04-26 02:00:00+02:00
pubmed
Maxime Beydon;Kevin Chevalier;Omar Al Tabaa;Sabrina Hamroun;Anne-Sophie Delettre;Marion Thomas;Julia Herrou;Elodie Riviere;Xavier Mariette
MRI;inflammation;polymyositis
2020-04-23 02:00:00+02:00
32327427
FR
Department of Rheumatology, Bicetre Hospital, Le Kremlin-Bicêtre, France.;Université Paris-Saclay, INSERM UMR1184, Le Kremlin Bicêtre, France.;Department of Rheumatology, Bicetre Hospital, Le Kremlin-Bicêtre, France xavier.mariette@aphp.fr.
377
10.2217/fon-2020-0313
Editorial
en
The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience.
Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong, 226006, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China.;Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou, 225300, China.;College of Life Sciences, Henan Normal University, Xinxiang, 453007, China.;Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China. zhangcy1999@ips.ac.cn.
381
Letter;Comment
en
Analysis of incidence of thrombotic complications in the presence of competing risks.
Sabine Mainbourg;Michel Cucherat;Jean-Christophe Lega
2020-05-03 02:00:00+02:00
32386984
FR
Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, F-69622 Villeurbanne, France, Département de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Département de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France, Département de pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, F-69622 Villeurbanne, France, Département de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France, Groupe d'Etude Multidisciplinaire des Maladies Thrombotiques (GEMMAT), Hospices Civils de Lyon, Lyon, France. Electronic address: jean-christophe.lega@chu-lyon.fr.
A Petit;L Martin;D Penso-Assathiany;S Consoli;P Assouly;C Velter;L Hefez;J-M Debarre;L Haddad
2020-05-03 02:00:00+02:00
32418776
FR
Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: antoine.petit@sls.aphp.fr.;Service de dermatologie, CHU, 49100 Angers, France.;Cabinet de dermatologie, 92130 Issy-les-Moulineaux, France.;Cabinet de psychanalyse, 75014 Paris, France.;Centre Sabouraud, 75010 Paris, France.;Cabinet de dermatologie, 75007 Paris, France.;Service de dermatologie, grand hôpital de l'Est Francilien, 77600 Jossigny, France.;Cabinet de dermatologie, Cholet, France, Laboratoire de recherche en droit, université Rennes 1, 35000 Rennes, France.;75017 Paris, France.
M L Solodky;C Galvez;B Russias;P Detourbet;V N'Guyen-Bonin;A-L Herr;P Zrounba;J-Y Blay
2020-05-01 02:00:00+02:00
32360743
FR
Centre Léon Bérard Cancer Center, Lyon, France.;Centre Léon Bérard Cancer Center, Lyon, France, Université Claude Bernard Lyon I, Lyon, France, Unicancer, Paris, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.
413
10.1016/j.eururo.2020.04.063
Journal Article;Review
en
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32414626
The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers.
Christopher J D Wallis;Giacomo Novara;Laura Marandino;Axel Bex;Ashish M Kamat;R Jeffrey Karnes;Todd M Morgan;Nicolas Mottet;Silke Gillessen;Alberto Bossi;Morgan Roupret;Thomas Powles;Andrea Necchi;James W F Catto;Zachary Klaassen
Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.;Department of Surgery, Oncology, and Gastroenterology-Urology Clinic, University of Padua, Padua, Italy.;Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science, London, UK.;Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.;Department of Urology, Mayo Clinic, Rochester, MN, USA.;Department of Urology, University of Michigan, Ann Arbor, MI, USA.;Department of Urology, University hospital Nord, St Etienne, France.;Department of Medical Oncology, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland, Università della Svizzera Italiana, Lugano, Switzerland.;Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.;Urology, GRC n°5, PREDICTIVE ONCO-URO, AP-HP, Pitié Salpetriere Hospital, Sorbonne University, Paris, France, European Section of Onco Urology, EAU.;Barts Cancer Center, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.;Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: j.catto@sheffield.ac.uk.;Department of Surgery, Division of Urology, Augusta University-Medical College of Georgia, Augusta, GA, USA, Georgia Cancer Center, Augusta, GA, USA. Electronic address: zklaassen19@gmail.com.
416
10.1016/j.encep.2020.04.010
Journal Article
fr
[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
https://www.ncbi.nlm.nih.gov/pubmed/32387014
The ongoing COVID-19 pandemic comprises a total of more than 2,350,000 cases and 160,000 deaths. The interest in anti-coronavirus drug development has been limited so far and effective methods to prevent or treat coronavirus infections in humans are still lacking. Urgent action is needed to fight this fatal coronavirus infection by reducing the number of infected people along with the infection contagiousness and severity. Since the beginning of the COVID-19 outbreak several weeks ago, we observe in GHU PARIS Psychiatrie & Neurosciences (Sainte-Anne hospital, Paris, France) a lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients (∼4%) compared to health care professionals (∼14%). Similar observations have been noted in other psychiatric units in France and abroad. Our hypothesis is that psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments. Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses. This first antipsychotic medication has been discovered in 1952 by Jean Delay and Pierre Deniker at Sainte-Anne hospital. In addition, to its antipsychotic effects, several in vitro studies have also demonstrated a CPZ antiviral activity via the inhibition of clathrin-mediated endocytosis. Recently, independent studies revealed that CPZ is an anti-MERS-CoV and an anti-SARS-CoV-1 drug. In comparison to other antiviral drugs, the main advantages of CPZ lie in its biodistribution: (i) preclinical and clinical studies have reported a high CPZ concentration in the lungs (20-200 times higher than in plasma), which is critical because of the respiratory tropism of SARS-CoV-2; (ii) CPZ is highly concentrated in saliva (30-100 times higher than in plasma) and could therefore reduce the contagiousness of COVID-19; (iii) CPZ can cross the blood-brain barrier and could therefore prevent the neurological forms of COVID-19.
0013-7006
2020-05-03 02:00:00+02:00
pubmed
Antiviral Agents__pharmacokinetics;Betacoronavirus;Biomarkers;Blood-Brain Barrier;Chlorpromazine__pharmacokinetics;Clinical Trials, Phase III as Topic__methods;Coronavirus Infections__drug therapy;Cytokines__blood;Dose-Response Relationship, Drug;Drug Repositioning;Endocytosis__drug effects;France__epidemiology;Humans;Lung__metabolism;Mental Disorders__drug therapy;Multicenter Studies as Topic__methods;Pandemics;Patient Selection;Pilot Projects;Pneumonia, Viral__drug therapy;Randomized Controlled Trials as Topic__methods;Research Design;Saliva__metabolism;Severity of Illness Index;Single-Blind Method;Tissue Distribution;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2
L'Encéphale
M Plaze;D Attali;A-C Petit;M Blatzer;E Simon-Loriere;F Vinckier;A Cachia;F Chrétien;R Gaillard
COVID-19;Chlorpromazine;Clinical trial;Essai clinique;Repositionnement de molécules;Repurposing of drugs;SARS-CoV-2
2020-04-29 02:00:00+02:00
32387014
FR
GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France. Electronic address: m.plaze@ghu-paris.fr.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France, Physics for medicine Paris, Inserm, ESPCI Paris, CNRS, PSL Research university, université Paris Diderot, Sorbonne Paris Cite, Paris, France.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Institut Pasteur, experimental neuropathology unit, Paris, France.;Institut Pasteur, experimental neuropathology unit, Paris, France.;Institut Pasteur, G5 evolutionary genomics of RNA viruses, Paris, France.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France.;Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France, Université de Paris, Laboratoire de Psychologie du développement et de l'Éducation de l'Enfant, CNRS, Paris, France.;Institut Pasteur, experimental neuropathology unit, Paris, France, GHU PARIS Psychiatrie et Neurosciences, site Sainte-Anne, service de Neuropathologie, Paris, France.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France, Institut Pasteur, experimental neuropathology unit, Paris, France.
420
10.1016/j.accpm.2020.04.010
Journal Article;Review
en
Sedation for critically ill patients with COVID-19: Which specificities? One size does not fit all.
Jean-François Payen;Gérald Chanques;Emmanuel Futier;Lionel Velly;Samir Jaber;Jean-Michel Constantin
COVID-19;Pain;Sedation;Ventilation
2020-04-29 02:00:00+02:00
32360979
FR
Department of Anaesthesia and Intensive Care, Grenoble-Alpes University Hospital, and Grenoble-Alpes University, Grenoble Institut des Neurosciences, INSERM U1216, 38000 Grenoble, France. Electronic address: jfpayen@univ-grenoble-alpes.fr.;Department of Anaesthesia and Intensive Care, University of Montpellier Saint-Éloi Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, 34295 Montpellier cedex 5, France.;Department of Anaesthesia and Intensive Care, Estaing Hospital, and Université Clermont-Auvergne, CNRS, INSERM U-1103, 63000 Clermont-Ferrand, France.;Department of Anaesthesiology and Critical Care Medicine, Aix-Marseille University, AP-HM, University Hospital La Timone, Marseille, France.;Sorbonne University, GRC 29, AP-HP, DMU DREAM, and Department of Anaesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France.
427
10.1016/j.chest.2020.04.033
Editorial
en
When the Game Changes: Guidance to Adjust Sarcoidosis Management During the COVID-19 Pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32360495
0012-3692
2020-05-03 02:00:00+02:00
pubmed
Chest
Nadera J Sweiss;Peter Korsten;Huzaefah J Syed;Aamer Syed;Robert P Baughman;Arthur M F Yee;Daniel A Culver;Teresa Sosenko;Arata Azuma;Francesco Bonella;Ulrich Costabel;Wonder P Drake;Marjolein Drent;Elyse E Lower;Dominique Israel-Biet;Remy L M Mostard;Hilario Nunes;Paola Rottoli;Paolo Spagnolo;Athol U Wells;Wim A Wuyts;Marc A Judson
Division of Rheumatology, University of Illinois at Chicago, Chicago, IL. Electronic address: nsweiss@uic.edu.;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.;Department of Internal Medicine, VCU Health, Richmond, VA.;Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH.;Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY.;Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH.;Division of Rheumatology, University of Illinois at Chicago, Chicago, IL.;Nippon Medical School, Tokyo, Japan.;Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany.;Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN.;Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.;Hôpital Européen Georges Pompidou, Université de Paris, Paris, France.;Department of Respiratory Medicine, Zuyderland Medical Center, Heerlen/Sittard, The Netherlands.;Department of Pulmonology, Avicenne Hospital, Paris, France.;Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.;Respiratory Disease Unit, University of Padova, Padova, Italy.;Royal Brompton Hospital, London, England.;Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium.;Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, NY.
428
Letter
en
Type I IFN immunoprofiling in COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pubmed/32360285
2020-05-03 02:00:00+02:00
pubmed
Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__blood;Female;Humans;Interferon Type I__blood;Male;Middle Aged;Pandemics;Pneumonia, Viral__blood;COVID-19;severe acute respiratory syndrome coronavirus 2
Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France, International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France. Electronic address: sophie.assant@chu-lyon.fr.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France, National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), Lyon, France, Lyon Immunopathology Federation LIFE, Hospices Civils de Lyon, Lyon, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Virology Department, Infective Agents Institute, National Reference Center for Respiratory Viruses, North Hospital Network, Lyon, France. Electronic address: alexandre.belot@chu-lyon.fr.;Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.;Lyon University, CREATIS, CNRS UMR5220, Inserm U1044, INSA, Lyon, France, Intensive Care Unit, Hospices Civils de Lyon, Lyon, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Virology Department, Infective Agents Institute, National Reference Center for Respiratory Viruses, North Hospital Network, Lyon, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), Lyon, France, Lyon Immunopathology Federation LIFE, Hospices Civils de Lyon, Lyon, France, Pediatric Nephrology, Rheumatology, Dermatology Unit, Hospices Civils de Lyon, Lyon, France.
432
Letter;Comment
en
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
Louise Biquard;Dominique Valla;Pierre-Emmanuel Rautou
2020-04-30 02:00:00+02:00
32360995
FR
Université de Paris, Centre de recherche sur l'inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France.;Université de Paris, Centre de recherche sur l'inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France, Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France, Centre de Référence des Maladies Vasculaires du Foie, French Network for Rare Liver Diseases (FILFOIE), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Beaujon, AP-HP, Clichy, France.;Université de Paris, Centre de recherche sur l'inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France, Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France, Centre de Référence des Maladies Vasculaires du Foie, French Network for Rare Liver Diseases (FILFOIE), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Beaujon, AP-HP, Clichy, France. Electronic address: pierre-emmanuel.rautou@inserm.fr.
438
10.1016/j.acvd.2020.04.002
Journal Article
en
One train may hide another: Acute cardiovascular diseases could be neglected because of the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32362433
Coronavirus disease 2019 (COVID-19) is likely to have significant implications for the cardiovascular care of patients. In most countries, containment has already started (on 17 March 2020 in France), and self-quarantine and social distancing are reducing viral contamination and saving lives. However, these considerations may only be the tip of the iceberg; most resources are dedicated to the struggle against COVID-19, and this unprecedented situation may compromise the management of patients admitted with cardiovascular conditions.
Acute cardiac care;Acute coronary syndrome;COVID-19;Heart failure;Insuffisance cardiaque;Intensive care unit;Soins cardiaques aigus ,Unité de soins intensifs;Syndrome coronarien aigu
2020-04-28 02:00:00+02:00
32362433
FR
Department of Cardiology, Hôpital Universitaire de Montpellier, 34295 Montpellier, France, PhyMedExp, Université de Montpellier, Inserm U1046, CNRS UMR 9214, 34295 Montpellier, France.;Department of Cardiology, Hôpital Cardiologique Louis Pradel, 69500 Bron, France.;Department of Cardiology, Institut Coeur Poumons, Hôpital Cardiologique, 59000 Lille, France.;Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut Lévêque, 33604 Pessac, France, Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, Hôpital Xavier Arnozan, 33600 Pessac, France.;Department of Cardiology, Hôpital Lariboisiere, 75010 Paris, France.;Department of Cardiology, Hôpital de Grenoble, 38700 La Tronche, France.;Department of Cardiology, Hôpital Rangueil, 31400 Toulouse, France.;Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Européen Georges-Pompidou, 75015 Paris, France.;CEPEL, Université de Montpellier, CNRS, 34090 Montpellier, France, Medico-Economic Research Unit, CHU de Montpellier, Université de Montpellier, 34295 Montpellier, France.;Department of Cardiology, CHU de Nimes, 30029 Nimes, France.;CEPEL, Université de Montpellier, CNRS, 34090 Montpellier, France, Clinical Research and Epidemiology Unit, CHU de Montpellier, Université de Montpellier, 34295 Montpellier, France.;Department of Cardiology, Hôpital Universitaire de Montpellier, 34295 Montpellier, France, PhyMedExp, Université de Montpellier, Inserm U1046, CNRS UMR 9214, 34295 Montpellier, France. Electronic address: francois.roubille@gmail.com.
442
10.1016/j.radonc.2020.04.035
Journal Article
en
A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises.
https://www.ncbi.nlm.nih.gov/pubmed/32342872
To derive evidence-based recommendations for the optimal utilisation of resources during unexpected shortage of radiotherapy capacity.
Department of Radiation Oncology, University Medical Centre Utrecht, The Netherlands, Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands.;Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom.;Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ) and German Cancer Consortium (DKTK), Germany.;Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands, Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands.;Department of Radiation Oncology & Proton Center, Institut Curie, France.;Aix-Marseille University, Oncology Radiotherapy Department, CRCM Inserm, UMR1068, CNRS UMR7258, AMU UM105, Genome Instability and Carcinogenesis, APHM, France.;Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, United Kingdom.;Danish Centre for Particle Therapy, Aarhus, Denmark.;Department of Radiotherapy Medical University Vienna, Austria.;Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes, Homburg, Germany.;Department of Radiotherapy, The Clatterbridge Cancer Centre, Wirral, United Kingdom, The Proton Beam Therapy Centre, The Christie Hospital, Manchester, United Kingdom.;Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, United Kingdom. Electronic address: thankamma.ajithkumar@addenbrookes.nhs.uk.;Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
444
Case Reports;Letter
fr
[Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant].
M Lahfaoui;M Azizi;M Elbakkaoui;R El Amrani;I Kamaoui;H Benhaddou
Child;Death;Décès;Nourrisson;SARS-CoV-2
2020-04-27 02:00:00+02:00
32471720
FR;MA
Service de chirurgie pédiatrique, CHU Mohammed VI Oujda, Oujda, Maroc. Electronic address: simo88_6@hotmail.com.;Service de néonatologie, CHU Mohammed VI Oujda, Oujda, Maroc.;Service de Radiologie, CHU Mohammed VI Oujda, Oujda, Maroc.;Service de chirurgie pédiatrique, CHU Mohammed VI Oujda, Oujda, Maroc.
459
10.1016/j.bulcan.2020.04.004
Editorial
fr
[Impact of the COVID-19 epidemic on requests for initial care for breast cancer].
https://www.ncbi.nlm.nih.gov/pubmed/32389352
0007-4551
2020-05-03 02:00:00+02:00
pubmed
Age Factors;Betacoronavirus;Breast Neoplasms__diagnosis;Coronavirus Infections__diagnosis;Delayed Diagnosis;Delivery of Health Care__organization & administration;Female;France__epidemiology;Health Services Needs and Demand__statistics & numerical data;Humans;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Societies, Medical;Universal Precautions__methods;COVID-19;severe acute respiratory syndrome coronavirus 2
Institut Curie, département d'oncologie chirurgicale, 35 rue Dailly, 92210 St Cloud, France, INSERM U900, institut Curie, St Cloud, France. Electronic address: delphine.hequet@curie.fr.;Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France, Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France, DNA repair and uveal melanoma (D.R.U.M.), Inserm U830, équipe labellisée par la Ligue nationale contre le cancer, 75005 Paris, France.;Institut Curie, département de radiologie, 26, rue d'Ulm, 75005 Paris, France.;Institut Curie, département de radiologie, 35, rue Dailly, 92210 St Cloud, France.;Institut Curie, département d'oncologie chirurgicale, 35 rue Dailly, 92210 St Cloud, France.;Institut Curie, département d'oncologie chirurgicale, 35 rue Dailly, 92210 St Cloud, France, INSERM U900, institut Curie, St Cloud, France.;Institut Curie, département de radiothérapie, 35 rue Dailly, 92210 St Cloud, France.;Institut Curie, département de radiothérapie, 26, rue d'Ulm, 75005 Paris, France.;Institut Curie, département d'oncologie médicale, 35 rue Dailly, 92210 St Cloud, France, Laboratory of Circulating Tumor Biomarkers, Inserm, institut Curie, UVSQ, Paris Saclay University, St Cloud, Paris, France.;Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France, Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
Centre de radiothérapie Charlebourg, groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.;Département d'oncologie radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94600 Villejuif, France, Inserm, U1030 radiothérapie moléculaire et innovations thérapeutiques, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Université Paris-Saclay, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: eric.deutsch@gustaveroussy.fr.;Centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France.;Département d'oncologie radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94600 Villejuif, France, Inserm, U1030 radiothérapie moléculaire et innovations thérapeutiques, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Université Paris-Saclay, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Service de santé des armées, école du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France, Institut de recherche biomédicale des armées, D19, 91220 Bretigny-sur-Orge, France.
481
Letter;Comment
en
Our challenge is to adapt the organization of our system to the six stages of the epidemic to go beyond the COVID-19 crisis.
Department of Digestive Surgery, Rouen, France.;UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, Rouen, France.;Department of Digestive Oncology, Rouen University Hospital, Rouen, France.
489
Letter;Comment
en
Working from home in the time of COVID-19: how to best preserve occupational health?
Hanifa Bouziri;David R M Smith;Alexis Descatha;William Dab;Kevin Jean
musculoskeletal;occupational health practice;public health;stress
2020-04-30 02:00:00+02:00
32354748
FR
Laboratoire MESuRS, Conservatoire national des Arts et Métiers, Paris, France hanifa.bouziri@lecnam.net.;Laboratoire MESuRS, Conservatoire national des Arts et Métiers, Paris, France.;Laboratoire Épidémiologie et modélisation de l'Échappement aux Antibiotiques, Institut Pasteur, Paris, France.;Occupational Health Unit-UMS 011 U1168, Université de Versailles St-Quentin-Inserm APHP, Paris, France.
490
10.1016/j.jfo.2020.04.014
Practice Guideline
fr
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
COVID-19 and rhinology, from the consultation room to the operating theatre.
https://www.ncbi.nlm.nih.gov/pubmed/32387072
The purpose of this article is to give rhinologists advice on how to adapt their standard practice during the COVID-19 pandemic. The main goal of these recommendations is to protect healthcare workers against COVID-19 while continuing to provide emergency care so as to prevent loss of chance for patients. We reviewed our recommendations concerning consultations, medical prescriptions and surgical activity in rhinology.
1879-7296
2020-05-03 02:00:00+02:00
pubmed
European Annals of Otorhinolaryngology, Head and Neck Diseases
T Radulesco;B Verillaud;E Béquignon;J-F Papon;R Jankowski;L Le Taillandier De Gabory;P Dessi;A Coste;E Serrano;S Vergez;F Simon;V Couloigner;C Rumeau;J Michel
Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France.;Department of otorhinolaryngology, head and neck surgery, Lariboisière university hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of otorhinolaryngology, head and neck surgery, Henri Mondor university hospitals, Créteil intercommunal hospital, Assistance publique-Hôpitaux de Paris, Créteil, France.;Department of otorhinolaryngology, head and neck surgery, Bicêtre university hospital, Assistance publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.;Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France.;Department of otorhinolaryngology, head and neck surgery, Pellegrin university hospital, Bordeaux, France.;Department of otorhinolaryngology, head and neck surgery, Larrey university hospital, Toulouse, France.;Oncopole-1, university cancer Institute of Toulouse, Toulouse, France.;Paediatric ENT department, Necker-Enfants malades university hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France. Electronic address: justin.michel@ap-hm.fr.
497
10.4193/rhin20.159
Journal Article
en
Sniffing out the evidence; It's now time for public health bodies recognize the link between COVID-19 and smell and taste disturbance.
https://www.ncbi.nlm.nih.gov/pubmed/32352450
Since the outbreak of the pandemic, anecdotal observations have been accumulating rapidly that sudden anosmia and dysgeusia are peculiar symptoms associated with the COVID-19 infection. Prof C. Hopkins, as President of British Rhinological Society, published a letter describing "the loss of sense of smell as a marker of COVID-19 infection" and proposed that adults presenting with anosmia but no other symptoms should self-isolate for seven days. The Hopkins team published the first case report and case series as well as other evidence that isolated sudden onset anosmia (ISOA), should be considered highly suspicious for SARS-CoV-2(1). Subsequently, a larger series of 2428 patients presenting with new onset anosmia during the COVID-19 pandemic has been reported, of whom 16% report loss of sense of smell as an isolated symptom. Only 51% reported the recognized symptoms of cough or fever. A major limitation of this series however, was a lack of access to testing to confirm the COVID-19 status of the patients(2); in the 80 who had been tested 74% were positive. In the same way, the American Academy of Otolaryngology-head and neck surgery (AA0-HNS) proposed "that anosmia could be added to the list of screening tools for possible COVID-19 infection. More, they warrant serious consideration for self-isolation and testing those patients".
0300-0729
2020-05-03 02:00:00+02:00
pubmed
Rhinology journal
J R Lechien;C Hopkins;S Saussez
2020-04-30 02:00:00+02:00
32352450
FR;BE;GB;UNK
COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS).;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Guys and St Thomas NHS Foundation Trust, London, UK.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Universite Libre de Bruxelles, Brussels, Belgium.
501
Letter
en
Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.
Department of Rheumatology, Hôpitaux Civils de Colmar, Colmar, Alsace, France pierremarie.duret@gmail.com.;Department of Rheumatology-Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Department of Rheumatology, Hôpitaux Civils de Colmar, Colmar, Alsace, France.;Department of Infectious Diseases, Hopitaux Civils de Colmar, Colmar, Alsace, France.
502
10.1016/j.jfo.2020.04.013
Journal Article;Practice Guideline
fr
[Neuro-ophthalmologic emergencies during this COVID-19 pandemic].
https://www.ncbi.nlm.nih.gov/pubmed/32471746
0181-5512
2020-05-03 02:00:00+02:00
pubmed
Age Factors;Anisocoria__complications;Betacoronavirus;Coronavirus Infections__complications;Emergencies;Eye Diseases__diagnosis;Humans;Oculomotor Nerve Diseases__diagnosis;Pandemics;Papilledema__diagnosis;Pneumonia, Viral__complications;Referral and Consultation;Vision Disorders__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2
Journal Français d'Ophtalmologie
S Defoort;C Lamirel;V Touitou;C Vignal
2020-04-30 02:00:00+02:00
32471746
FR
Cité Hospitalière, 2, avenue Oscar Lambret, 59000 Lille, France.;Fondation Ophtalmologique de Rothschild, 29, rue Manin, 75019 Paris, France.;Service d'ophtalmologie, CHU Pitié Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.;Fondation Ophtalmologique de Rothschild, 29, rue Manin, 75019 Paris, France. Electronic address: cvignal@fo-rothschild.fr.
Paul E Verweij;Jean-Pierre Gangneux;Matteo Bassetti;Roger J M Brüggemann;Oliver A Cornely;Philipp Koehler;Cornelia Lass-Flörl;Frank L van de Veerdonk;Arunaloke Chakrabarti;Martin Hoenigl
2020-05-10 02:00:00+02:00
32835328
FR;US;IT;NL;DE;IN;AT
Departments of Medical Microbiology, Radboud University Medical Centre, Nijmegen, Netherlands.;Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, Netherlands.;University of Rennes, Centre Hospitalier Universitaire (CHU) de Rennes, Inserm, EHESP, Institut de Recherche en Santé Environnement et Travail - UMR_S 1085, Rennes, France.;Clinica Malattie Infettive, Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere, Genoa, Italy.;Department of Health Sciences, University of Genoa, Genoa, Italy.;Department of Pharmacy, Radboud University Medical Centre, Nijmegen, Netherlands.;Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine, University of Cologne, Cologne, Germany.;Department I of Internal Medicine, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.;Excellence Center for Medical Mycology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.;German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.;Clinical Trials Centre Cologne, Cologne, Germany.;Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Dpeartment of Infectious Diseases, Radboud University Medical Centre, Nijmegen, Netherlands.;Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA, USA.;section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria.
511
10.1016/j.medmal.2020.05.001
Journal Article
en
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pubmed/32387320
No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
COVID-19;Intensive care unit;Mortality;SARS-CoV-2;Tocilizumab
2020-05-06 02:00:00+02:00
32387320
FR
Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.;Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: souhail.zayet@gmail.com.;Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Intensive Care Unit Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Pharmacology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Biological Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.
525
10.1016/j.encep.2020.05.001
Journal Article;Review
fr
[Suicidal behavior in light of COVID-19 outbreak: Clinical challenges and treatment perspectives].
https://www.ncbi.nlm.nih.gov/pubmed/32471707
The COVID-19 pandemic affected today more than 3,000,000 worldwide, and more than half of humanity has been placed in quarantine. The scientific community and the political authorities fear an epidemic of suicide secondary to this crisis. The aim of this review is to analyze the impact of the COVID-19 pandemic on the dimensions of the suicidal process and its interaction with the various risk factors. We also propose innovative strategies to manage suicidal behavior in the context of pandemic.
Inserm, PSNREC, université Montpellier, CHU de Montpellier, Montpellier, France, Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, CHU de Montpellier, Montpellier, France, FondaMental Foundation, Créteil, France.;CHU de Brest, université de Bretagne Occidentale, Brest, France.;Inserm, fondation FondaMental, université Paris Est Créteil, AP-HP, Paris, France.;Pôle de psychiatrie, médecine légale et médecine en milieu pénitentiaire, CHU de Lille, Lille, France.;Inserm, PSNREC, université Montpellier, CHU de Montpellier, Montpellier, France, Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, CHU de Montpellier, Montpellier, France, FondaMental Foundation, Créteil, France. Electronic address: philippe.courtet@univ-montp1.fr.
526
10.1016/j.tmaid.2020.101738
Journal Article
en
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
https://www.ncbi.nlm.nih.gov/pubmed/32387409
In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19.
IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;Aix Marseille Univ., Laboratoire de Pharmacie Clinique, Marseille, France, AP-HM, hôpital Timone, service Pharmacie, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France, Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille, France, AP-HM, Marseille, France.;Department of Radiology and Cardiovascular Imaging, Aix-Marseille Univ., UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale-Centre d'Exploration Métaboliques par Résonance Magnétique), Marseille, France.;AP-HM, Aix Marseille Univ., hôpital Timone, Cardiologie, Rythmologie, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com.
531
10.1016/j.meegid.2020.104351
Journal Article
en
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32387564
SARS-CoV-2 is a SARS-like coronavirus of likely zoonotic origin first identified in December 2019 in Wuhan, the capital of China's Hubei province. The virus has since spread globally, resulting in the currently ongoing COVID-19 pandemic. The first whole genome sequence was published on January 5 2020, and thousands of genomes have been sequenced since this date. This resource allows unprecedented insights into the past demography of SARS-CoV-2 but also monitoring of how the virus is adapting to its novel human host, providing information to direct drug and vaccine design. We curated a dataset of 7666 public genome assemblies and analysed the emergence of genomic diversity over time. Our results are in line with previous estimates and point to all sequences sharing a common ancestor towards the end of 2019, supporting this as the period when SARS-CoV-2 jumped into its human host. Due to extensive transmission, the genetic diversity of the virus in several countries recapitulates a large fraction of its worldwide genetic diversity. We identify regions of the SARS-CoV-2 genome that have remained largely invariant to date, and others that have already accumulated diversity. By focusing on mutations which have emerged independently multiple times (homoplasies), we identify 198 filtered recurrent mutations in the SARS-CoV-2 genome. Nearly 80% of the recurrent mutations produced non-synonymous changes at the protein level, suggesting possible ongoing adaptation of SARS-CoV-2. Three sites in Orf1ab in the regions encoding Nsp6, Nsp11, Nsp13, and one in the Spike protein are characterised by a particularly large number of recurrent mutations (>15 events) which may signpost convergent evolution and are of particular interest in the context of adaptation of SARS-CoV-2 to the human host. We additionally provide an interactive user-friendly web-application to query the alignment of the 7666 SARS-CoV-2 genomes.
Lucy van Dorp;Mislav Acman;Damien Richard;Liam P Shaw;Charlotte E Ford;Louise Ormond;Christopher J Owen;Juanita Pang;Cedric C S Tan;Florencia A T Boshier;Arturo Torres Ortiz;François Balloux
UCL Genetics Institute, University College London, London WC1E 6BT, UK. Electronic address: lucy.dorp.12@ucl.ac.uk.;UCL Genetics Institute, University College London, London WC1E 6BT, UK.;Cirad, UMR PVBMT, F-97410, St Pierre, Réunion, France, Université de la Réunion, UMR PVBMT, F-97490, St Denis, Réunion, France.;Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.;UCL Genetics Institute, University College London, London WC1E 6BT, UK, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.;Division of Infection and Immunity, University College London, London WC1E 6BT, UK.;UCL Genetics Institute, University College London, London WC1E 6BT, UK, Department of Infectious Disease, Imperial College, London W2 1NY, UK.;UCL Genetics Institute, University College London, London WC1E 6BT, UK. Electronic address: f.balloux@ucl.ac.uk.
532
10.1016/s2213-2600(20)30221-6
Journal Article
en
Airway management for COVID-19: a move towards universal videolaryngoscope?
Audrey De Jong;Emmanuel Pardo;Amélie Rolle;Sandra Bodin-Lario;Yvan Pouzeratte;Samir Jaber
2020-05-05 02:00:00+02:00
32536367
FR
Intensive Care Unit and Transplantation, Critical Care and Anesthesia Department, Hôpital Saint-Éloi, Montpellier University Hospital, PhyMed Exp INSERM U1046, 34090 Montpellier, France.;Intensive Care Unit, Critical Care and Anesthesia Department, Hôpital Saint-Antoine, APHP, Sorbonne Université, Paris, France.;Intensive Care Unit and Transplantation, Critical Care and Anesthesia Department, Hôpital Saint-Éloi, Montpellier University Hospital, PhyMed Exp INSERM U1046, 34090 Montpellier, France. Electronic address: s-jaber@chu-montpellier.fr.
534
Letter
en
Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis.
Amiens, France. Electronic address: beyls.christophe@chu-amiens.fr.;Amiens, France.
536
10.1007/s00259-020-04834-7
Journal Article
en
Tracheobronchitis signs observed on ventilation lung scintigraphy during the course of COVID-19 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32378021
1619-7070,1619-7089
2020-05-10 02:00:00+02:00
pubmed
European Journal of Nuclear Medicine and Molecular Imaging
Antoine Verger;Achraf Bahloul;Saifeddine Melki;Gilles Karcher;Laetitia Imbert;Pierre-Yves Marie
2020-05-06 02:00:00+02:00
32378021
FR
Department of Nuclear Medicine, CHRU-Nancy, Nancy, F-54000, France.;Nancyclotep Imaging Platform, CHRU-Nancy, Nancy, F-54000, France.;Inserm, IADI, Université de Lorraine, Nancy, F-54000, France.;Department of Nuclear Medicine, CHRU-Nancy, Nancy, F-54000, France. l.imbert@chru-nancy.fr.;Nancyclotep Imaging Platform, CHRU-Nancy, Nancy, F-54000, France. l.imbert@chru-nancy.fr.;Inserm, IADI, Université de Lorraine, Nancy, F-54000, France. l.imbert@chru-nancy.fr.;Inserm, DCAC, Université de Lorraine, Allée du Morvan, Vandœuvre-les-Nancy, F-54000, France. l.imbert@chru-nancy.fr.
545
10.1016/j.medin.2020.04.016
Journal Article;Review
en
Ultrasound in the management of the critically ill patient with SARS-CoV-2 infection (COVID-19): narrative review.
https://www.ncbi.nlm.nih.gov/pubmed/32527471
The clinical picture of SARS-CoV-2 infection (COVID-19) is characterized in its more severe form, by an acute respiratory failure which can worsen to pneumonia and acute respiratory distress syndrome (ARDS) and get complicated with thrombotic events and heart dysfunction. Therefore, admission to the Intensive Care Unit (ICU) is common. Ultrasound, which has become an everyday tool in the ICU, can be very useful during COVID-19 pandemic, since it provides the clinician with information which can be interpreted and integrated within a global assessment during the physical examination. A description of some of the potential applications of ultrasound is depicted in this document, in order to supply the physicians taking care of these patients with an adapted guide to the intensive care setting. Some of its applications since ICU admission include verification of the correct position of the endotracheal tube, contribution to safe cannulation of lines, and identification of complications and thrombotic events. Furthermore, pleural and lung ultrasound can be an alternative diagnostic test to assess the degree of involvement of the lung parenchyma by means of the evaluation of specific ultrasound patterns, identification of pleural effusions and barotrauma. Echocardiography provides information of heart involvement, detects cor pulmonale and shock states.
0210-5691
2020-05-10 02:00:00+02:00
pubmed
Medicina Intensiva
V Fraile Gutiérrez;J M Ayuela Azcárate;D Pérez-Torres;L Zapata;A Rodríguez Yakushev;A Ochagavía
Servicio de Medicina Intensiva, Hospital Universitario Río Hortega, Valladolid, España. Electronic address: vicky_uvi@yahoo.es.;Especialista en Medicina Intensiva, Burgos, España.;Servicio de Medicina Intensiva, Hospital Universitario Río Hortega, Valladolid, España.;Servicio de Medicina Intensiva, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, España.;Servicio de Medicina Intensiva, Área de Críticos, Corporación Sanitaria Parc Taulí Sabadell, Barcelona, España.
553
Letter
en
A 5-point strategy for improved connection with relatives of critically ill patients with COVID-19.
Médecine Intensive et Réanimation, Hôpital Saint-Louis AP-HP, Paris University, Paris 75010, France. Electronic address: elie.azoulay@aphp.fr.;Médecine Intensive et Réanimation, Hôpital Saint-Louis AP-HP, Paris University, Paris 75010, France.
557
10.1016/j.ajog.2020.04.039
Journal Article
en
Evidence for and against vertical transmission for severe acute respiratory syndrome coronavirus 2.
https://www.ncbi.nlm.nih.gov/pubmed/32376317
COVID-19 can severely affect pregnant women Furthermore, issues regarding vertical transmission of severe acute respiratory syndrome coronavirus 2 are emerging. In patients and neonates who are showing symptoms of coronavirus disease 2019, real-time polymerase chain reaction of nasal and throat swabs, sputum, and feces is performed to detect the presence of severe acute respiratory syndrome coronavirus 2. In addition, real-time polymerase chain reaction of vaginal swabs, amniotic fluid, placenta, cord blood, neonatal blood, or breast milk for the detection of severe acute respiratory syndrome coronavirus 2 did not show substantial results. Viremia was present in 1% of adult patients who were showing symptoms of coronavirus disease 2019. Here, we reviewed 12 articles published between Feb. 10, 2020, and April 4, 2020, that reported on 68 deliveries and 71 neonates with maternal infection in the third trimester of pregnancy. To determine whether infection occurred congenitally or perinatally, perinatal exposure, mode of delivery, and time interval from delivery to the diagnosis of neonatal infection were considered. Neonates with severe acute respiratory syndrome coronavirus 2 infection are usually asymptomatic. In 4 cases, a diagnostic test for severe acute respiratory syndrome coronavirus 2 infection was performed within 48 hours of life. Furthermore, detection rates of real-time polymerase chain reaction and the interpretation of immunoglobulin M and immunoglobulin G antibodies levels in cord and neonatal blood were discussed in relation with the immaturity of the fetal and neonatal immune system.
Department of Fetal Pathology and Genetics, Nimes and Montpellier University Hospitals, University of Montpellier, Montpellier, France.;Department of Embryology, Fetal Pathology, and Genetics, Imagine Institute, Necker-Enfants Malades Hospital, University of Paris, Paris, France.;Department of Fetal Pathology, Antoine-Béclère Hospital, Paris Saclay University, Clamart, France.;Departments of Medical Virology, Necker-Enfants Malades Hospital, University of Paris, Paris, France.;Obstetrics and Fetal Medicine, Necker-Enfants Malades Hospital, University of Paris, Paris, France. Electronic address: ville.yves@gmail.com.
Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32482571
This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections.
1879-7296
2020-05-10 02:00:00+02:00
pubmed
European Annals of Otorhinolaryngology, Head and Neck Diseases
Anosmia;Bell's palsy;COVID-19;Prednisone;SARS-CoV-2;Sudden hearing loss
2020-05-04 02:00:00+02:00
32482571
FR
Department of otorhinolaryngology, head and neck surgery, Lariboisière university hospital, AP-HP, Paris, France. Electronic address: philippe.herman099@gmail.com.;Department of otorhinolaryngology, head and neck surgery, Lille university hospital, Lille, France.;Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France.;Department of otorhinolaryngology, head and neck surgery, Necker hospital for sick children, AP-HP, Paris, France.;Department of otorhinolaryngology, head and neck surgery, La Pitié-Salpêtrière university hospital, AP-HP, Paris, France.;Department of otorhinolaryngology, head and neck surgery, Lyon south university hospital, Lyon, France.;Department of otorhinolaryngology, head and neck surgery, Bicêtre university hospital, AP-HP, Le Kremlin Bicêtre, France.;Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, AP-HM, Marseille, France.;Department of otorhinolaryngology, head and neck surgery, Hautepierre university hospital, Strasbourg, France.;Department of otorhinolaryngology, head and neck surgery, CHU38 university hospital, Grenoble, France.
566
Letter
en
COVID-19 outcomes in patients with hematologic disease.
https://www.ncbi.nlm.nih.gov/pubmed/32376969
2020-05-10 02:00:00+02:00
pubmed
Florent Malard;Alexis Genthon;Eolia Brissot;Zoe van de Wyngaert;Zora Marjanovic;Souhila Ikhlef;Anne Banet;Simona Lapusan;Simona Sestilli;Elise Corre;Annalisa Paviglianiti;Rosa Adaeva;Fella M 'Hammedi-Bouzina;Myriam Labopin;Ollivier Legrand;Rémy Dulery;Mohamad Mohty
2020-05-06 02:00:00+02:00
32376969
FR
Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France. florent.malard@inserm.fr.;Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France.
573
10.1016/j.micinf.2020.05.002
Editorial
en
Could nasal nitric oxide help to mitigate the severity of COVID-19?
https://www.ncbi.nlm.nih.gov/pubmed/32387333
The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail.
Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.;Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, Chang Gung Biotechnology Corporation, Taipei, Taiwan, Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City, Taiwan.;Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan, Chang Gung Biotechnology Corporation, Taipei, Taiwan.;Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA, University of Paris, Paris, France. Electronic address: dojcius@pacific.edu.
Single-cell longitudinal analysis of SARS-CoV-2 infection in human bronchial epithelial cells.
https://www.ncbi.nlm.nih.gov/pubmed/32511382
SARS-CoV-2, the causative agent of COVID-19, has resulted in more than 3,000,000 infections and 200,000 deaths. There are currently no approved drugs or vaccines for the treatment or prevention of COVID-19. Enhanced understanding of SARS-CoV-2 infection and pathogenesis is critical for the development of therapeutics. To reveal insight into viral replication, cell tropism, and host-viral interactions of SARS-CoV-2 we performed single-cell RNA sequencing of experimentally infected human bronchial epithelial cells (HBECs) in air-liquid interface cultures over a time-course. This revealed novel polyadenylated viral transcripts and highlighted ciliated cells as the major target of infection, which we confirmed by electron microscopy. Over the course of infection, cell tropism of SARS-CoV-2 expands to other epithelial cell types including basal and club cells. Infection induces cell intrinsic expression of type I and type III IFNs and IL6 but not IL1. This results in expression of interferon stimulated genes in both infected and bystander cells. Here, we have conducted an in-depth analysis of SARS-CoV-2 infection in HBECs and provide a detailed characterization of genes, cell types, and cell state changes associated with the infection.
2020-05-10 02:00:00+02:00
pubmed
Neal G Ravindra;Mia Madel Alfajaro;Victor Gasque;Jin Wei;Renata B Filler;Nicholas C Huston;Han Wan;Klara Szigeti-Buck;Bao Wang;Ruth R Montgomery;Stephanie C Eisenbarth;Adam Williams;Anna Marie Pyle;Akiko Iwasaki;Tamas L Horvath;Ellen F Foxman;David van Dijk;Craig B Wilen
Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.;Department of Computer Science, Yale University, New Haven, CT, USA.;Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.;Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.;Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Est, Lyon, France.;Département de Bioinformatique, Univ Evry, Université Paris-Saclay, Paris, France.;Department of Molecular Biophysics & Biochemistry, Yale School of Medicine, New Haven, CT, USA.;Department of Molecular, Cellular, and Developmental Biology, Yale School of Medicine, New Haven, CT, USA.;Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, USA.;Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA.;Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.;Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.;The Jackson Laboratory, Farmington, CT, USA.;Howard Hughes Medical Institute, Chevy Chase, MD, USA.
577
Letter
en
COVID-19 and ethical considerations: Valuable decision-making tools from the leading medical societies in France.
https://www.ncbi.nlm.nih.gov/pubmed/32414630
2020-05-10 02:00:00+02:00
pubmed
Betacoronavirus;Comorbidity;Coronavirus Infections__epidemiology;Critical Care__ethics;Decision Making, Organizational;Decision Support Techniques;France__epidemiology;Health Priorities__ethics;Health Resources__ethics;Health Services Needs and Demand;Humans;Life Tables;Organ Dysfunction Scores;Pandemics;Personal Autonomy;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Resource Allocation__ethics;Societies, Medical;Treatment Refusal__ethics;Triage__ethics;COVID-19;severe acute respiratory syndrome coronavirus 2
Antoine Lamblin;Sandrine de Montgolfier
2020-05-07 02:00:00+02:00
32414630
FR
Department of Civilian and Military Anaesthesia, Édouard-Herriot Hospital, Lyon University Hospital, 5, place d'Arsonval, 69003 Lyon, France, UMR ADéS 7268, Aix-Marseille University/EFS/CNRS, Espace éthique méditerranéen, University Hospital La Timone (adults), Marseille, France. Electronic address: antoine.lamblin@chu-lyon.fr.;IRIS Institut de recherche interdisciplinaire sur les enjeux sociaux, UMR 8156 CNRS - 997 Inserm - EHESS - UP13, 74, rue Marcel Cachin, 93017 Bobigny.
578
10.1016/j.schres.2020.05.009
Case Reports
en
Coronovirus infection as a novel delusional topic.
https://www.ncbi.nlm.nih.gov/pubmed/32404258
Delusional topics tend to rapidly incorporate popular hot topical issues. Thus, the current coronavirus COVID-19 pandemic has rapidly reached delusional themes in patients with psychiatric disorders. Here we present the clinical case of a Spanish woman with bipolar disorder that included coronavirus infection in her delusional themes even faster than the real infection reached mainland Spain.
0920-9964
2020-05-10 02:00:00+02:00
pubmed
Schizophrenia Research
Santiago Ovejero;Enrique Baca-García;María Luisa Barrigón
COVID-19;Coronavirus;Delusional topics;Psychosis
2020-05-08 02:00:00+02:00
32404258
FR;ES;CL
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain, Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain, Department of Psychiatry, General Hospital of Villalba, Madrid, Spain, Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain, Universidad Catolica del Maule, Talca, Chile, Department of Psychiatry, Centre Hospitalier Universitaire de Nîmes, France.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain. Electronic address: luisa.barrigon@fjd.es.
580
Letter
en
COVID-19 Outbreak in France: Setup and Activities of a Mobile Extracorporeal Membrane Oxygenation Team During the First 3 Weeks.
Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards.
https://www.ncbi.nlm.nih.gov/pubmed/32385126
Disadvantaged socioeconomic position (SEP) is widely associated with disease and mortality, and there is no reason to think this will not be the case for the newly emerged coronavirus disease 2019 (COVID-19) that has reached a pandemic level. Individuals with a more disadvantaged SEP are more likely to be affected by most of the known risk factors of COVID-19. SEP has been previously established as a potential determinant of infectious diseases in general. We hypothesise that SEP plays an important role in the COVID-19 pandemic either directly or indirectly via occupation, living conditions, health-related behaviours, presence of comorbidities and immune functioning. However, the influence of socioeconomic factors on COVID-19 transmission, severity and outcomes is not yet known and is subject to scrutiny and investigation. Here we briefly review the extent to which SEP has been considered as one of the potential risk factors of COVID-19. From 29 eligible studies that reported the characteristics of patients with COVID-19 and their potential risk factors, only one study reported the occupational position of patients with mild or severe disease. This brief overview of the literature highlights that important socioeconomic characteristics are being overlooked when data are collected. As COVID-19 spreads worldwide, it is crucial to collect and report data on socioeconomic determinants as well as race/ethnicity to identify high-risk populations. A systematic recording of socioeconomic characteristics of patients with COVID-19 will be beneficial to identify most vulnerable groups, to identify how SEP relates to COVID-19 and to develop equitable public health prevention measures, guidelines and interventions.
Faculty of Medicine and Health, The University of Sydney School of Public Health, Sydney, Australia saman.khalatbarisoltani@sydney.edu.au.;ARC Centre of Excellence in Population Ageing Research (CEPAR), The University of Sydney, Sydney, Australia.;The University of Sydney School of Public Health, Sydney, Australia.;ARC Centre of Excellence in Population Ageing Research (CEPAR), The University of Sydney Faculty of Medicine and Health, Sydney, Australia.;LEASP, Université Toulouse III Paul Sabatier, Toulouse, France.;Umr 1027, Inserm, Toulouse, France.;IFERISS, Université de Toulouse, Toulouse, France.
588
10.1016/j.resmer.2020.100758
Editorial
en
Impact of the Covid-19 pandemic and lung transplantation program in France.
Respiratory medicine and lung transplantation group, Foch Hospital, 40, rue Worth, 92150 Suresnes, France.;Service de Transplantation, Chirurgie Thoracique et Vasculaire, Centre Chirugical Marie Lannelongue, Hôpital Marie Lannelongue, 133, avenue de la Résistance, 92350 Le Plessis-Robinson, France.;Service de Pneumologie et de Transplantation Pulmonaire, Centre Hospitalier Universitaire de Nantes, hôpital Nord Laennec, boulevard Jacques-Monod, 44093 Saint-Herblain, France.
589
10.1177/2048872620923639
Journal Article
en
Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes.
https://www.ncbi.nlm.nih.gov/pubmed/32375487
Hospitals play a critical role in providing communities with essential medical care during all types of disaster. Depending on their scope and nature, disasters can lead to a rapidly increasing service demand that can overwhelm the functional capacity and safety of hospitals and the healthcare system at large. Planning during the community outbreak of coronavirus disease 2019 (Covid-19) is critical for maintaining healthcare services during our response. This paper describes, besides general measures in times of a pandemic, also the necessary changes in the invasive diagnosis and treatment of patients presenting with different entities of acute coronary syndromes including structural adaptations (networks, spokes and hub centres) and therapeutic adjustments.
3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Austria.;Medical School, Sigmund Freud University, Austria.;Lille University Hospital and SAMU59, France.
601
10.1016/j.bulcan.2020.04.007
Editorial
fr
[Clinical trials during pandemic crisis: How to ensure safety and maintain access to innovation].
Stéphane Vignot;Olivier Le Blaye;Laurence Fluckiger;Sonia Errard;Benoît Marin;Elodie Chapel
2020-05-07 02:00:00+02:00
32414537
FR
Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), 143-147, boulevard Anatole France, 93285 Saint-Denis cedex, France. Electronic address: stephane.vignot@ansm.sante.fr.;Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), 143-147, boulevard Anatole France, 93285 Saint-Denis cedex, France.;Direction Générale de la Santé (DGS), 14, avenue Duquesne, 75350 Paris, France.
604
Letter;Research Support, N.I.H., Extramural;Research Support, U.S. Gov't, Non-P.H.S.;Comment
en
Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable.
Carla Mavian;Sergei Kosakovsky Pond;Simone Marini;Brittany Rife Magalis;Anne-Mieke Vandamme;Simon Dellicour;Samuel V Scarpino;Charlotte Houldcroft;Julian Villabona-Arenas;Taylor K Paisie;Nídia S Trovão;Christina Boucher;Yun Zhang;Richard H Scheuermann;Olivier Gascuel;Tommy Tsan-Yuk Lam;Marc A Suchard;Ana Abecasis;Eduan Wilkinson;Tulio de Oliveira;Ana I Bento;Heiko A Schmidt;Darren Martin;James Hadfield;Nuno Faria;Nathan D Grubaugh;Richard A Neher;Guy Baele;Philippe Lemey;Tanja Stadler;Jan Albert;Keith A Crandall;Thomas Leitner;Alexandros Stamatakis;Mattia Prosperi;Marco Salemi
2020-05-07 02:00:00+02:00
32381734
FR;SE;PT;CN;GB;US;HK;CH;ZA;DE;BE;AT
Emerging Pathogens Institute, University of Florida, Gainesville, FL 32609, salemi@pathology.ufl.edu cmavian@ufl.edu m.prosperi@ufl.edu.;Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610.;Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, PA 19122.;Emerging Pathogens Institute, University of Florida, Gainesville, FL 32609.;Department of Epidemiology, University of Florida, Gainesville, FL 32610.;Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.;Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisboa, Portugal.;Spatial Epidemiology Laboratory, Université Libre de Bruxelles, 1050 Bruxelles, Belgium.;Network Science Institute, Northeastern University, Boston, MA 02115.;Department of Medicine, University of Cambridge, Cambridge CB2 3QG, United Kingdom.;Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.;Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.;Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD 20892.;Department of Computer & Information Science & Engineering, University of Florida, Gainesville, FL 32611.;Department of Informatics, Craig Venter Institute, La Jolla, CA 92037.;Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA 92037.;Department of Pathology, University of California San Diego, La Jolla, CA 92093.;Unité Bioinformatique Evolutive, Centre de Bioinformatique, Biostatistique et BiologieIntégrative (C3BI)-USR 3756 CNRS and Institut Pasteur, 75015 Paris, France.;State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong SAR, China.;Department of Biomathematics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.;Department of Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.;Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.;KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban 4041, South Africa.;Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN 47405.;Max F. Perutz Laboratories, Center for Integrative Bioinformatics Vienna (CIBIV), Medical University of Vienna, University of Vienna, 1030 Vienna, Austria.;Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.;Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.;Department of Zoology, University of Oxford, Oxford OX1 3PS, United Kingdom.;Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510.;Biozentrum, University of Basel, 4056 Basel, Switzerland.;Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology, 4058 Basel, Switzerland.;Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden.;Department of Biostatistics & Bioinformatics, Computational Biology Institute, Milken Institute School of Public Health, George Washington University, Washington, DC 20052.;Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.;Computational Molecular Evolution Group, Heidelberg Institute for Theoretical Studies, 69118 Heidelberg, Germany.;Institute for Theoretical Informatics, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
611
10.1038/s41433-020-0944-7
Journal Article
en
Impact of the COVID-19 lockdown on basic science research in ophthalmology: the experience of a highly specialized research facility in France.
Marco Nassisi;Isabelle Audo;Christina Zeitz;Juliette Varin;Juliette Wohlschlegel;Vasily Smirnov;Dominique Santiard-Baron;Serge Picaud;José-Alain Sahel
2020-05-07 02:00:00+02:00
32382143
FR;GB;US
Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.;CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DGOS CIC1423, 28 rue de Charenton, F-75012, Paris, France.;Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France. isabelle.audo@inserm.fr.;CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DGOS CIC1423, 28 rue de Charenton, F-75012, Paris, France. isabelle.audo@inserm.fr.;Institute of Ophthalmology, University College of London, London, EC1V 9EL, UK. isabelle.audo@inserm.fr.;Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France. christina.zeitz@inserm.fr.;Fondation Ophtalmologique Adolphe de Rothschild, F-75019, Paris, France.;Department of Ophthalmology, University of Pittsburgh Medical School, Pittsburgh, PA, 15213, USA.;Académie des Sciences-Institut de France, F-75006, Paris, France.
616
10.1093/ajhp/zxaa146
Journal Article
en
Clinical trials: Management of investigational products during the COVID-19 pandemic.
Department of Pharmacy Nantes University Hospital Nantes, France.;Agence Générale des Equipements et Produits de Santé Hôpitaux de Paris, France.
633
10.5588/ijtld.20.0176
Journal Article
en
Monitoring the COVID-19 pandemic in sub-Saharan Africa: focusing on health facility admissions and deaths.
https://www.ncbi.nlm.nih.gov/pubmed/32398216
1027-3719
2020-05-17 02:00:00+02:00
pubmed
Africa South of the Sahara__epidemiology;Betacoronavirus;Coronavirus Infections__epidemiology;Disease Notification__methods;Health Facilities;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2
The International Journal of Tuberculosis and Lung Disease
A D Harries;L Martinez;J M Chakaya
2020-05-14 02:00:00+02:00
32398216
FR;KE;GB;US
International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.;Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, CA, USA.;International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya, <email></email>, Email: adharries@theunion.org.
Foch Hospital.;Université de Paris.;International Academy of Medical Ethics and Public Health, Université de Paris.
646
10.1038/s41409-020-0919-0
Journal Article;Review
en
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.
https://www.ncbi.nlm.nih.gov/pubmed/32404975
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed.
0268-3369,1476-5365
2020-05-17 02:00:00+02:00
pubmed
Bone Marrow Transplantation
Per Ljungman;Malgorzata Mikulska;Rafael de la Camara;Grzegorz W Basak;Christian Chabannon;Selim Corbacioglu;Rafael Duarte;Harry Dolstra;Arjan C Lankester;Mohamad Mohty;Silvia Montoto;John Murray;Régis Peffault de Latour;John A Snowden;Ibrahim Yakoub-Agha;Bregje Verhoeven;Nicolaus Kröger;Jan Styczynski
2020-05-13 02:00:00+02:00
32404975
FR;SE;GB;IT;PL;NL;ES;DE
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se.;Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Per.Ljungman@ki.se.;Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy.;Department of Hematology, Hospital de la Princesa, Madrid, Spain.;Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.;Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.;Pediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, Germany.;Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.;Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.;Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre Leiden, Leiden, the Netherlands.;Department of Hematology, Hospital Saint Antoine, Paris, France.;St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.;The Christie NHS Foundation Trust, Manchester, UK.;BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.;Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.;CHU de Lille, Univ Lille, INSERM, U1285, Lille, France.;Foundation Hematon, Utrecht, the Netherlands.;Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.;Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
652
Letter
en
Influence of the containment on the epidemiology of maxillo-facial emergencies during the COVID-19 pandemic. Why no more cellulites of odontogenic origin?
Department of oral and maxillo-facial surgery, Angers University Hospital, 4, rue Larrey, 49933 Angers cedex, France. Electronic address: daniel.kun-darbois@univ-angers.fr.;Department of oral and maxillo-facial surgery, Angers University Hospital, 4, rue Larrey, 49933 Angers cedex, France.;Department of oral and maxillo-facial surgery, Nantes University Hospital, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France.
655
10.1016/j.clinph.2020.05.006
Journal Article;Review
en
How to carry out and interpret EEG recordings in COVID-19 patients in ICU?
https://www.ncbi.nlm.nih.gov/pubmed/32405259
There are questions and challenges regarding neurologic complications in COVID-19 patients. EEG is a safe and efficient tool for the evaluation of brain function, even in the context of COVID-19. However, EEG technologists should not be put in danger if obtaining an EEG does not significantly advance diagnosis or change management in the patient. Not every neurologic problem stems from a primary brain injury: confusion, impaired consciousness that evolves to stupor and coma, and headaches are frequent in hypercapnic/hypoxic encephalopathies. In patients with chronic pulmonary disorders, acute symptomatic seizures have been reported in acute respiratory failure in 6%. The clinician should be aware of the various EEG patterns in hypercapnic/hypoxic and anoxic (post-cardiac arrest syndrome) encephalopathies as well as encephalitides. In this emerging pandemic of infectious disease, reduced EEG montages using single-use subdermal EEG needle electrodes may be used in comatose patients. A full 10-20 EEG complement of electrodes with an ECG derivation remains the standard. Under COVID-19 conditions, an expedited study that adequately screens for generalized status epilepticus, most types of regional status epilepticus, encephalopathy or sleep may serve for most clinical questions, using simplified montages may limit the risk of infection to EEG technologists. We recommend noting whether the patient is undergoing or has been placed prone, as well as noting the body and head position during the EEG recording (supine versus prone) to avoid overinterpretation of respiratory, head movement, electrode, muscle or other artifacts. There is slight elevation of intracranial pressure in the prone position. In non-comatose patients, the hyperventilation procedure should be avoided. At present, non-specific EEG findings and abnormalities should not be considered as being specific for COVID-19 related encephalopathy.
1388-2457
2020-05-17 02:00:00+02:00
pubmed
Brain Diseases__diagnosis;Coronavirus Infections__complications;Critical Care__methods;Electroencephalography__instrumentation;Humans;Pandemics;Patient Positioning__methods;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19
Clinical Neurophysiology
Philippe Gélisse;Andrea O Rossetti;Pierre Genton;Arielle Crespel;Peter W Kaplan
COVID-19;Coma;EEG;ICU;Prone position
2020-05-13 02:00:00+02:00
32405259
FR;CH;US
Epilepsy Unit, Hôpital Gui de Chauliac, Montpellier, France, Research Unit (URCMA: Unité de Recherche sur les Comportements et Mouvements Anormaux), INSERM, U661, Montpellier F-34000, France. Electronic address: p-gelisse@chu-montpellier.fr.;Department of Clinical Neuroscience, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.;Neurology Department, Hôpital Saint Charles, 13100 Aix en Provence, France.;Epilepsy Unit, Hôpital Gui de Chauliac, Montpellier, France, Research Unit (URCMA: Unité de Recherche sur les Comportements et Mouvements Anormaux), INSERM, U661, Montpellier F-34000, France.;Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
656
Case Reports;Letter
en
Prone positioning and high-flow oxygen improved respiratory function in a 25-week pregnant woman with COVID-19.
Florence Vibert;Mathilda Kretz;Vincent Thuet;Florian Barthel;Fanny De Marcillac;Philippe Deruelle;Lise Lecointre
2020-05-13 02:00:00+02:00
32405137
FR
Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: florence.vibert@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: mathilda.kretz@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: vincent.thuet@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: florian.barthel@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: fanny.demarcillac@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: philippe.deruelle@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: lise.lecointre@chru-strasbourg.fr.
661
10.1016/j.accpm.2020.05.005
Journal Article
en
Preliminary pragmatic lessons from the SARS-CoV-2 pandemic in France.
https://www.ncbi.nlm.nih.gov/pubmed/32405518
The first wave of the SARS-CoV-2 pandemic required an unprecedented and historic increase in critical care capacity on a global scale in France. Authors and members from the ACUTE and REANIMATION committees of the French Society of Anaesthesia and Intensive Care (SFAR) wished to share experience and insights gained during the first weeks of this pandemic. These were summarised following the World Health Organization Response Checklist and detailed according to the subsequent subheadings: 1. Command and Control, 2. Communication, 3. Safety and Security, 4. Triage, 5. Surge Capacity, 6. Continuity of essential services, 7. Human resources, 8. Logistics and supply management, 9. Training/Preparation, 10. Psychological comfort for patients and next of kin, 11. Learning and 12. Post disaster recovery. These experience-based recommendations, consensual across all members from both committees of our national society, establish a practical framework for medical teams, either spared by the first wave of severe COVID patients or preparing for the second one.
2352-5568
2020-05-17 02:00:00+02:00
pubmed
Bed Conversion;Betacoronavirus;Checklist;Continuity of Patient Care__organization & administration;Coronavirus Infections__epidemiology;Disaster Planning__organization & administration;France__epidemiology;Health Personnel__education;Health Services Accessibility__organization & administration;Health Services Needs and Demand;Humans;Interdisciplinary Communication;Pandemics;Patient Safety;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Professional Staff Committees__organization & administration;Professional-Family Relations;Social Support;Triage__organization & administration;Workforce__organization & administration;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2
Anesthésie-Réanimation, Hôpital Beaujon, DMU PARABOL AP-HP Nord, Université de Paris, Paris, France.;Percy Military Training Hospital, Clamart, France Val-de-Grâce French Military Medical Academy, Paris, France.;Service d'Anesthésie-Réanimation Sud, Centre Médico-Chirurgical Magellan, Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000 Bordeaux, France.;Réanimation Chirurgicale et Polyvalente, Département d'Anesthésie-Réanimation, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.;Department of Anaesthesia and Intensive Care, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, France.;Grenoble Alps Trauma centre, Grenoble University Hospital, Grenoble Alps University, 38000 Grenoble, France.;Service d'Anesthésie-Réanimation & Médecine Péri-Opératoire, Hôpitaux Universitaires de Strasbourg-FMTS, Université de Strasbourg, Strasbourg, France. Electronic address: julien.pottecher@chru-strasbourg.fr.
664
10.1016/j.annemergmed.2020.05.018
Journal Article
en
Preparedness and response to Pediatric CoVID-19 in European Emergency Departments: a survey of the REPEM and PERUKI networks.
https://www.ncbi.nlm.nih.gov/pubmed/32419713
We aimed to describe the variability and identify gaps in preparedness and response to the COVID-19 pandemic in European EDs caring for children.
0196-0644
2020-05-17 02:00:00+02:00
pubmed
Annals of Emergency Medicine
Silvia Bressan;Danilo Buonsenso;Ruth Farrugia;Niccolo' Parri;Rianne Oostenbrink;Luigi Titomanlio;Damian Roland;Ruud G Nijman;Ian Maconochie;Liviana Da Dalt;Santiago Mintegi
2020-05-15 02:00:00+02:00
32419713
FR;ES;GB;IT;NL;MT
Division of Pediatric Emergency Medicine, Department of Women's and Children's Health - University Hospital of Padova, Italy.;Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Università Cattolica del Sacro Cuore, Roma, Italia.;Department of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta.;Emergency Department & Trauma Center, Ospedale Pediatrico Meyer Firenze, Florence, Italy.;Department general Pediatrics, ErasmusMC - Sophia, Rotterdam, The Netherlands.;Pediatric Emergency Department, Hopital Universitaire Robert-Debre, Paris, France.;SAPPHIRE Group, Health Sciences, Leicester University, Leicester, UK.;Department of Pediatric Emergency Medicine, Division of Medicine, St. Mary's hospital - Imperial College NHS Healthcare Trust, London, London, London, UK.;Faculty of Medicine, Department of Infectious Diseases, Section of Pediatric Infectious Diseases, Imperial College London, UK.;Pediatric Emergency Department, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces. University of the Basque Country, UPV/EHU. Bilbao, Basque Country, Spain.
Asthma;Asthme;COVID-19;Coronavirus 2019;Facteurs de risque;Risk factors;SARS-CoV-2
2020-05-15 02:00:00+02:00
32419737
FR
Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers, France. Electronic address: mike.underner@orange.fr.;Service de pneumologie, CHR de Metz-Thionville, 57038 Metz, France.;Dispensaire Emile-Roux, centre de tabacologie, 63100 Clermont-Ferrand, France.;Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers, France.
668
10.1016/j.dld.2020.03.031
Journal Article;Practice Guideline
en
COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
https://www.ncbi.nlm.nih.gov/pubmed/32418773
Patients treated for malignancy are considered at risk of severe COVID-19. This exceptional pandemic has affected countries on every level, particularly health systems which are experiencing saturation. Like many countries, France is currently greatly exposed, and a complete reorganization of hospitals is ongoing. We propose here adaptations of diagnostic procedures, therapies and care strategies for patients treated for digestive cancer during the COVID-19 epidemic.
Frederic Di Fiore;Olivier Bouché;Come Lepage;David Sefrioui;Alice Gangloff;Lilian Schwarz;Jean Jacques Tuech;Thomas Aparicio;Thierry Lecomte;Camille Boulagnon-Rombi;Astrid Lièvre;Sylvain Manfredi;Jean Marc Phelip;Pierre Michel
COVID-19 infection;Chemotherapy;Digestive cancer;French Clinical Practice Guidelines;Surgery
2020-05-14 02:00:00+02:00
32418773
FR
Department of Hepatogastroenterology, Normandie Université, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, F 76000 Rouen, France. Electronic address: frederic.di-fiore@chu-rouen.fr.;Digestive Oncology, CHU Reims, University Reims Champagne Ardennes, France.;Hepato-Gastroenterology Department, University Hospital Le Bocage, EPICAD INSERM LNC-UMR 1231, Université de Bourgogne et Franche Comté, Dijon, France.;Department of Hepatogastroenterology, Normandie Université, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, F 76000 Rouen, France.;Department of Digestive Surgery, Normandie Université, UNIROUEN, Inserm U1245, IRON group, F 76000 Rouen, France.;Gastroenterology and Digestive Oncology, Saint Louis Hospital, APHP, Université de Paris, Paris, France.;Gastroenterology and Endoscopy Department, Trousseau Hospital, University F Rabelais Tours, France.;Pathology, CHU Reims, University Reims Champagne Ardennes, France.;Rennes 1 University, Rennes, France, Association pour le Dépistage des Cancers en Ille-et-Vilaine, ADECI35, Rennes, France, Department of Gastroenterology, CHU Pontchaillou, Rennes, France, INSERM UMR 1242, COSS "Chemistry, Oncogenesis, Stress Signaling", Rennes, France.;Department of Gastroenterology and Digestive Oncology, University Hospital of Saint Etienne, Saint Etienne, France.;Department of Hepatogastroenterology, Normandie Université, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, F 76000 Rouen, France. Electronic address: pierre.michel@chu-rouen.fr.
677
10.1111/eje.12542
Journal Article
en
COVID-19: The immediate response of european academic dental institutions and future implications for dental education.
https://www.ncbi.nlm.nih.gov/pubmed/32394605
The COVID-19 pandemic has had an immediate and dramatic impact on dental education. The Association of Dental Education in Europe decided to carry out an investigation to assess the immediate response of European Academic Dental Institutions. An online survey was sent to both member and non-member dental schools to investigate the impact on non-clinical and clinical education, assessment and the well-being/pastoral care measures implemented. The preliminary findings and discussion are presented in this paper, for the responses collected between the 25 March and 5 April 2020. The survey at this time of publication is ongoing, and detailed results can be accessed https://adee.org/covid-19-european-dental-education%E2%80%99s-immediate-response.
King's College London, Faculty of Dentistry, Oral and Craniofacial Sciences, London, UK.;Cardiff University, Sheffield, UK.;Academisch Centrum Tandheelkunde Amsterdam, Amsterdam, Netherlands.;Riga Stradins University, Riga, Latvia.;University of Barcelona, Barcelona, Spain.;University of Brescia, Brescia, Italy.;Malmo University, Malmo, Sweden.;Semmelweis University, Budapest, Hungary.;Centre for Research in Higher Education Policies, University of Porto and Case Western Reserve University, Cleveland, OH, USA.;University of Freiburg, Freiburg, Germany.;University of Paris, Paris, France.;Dental Education in Europe, Dublin, Ireland.;University Clermont Auvergne, Clermont-Ferrand, France.
691
Letter
en
Cerebral venous thrombosis associated with COVID-19 infection: Causality or coincidence?
Department of Neuroradiology, Adolphe de Rothschild Foundation Hospital, 29, rue Manin, 75019 Paris, France. Electronic address: gpoillon@for.paris.;Department of Neurology, Adolphe de Rothschild Foundation Hospital, Paris, France.;Neuro-Intensive Care Unit, Adolphe de Rothschild Foundation Hospital, Paris, France.;Department of Neuroradiology, Adolphe de Rothschild Foundation Hospital, 29, rue Manin, 75019 Paris, France.
693
10.1016/j.purol.2020.05.001
Journal Article;Multicenter Study
fr
[Impact of the COVID-19 pandemic on surgical activity within academic urological departments in Paris].
https://www.ncbi.nlm.nih.gov/pubmed/32430140
As a result of the COVID-19 pandemic in France, all non-emergency surgical activity has been cancelled since March 12, 2020. In order to anticipate the reinstatement of delayed interventions, surgical activity reduction analysis is essential. The objective of this study was to evaluate the reduction of urological surgery in adult during the COVID-19 pandemic compared to 2019.
Sorbonne Paris-Nord University (Paris 13), Bobigny, France, Inserm, UMR 1135 CIMI, Paris, France, APHP, HUPSSD, Internal medicine department, Bondy, France. Electronic address: simonetunesi88@gmail.com.;Sorbonne Paris-Nord University (Paris 13), Bobigny, France, Inserm, UMR 1135 CIMI, Paris, France, APHP, HUPSSD, Internal medicine department, Bondy, France.
717
10.3389/fmed.2020.00223
Journal Article
en
COVID-19: The Conjunction of Events Leading to the Coronavirus Pandemic and Lessons to Learn for Future Threats.
https://www.ncbi.nlm.nih.gov/pubmed/32574324
2296-858X
2020-05-17 02:00:00+02:00
pubmed
Frontiers in Medicine
Roger Frutos;Marc Lopez Roig;Jordi Serra-Cobo;Christian A Devaux
Cirad, UMR 17, Intertryp, Montpellier, France.;IES, UMR 5214 Univ. Montpellier-CNRS, Montpellier, France.;Department of Evolutionary Biology, Ecology and Environmental Sciences, Biodiversity Research Institute, University of Barcelona, Barcelona, Spain.;IHU-Méditerranée Infection and CNRS, Marseille, France.
718
10.1111/ene.14316
Journal Article
en
Impact of the COVID-19 outbreak on acute stroke pathways - insights from the Alsace region in France.
https://www.ncbi.nlm.nih.gov/pubmed/32399995
To date, no study has attempted to quantify the impact of the COVID-19 outbreak on the incidence and treatment of acute stroke.
1351-5101,1468-1331
2020-05-17 02:00:00+02:00
pubmed
European Journal of Neurology
R Pop;V Quenardelle;A Hasiu;D Mihoc;F Sellal;M H Dugay;P A Lebedinsky;E Schluck;A LA Porta;S Courtois;R Gheoca;V Wolff;R Beaujeux
Interventional Neuroradiology Department, Strasbourg University Hospitals, Strasbourg, France.;Institut de Chirurgie Minime Invasive Guidée par l'Image, Strasbourg, France.;Stroke Unit, Strasbourg University Hospitals, Strasbourg, France.;Neurology Department, Hôpitaux Civils de Colmar, Colmar, France.;Interventional Neuroradiology Department, Hôpitaux Civils de Colmar, Colmar, France.;Neurology Department, Mulhouse and South Alsace Region Hospital Group, Mulhouse, France.
720
Letter
en
Protecting the Prehospital Professional First Aid Teams from Airborne Viral Particles in the Case of Out-of-Hospital Pediatric Cardiac Arrest during the COVID-19 Pandemic.
Paris Fire Brigade, Medical Emergency Department, Paris, France.
725
10.1111/bju.15071
Journal Article;Review
en
COVID-19 and urology: a comprehensive review of the literature.
https://www.ncbi.nlm.nih.gov/pubmed/32249538
To discuss the impact of COVID-19 on global health, particularly on urological practice and to review some of the available recommendations reported in the literature.
Urology Department, University of Modena and Reggio Emilia, Modena, Italy.;ORSI Academy, Melle, Belgium.;Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium.;Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.;Microbiology and Virology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.;Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.;Global Robotics Institute, Florida Hospital-Celebration Health Celebration, University of Central Florida School of Medicine, Orlando, FL, USA.;Department of Urology, Karolinska University Hospital, Stockholm, Sweden.;Department of urology, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil.;Chirurgie Urologique, CHU de Bordeaux, France.;Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.;MRC Centre for Transplantation, King's College London, King's Health Partners, London, UK.
Translational Approach to Epithelial Injury and Repair, GReD, CNRS, INSERM, Université Clermont Auvergne, Clermont-Ferrand, France.;Ophthalmology, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.;Physiological and Psychosocial Stress, LaPSCo, CNRS, Université Clermont Auvergne, Clermont-Ferrand, France.;Preventive and Occupational Medicine, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Witty Fit, Clermont-Ferrand, France.
727
10.5152/eurjrheum.2020.2062
Journal Article
en
Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation.
https://www.ncbi.nlm.nih.gov/pubmed/32412405
2147-9720,2148-4279
2020-05-17 02:00:00+02:00
pubmed
European Journal of Rheumatology
Pierre Miossec
2020-05-11 02:00:00+02:00
32412405
FR
Departments of Immunology and Rheumatology, University of Lyon, Lyon, France.
729
Letter;Research Support, Non-U.S. Gov't;Comment
en
Organ procurement and transplantation during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32407668
2020-05-17 02:00:00+02:00
pubmed
Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Tissue and Organ Procurement;COVID-19;severe acute respiratory syndrome coronavirus 2
Alexandre Loupy;Olivier Aubert;Peter P Reese;Olivier Bastien;Florian Bayer;Christian Jacquelinet
2020-05-11 02:00:00+02:00
32407668
FR;US
Paris University, Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: alexandre.loupy@inserm.fr.;Paris University, Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Paris University, Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.;Agence de la Biomédecine, Saint Denis la Plaine, France.;Agence de la Biomédecine, Saint Denis la Plaine, France, INSERM U1018, Center for Research in Epidemiology and Population Health, Université Paris Sud, Villejuif, France.
731
10.1016/j.therap.2020.05.006
Journal Article
en
Diabetes and COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32425249
According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many research data on antidiabetic drugs in this context. The potential influence of glucose-lowering agents on the severity of COVID-19 has not been described yet. Dipeptidylpeptidase-4 (DPP-4) is a cell surface protein ubiquitously expressed in many tissues and it is also a soluble molecule found in serum/plasma fluids. DPP-4 is involved in infection of cells by some viruses. This paper reviews data about the use of DPP-4 inhibitors and others diabetes drugs on COVID-19 patients. As such, no available evidence has yet suggested that glucose-lowering drugs - including those targeting DPP4-related pathways - produce any significant harm or benefit in the context of human infections. However, insulin must remain the first-choice agent in the management of critically ill-hospitalized patients, while it is recommended to suspend other agents in unstable patients. This paper provides related French and international recommendations for people with diabetes who got infected by COVID-19 and upholds that infections may alter glucose control and may require additional vigilance.
Service d'hypertension artérielle et thérapeutique PCVM, UMR 1027, université de Toulouse 3, CHU de Rangueil, 31059 Toulouse, France. Electronic address: duly-bouhanick.b@chu-toulouse.fr.;INSERM, HP2, centre régional de pharmacovigilance et centre d'investigation clinique de Grenoble, université de Grenoble-Alpes, 38000 Grenoble, France.;Département de pharmacologie médicale et toxicologie, centre régional de pharmacovigilance Occitanie-Est, université de Montpellier, CHU de Montpellier, 34295 Montpellier, France.
735
Medical Research Council
10.1016/s2213-2600(20)30230-7
Journal Article;Review
en
Tracheostomy in the COVID-19 era: global and multidisciplinary guidance.
https://www.ncbi.nlm.nih.gov/pubmed/32422180
Global health care is experiencing an unprecedented surge in the number of critically ill patients who require mechanical ventilation due to the COVID-19 pandemic. The requirement for relatively long periods of ventilation in those who survive means that many are considered for tracheostomy to free patients from ventilatory support and maximise scarce resources. COVID-19 provides unique challenges for tracheostomy care: health-care workers need to safely undertake tracheostomy procedures and manage patients afterwards, minimising risks of nosocomial transmission and compromises in the quality of care. Conflicting recommendations exist about case selection, the timing and performance of tracheostomy, and the subsequent management of patients. In response, we convened an international working group of individuals with relevant expertise in tracheostomy. We did a literature and internet search for reports of research pertaining to tracheostomy during the COVID-19 pandemic, supplemented by sources comprising statements and guidance on tracheostomy care. By synthesising early experiences from countries that have managed a surge in patient numbers, emerging virological data, and international, multidisciplinary expert opinion, we aim to provide consensus guidelines and recommendations on the conduct and management of tracheostomy during the COVID-19 pandemic.
Brendan A McGrath;Michael J Brenner;Stephen J Warrillow;Vinciya Pandian;Asit Arora;Tanis S Cameron;José Manuel Añon;Gonzalo Hernández Martínez;Robert D Truog;Susan D Block;Grace C Y Lui;Christine McDonald;Christopher H Rassekh;Joshua Atkins;Li Qiang;Sébastien Vergez;Pavel Dulguerov;Johannes Zenk;Massimo Antonelli;Paolo Pelosi;Brian K Walsh;Erin Ward;You Shang;Stefano Gasparini;Abele Donati;Mervyn Singer;Peter J M Openshaw;Neil Tolley;Howard Markel;David J Feller-Kopman
2020-05-15 02:00:00+02:00
32422180
FR;CN;BO;GB;US;HK;CH;IT;AU;ES;DE
[{"country": "United Kingdom", "agency": "Medical Research Council", "grantid": "MR/T50256X/1"}]
Manchester University NHS Foundation Trust, Manchester, UK, Manchester Academic Critical Care, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK.;University of Michigan, Ann Arbor, USA.;Austin Health, Melbourne, VIC, Australia.;Johns Hopkins University, Baltimore, MD, USA.;Guy's and St Thomas' NHS Foundation Trust, London, UK.;La Paz-Carlos III University Hospital, IdiPAZ, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.;Virgen de la Salud Hospital, Health Service of Castilla-La Mancha, Toledo, Spain.;Center for Bioethics, Harvard Medical School, Boston, MA, USA, Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.;Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.;Austin Health, Institute for Breathing and Sleep (IBAS), Melbourne, VIC, Australia.;University of Pennsylvania, Philadelphia, PA, USA.;East Hospital of Shanghai, TongJi University, Shanghai, China.;University Hospital Rangueil-Larrey, Toulouse, France.;Hôpital de la Tour, Meyrin, Geneva University, Geneva, Switzerland.;Universitätsklinikum Augsburg Klinik für HNO-Heilkunde, Augsburg, Germany.;Dipartimento di Scienze dell' Emergenza Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.;Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy, Anesthesia and Intensive Care, San Martino Policlinico Hospital, Genoa, Italy.;Liberty University, Lynchburg, VA, USA.;Tracheostomy Team, Institute for Professionalism and Ethical Practice, Boston Children's Hospital, Boston, MA, USA.;Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Region - Azienda Ospedali Riuniti, Ancona, Italy.;University College London, London, UK.;National Heart and Lung Institute, Imperial College of London, London, UK.;Imperial College Healthcare NHS Trust, London, UK.;Johns Hopkins University, Baltimore, MD, USA. Electronic address: dfk@jhmi.edu.
738
10.1007/s10029-020-02212-8
Journal Article
en
European Hernia Society (EHS) guidance for the management of adult patients with a hernia during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32415652
1265-4906,1248-9204
2020-05-17 02:00:00+02:00
pubmed
Hernia
C Stabilini;B East;R Fortelny;J-F Gillion;R Lorenz;A Montgomery;S Morales-Conde;F Muysoms;M Pawlak;W Reinpold;M Simons;A C de Beaux
2020-05-15 02:00:00+02:00
32415652
FR;SE;GB;US;IT;NL;CZ;ES;DE;BE;AT
Department of Surgery, University of Genoa, Policlinico San Martino, Largo R. Benzi 8, 16132, Genoa, Italy. cesarestabil@hotmail.com.;3rd Department of Surgery at 1st Faculty of Medicine at Charles University, Motol University Hospital, Prague, Czech Republic.;2nd Faculty of Medicine, Charles University, Prague, Czech Republic.;Department of General, Visceral and Oncologic Surgery, Wilhelminenspital, Vienna, Austria.;Hôpital Privé d'Antony, 1 rue Velpeau, 92160, Antony, France.;Hernia Center, CHIRURGEN 3+, Berlin, Germany.;Department of Surgery, Lund University, Skåne University Hospital, Malmö, Sweden.;Unit of Innovation in Minimally Invasive Surgery, University Hospital Virgen del Rocio, University of Sevilla, Seville, Spain.;Unit of General and Digestive Surgery, Hospital Quironsalud Sagrado Corazón (Sevilla), Seville, Spain.;Department of Surgery, Maria Middelares Hospital, Ghent, Belgium.;Northern Devon Healthcare NHS Trust, Barnstaple, UK.;Department of Surgery, Wilhelmsburger Hospital Gross Sand, Academic Teaching Hospital of University Hamburg, Hamburg, Germany.;Department of Surgery, OLVG Hospital, Oosterpark 9, 1091 AC, Amsterdam, The Netherlands.;Department of General Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.
744
10.1007/s00134-020-06088-1
Journal Article
en
Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.
EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France.;UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris, France.;EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France. agnes.veyradier@aphp.fr.
745
Letter;Comment
en
Transesophageal Echocardiography Remains Essential and Safe during Prone Ventilation for Hemodynamic Monitoring of Patients with COVID-19.
Réanimation Polyvalente, CHU Dupuytren, Limoges, France.;Réanimation Polyvalente, CHU Dupuytren, Limoges, France, Inserm CIC 1435 and UMR 1092, CHU Dupuytren, Limoges, France, Faculté de Médecine, Université de Limoges, Limoges, France.
749
Case Reports;Letter
en
COVID-19 as a cause of immune thrombocytopenia.
https://www.ncbi.nlm.nih.gov/pubmed/32445664
2020-05-24 02:00:00+02:00
pubmed
Adrenal Cortex Hormones__therapeutic use;Aged, 80 and over;Betacoronavirus__immunology;Coronavirus Infections__complications;Humans;Male;Pandemics;Pneumonia, Viral__complications;Prognosis;Purpura, Thrombocytopenic, Idiopathic__diagnosis;Seroconversion__physiology;Severity of Illness Index;Time-to-Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2
S Humbert;J Razanamahery;C Payet-Revest;K Bouiller;C Chirouze
COVID-19;Immune thrombocytopenia;SARS-CoV-2
2020-05-20 02:00:00+02:00
32445664
FR
Internal Medicine Department, Besancon University Hospital, Besançon, France. Electronic address: shumbert@chu-besancon.fr.;Internal Medicine Department, Besancon University Hospital, Besançon, France.;Infectious Diseases Department, Besancon University Hospital, Besançon, France.
755
10.1159/000508512
Journal Article;Multicenter Study
en
Urology in the Time of Coronavirus: Reduced Access to Urgent and Emergent Urological Care during the Coronavirus Disease 2019 Outbreak in Italy.
https://www.ncbi.nlm.nih.gov/pubmed/32434207
The coronavirus disease 2019 (COVID-19) pandemic has put a substantial burden on the Italian healthcare system, resulting in the restructuring of hospitals to care for COVID-19 patients. However, this has likely impacted access to care for patients experiencing other conditions. We aimed to quantify the impact of COVID-19 on access to care for patients with urgent/emergent urological conditions throughout Italy.
Angelo Porreca;Michele Colicchia;Daniele D'Agostino;Michele Amenta;Alfio Corsaro;Stefano Zaramella;Luisa Zegna;Fabrizio Gallo;Maurizio Schenone;Giorgio Bozzini;Alberto Calori;Antonio L Pastore;Yazan Al Salhi;Carmine Sciorio;Lorenzo Spirito;Virginia Varca;Carlo Marenghi;Francesco Greco;Vincenzo M Altieri;Paolo Verze;Ciro Barba;Alessandro Antonelli;Maria A Cerruto;Roberto Falabella;Silvana Di Bello;Costantino Leonardo;Antonio Tufano;Alessandro Volpe;Paolo Umari;Paolo Parma;Mattia Nidini;Giovannalberto Pini;Marco Borghesi;Carlo Terrone;Giovanni E Cacciamani;Maria C Sighinolfi;Gian Maria Busetto;Alexandra M Wennberg;Marinella Finocchiaro;Mario Falsaperla;Marco Oderda;Carlo Ceruti;Bernardo Rocco;Riccardo Schiavina;Lorenzo Bianchi;Andrea Mari;Fabrizio Di Maida;Orietta Dalpiaz;Antonio Celia;Marco Pirozzi;Pierluigi Bove;Valerio Iacovelli;Angelo Cafarelli;Luca Cindolo;Giovanni Ferrari;Lorenzo Gatti;Giacomo Pirola;Filippo Annino;Luigi Pucci;Daniele Romagnoli;Walter Artibani;Andrea Minervini
Coronavirus disease 2019;Italy;Outbreak;Urological care
2020-05-20 02:00:00+02:00
32434207
FR;IT;US;AT
Department of Urology, Policlinico Abano Terme, Abano Terme, Italy.;Department of Urology, Policlinico Abano Terme, Abano Terme, Italy, michelecolicchia@gmail.com.;Department of Urology, Ospedale Civile di Portogruaro, Portogruaro, Italy.;Department of Urology, Biella Hospital, Ponderano, Italy.;Department of Surgery, Division of Urology, San Paolo Hospital, Savona, Italy.;Department of Urology, ASST Valle Olona, Busto Arsizio, Italy.;Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Urology Unit, ICOT Hospital Latina, Rome, Italy.;Urology Unit, Manzoni Hospital, Lecco, Italy.;Hospital G. Salvini, ASST Rhodense Garbagnate Milanese, Milan, Italy.;Department of Urology, Humanitas Gavazzeni, Bergamo, Italy.;Department of Urology, Scuola Medica Salernitana, University of Salerno, Salerno, Italy.;Department of Urology, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, Verona, Italy.;Department of Urology, Azienda Ospedaliera Regionale di Potenza, Potenza, Italy.;UO Pronto Soccorso, Accettazione, Medicina Urgenza, Azienda Ospedaliera Regionale di Potenza, Potenza, Italy.;Department of Urology, La Sapienza University of Rome, Rome, Italy.;Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.;Urology Department, ASST Mantova, Mantova, Italy.;Urologia Ospedale San Raffaele Turro, Milan, Italy.;Department of Urology, S. Martino Hospital, Department of Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy.;USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.;Urology Department, University of Modena and Reggio Emilia, Modena, Italy.;Department of Urology, Sapienza Rome University Policlinico Umberto I, Rome, Italy.;Department of Neurosciences (Padova Neuroscience Centre), Università degli Studi di Padova, Padova, Italy.;U.O.C. Urologia Ospedale Vittorio Emanuele, Catania, Italy.;Università di Torino, Città della Salute e della Scienza di Torino, Turin, Italy.;Department of Urology, University of Bologna, Bologna, Italy.;Department of Urology, University of Florence, Florence, Italy.;Department of Urology, Medical University of Graz, Graz, Austria.;Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.;Urology Unit, San Carlo Di Nancy Hospital, GVM Care and Research, Rome, Italy.;Department of Urology, Casa di Cura Villa Igea, Ancona, Italy.;Department of Urology, Villa Stuart Casa di Cura, Rome, Italy.;Department of Urology, Hesperia Hospital, Modena, Italy.;Department of Urology, San Donato Hospital, USL Toscana Sudest, Arezzo, Italy.;Department of Urology, AORN A. Cardarelli, Naples, Italy.
761
10.1016/j.therap.2020.05.009
Journal Article
en
Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32553503
Some concerns about the prescription of drugs acting on the renin-angiotensin system (angiotensin-converting enzyme 1 (ACE1) inhibitors, ACEi; angiotensin II type 1 receptor blockers, ARB) have emerged due to SARS COV2 and COVID-19 pandemic. These very legitimate questions are directly the consequence of the recent recognition of the fundamental role of ACE2 (angiotensin-converting enzyme 2) in COVID-19 infection. Indeed, SARS COV2 utilizes ACE2 as a membrane receptor to enter target cells. Consequently, the putative impact of drugs modulating the renin-angiotensin system on the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection emerged. As a membrane-bound enzyme (carboxypeptidase), ACE2 inactivates angiotensin II and therefore physiologically counters its effects. Due to a different structure compared with ACE1, ACE2 is insensitive to ACEIs. In vitro, both ARBs and ACEi appear able to upregulate ACE2 tissue expression and activity but these results were not confirmed in Humans. The exact impact of both ARBs and ACEis on COVID-19 infection is definitively known and preliminary results are even in favor of a protective role confers by these drugs. Due to the crucial role of ACE2, some groups support the hypothesis that a modulation of ACE2 expression could represent a valuable therapeutic target could confer protective properties against inflammatory tissue damage in COVID-19 infection. So, studies are currently ongoing to test the impact of elevated ACE2 membrane expression, administration of ARB and infusion of soluble ACE2. In summary, based on the currently available evidences and as recommended by several medical societies, ACEi or ARB should not be systematically discontinued because to date no safety signal was raised with the use of these drugs.
0040-5957
2020-05-24 02:00:00+02:00
pubmed
Therapies
Joachim Alexandre;Jean-Luc Cracowski;Vincent Richard;Béatrice Bouhanick
Arterial hypertension;Renin-angiotensin-aldosterone system
2020-05-20 02:00:00+02:00
32553503
FR
Service de pharmacologie, université de Caen-Normandie, UNICAEN, CHU de Caen Normandie, EA 4650, 14000 Caen, France. Electronic address: alexandre-j@chu-caen.fr.;University Grenoble Alpes, centre régional de pharmacovigilance de Grenoble, Inserm, HP2, 38000 Grenoble, France.;Service de pharmacologie, université de Rouen Normandie, UNIROUEN, CHU de Rouen Normandie, UMR Inserm U1096 EnVI, 76000 Rouen, France.;Service d'hypertension artérielle et thérapeutique PCVM, UMR 1027 université Toulouse 3, CHU Rangueil, 31000 Toulouse, France.
764
Letter;Comment
en
Surgical resection for liver cancer during the COVID-19 outbreak.
Department of Hepatobiliary and Digestive Surgery, Pontchaillou Hospital, Rennes 1 University, 35000, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou Hospital, Rennes 1 University, 35000, Rennes, France. karim.boudjema@chu-rennes.fr.
765
10.1007/s12350-020-02197-y
Journal Article
en
Increased lung signal as a hint of COVID-19 infection on Tc-99m-sestamibi myocardial perfusion scintigraphy.
https://www.ncbi.nlm.nih.gov/pubmed/32436114
1071-3581,1532-6551
2020-05-24 02:00:00+02:00
pubmed
Journal of Nuclear Cardiology
Pierre Delabie;Fabien Hyafil
2020-05-20 02:00:00+02:00
32436114
FR
Department of Nuclear Medicine, Centre Hospitalier Universitaire Bichat, Assistance Publique - Hôpitaux de Paris, Inserm, 1148, Université de Paris, Paris, France.;Department of Nuclear Medicine, Centre Hospitalier Universitaire Bichat, Assistance Publique - Hôpitaux de Paris, Inserm, 1148, Université de Paris, Paris, France. fabien.hyafil@aphp.fr.
766
10.1007/s12630-020-01704-6
Journal Article
en
A proposed lung ultrasound and phenotypic algorithm for the care of COVID-19 patients with acute respiratory failure.
https://www.ncbi.nlm.nih.gov/pubmed/32440906
Pulmonary complications are the most common clinical manifestations of coronavirus disease (COVID-19). From recent clinical observation, two phenotypes have emerged: a low elastance or L-type and a high elastance or H-type. Clinical presentation, pathophysiology, pulmonary mechanics, radiological and ultrasound findings of these two phenotypes are different. Consequently, the therapeutic approach also varies between the two. We propose a management algorithm that combines the respiratory rate and oxygenation index with bedside lung ultrasound examination and monitoring that could help determine earlier the requirement for intubation and other surveillance of COVID-19 patients with respiratory failure.
0832-610X,1496-8975
2020-05-24 02:00:00+02:00
pubmed
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
André Y Denault;Stéphane Delisle;David Canty;Alistair Royse;Colin Royse;Ximena Cid Serra;Caroline E Gebhard;Étienne J Couture;Martin Girard;Yiorgos Alexandros Cavayas;Nicolas Peschanski;Stéphan Langevin;Paul Ouellet
Division of Critical Care, Centre Hospitalier de l'Université Montréal, Montreal, QC, Canada. andre.denault@umontreal.ca.;Department of Anesthesiology and Critical Care Division, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, QC, Canada, H1T 1C8. andre.denault@umontreal.ca.;Département de médecine de famille et médecine d'urgence, Université de Montréal, Montreal, QC, Canada.;Collège Ellis, Trois-Rivières, QC, Canada.;Department of Surgery, University of Melbourne, Melbourne, Australia.;Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Australia.;Department of Medicine, Monash University, Melbourne, Australia.;Department of Anaesthesia and Perioperative Medicine, Monash Health, Melbourne, Australia.;Cardiothoracic Surgeon, Royal Melbourne Hospital, Melbourne, Australia.;Royal Melbourne Hospital, Melbourne, Australia.;Outcomes Research Consortium, Cleveland Clinic, Cleveland, USA.;Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.;Department of Anesthesiology and Department of Medicine, Division of Intensive Care Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC, Canada.;Université Laval, Quebec, QC, Canada.;Department of Anesthesiology and Division of Critical Care, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Critical Care, Hôpital Sacré-Coeur de Montréal and Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.;Emergency Department, University of Rennes 1, Rennes, France.;Emergency Physician, University Hospital of Rennes, Rennes, France.;Department of Surgery, Sherbrooke University, Sherbrooke, QC, Canada.;Clinical Consultant, Vitalité Health Network, Edmundston, NB, Canada.
774
Letter;Research Support, Non-U.S. Gov't
en
Prevalence of obesity among adult inpatients with COVID-19 in France.
CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France. Electronic address: cyrielle.caussy@chu-lyon.fr.;Université Lille, Inserm Pasteur Lille, Inserm U1190 European Genomic Institute of Diabetes, CHU Lille, Lille, France.;Medical Intensive Care Unit, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France.;CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France.;Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France.;Department of Intensive Care, CHU Lille, Lille, France.;Hospices Civils de Lyon, Service de Biostatistique, Lyon, France, Université Claude Bernard Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France.;Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Lyon, France, Equipe Virpath, Centre International de Recherche en Infectiologie, INSERM U1111 CNRS UMR 5308, ENS, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.;FCRIN/FORCE Network, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Lyon, France.;Laboratoire des Pathogènes Emergents-Fondation Mérieux, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon 1, Lyon, France, Centre National de La Recherche Scientifique, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Service D'Hygiène, Epidémiologie et Prévention, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.;CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France, FCRIN/FORCE Network, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Lyon, France.;CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France.
784
10.1016/j.jcv.2020.104447
Journal Article;Review
en
Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32425663
While SARS-CoV-2 infection has spread rapidly worldwide, data remains scarce about the natural history of infection in pregnant women and the risk of mother-to-fetal transmission. Current data indicates that viral RNA levels in maternal blood are low and there is no evidence of placental infection with SARS-CoV-2. Published reports to date suggest that perinatal transmission of SARSCoV- 2 can occur but is rare. Among 179 newborns tested for SARS-CoV2 at birth from mothers with COVID-19, transmission was suspected in 8 cases, 5 with positive nasopharyngeal SARS-CoV-2 RT-PCR and 3 with SARS-CoV-2 IgM. However, these cases arise from maternal infection close to childbirth and there are no information about exposition during first or second trimester of pregnancy. Welldesigned prospective cohort studies with rigorous judgement criteria are needed to determine the incidence and risk factors for perinatal transmission of SARS-CoV-2.
Service de gynécologie-obstétrique, Hôpital Louis Mourier, AP-HP, Université de PARIS, IAME INSERM U1137, Paris, France, IDMIT, CEA, IMVA INSERM U1184, Université Paris Saclay, Fontenay aux Roses, France. Electronic address: charles.egloff@cea.fr.;Service de Virologie, Hôpital Paul Brousse, AP-HP, Inserm U 1193, Université Paris Saclay, Villejuif, France.;Service de gynécologie-obstétrique, Hôpital Louis Mourier, AP-HP, Université de PARIS, IAME INSERM U1137, Paris, France.;IDMIT, CEA, IMVA INSERM U1184, Université Paris Saclay, Fontenay aux Roses, France. Electronic address: pierre.roques@cea.fr.
786
Letter
en
Teledermatology for COVID-19 cutaneous lesions: substitute or supplement?
https://www.ncbi.nlm.nih.gov/pubmed/32422693
2020-05-24 02:00:00+02:00
pubmed
C Skayem;C Cassius;M Ben Kahla;C Fiani;L Frumholtz;M Mrad;A Petit;E Zuelgaray;M Bagot;J D Bouaziz;T A Duong
2020-05-18 02:00:00+02:00
32422693
FR
Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.;Faculty of Medicine, Paris Diderot University, Paris, France.;Dermatology Department, AP-HP, Paris University, Saint-Louis Hospital, Paris, France.;INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Université de Paris, Paris, France.;Chaire Avenir Santé numérique, Equipe 8 IMRB U955, INSERM, Université Paris Est Créteil, Créteil, France.
787
10.1016/j.surg.2020.05.006
Journal Article
en
Surgical outcomes after systematic preoperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) screening.
Department of Digestive Surgery and Liver Transplantation, Croix Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.;Department of Digestive Surgery and Liver Transplantation, Croix Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France. Electronic address: mickael.lesurtel@chu-lyon.fr.
788
10.12688/f1000research.23843.1
Journal Article
en
A snapshot of the ongoing clinical research on COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32518636
The pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov and report the extent to which they have incorporated features that are desirable for generating high-quality evidence. On April 28, 2020, a total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov; 586 studies are interventional (62.0%), the most frequent allocation scheme is the parallel group assignment (437; 74.6%), they are open-label and the most common primary purpose is the research on treatment. Too many of the ongoing interventional studies have a small expected sample size and may not generate credible evidence at completion. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.
2046-1402
2020-05-24 02:00:00+02:00
pubmed
Betacoronavirus;Biomedical Research__trends;Clinical Trials as Topic;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, Italy.;Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, 20089, Italy.;Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France.
789
10.3390/jcm9051521
Journal Article;Review
en
SARS-CoV-2 in Pregnancy: A Comprehensive Summary of Current Guidelines.
https://www.ncbi.nlm.nih.gov/pubmed/32443538
Since the declaration of the global pandemic of COVID-19 by the World Health Organization on 11 March 2020, we have continued to see a steady rise in the number of patients infected by SARS-CoV-2. However, there is still very limited data on the course and outcomes of this serious infection in a vulnerable population of pregnant patients and their fetuses. International perinatal societies and institutions including SMFM, ACOG, RCOG, ISUOG, CDC, CNGOF, ISS/SIEOG, and CatSalut have released guidelines for the care of these patients. We aim to summarize these current guidelines in a comprehensive review for patients, healthcare workers, and healthcare institutions. We included 15 papers from 10 societies through a literature search of direct review of society's websites and their journal publications up till 20 April 2020. Recommendations specific to antepartum, intrapartum, and postpartum were abstracted from the publications and summarized into Tables. The summary of guidelines for the management of COVID-19 in pregnancy across different perinatal societies is fairly consistent, with some variation in the strength of recommendations. It is important to recognize that these guidelines are frequently updated, as we continue to learn more about the course and impact of COVID-19 in pregnancy.
Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.;Obstetrics Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.;Department of Obstetrics and Gynecology, Escola Paulista de Medicina - Universidade Federal de São Paulo, São Paulo 04021, Brazil.;Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), CNGOF, Service de Gynécologie-Obstétrique Colombes, Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Université de Paris, Inserm IAME-U1137, 75000 Paris, France.;Fetal Medicine Centre, Birmingham Women's and Children's Foundation Trust, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.;.Catalan Health Service, Government of Catalonia, Barcelona 080028, Spain.;Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, 080028 Barcelona, Spain.;Prenatal Diagnostic Division, Department of Obstetrics and Gynecology, AUSL di Reggio Emilia Istituto di Ricerca a Carattere Clinico Scientifico, 42100 Reggio Emilia, Italy.
792
Letter
en
Encephalopathy in patients with COVID-19: 'Causality or coincidence?'
https://www.ncbi.nlm.nih.gov/pubmed/32427357
The main tropism of the novel coronavirus disease 2019 (COVID-19) is respiratory. Increasing evidences show that SARS-CoV-2 is not always confined to the respiratory tract but can also invade the central nervous system (CNS) and induce neurological diseases. We report two cases illustrating this phenomenon. This article is protected by copyright. All rights reserved.
2020-05-24 02:00:00+02:00
pubmed
Souheil Zayet;Yousri Ben Abdallah;Pierre-Yves Royer;Lynda Toko-Tchiundzie;Vincent Gendrin;Timothee Klopfenstein
Coronavirus;Nervous system;SARS coronavirus
2020-05-19 02:00:00+02:00
32427357
FR
Nord Franche-Comté Hospital, Department of Infectious Diseases, Trevenans, 90400, France.;Nord Franche-Comté Hospital, Department of Pneumology, Trevenans, 90400, France.
798
10.1016/j.amp.2020.05.002
English Abstract;Journal Article
fr
[Jail incarceration, social sanitary confinement and ways of escape].
https://www.ncbi.nlm.nih.gov/pubmed/32836295
Jail incarceration and social confinement due to a sanitary stay-at-home law against the ongoing COVID-19 pandemic are compared to the introduction of dance workshops for imprisoned women charged with long sentences, then followed by an outside performance Soul Kitchen. The whole experience, organized by a famous contemporary choreographer Angelin Preljocaj, is filmed by Valérie Müller, producing Danser sa peine (To dance her sentence/her sorrow), nominated for an award. The sessions are planned: two hours and a half, 2 times a week, for four months, no technique required. A group of five women start with ordinary easy functional movements, gaining in innovative and expressive qualities, spatial perceptions, feelings and interpersonal interactions, lead by A. Preljocaj in a helpful and empathic mood. At the same time, he discovers the cooking authorization in their jail cell. The relevant results shift into a dynamic successful piece Soul Kitchen (2019) performed in town (Dance Festival in Montpellier, south of France) with dancing and cooking occurrences on stage. It makes sense, specially about self-esteem, body image and positive opinion from the audience. The women's physical and psychological states linked with a long lack of space and sensitivity… move to a better self-balance and feelings of well-being. In a similar state of mind, the French confined population - youth to elderly - try to find different and imaginative strategies at home as moving in a restrictive area, enjoying family cooking… through trainings provided by Internet, looking for reducing anxiety, depressive disorders and other social problems. A panel of situations goes from deleterious conflictual relationships, dramatic isolation, to funny and positive ones using creativeness to escape, facing the disruption of daily life.
Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, France.;Institute of Functional Genomics, CNRS UMR 5203, INSERM U1191, University of Montpellier, France.;INSERM Clinical Investigation Centre 1411, Montpellier, France.
805
10.3390/diagnostics10050319
Journal Article
en
Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis.
https://www.ncbi.nlm.nih.gov/pubmed/32438677
The emergence of Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 made imperative the need for diagnostic tests that can identify the infection. Although Nucleic Acid Test (NAT) is considered to be the gold standard, serological tests based on antibodies could be very helpful. However, individual studies are usually inconclusive, thus, a comparison of different tests is needed. We performed a systematic review and meta-analysis in PubMed, medRxiv and bioRxiv. We used the bivariate method for meta-analysis of diagnostic tests pooling sensitivities and specificities. We evaluated IgM and IgG tests based on Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence Enzyme Immunoassays (CLIA), Fluorescence Immunoassays (FIA), and the Lateral Flow Immunoassays (LFIA). We identified 38 studies containing data from 7848 individuals. Tests using the S antigen are more sensitive than N antigen-based tests. IgG tests perform better compared to IgM ones and show better sensitivity when the samples were taken longer after the onset of symptoms. Moreover, a combined IgG/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody alone. All methods yield high specificity with some of them (ELISA and LFIA) reaching levels around 99%. ELISA- and CLIA-based methods perform better in terms of sensitivity (90%-94%) followed by LFIA and FIA with sensitivities ranging from 80% to 89%. ELISA tests could be a safer choice at this stage of the pandemic. LFIA tests are more attractive for large seroprevalence studies but show lower sensitivity, and this should be taken into account when designing and performing seroprevalence studies.
2075-4418
2020-05-24 02:00:00+02:00
pubmed
Diagnostics
Panagiota I Kontou;Georgia G Braliou;Niki L Dimou;Georgios Nikolopoulos;Pantelis G Bagos
COVID-19;ELISA;IgG;IgM;SARS-CoV-2;antibody test
2020-05-19 02:00:00+02:00
32438677
FR;GR;CY
Department of Computer Science and Biomedical Informatics, University of Thessaly, Papasiopoulou 2-4, 35131 Lamia, Greece.;International Agency for Research on Cancer, 69372 Lyon, France.;Medical School, University of Cyprus, 1678 Nicosia, Cyprus.
807
10.12890/2020_001728
Journal Article
en
Respiratory Distress in SARS-CoV-2 without Lung Damage: Phrenic Paralysis Should Be Considered in COVID-19 Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32523929
We describe an overweight COVID-19 patient with respiratory distress preceded by anosmia/dysgeusia with no lung injury shown on CT, angio-CT or ventilation/perfusion scans. Orthopnoea and paradoxical abdominal respiration were identified. Phrenic paralysis, demonstrated by examination of patient breathing, and on x-ray while standing breathing in and out, explained the respiratory distress. This is a rare and previously undescribed neurological complication of COVID-19 infection caused by vagus nerve injury.
Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
https://www.ncbi.nlm.nih.gov/pubmed/32450109
0140-6736
2020-05-24 02:00:00+02:00
pubmed
The Lancet
Christian Funck-Brentano;Joe-Elie Salem
2020-05-22 02:00:00+02:00
32450109
FR
AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France. Electronic address: christian.funck-brentano@aphp.fr.;AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France.
812
10.1016/j.anorl.2020.05.006
Journal Article
en
How and why use the EasyBreath® surface snorkeling mask as a personal protective equipment during the COVID-19 pandemic?
https://www.ncbi.nlm.nih.gov/pubmed/32493648
During the COVID-19 outbreak, personal protective equipment is widely used to limit infection of caregivers. Innovative solutions have been described to overcome supply shortage. The adaptation of the EasyBreath® surface snorkeling mask by the Prakash team has benefited from outstanding media coverage. We present four 3D-printed devices that we have modified from the initial innovative design in order to adapt to local constraints. We tested the mask during surgery. The modifications that we made provide better ergonomics, visibility and communication capacities, but that have no official approval for use and can therefore only be recommended in the absence of a validated alternative solution. 3D printing is a tool of prime importance in the production of devices for medical use in health crisis situations.
1879-7296
2020-05-24 02:00:00+02:00
pubmed
European Annals of Otorhinolaryngology, Head and Neck Diseases
B Thierry;C Célérier;F Simon;C Lacroix;R-H Khonsari
3D printing;COVID-19;Personal protective equipment;SARS-CoV-2;Tracheostomy
2020-05-23 02:00:00+02:00
32493648
FR
Pediatric ENT Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, 149, rue de Sèvres, 75015 Paris, France. Electronic address: briac.thierry@aphp.fr.;Pediatric ENT Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, 149, rue de Sèvres, 75015 Paris, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, Paris, France.;Department of Pediatric Maxillofacial and Plastic Surgery, Head and Neck Surgery, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, Paris, France.
815
10.1016/j.therap.2020.05.010
Journal Article
en
Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.
https://www.ncbi.nlm.nih.gov/pubmed/32473812
Chloroquine and hydroxychloroquine are drugs that have shown in vitro activity on the replication of certain coronaviruses. In the context of the SARS-Cov-2 epidemic, the virus responsible for the novel coronavirus disease (COVID-19), these two drugs have been proposed as possible treatments. The results of the first clinical studies evaluating the effect of hydroxychloroquine do not support any efficacy of this drug in patients with COVID-19, due to major methodological weaknesses. Yet, these preliminary studies have aroused considerable media interest, raising fears of massive and uncontrolled use. In the absence of evidence of clinical benefits, the main risk is of exposing patients unnecessarily to the well-known adverse effects of hydroxychloroquine, with a possibly increased risk in the specific setting of COVID-19. In addition, widespread use outside of any recommendation risks compromising the completion of good quality clinical trials. The chloroquine hype, fueled by low-quality studies and media announcements, has yielded to the implementation of more than 150 studies worldwide. This represents a waste of resources and a loss of opportunity for other drugs to be properly evaluated. In the context of emergency, rigorous trials are more than ever needed in order to have, as soon as possible, reliable data on drugs that are possibly effective against the disease. Meanwhile, serious adverse drug reactions have been reported in patients with COVID-19 receiving hydroxychloroquine, justifying to limit its prescription, and to perform suitable cardiac and therapeutic drug monitoring.
0040-5957
2020-05-24 02:00:00+02:00
pubmed
Therapies
M Roustit;R Guilhaumou;M Molimard;M-D Drici;S Laporte;J-L Montastruc
Pharmacologie clinique, Université Grenoble Alpes, CHU de Grenoble, 38043 Grenoble, France. Electronic address: mroustit@chu-grenoble.fr.;Aix Marseille Université, hôpital de la Timone, institut de neuroscience des systèmes, 13005 Marseille, France.;Service de pharmacologie médicale, University Bordeaux, Inserm U1219, 33076 Bordeaux, France.;Pharmacovigilance - Department of Pharmacology, Pasteur Hospital, 06001 Nice, France.;Université Jean Monnet, Université de Lyon, et unité de recherche clinique, innovation, pharmacologie, CHU Saint-Etienne, 42055 Saint-Étienne, France.;Service de pharmacologie médicale et clinque, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, faculté de Médecine, centre hospitalier universitaire de Toulouse, 31000 Toulouse, France.
821
10.1016/j.resmer.2020.100769
Practice Guideline
en
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32563968
The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.
Department of Medical Oncology, Institut Curie, 75005 Paris, France. Electronic address: Nicolas.girard2@curie.fr.;Aix-Marseille Université, AP-HM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, 13915 Marseille, France.;Department of Thoracic Oncology, CIC 1425, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France.;Department of Thoracic Oncology, AP-HP, Hôpital Tenon, 75020 Paris, France.;Department of Pneumology, University Hospital of Grenoble, 38043 Grenoble, France.;Department of Pneumology, University Hospital of Toulouse, 31059 Toulouse, France.;Department of Pneumology, Hôpital Sainte-Musse, 83100 Toulon, France.;Department of Medical Oncology, University Hospital of Nantes, 44000 Nantes, France.;Department of Medical Oncology, Institut Gustave-Roussy, 94800 Villejuif, France.;Department of Pneumology, University Hospital of Lille, 59000 Lille, France.;Department of Pneumology and Thoracic Oncology, University Hospital of Lyon, 69002 Lyon, France.;Department of Thoracic Oncology, AP-HP, Hôpital Ambroise-Paré, 92100 Boulogne-Billancourt, France.;Department of Pneumology and Thoracic Oncology, University Hospital of Besançon, INSERM UMR 1098, Université de Franche-Comté, 25000 Besançon, France.;Department of Thoracic Oncology, AP-HP, Hôpital Cochin, Inserm UMR_S 1138, Université de Paris, 75014 Paris, France.
824
Letter;Comment
en
Psychotic relapse from COVID-19 quarantine, a case report.
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain. Electronic address: serj.sad@gmail.com.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain, Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain, Department of Psychiatry, General Hospital of Villalba, Madrid, Spain, Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain, Universidad Católica del Maule, Talca, Chile, Department of Psychiatry. Centre Hospitalier Universitaire de Nîmes, Spain.
826
Case Reports;Letter
en
Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.
Mrinal M Patnaik;Terra Lasho;Eric Padron;Kristen McCullough;Aref Al-Kali;Ayalew Tefferi;Amer M Zeidan;Naseema Gangat;Michael Savona;David P Steensma;Eric Solary
2020-05-22 02:00:00+02:00
32356322
FR;US
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.;Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.;Section of Hematology, Department of Internal Medicine , School of Medicine, Yale University and Yale Cancer Center, New Haven, Conneticut, USA.;Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.;Adult Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusets, USA.;Department of Hematology, Institute Gustave Roussy, Paris, France.
832
Case Reports;Letter
en
Pay more attention to EEG in COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32482439
2020-05-24 02:00:00+02:00
pubmed
Aged, 80 and over;Brain Diseases__diagnosis;Coronavirus Infections__complications;Electroencephalography__methods;Female;Humans;Pandemics;Pneumonia, Viral__complications;COVID-19
M Flamand;A Perron;Y Buron;W Szurhaj
2020-05-22 02:00:00+02:00
32482439
FR
Department of Clinical Neurophysiology, Amiens University Medical Center, Amiens, France.;Department of Neurology, Amiens University Medical Center, Amiens, France.;Department of Clinical Neurophysiology, Amiens University Medical Center, Amiens, France. Electronic address: szurhaj.william@chu-amiens.fr.
833
10.1002/hed.26278
Journal Article;Review
en
Is the ultrasonic scalpel recommended in head and neck surgery during the COVID-19 pandemic? State-of-the-art review.
https://www.ncbi.nlm.nih.gov/pubmed/32441394
Guidelines for ultrasonic devices use are imperative because infectious aerosols arising from airway procedures were a key etiologic factor in prior coronavirus outbreaks. This manuscript aims to summarize the available recommendations and the most relevant concepts about the use of ultrasonic scalpel during the SARS-CoV-2 pandemic.
Otorhinolaryngology-Head and Neck Surgery Department, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Galicia, Spain.;Clinical Research in Medicine, International Center for Doctorate and Advanced Studies (CIEDUS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.;Otorhinolaryngology-Head and Neck Surgery Department, Complexo Hospitalario Universitario Santiago de Compostela (CHUS), Santiago de Compostela, Galicia, Spain.;Human Anatomy & Experimental Oncology Department, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology , University of Mons (UMons), Mons, Belgium.;Otorhinolaryngology and Head and Neck Surgery Department, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Otolaryngology-Head and Neck Surgery Department, Universitary Hospital of la Conception Marseille, France.;Division of Otolaryngology-Head & Neck Surgery , Centre Hospitalier de l'Université de Montréal, Montreal, Canada.;Otorhinolaryngology-Head and Neck Surgery Department, Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain.
834
10.1016/j.encep.2020.05.012
Journal Article
fr
[Coronavirus: Predictive brain and terror management].
https://www.ncbi.nlm.nih.gov/pubmed/32517998
Emerging infectious diseases like Covid-19 cause a major threat to global health. When confronted with new pathogens, individuals generate several beliefs about the epidemic phenomenon. Many studies have shown that individual protective behaviors largely depend on these beliefs. Due to the absence of treatment and vaccine against these emerging pathogens, the relation between these beliefs and these behaviors represents a crucial issue for public health policies. In the premises of the Covid-19 pandemic, several preliminary studies have highlighted a delay in the perception of risk by individuals, which potentially holds back the implementing of the necessary precautionary measures: people underestimated the risks associated with the virus, and therefore also the importance of complying with sanitary guidelines. During the peak of the pandemic, the salience of the threat and of the risk of mortality could then have transformed the way people generate their beliefs. This potentially leads to upheavals in the way they understand the world. Here, we propose to explore the evolution of beliefs and behaviors during the Covid-19 crisis, using the theory of predictive coding and the theory of terror management, two influential frameworks in cognitive science and in social psychology.
Bayesian brain;Belief;Biais cognitif;Cerveau bayésie;Codage prédictif;Cognitive biases;Coronavirus;Covid-19;Croyance;Perceived risk;Perception du risque;Predictive coding;Terror management theory;Théorie de la gestion de la terreur
2020-05-22 02:00:00+02:00
32517998
FR
Control-Interoception-Attention team, Institut du cerveau et de la moelle épinière (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/INSERM, Paris, France, Department for adult psychiatry, Pitié-Salpêtrière hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: hugo.bottemanne@gmail.com.;Control-Interoception-Attention team, Institut du cerveau et de la moelle épinière (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/INSERM, Paris, France.;Control-Interoception-Attention team, Institut du cerveau et de la moelle épinière (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/INSERM, Paris, France, Department for adult psychiatry, Pitié-Salpêtrière hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
844
Letter;Comment
en
Sudden onset anosmia and dysgeusia in two patients: An early sign of SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32447056
2020-05-24 02:00:00+02:00
pubmed
Betacoronavirus;Centers for Disease Control and Prevention, U.S.;China;Coronavirus;Coronavirus Infections;Dysgeusia;Humans;Olfaction Disorders;Pandemics;Pneumonia, Viral;United States;COVID-19;severe acute respiratory syndrome coronavirus 2
Ahmad Alamri;Constance Oriez;Florence Bouilloud;Olivier Dupuy;Adrien Ben Hamou
2020-05-21 02:00:00+02:00
32447056
FR
Paris Saint-Joseph hospital, 75014 Paris, France, Diabetology, endocrinology and nutrition department, 75014, Paris, France.;Paris Saint-Joseph hospital, 75014 Paris, France, Diabetology, endocrinology and nutrition department, 75014, Paris, France. Electronic address: abenhamou@hpsj.fr.
848
10.1097/mpg.0000000000002729
Journal Article
en
Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition.
https://www.ncbi.nlm.nih.gov/pubmed/32443020
With the current coronavirus disease 2019 (COVID-19) pandemic, concerns have been raised about the risk to children with inflammatory bowel diseases (IBD). We aimed to collate global experience and provide provisional guidance for managing paediatric IBD (PIBD) in the era of COVID-19.
0277-2116
2020-05-24 02:00:00+02:00
pubmed
Adolescent;Adult;Betacoronavirus;Child;Consensus;Coronavirus Infections__chemically induced;Health Care Surveys;Humans;Immunologic Factors__adverse effects;Inflammatory Bowel Diseases__complications;Pandemics;Pneumonia, Viral__chemically induced;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2
Journal of Pediatric Gastroenterology & Nutrition
Dan Turner;Ying Huang;Javier Martín-de-Carpi;Marina Aloi;Gili Focht;Ben Kang;Ying Zhou;Cesar Sanchez;Michael D Kappelman;Holm H Uhlig;Gemma Pujol-Muncunill;Oren Ledder;Paolo Lionetti;Jorge Amil Dias;Frank M Ruemmele;Richard K Russell
2020-05-23 02:00:00+02:00
32443020
IL;FR;CN;PT;GB;US;IT;ES;KR
Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.;Department of Gastroenterology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.;Hospital Sant Joan de Déu, Barcelona, Spain.;Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy.;Kyungpook National University Children's Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.;Pediatric Gastrointestinal Unit H.G.U. Gregorio Maranon, Madrid, Spain.;Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, NC.;Translational Gastroenterology Unit, University of Oxford, Department of Paediatrics, John Radcliffe Hospital, University of Oxford, Biomedical Research Center Oxford, Oxford, UK.;Departement NEUROFARBA - University of Florence - Meyer children's Hospital - Florence, Florence, Italy.;Pediatric Gastroenterology, Centro Hospitalar Universitário S. João, Porto, Portugal.;Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Paris, France.;Department of Paediatric Gastroenterology, The Royal Hospital for Sick Children, Edinburgh, UK.
849
10.1136/esmoopen-2020-000793
Journal Article;Practice Guideline;Review
en
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
https://www.ncbi.nlm.nih.gov/pubmed/32439716
The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.
Evandro de Azambuja;Dario Trapani;Sibylle Loibl;Suzette Delaloge;Elzbieta Senkus;Carmen Criscitiello;Philip Poortman;Michael Gnant;Serena Di Cosimo;Javier Cortes;Fatima Cardoso;Shani Paluch-Shimon;Giuseppe Curigliano
COVID-19;ESMO adapted recommendations;breast cancer
2020-05-23 02:00:00+02:00
32439716
FR;IL;PT;AT;IT;PL;ES;BE;PS;DE
Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels, Belgium.;European Institute of Oncology (IEO) IRCCS, Milan, Italy.;GBG Forschungs GmbH, Neu-Isenburg, Germany.;Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.;Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.;European Institute of Oncology IRCCS, Milan, Italy.;Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.;Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.;Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona), Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.;Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.;Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.;Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it.
851
10.1007/s11523-020-00721-1
Journal Article;Review
en
Impact of the COVID-19 Outbreak on the Management of Patients with Cancer.
https://www.ncbi.nlm.nih.gov/pubmed/32445083
The coronavirus SARS-CoV-2 (COVID-19) outbreak is having a profound impact on the management of patients with cancer. In this review, we comprehensively investigate the various aspects of cancer care during the pandemic, taking advantage of data generated in Asia and Europe at the frontline of the COVID-19 pandemic spread. Cancer wards have been subjected to several modifications to protect patients and healthcare professionals from COVID-19 infection, while attempting to maintain cancer diagnosis, therapy, and research. In this setting, the management of COVID-19 infected patients with cancer is particularly challenging. We also discuss the direct and potential remote impacts of the global pandemic on the mortality of patients with cancer. As such, the indirect impact of the pandemic on the global economy and the potential consequences in terms of cancer mortality are discussed. As the infection is spreading worldwide, we are obtaining more knowledge on the COVID-19 pandemic consequences that are currently impacting and may continue to further challenge cancer care in several countries.
Eric Raymond;Catherine Thieblemont;Severine Alran;Sandrine Faivre
2020-05-24 02:00:00+02:00
32445083
FR
Department of Medical Oncology, Paris Saint-Joseph Hospital Group, 185 rue Raymond Losserand, 75014, Paris, France. eraymond@hpsj.fr.;Hemato-oncology, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris, France.;Department of Gynecological and Mammary Surgery, Paris Saint-Joseph Hospital Group, Paris, France.;Medical Oncology, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris, France.
852
10.1016/j.jemep.2020.100528
Journal Article
fr
[Historical setting of a dialogue between two pioneers of ethical reflection during the COVID-19 period].
https://www.ncbi.nlm.nih.gov/pubmed/32835051
2352-5525
2020-05-24 02:00:00+02:00
pubmed
Ethics, Medicine and Public Health
C Hervé
Assisted suicide;Covid-19;End of life;Ethical history;Religions;Sober medicine
2020-05-21 02:00:00+02:00
32835051
FR
Académie internationale éthique, médecine et politiques publiques (IAMEPH), université de Paris, 45, rue des Saints-Pères, 75006 Paris, France.
858
10.1016/j.nrl.2020.05.006
Journal Article;Multicenter Study;Observational Study
en
Impact of the COVID-19 pandemic on headache management in Spain: an analysis of the current situation and future perspectives.
https://www.ncbi.nlm.nih.gov/pubmed/32561333
The COVID-19 pandemic has had a great impact on healthcare systems. Spain, where headache is the main reason for outpatient neurology consultation, is one of the countries with the most reported cases of the disease.
0213-4853
2020-05-24 02:00:00+02:00
pubmed
Analgesics__therapeutic use;Antibodies, Monoclonal__therapeutic use;Betacoronavirus;Calcitonin Gene-Related Peptide Receptor Antagonists__therapeutic use;Coronavirus Infections;Cross-Sectional Studies;Disease Management;Emergency Medical Services__organization & administration;Forecasting;Headache__drug therapy;Health Care Surveys;Humans;Office Visits__statistics & numerical data;Pandemics;Patient Acceptance of Health Care;Personal Protective Equipment;Pneumonia, Viral;Referral and Consultation;Spain__epidemiology;Telemedicine__statistics & numerical data;Time-to-Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2
Neurología
A López-Bravo;D García-Azorín;R Belvís;C González-Oria;G Latorre;S Santos-Lasaosa;Á L Guerrero-Peral
Servicio de Neurología-Unidad de Tratamiento del Dolor, Hospital Reina Sofía, Navarra, España, Instituto de Investigación Sanitaria Aragón (IIS-A).;Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España. Electronic address: davilink@hotmail.com.;Unidad de Cefaleas, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Unidad de Cefaleas, Hospital Virgen del Rocío, Sevilla, España.;Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario de Fuenlabrada, Fuenlabrada, España, Departamento de Medicina, Universidad Rey Juan Carlos, Madrid, España.;Instituto de Investigación Sanitaria Aragón (IIS-A), Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.;Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España, Instituto de Investigación de Salamanca (IBSAL), Salamanca, España, Departamento de Medicina, Universidad de Valladolid, Valladolid, España.
862
Letter;Comment
en
Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?
Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France, Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.;Université de La Réunion, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France, CHU de La Réunion, Saint-Pierre F-97410, France.;Cellular and Molecular Biology Consultant, Rennes F-35033, France.;Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.;Vascular Medicine Unit, Inserm, (Clinical Investigation Center 1414), Univ Rennes, CHU Rennes, Rennes F-35033, France.
863
10.1530/eje-20-0445
Journal Article;Review
en
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism.
https://www.ncbi.nlm.nih.gov/pubmed/32438340
This manuscript provides guidance on the management of thyroid dysfunction during the COVID-19 pandemic. Autoimmune thyroid diseases are not linked to increased risks of COVID-19. Uncontrolled thyrotoxicosis may result in more severe complications from SARS-CoV-2 infection, including thyroid storm. The management of patients with a new diagnosis of hyperthyroidism is best undertaken with a block-and-replace regimen due to limited biochemical testing availability. Antithyroid drug (ATD)-induced neutropenia may favour the progression of COVID-19 and symptoms of infection may be confused with SARS-CoV-2 infection. The withdrawal of ATDs and urgent measurement of neutrophils should be considered in case of flu-like manifestations occurring in the initial months of treatment. Urgent surgery or 131-I may be undertaken in selected cases of uncontrolled thyrotoxicosis. Patients with COVID-19 infection may present with conjunctivitis, which could cause diagnostic difficulties in patients with new or existing Graves' ophthalmopathy. Patients who are on replacement treatment with thyroid hormones should ensure they have sufficient supply of medication. The usual advice to increase dosage of levothyroxine during pregnancy should be adhered to. Many newly presenting and previously diagnosed patients with thyroid dysfunction can be managed through virtual telephone or video clinics supported by a dedicated nurse-led service, depending on available facilities.
Kristien Boelaert;W Edward Visser;Peter Nicholas Taylor;Carla Moran;Juliane Léger;Luca Persani
2020-05-22 02:00:00+02:00
32438340
FR;IE;GB;IT;NL
Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Academic Centre for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.;Thyroid Research Group School of Medicine Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK.;Beacon Hospital, Sandyford, Dublin, Ireland.;Pediatric Endocrinology Diabetology Department, Reference Center for Growth and Development Endocrine Diseases, Université de Paris, Hopital Robert Debre, Paris, France.;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.;Postgraduate School of Endocrinology and Metabolic Diseases, University of Milan, Milan, Italy.;Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan, Italy.
871
10.1093/jac/dkaa213
Journal Article
en
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
https://www.ncbi.nlm.nih.gov/pubmed/32457980
0305-7453,1460-2091
2020-05-31 02:00:00+02:00
pubmed
Journal of Antimicrobial Chemotherapy
Juliette Kauv;Minh P Lê;Marc Veyrier;Quentin Le Hingrat;Benoit Visseaux;Laurent Massias;Marie-Paule Chauveheid;Diane Descamps;Jade Ghosn;Gilles Peytavin
2020-05-28 02:00:00+02:00
32457980
FR
AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.;INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Pharmacy Department, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Virology Department, 75018 Paris, France.;IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Internal Medicine Department, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Infectious Diseases Department, 75018 Paris, France.
879
10.1093/jac/dkaa191
Journal Article
en
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
https://www.ncbi.nlm.nih.gov/pubmed/32473020
Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial.
0305-7453,1460-2091
2020-05-31 02:00:00+02:00
pubmed
Journal of Antimicrobial Chemotherapy
Minh Patrick Lê;Nathan Peiffer-Smadja;Jeremie Guedj;Nadège Néant;France Mentré;Florence Ader;Yazdan Yazdanpanah;Gilles Peytavin
2020-05-31 02:00:00+02:00
32473020
FR
AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.;INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.;IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.;Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004, France.;Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon, France.
885
10.1097/rlu.0000000000003113
Case Reports;Journal Article
en
FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings.
https://www.ncbi.nlm.nih.gov/pubmed/32453077
A 52-year-old woman with no medical history was admitted on March 18, 2020, presenting since 3 days asthenia, abdominal pain, and dry cough but no fever. Adenomegalies, splenomegaly, leukocytosis, and elevated LDH suggested mature lymphoproliferation. Considering the current health context, an RT-PCR testing for COVID-19 (coronavirus disease 2019) was performed and found to be positive. Early chest CT showed no sign of pulmonary infection but multiple adenomegalies. An F-FDG PET/CT performed 5 days later to assess the extent of the hemopathy revealed the apparition of FDG-avid bilateral ground glass and subpleural curvilinear opacities suggesting COVID-19-associated pneumopathy.
From the Departments of Nuclear Medicine.;Hematology, Avicenne Hospital, Hopitaux universitaires Paris Seine Saint Denis, AP-HP, France.;UMR 1288, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Inserm, Institut Curie, France.
886
10.1007/s10554-020-01892-8
Journal Article;Review
en
Cardiac imaging procedures and the COVID-19 pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR).
https://www.ncbi.nlm.nih.gov/pubmed/32451877
The severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) pandemic currently constitutes a significant burden on worldwide health care systems, with important implications on many levels, including radiology departments. Given the established fundamental role of cardiovascular imaging in modern healthcare, and the specific value of cardiopulmonary radiology in COVID-19 patients, departmental organisation and imaging programs need to be restructured during the pandemic in order to provide access to modern cardiovascular services to both infected and non-infected patients while ensuring safety for healthcare professionals. The uninterrupted availability of cardiovascular radiology services remains, particularly during the current pandemic outbreak, crucial for the initial evaluation and further follow-up of patients with suspected or known cardiovascular diseases in order to avoid unnecessary complications. Suspected or established COVID-19 patients may also have concomitant cardiovascular symptoms and require further imaging investigations. This statement by the European Society of Cardiovascular Radiology (ESCR) provides information on measures for safety of healthcare professionals and recommendations for cardiovascular imaging during the pandemic in both non-infected and COVID-19 patients.
1569-5794,1573-0743
2020-05-31 02:00:00+02:00
pubmed
The International Journal of Cardiovascular Imaging
COVID-19;Cardiac magnetic resonance;Cardiovascular computed tomography;SARS-Cov-2;Safety
2020-05-26 02:00:00+02:00
32451877
FR;CH;AT;GB;US;IT;NL;BE;DE
Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Wien, Austria.;Department of Radiology, Antwerp University Hospital & Holy Heart Hospital, Antwerp/Lier, Belgium. rodrigo.salgado@uza.be.;Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Policlinico Umberto I, Rome, Italy.;Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.;Department of Radiological and Haematological Sciences - Institute of Radiology, Catholic University of Rome, Fondazione Policlinico Universitario Gemelli - IRCCS, Rome, Italy.;Department of Radiology, University Hospital Basel, Basel, Switzerland.;Department of Radiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.;Department of Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Department for Diagnostic and Interventional Radiology, University Hospital Tuebingen, Tuebingen, Germany.;Department of Cardiothoracic Radiology, University Hospital Southampton, Southampton, UK.;Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands.;Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC, USA.;German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.
891
10.1016/j.revmed.2020.05.003
Journal Article;Review
fr
[COVID-19: Pathogenesis of a multi-faceted disease].
https://www.ncbi.nlm.nih.gov/pubmed/32507520
SARS-CoV-2 infection, named COVID-19, can lead to a dysregulated immune response and abnormal coagulation responsible for a viral sepsis. In this review, we specify physiopathological mechanisms of each phase of COVID-19 - viral, immune and pro-thrombotic - notably because they involve different treatment. Finally, we specify the physiopathological mechanisms of organ injury.
Interne en DES de pneumologie, Sorbonne-université, France.;Interne en DES de maladies infectieuses, MSc, Université de Paris, France.;DES de néphrologie, MSc, Sorbonne-université, France.;Interne en DES de médecine interne, MSc, Sorbonne-université, France.;Interne en DES de médecine interne Paris, MSc, Université de Paris, France. Electronic address: quentin.richier@hotmail.fr.
899
ANR
10.1007/s10456-020-09730-0
Journal Article
en
Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pubmed/32458111
Coronavirus disease-2019 (COVID-19), a respiratory disease has been associated with ischemic complications, coagulation disorders, and an endotheliitis.
0969-6970,1573-7209
2020-05-31 02:00:00+02:00
pubmed
Angiogenesis
David M Smadja;Coralie L Guerin;Richard Chocron;Nader Yatim;Jeremy Boussier;Nicolas Gendron;Lina Khider;Jérôme Hadjadj;Guillaume Goudot;Benjamin Debuc;Philippe Juvin;Caroline Hauw-Berlemont;Jean-Loup Augy;Nicolas Peron;Emmanuel Messas;Benjamin Planquette;Olivier Sanchez;Bruno Charbit;Pascale Gaussem;Darragh Duffy;Benjamin Terrier;Tristan Mirault;Jean-Luc Diehl
Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France. david.smadja@aphp.fr.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France. david.smadja@aphp.fr.;Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France.;Cytometry Department, Curie Institute, 75006, Paris, France.;Université de Paris, PARCC, INSERM, 75015, Paris, France.;Emergency Department, AP-HP, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Laboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Université de Paris Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, 75015, Paris, France.;Université de Paris, Plastic Surgery Department, Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), 75015, Paris, France.;Université de Paris, Emergency Department, Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), 75015, Paris, France.;Université de Paris, Intensive Care Unit, AH-HP, Georges Pompidou European Hospital, 75015, Paris, France.;Vascular Medicine Department, Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Institut Pasteur, Center for Translational Research, 75015, Paris, France.;Hematology Department, Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Université de Paris, PARCC, INSERM U970, Paris, France.;Internal Medicine Department, AH-HP-Centre Université de Paris (CUP), 75014, Paris, France.;Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.
907
Letter
en
Right-to-left interatrial shunt in COVID-19 patients with pulmonary embolism.
https://www.ncbi.nlm.nih.gov/pubmed/32492443
2020-05-31 02:00:00+02:00
pubmed
Olivier Fabre;Olivier Rebet;Ilir Hysi
2020-05-31 02:00:00+02:00
32492443
FR
Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Santé, France.;Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Santé, France. Electronic address: ilirhysi@gmail.com.
911
10.1016/j.encep.2020.05.004
Journal Article;Review
fr
[Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic].
https://www.ncbi.nlm.nih.gov/pubmed/32471705
The sudden changes of healthcare system due to COVID-19 particularly affect the organization of psychiatry. The objective of this review is to examine the adaptations of psychiatric care in France during this pandemic.
COVID-19;Health system;Hospitalisation;Hospitalization;Organisation des soins;Psychiatrie;Psychiatry;SARS-COV-2
2020-05-26 02:00:00+02:00
32471705
FR
Pôle hospitalo-universitaire de psychiatrie et d'addictologie, CHU de Nantes, 85, rue Saint-Jacques, 44093 Nantes cedex 01, France. Electronic address: rachel.bocher@chu-nantes.fr.;Centre psychothérapique de Nancy, pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie, 54520 Laxou, France, Faculté de médecine de Nancy, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.;Pôle hospitalo-universitaire de psychiatrie et d'addictologie, CHU de Nantes, 85, rue Saint-Jacques, 44093 Nantes cedex 01, France.;GHU Paris psychiatrie et neurosciences, CMME, hôpital Sainte-Anne, 75014 Paris, France, Université de Paris, institute of psychiatry and neuroscience of Paris (IPNP), Inserm U1266, 75014 Paris, France.;Centre psychothérapique de Nancy, pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie, 54520 Laxou, France, Faculté de médecine de Nancy, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France, Pôle de psychiatrie, fédération de médecine translationnelle de Strasbourg, institut national de la santé et de la recherche médicale U1114, université de Strasbourg, centre hospitalier régional universitaire de Strasbourg, Strasbourg, France.
919
10.1016/j.jbusres.2020.05.026
Journal Article
en
Managing uncertainty during a global pandemic: An international business perspective.
https://www.ncbi.nlm.nih.gov/pubmed/32501304
Despite the perennial need to understand and manage uncertainty in international business, there is no comprehensive framework that incorporates different types of uncertainty, their antecedents and outcomes, and the different coping strategies used by managers and their outcomes. This makes it difficult for international business managers to understand the types of uncertainty in their businesses and develop appropriate strategies to deal with it effectively, especially during times such as the ongoing Covid-19 pandemic. This paper uses an extensive review of the international business literature to address the above research gap by identifying the different types of uncertainty, their antecedents and outcomes, the coping strategies used to mitigate their impact, and the consequences of these actions. The authors also use examples from the current Covid-19 crisis to assess the firms' responses and their consequences. The paper concludes with some implications for international business managers and directions for future research.
0148-2963
2020-05-31 02:00:00+02:00
pubmed
Journal of Business Research
Piyush Sharma;T Y Leung;Russel P J Kingshott;Nebojsa S Davcik;Silvio Cardinali
School of Marketing, Curtin University, Bentley, WA 6102, Australia.;Lee Shau Kee School of Business & Administration, The Open University of Hong Kong.;EM Normandie Business School, Métis Lab, Oxford, UK.;Faculty of Economics "Giorgio Fuà", Università Politecnica delle Marche, Ancona, Italy.
924
Letter
en
Call for comments: climate and clean air responses to covid-19.
Organization for Economic Co-operation and Development, Paris, France.;International Institute for Applied Systems Analysis, Laxenburg, Austria.;Universidad Nacional Autónoma de México, Mexico City, Mexico.;Climate and Clean Air Coalition, Paris, France. Nathan.borgford-parnell@un.org.;School of Population and Public Health, University of British Columbia, Vancouver, Canada.;New Zealand Agricultural Greenhouse Gas Research Centre, Palmerston North, New Zealand.;Stockholm Environment Institute, York, UK.;London School of Hygiene and Tropical Medicine, London, UK.;Energy Research Institute, National Development and Reform Commission, Beijing, China.;Swiss Tropical and Public Health Institute, Bern, Switzerland.;UN Environment Programme, Nairobi, Kenya.;Department of Science, Technology, Engineering and Public Policy, University College London, London, UK.;Scripps Institution of Oceanography, University of California San Diego, La Jolla, USA.;Department of Atmospheric Science, Colorado State University, Fort Collins, USA.;Nicholas School of the Environment, Duke University, Durham, USA.;Faculty of Public Health, Thammasat University, Bangkok, Thailand.
930
Letter
en
Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients.
Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, University of Franche-Comte, Besancon, France.;EA 3920, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besancon, France.;Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, University of Franche-Comte, Besancon, France. gbesch@chu-besancon.fr.;EA 3920, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besancon, France. gbesch@chu-besancon.fr.
932
Letter
en
Non-COVID-19 emergencies: where have all the patients gone?
https://www.ncbi.nlm.nih.gov/pubmed/32458174
• Early in the pandemic, numbers of patients undergoing non-COVID-19 emergent CTs dropped sharply but diagnostic yield did not increase, suggesting potentially undiagnosed emergencies in patients not seen in healthcare institutions.
Tom Boeken;Alice Le Berre;Anne Mebazaa;Isabelle Boulay-Coletta;Jérôme Hodel;Marc Zins
2020-05-26 02:00:00+02:00
32458174
FR
Department of Radiology, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.;Department of Radiology, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France. mzins@hpsj.fr.
934
10.1111/jth.14856
Case Reports
en
COVID-19 and acute coagulopathy in pregnancy.
https://www.ncbi.nlm.nih.gov/pubmed/32302459
We present a putative link between maternal COVID-19 infection in the peripartum period and rapid maternal deterioration with early organ dysfunction and coagulopathy. The current pandemic with SARS-CoV-2 has already resulted in high numbers of critically ill patients and deaths in the non-pregnant population, mainly due to respiratory failure. During viral outbreaks, pregnancy poses a uniquely increased risk to women due to changes to immune function, alongside physiological adaptive alterations, such as increased oxygen consumption and edema of the respiratory tract. The laboratory derangements may be reminiscent of HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome, and thus knowledge of the COVID-19 relationship is paramount for appropriate diagnosis and management. In addition to routine measurements of D-dimers, prothrombin time, and platelet count in all patients presenting with COVID-19 as per International Society on Thrombosis and Haemostasis (ISTH) guidance, monitoring of activated partial thromboplastin time (APTT) and fibrinogen levels should be considered in pregnancy, as highlighted in this report. These investigations in SARS-CoV-2-positive pregnant women are vital, as their derangement may signal a more severe COVID-19 infection, and may warrant pre-emptive admission and consideration of delivery to achieve maternal stabilization.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.;Division of Hematology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.;Department of Obstetrics and Gynecology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, Clamart, France.;Anaesthesia and Critical Care Department, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, Clamart, France.;Biological Hematology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, Clamart, France.
935
Letter;Comment
en
More on Neurologic Features in Severe SARS-CoV-2 Infection. Reply.
Anesthesia and Intensive Care Unit, American Hospital of Paris, Neuilly S/Seine, France. Electronic address: gilles.boccara@ahparis.org.;Well-Cornell Medical School, Presbyterian Hospital of New York, NYC, USA.;Anesthesia and Intensive Care Unit, American Hospital of Paris, Neuilly S/Seine, France.;Department of Surgery, American Hospital of Paris, Neuilly S/Seine, France.;University Hospital of Bichat, Paris 75018, France, Louis-Mourier, Colombes 92000, France.
948
10.1212/nxi.0000000000000785
Case Reports;Journal Article
en
Guillain-Barré syndrome related to SARS-CoV-2 infection.
From the Service de Neurologie (K.B., P.V., L.K., J.-B.C., J.S.), Hôpitaux Universitaires de Strasbourg, Service de Neurologie (M.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service de Neuroradiologie (S.B.), Hôpitaux Universitaires de Strasbourg, Institut de Biologie Structurale (IBS) (B.N., P.M.), Université de Grenoble Alpes, CEA, CNRS, Laboratoire de virologie (B.N., P.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service d'Accueil des Urgences (F.B.), Hôpitaux Universitaires de Strasbourg, and Service de Réanimation Polyvalente Chirurgicale (A.G.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, France. kevin.bigaut@chru-strasbourg.fr.;From the Service de Neurologie (K.B., P.V., L.K., J.-B.C., J.S.), Hôpitaux Universitaires de Strasbourg, Service de Neurologie (M.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service de Neuroradiologie (S.B.), Hôpitaux Universitaires de Strasbourg, Institut de Biologie Structurale (IBS) (B.N., P.M.), Université de Grenoble Alpes, CEA, CNRS, Laboratoire de virologie (B.N., P.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service d'Accueil des Urgences (F.B.), Hôpitaux Universitaires de Strasbourg, and Service de Réanimation Polyvalente Chirurgicale (A.G.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, France.
949
10.1055/s-0040-1713152
Journal Article;Review
en
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
https://www.ncbi.nlm.nih.gov/pubmed/32473596
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Behnood Bikdeli;Mahesh V Madhavan;Aakriti Gupta;David Jimenez;John R Burton;Caroline Der Nigoghossian;Taylor Chuich;Shayan Nabavi Nouri;Isaac Dreyfus;Elissa Driggin;Sanjum Sethi;Kartik Sehgal;Saurav Chatterjee;Walter Ageno;Mohammad Madjid;Yutao Guo;Liang V Tang;Yu Hu;Laurent Bertoletti;Jay Giri;Mary Cushman;Isabelle Quéré;Evangelos P Dimakakos;C Michael Gibson;Giuseppe Lippi;Emmanuel J Favaloro;Jawed Fareed;Alfonso J Tafur;Dominic P Francese;Jaya Batra;Anna Falanga;Kevin J Clerkin;Nir Uriel;Ajay Kirtane;Claire McLintock;Beverley J Hunt;Alex C Spyropoulos;Geoffrey D Barnes;John W Eikelboom;Ido Weinberg;Sam Schulman;Marc Carrier;Gregory Piazza;Joshua A Beckman;Martin B Leon;Gregg W Stone;Stephan Rosenkranz;Samuel Z Goldhaber;Sahil A Parikh;Manuel Monreal;Harlan M Krumholz;Stavros V Konstantinides;Jeffrey I Weitz;Gregory Y H Lip
2020-05-30 02:00:00+02:00
32473596
IL;FR;RU;CA;NZ;CN;GR;GB;US;IT;AU;ES;DK;DE
New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.;Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.;Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.;Respiratory Department, Hospital Ramón y Cajal, Madrid, Spain.;Medicine Department, Universidad de Alcalá (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.;Harvard Medical School, Boston, Massachusetts, United States.;Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.;North Shore and Long Island Jewish University Hospitals, Queens, New York, United States.;Department of Medicine and Surgery, University of Insubria, Varese, Italy.;McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, United States.;Department of Cardiology, Chinese PLA General Hospital, Beijing, China.;Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.;Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Department of "Médecine Vasculaire et Thérapeutique," CIC 1408, INNOVTE, CHU de St-Etienne and INSERM UMR1059, Université Jean-Monnet, Saint-Etienne, France.;Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States.;Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, United States.;Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States.;Larner College of Medicine, University of Vermont, Burlington, Vermont, United States.;Department of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN Network, Montpellier, France.;Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece.;Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.;Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.;Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia.;Loyola University Medical Center, Chicago, Illinois, United States.;Pritzker School of Medicine at the University of Chicago, Chicago, Illinois, United States.;Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois, United States.;Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.;Auckland City Hospital, Auckland, New Zealand.;St Thomas' Hospital, London, United Kingdom.;The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York, United States.;Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, United States.;Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States.;Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.;Massachusetts General Hospital, Boston, Massachusetts, United States.;Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.;McMaster University, Hamilton, Ontario, Canada.;Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada.;The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.;Brigham and Women's Hospital, Boston, Massachusetts, United States.;Vanderbilt University School of Medicine, Nashville, Tennessee, United States.;The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.;Department of Cardiology, Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of Cologne, University of Cologne, Cologne, Germany.;Department of Internal Medicine, Hospital Universitari Germans Trials I Pujol, Universidad Católica de Murcia, Barcelona, Spain.;Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut, United States.;Section of Cardiovascular Medicine, Department of Internal Medicie, Yale School of Medicine, New Haven, Connecticut, United States.;Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.;Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark.
963
10.1016/j.biochi.2020.05.013
Journal Article
en
The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.
https://www.ncbi.nlm.nih.gov/pubmed/32485205
The anti-malarial drug Chloroquine (CQ) and its derivative hydroxychloroquine have shown antiviral activities in vitro against many viruses, including coronaviruses, dengue virus and the biosafety level 4 Nipah and Hendra paramyxoviruses. The in vivo efficacy of CQ in the treatment of COVID-19 is currently a matter of debate. CQ is a lysosomotrophic compound that accumulates in lysosomes, as well as in food vacuoles of Plasmodium falciparum. In the treatment of malaria, CQ impairs the digestion and growth of the parasite by increasing the pH of the food vacuole. Similarly, it is assumed that the antiviral effects of CQ results from the increase of lysosome pH and the inhibition of acidic proteases involved in the maturation of virus fusion protein. CQ has however other effects, among which phospholipidosis, characterized by the accumulation of multivesicular bodies within the cell. The increase in phospholipid species particularly concerns bis(monoacylglycero)phosphate (BMP), a specific lipid of late endosomes involved in vesicular trafficking and pH-dependent vesicle budding. It was shown previously that drugs like progesterone, the cationic amphiphile U18666A and the phospholipase inhibitor methyl arachidonyl fluoro phosphonate (MAFP) induce the accumulation of BMP in THP-1 cells and decrease cell infection by human immunodeficiency virus. HIV viral particles were found to be retained into large endosomal-type vesicles, preventing virus spreading. Since BMP was also reported to favour virus entry through hijacking of the endocytic pathway, we propose here that BMP could play a dual role in viral infection, with its antiviral effects triggered by lysosomotropic drugs like CQ.
0300-9084
2020-05-31 02:00:00+02:00
pubmed
Biochimie
Frédéric Carrière;Sonia Longhi;Michel Record
2020-05-30 02:00:00+02:00
32485205
FR
Aix Marseille Univ, CNRS, BIP, UMR7281, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 9, France. Electronic address: carriere@imm.cnrs.fr.;Aix Marseille Univ, CNRS, AFMB, UMR7257, 163 Avenue de Luminy, 13288, Marseille cedex 09, France.;UMR INSERM 1037-CRCT (Cancer Research Center of Toulouse), University of Toulouse III Paul Sabatier, Team "Cholesterol Metabolism and Therapeutic Innovations,", 2 Avenue Hubert Curien, 31037, Toulouse cedex 1, France. Electronic address: michel.record@inserm.fr.
965
10.3390/pathogens9060430
Journal Article;Review
en
SARS-CoV-2 Infection and the Liver.
https://www.ncbi.nlm.nih.gov/pubmed/32486188
A novel strain of coronoviridae (SARS-CoV-2) was reported in Wuhan China in December 2019. Initially, infection presented with a broad spectrum of symptoms which typically included muscle aches, fever, dry cough, and shortness of breath. SARS-CoV-2 enters cells via ACE2 receptors which are abundant throughout the respiratory tract. However, there is evidence that these receptors are abundant throughout the body, and just as abundant in cholangiocytes as alveolar cells, posing the question of possible direct liver injury. While liver enzymes and function tests do seem to be deranged in some patients, it is questionable if the injury is due to direct viral damage, drug-induced liver injury, hypoxia, or microthromboses. Likely, the injury is multifactoral, and management of infected patients with pre-existing liver disease should be taken into consideration. Ultimately, a vaccine is needed to aid in reducing cases of SARS-CoV-2 and providing immunity to the general population. However, while considering the types of vaccines available, safety concerns, particularly of RNA- or DNA-based vaccines, need to be addressed.
2076-0817
2020-05-31 02:00:00+02:00
pubmed
Pathogens
Katie Morgan;Kay Samuel;Martin Vandeputte;Peter C Hayes;John N Plevris
The University of Edinburgh Hepatology Laboratory, Division of Heath Sciences, University of Edinburgh Medical School, Chancellor's Building, Edinburgh BioQuarter, 49 Little France Crescent, Edinburgh EH16 4SB, UK.;The Jack Copland Centre, Advanced Therapeutics, Scottish National Blood Transfusion Service, 52 Research Avenue North, Edinburgh EH14 4BE, UK.
970
Letter
en
Does spitting in public play a role in transmitting SARS-CoV-2?
https://www.ncbi.nlm.nih.gov/pubmed/32492484
2020-05-31 02:00:00+02:00
pubmed
Philippe Gautret;Philippe Colson;Jean-Christophe Lagier;Philippe Parola;Didier Raoult
2020-05-31 02:00:00+02:00
32492484
FR
IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: philippe.gautret@club-internet.fr.
974
Letter
en
Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32631576
2020-05-31 02:00:00+02:00
pubmed
Charbel Skayem;Nakhle Ayoub
2020-05-28 02:00:00+02:00
32631576
FR;LB
Université de Paris, Faculté de Médecine, Paris, Assistance Publique des Hôpitaux de Paris (APHP), Paris, Hôpital Henri Mondor, Créteil, France. Electronic address: charbelskayem@hotmail.com.;Holy Spirit University of Kaslik, Lebanon, Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos, Lebanon.
983
10.3390/nu12061583
Journal Article
en
Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey.
https://www.ncbi.nlm.nih.gov/pubmed/32481594
Public health recommendations and governmental measures during the COVID-19 pandemic have resulted in numerous restrictions on daily living including social distancing, isolation and home confinement. While these measures are imperative to abate the spreading of COVID-19, the impact of these restrictions on health behaviours and lifestyles at home is undefined. Therefore, an international online survey was launched in April 2020, in seven languages, to elucidate the behavioural and lifestyle consequences of COVID-19 restrictions. This report presents the results from the first thousand responders on physical activity (PA) and nutrition behaviours.
Institute of Sport Science, Otto-von-Guericke University, 39106 Magdeburg, Germany.;Research Laboratory, Molecular Bases of Human Pathology, LR12ES17, Faculty of Medicine, University of Sfax, Sfax 3000, Tunisia.;Institute of Sport and Exercise Sciences, University of Münster, 48149 Münster, Germany.;High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax 3000, Tunisia.;Research Laboratory: Education, Motricity, Sport and Health, EM2S, LR19JS01, University of Sfax, Sfax 3000, Tunisia.;Research Unit: Physical Activity, Sport, and Health, UR18JS01, National Observatory of Sport, Tunis 1003, Tunisia.;Higher Institute of Computer Science and Multimedia of Sfax, University of Sfax, Sfax 3000, Tunisia.;Research Group Neuroprotection, German Center for Neurodegenerative Diseases (DZNE), Leipziger Str. 44, 39120 Magdeburg, Germany.;Medical Faculty, Department of Neurology, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany.;High Institute of Sport and Physical Education, University of Gafsa, Gafsa 2112, Tunisia.;Laboratório de Vibrações Mecânicas e Práticas Integrativas, LAVIMPI-UERJ, Universidade do Estado do Rio de Janeiro, Rio de Janeiro RJ 20950-003, Brazil.;Faculdade Bezerra de Araújo, Rio de Janeiro Rj 23052-180, Brazil.;Department of Psychology, Health & Technology, University of Twente, 7522 Enschede, The Netherlands.;Department of Psychology, Università Cattolica del Sacro Cuore, 20123 Milano, Italy.;Laboratório de Fisiologia do Exercício, Estácio de Sá University, Rio de Janeiro 20261-063, Brazil.;College of Business Administration, American University in the Emirates, 503000-Dubai Academic City, Dubai, UAE.;Faculty of social science, Imam Khomeini International University, Qazvin 34148-96818, Iran.;UVHC, DeVisu, Valenciennes, LIRTES-EA 7313, Université Paris Est Créteil Val de Marne, 94000 Créteil, France.;Department of Health Sciences (DISSAL), Postgraduate School of Public Health, University of Genoa, 16132 Genoa, Italy.;Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, 4700 Keele Street, Toronto, ON M3J 1P3, Canada.;ASPETAR, Qatar Orthopaedic and Sports Medicine Hospital, Doha 29222, Qatar.;Laboratory "Sport Performance Optimization", (CNMSS), ISSEP Ksar-Said, Manouba University, Manouba 2010, Tunisia.;Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, AR 72701, USA.;Clinical Excellence Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.;Computer science department, University of Toulouse, IRIT-INP-ENSEEIHT (UMR 5505), BP 7122, Toulouse, France.;Faculty of Physical Education, Assiut University, Assiut 71515, Egypt.;Institute for Sports and Sports Science, Karlsruher Institut für Technologie, 76131 Karlsruher, Germany.;Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, GA 30458, USA.;PharmD, BCBS, PharmIAD, Inc,Savannah, GA 30458, USA.;FundeSalud, Dept. of Health and Social Services, Government of Extremadura, 06800 Merida, Spain.;The E-Senior Association, 75020 Paris, France.;Department of Health Psychology, University Medical Center Groningen, University of Groningen, 9712 Groningen, The Netherlands.;Sports- and Rehabilitation Medicine, Ulm University Hospital, Leimgrubenweg 14, 89075 Ulm, Germany.;Department of Exercise Science, Yarmouk University, Irbid 21163, Jordan.;Faculty of Physical Education, The University of Jordan, Amman 11942, Jordan.;Digital Research Centre of Sfax, Sfax 3000, Tunisia.;Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, 4200-135 Porto, Portugal.;Institute for Kinesiology Research, Science and Research Centre Koper, Garibaldijeva 1, 6000 Koper, Slovenia.;Applied Technology for Neuro-Psychology Lab, I.R.C.C.S. Istituto Auxologico Italiano, 20149 Milan, Italy.;School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough E11 3TU, UK.;Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology: Physical Activity, Health and Learning (LINP2-2APS), UFR STAPS, UPL, Paris Nanterre University, 92000 Nanterre, France.
990
10.1016/j.ssci.2020.104854
Journal Article
en
Prediction of CoVid-19 infection, transmission and recovery rates: A new analysis and global societal comparisons.
https://www.ncbi.nlm.nih.gov/pubmed/32518471
We analyze the process of infection rate growth and decline for the recent global pandemic, applying a new method to the available global data. We describe and utilize an original approach based on statistical physics to predict the societal transmission timescale and the universal recovery trajectory resulting from the countermeasures implemented in entire societies. We compare the whole-society infection growth rates for many countries and local regions, to illustrate the common physical and mathematical basis for the viral spread and infection rate reduction, and validate the theory and resulting correlations. We show that methods traditionally considered for the numerical analysis and the control of individual virus transmission (e.g. ℜ0 scaling) represent one special case of the theory, and also compare our results to the available IHME computer model outcomes. We proceed to illustrate several interesting features of the different approaches to the mitigation of the pandemic, related to social isolation and "lockdown" tactics. Finally, we use presently available data from many countries to make actual predictions of the time needed for securing minimum infection rates in the future, highlighting the differences that emerge between isolated "islands" and mobile cities, and identifying the desired overall recovery trajectory.
Idaho Falls, ID, USA.;Centre de Recherche sur les Risques et les Crises (CRC), MINES ParisTech/PSL Université Paris, Sophia Antipolis, France.;Department of Energy, Politecnico di Milano, Milan, Italy.;Eminent Scholar at the Department of Nuclear Engineering, Kyung Hee University, Seoul, South Korea.
991
Letter;Comment
en
Cluster of chalazia in nurses using eye protection while caring for critically ill patients with COVID-19 in intensive care.
Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France bruno.megarbane@lrb.aphp.fr.;Department of Ophtalmology, Lariboisière Hospital, University of Paris, Paris, France.
Collège de France, Paris, France. alain.fischer@aphp.fr.;Immunology and Pediatric Hematology Department, Assistance Publique-Hôpitaux de Paris, Paris, France. alain.fischer@aphp.fr.;INSERM UMR 1163, Institut Imagine, Paris, France. alain.fischer@aphp.fr.
999
10.1016/j.isci.2020.101212
Journal Article
en
Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site.
https://www.ncbi.nlm.nih.gov/pubmed/32512386
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19) has rapidly spread to the entire world within a few months. The origin of SARS-CoV-2 has been related to the lineage B Betacoronavirus SARS-CoV and SARS-related coronaviruses found in bats. Early characterizations of the SARS-CoV-2 genome revealed the existence of a distinct four amino acid insert within the spike (S) protein (underlined, SPRRAR↓S), at the S1/S2 site located at the interface between the S1 receptor binding subunit and the S2 fusion subunit. Notably, this insert appears to be a distinguishing feature among SARS-related sequences and introduces a potential cleavage site for the protease furin. Here, we investigate the potential role of this novel S1/S2 cleavage site and present direct biochemical evidence for proteolytic processing by a variety of proteases. We discuss these findings in the context of the origin of SARS-CoV-2, viral stability, and transmission.
2589-0042
2020-05-31 02:00:00+02:00
pubmed
iScience
Javier A Jaimes;Jean K Millet;Gary R Whittaker
Biochemistry;Virology
2020-05-28 02:00:00+02:00
32512386
FR;US
Department of Microbiology & Immunology, Cornell University, 930 Campus Road, Ithaca, NY 14853, USA.;Université Paris-Saclay, INRAE, UVSQ, Virologie et Immunologie Moléculaires, 78352 Jouy-en-Josas, France.;Department of Microbiology & Immunology, Cornell University, 930 Campus Road, Ithaca, NY 14853, USA, Master of Public Health Program, Cornell University, Ithaca, NY 14853, USA. Electronic address: grw7@cornell.edu.
1000
10.1186/s13033-020-00371-w
Editorial
en
Mental health and psychosocial well-being during the COVID-19 pandemic: the invisible elephant in the room.
https://www.ncbi.nlm.nih.gov/pubmed/32514302
The novel SARS-CoV-2 coronavirus pandemic has emerged as a truly formidable threat to humankind's existence. In the wake of the massively volatile global situation created by COVID-19, it is vital to recognize that the trauma it causes can affect people in different ways, at the individual and collective levels, resulting in mental health challenges for many. Although mental health problems account for about one-third of the world's disability among adults, these issues tend to be under-addressed and overlooked in society and are closely associated with deadly disease outbreaks. In large scale outbreaks, the mental health problems experienced are not limited to infected persons but also extend to involve frontline health workers and community members alike. While it is crucial to limit the spread of infections during an outbreak, previous experience suggests that mental and behavioural health interventions should be fully included in public health response strategies.
Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.;Department of Internal Medicine, College of Medical Sciences, University of Calabar, Calabar, Cross River State Nigeria.;Department of Sociology, McMaster University, Hamilton, ON Canada.;Geography at the Laboratoire Caribéen de Sciences Sociales du Centre National de la Recherche Scientifique, Université des Antilles, Schoelcher, Martinique, France.;School of International Development and Global Studies, University of Ottawa, Ottawa, ON Canada.;The George Institute for Global Health, The University of Oxford, Oxford, UK.
1001
Letter
en
Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics.
Department of Infectious Diseases, Centre Hospitalier Universitaire (CHU) Saint-Pierre.;Centre for Environmental Health and Occupational Health, School of Public Health.;Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium.
1008
10.1063/5.0008834
Journal Article
en
Asymptotic estimates of SARS-CoV-2 infection counts and their sensitivity to stochastic perturbation.
https://www.ncbi.nlm.nih.gov/pubmed/32491888
Despite the importance of having robust estimates of the time-asymptotic total number of infections, early estimates of COVID-19 show enormous fluctuations. Using COVID-19 data from different countries, we show that predictions are extremely sensitive to the reporting protocol and crucially depend on the last available data point before the maximum number of daily infections is reached. We propose a physical explanation for this sensitivity, using a susceptible-exposed-infected-recovered model, where the parameters are stochastically perturbed to simulate the difficulty in detecting patients, different confinement measures taken by different countries, as well as changes in the virus characteristics. Our results suggest that there are physical and statistical reasons to assign low confidence to statistical and dynamical fits, despite their apparently good statistical scores. These considerations are general and can be applied to other epidemics.
Chaos: An Interdisciplinary Journal of Nonlinear Science
Davide Faranda;Isaac Pérez Castillo;Oliver Hulme;Aglaé Jezequel;Jeroen S W Lamb;Yuzuru Sato;Erica L Thompson
2020-06-04 02:00:00+02:00
32491888
FR;GB
Laboratoire des Sciences du Climat et de l'Environnement, CEA Saclay l'Orme des Merisiers, UMR 8212 CEA-CNRS-UVSQ, Université Paris-Saclay and IPSL, 91191 Gif-sur-Yvette, France.;London Mathematical Laboratory, 8 Margravine Gardens, London W6 8RH, United Kingdom.;LMD/IPSL, ENS, PSL Université, École Polytechnique, Institut Polytechnique de Paris, Sorbonne Université, CNRS, 75005 Paris, France.
1014
10.1038/s41577-020-0353-y
Journal Article;Published Erratum
en
Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.
https://www.ncbi.nlm.nih.gov/pubmed/32488203
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
1474-1733,1474-1741
2020-06-07 02:00:00+02:00
pubmed
Nature Reviews Immunology
Miriam Merad;Jerome C Martin
2020-06-04 02:00:00+02:00
32488203
FR;US
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Université de Nantes, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Nantes, France. jerome.martin@univ-nantes.fr.;CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France. jerome.martin@univ-nantes.fr.
1015
10.1093/pubmed/fdaa075
Journal Article
en
The substantial awareness role of web-based and social media platforms in developing countries during a pandemic scenario: the example of COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32490518
During the outbreak of coronavirus COVID-19, social media platforms have shown effectiveness in information dissemination. Delivering evidence-based medical knowledge and trustworthy recommendations is a difficult mission for classical entities, especially in a war-torn country with a fragile health system. In this context, the role of non-governmental scientific organizations was proven, filling the gap between original scientific sources and a non-English speaking population.
Faculty of Medicine, University of Hama, 0500 Hama, Syria.;Department of Gastroenterology and Hepatology, Faculty of Medicine, Damascus University, 0100 Damascus, Syria.;Hematology and Cell Therapy Department, Saint-Antoine Hospital, AP-HP Sorbonne University, 75012 Paris, France.
1020
10.1016/j.amp.2020.06.004
English Abstract;Journal Article
fr
[Optimism and COVID-19: A resource to support people in confinement?]
https://www.ncbi.nlm.nih.gov/pubmed/32836302
This text envisages looking at the psychological consequences of the health situation related to COVID-19 from the concept of optimism. Positive psychology has for several years been dealing with this concept, which is well known to the general public, but which has been the subject of major conceptual development in the field of science. It seems to us that the concept of optimism can be particularly useful in understanding and influencing the behaviour of our fellow citizens during the period of confinement that is currently imposed on everyone, in the same way that we must consider the consequences in the short, medium and long term, both economically and in terms of the moral and physical health of our fellow citizens, that is, after the period of confinement. Traditionally, being optimistic means being confident in the positive outcome of an event, whereas pessimism means expecting the worst. The uncertainty that this virus imposes on us and the new situations that it brings about, forces us to think the world in uncertain terms, which can be destabilizing. Understanding the contribution of the concept of optimism in the potential of the adaptive processes that each of us may or may not be able to mobilize to face and adapt to this unprecedented and unprecedented health crisis is essential. This will undoubtedly be a major challenge for the social sciences and psychology. This is why we believe that the concept of optimism can help to provide additional insights that will enable us to better grasp the rational (or non-rational) behaviours that we may face in the future, and in which we are already involved.
Charles Martin-Krumm;Cyril Tarquinio;Camille Tarquinio
COVID-19;Containment;Health;Hope;Optimism
2020-06-05 02:00:00+02:00
32836302
FR
Laboratoire VCR, École de Psychologues Praticiens de l'Institut Catholique de Paris - Equipe d'accueil Religion, culture et société, Paris, France.;ChartUpon Nanterre Paris Ouest, Paris, France.;IRBA Brétigny, Brétigny, France.;ChartUpon EA 4004 Nanterre Paris Ouest, Nanterre, France.
1025
10.1186/s13054-020-03013-2
Editorial
en
The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients.
Bruno François;Pierre-François Laterre;Charles-Edouard Luyt;Jean Chastre
2020-06-05 02:00:00+02:00
32503590
FR;BE
Intensive Care Unit and Inserm CIC1435 & UMR1092, CHU Dupuytren, Limoges, France. b.francois@unilim.fr.;Intensive Care Unit, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.;Intensive Care Unit, Hôpital La Pitié-Salpétrière, APHP-Sorbonne Université, Paris, France.
1034
10.1111/tbed.13659
Journal Article
en
First detection and genome sequencing of SARS-CoV-2 in an infected cat in France.
https://www.ncbi.nlm.nih.gov/pubmed/32500944
After its first description in Wuhan (China), SARS-CoV-2 the agent of coronavirus disease 2019 (COVID-19) rapidly spread worldwide. Previous studies suggested that pets could be susceptible to SARS-CoV-2. Here, we investigated the putative infection by SARS-CoV-2 in 22 cats and 11 dogs from owners previously infected or suspected of being infected by SARS-CoV-2. For each animal, rectal, nasopharyngeal swabs and serum were taken. Swabs were submitted to RT-qPCR assays targeting 2 genes of SARS-CoV-2. All dogs were tested SARS-CoV-2 negative. One cat was tested positive by RT-qPCR on rectal swab. Nasopharyngeal swabs from this animal were tested negative. This cat showed mild respiratory and digestive signs. Serological analysis confirms the presence of antibodies against the SARS-CoV-2 in both serum samples taken 10 days apart. Genome sequence analysis revealed that the cat SARS-CoV-2 belongs to the phylogenetic clade A2a like most of the French human SARS-CoV-2. This study reports for the first time the natural infection of a cat in France (near Paris) probably through their owners. There is currently no evidence that cats can spread COVID-19 and owners should not abandon their pets or compromise their welfare.
1865-1674,1865-1682
2020-06-07 02:00:00+02:00
pubmed
Transboundary and Emerging Diseases
Corinne Sailleau;Marine Dumarest;Jessica Vanhomwegen;Manon Delaplace;Valerie Caro;Aurélia Kwasiborski;Véronique Hourdel;Patrick Chevaillier;Alix Barbarino;Loic Comtet;Philippe Pourquier;Bernard Klonjkowski;Jean-Claude Manuguerra;Stephan Zientara;Sophie Le Poder
UMR VIROLOGIE, INRAE, Ecole Nationale Vétérinaire d'Alfort, ANSES, Laboratoire de santé animale, Université Paris-Est, Maisons-Alfort, France.;Environment and Infectious Risk Unit, Laboratory for Urgent Response to Biological Threats, Institut Pasteur, Paris, France.;The OIE Collaborating Centre for Detection and Identification in Humans of Emerging Animal Pathogens, Institut Pasteur, Paris, France.;Clinique vétérinaire, Savigny sur Orge, France.;CHUVA, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, France.;IDVET, Grabels, France.
1037
Letter;Comment
en
Early administered antibiotics do not impact mortality in critically ill patients with COVID-19.
Antibiotics;COVID-19;Intensive care unit;SARS-CoV-2
2020-06-05 02:00:00+02:00
32512022
FR;CH
Ente Ospedaliero Cantonale, Locarno Community Hospital, Locarno, Switzerland, INSERM IAME, U1137, Team DeSCID, Paris, France. Electronic address: niccolo.buetti@gmail.com.;Ente Ospedaliero Cantonale, Locarno Community Hospital, Locarno, Switzerland.;Ente Ospedialiero Cantonale, Infection Control Program, Ticino, Switzerland, Ente Ospedialiero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland, Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.;Ente Ospedialiero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.
1039
10.1016/j.jhin.2020.06.003
Journal Article
en
Preventing SARS-CoV-2 transmission in rehabilitation pools and therapeutic water environments.
https://www.ncbi.nlm.nih.gov/pubmed/32522671
SARS-CoV-2 is mainly transmitted by respiratory droplets and contact with contaminated surfaces. It can be retrieved in faeces but there is no evidence of faecal-oral transmission, which is the main route of contamination in recreational waters. Standard cleaning and disinfecting procedures, microbiological control and health rules aim to prevent infectious risk regardless of the micro-organisms. In the context of progressive lockdown exit and hospital activities recovery, we assessed the risk of SARS-CoV-2 transmission in rehabilitation pools and therapeutic water environments in order to provide specific recommendations to control the spread of SARS-CoV-2 while ensuring essential rehabilitation care for patients.
HydroSciences Montpellier, IRD, CNRS, Montpellier University, Montpellier, France, Hospital Hygiene and Infection Control Team, University Hospital of Montpellier, Montpellier, France. Electronic address: sara.romano-bertrand@umontpellier.fr.;Department of Epidemiology and Infection Control, Dijon University Hospital, Dijon, France.;Department of Preventive Medicine, Infection Prevention and Control Team, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.;MiHAR Lab, EE 1701 S, Nantes University, Nantes, France, Department of Bacteriology and Infection Control, Nantes University Hospital, Nantes, France.
1059
10.1093/ckj/sfaa099
Journal Article
en
Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019.
https://www.ncbi.nlm.nih.gov/pubmed/32695326
Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and characterization in critically ill patients has not been reported.
Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.;Unité INSERM U1034, Université de Bordeaux, Bordeaux, France.;Service de Médecine Intensive Réanimation, Hôpital Pellegrin et Hôpital Saint André, CHU de Bordeaux, Bordeaux, France.;Service de Biochimie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.;Service d'Anesthésie-Réanimation Sud, Centre Médico-Chirurgical Magellan, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.;Service d'Anesthésie-Réanimation, Pellegrin CHU de Bordeaux, Bordeaux, France.
1060
10.1016/j.therap.2020.06.002
Editorial
en
Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32553502
0040-5957
2020-06-07 02:00:00+02:00
pubmed
Therapies
Jean-Luc Cracowski;Mathieu Molimard;Vincent Richard
2020-06-06 02:00:00+02:00
32553502
FR
Université Grenoble Alpes, centre régional de pharmacovigilance et CIC1406, INSERM, HP2, 38000 Grenoble, France. Electronic address: jean-luc.cracowski@univ-grenoble-alpes.fr.;Service de pharmacologie médicale, University Bordeaux, INSERM U1219, 33076 Bordeaux, France.;Université de Rouen Normandie, UNIROUEN, CHU de Rouen Normandie, service de pharmacologie, UMR Inserm U1096 EnVI, 76000 Rouen, France.
1061
10.1016/j.ad.2020.05.004
Case Reports
en
Managing Psoriasis Consultations During the COVID-19 Pandemic: Recommendations From the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV).
https://www.ncbi.nlm.nih.gov/pubmed/32522413
0001-7310
2020-06-07 02:00:00+02:00
pubmed
Actas Dermo-Sifiliográficas
I Belinchón;L Puig;L Ferrándiz;P de la Cueva;J M Carrascosa
2020-06-06 02:00:00+02:00
32522413
FR;ES
Servicio de Dermatología, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, España. Electronic address: belinchon_isa@gva.es.;Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Dermatología, Hospital Universitario Virgen Macarena, Sevilla, España.;Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, España.;Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP, Barcelona, España.
1065
Letter
en
A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2?
https://www.ncbi.nlm.nih.gov/pubmed/32534339
2020-06-07 02:00:00+02:00
pubmed
Dan Lipsker
2020-06-06 02:00:00+02:00
32534339
FR
Clinique Dermatologique, Hôpitaux Universitaires, Strasbourg cedex, France, Faculté de Médecine, Université de Strasbourg, France. Electronic address: dan.lipsker@chru-strasbourg.fr.
1066
Case Reports;Letter
en
Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, Institut national de la santé et de la recherche médical, immunorhumatologie moléculaire unité mixte de recherche-S 1109, Strasbourg, France. Electronic address: gabriela.gautier-vargas@chru-strasbourg.fr.;Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France.;Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, Institut national de la santé et de la recherche médical, immunorhumatologie moléculaire unité mixte de recherche-S 1109, Strasbourg, France, Department of Virology, Strasbourg University Hospital, Strasbourg, France.;Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, Institut national de la santé et de la recherche médical, immunorhumatologie moléculaire unité mixte de recherche-S 1109, Strasbourg, France.
1077
10.1002/oby.22924
Journal Article
en
COVID-19: A Lever for the Recognition of Obesity as a Disease? The French Experience.
Assistance-Publique-Hôpitaux de Paris, Nutrition Department, Pitié-Salpêtrière hospital, Sorbonne University, Paris, France.;Sorbonne University, INSERM, Nutrition and obesity: systemic approaches (NutriOmics) research unit, F-CRIN/FORCE Network, Paris, France.;Assistance Publique Hôpitaux de Paris, Explorations Fonctionnelles Department, Obesity Reference Center, Louis Mourier Hospital, Université de Paris, Inserm UMR 1149, F-CRIN/FORCE Network, F-92000 , Colombes, France.;Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Univ-Lyon, CarMeN Laboratory, Université Claude Bernard Lyon1, F-CRIN/FORCE Network, Pierre Bénite, Lyon, France.;Specialized Obesity Center and Endocrinology, Diabetology, Nutrition dept, Brabois Hospital, CHRU of Nancy, F-CRIN/FORCE Network, Vandoeuvre-Les-Nancy, France.
1078
Case Reports;Letter
en
Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection.
Dermatology Department, Ambroise Paré University Hospital Center, Mons, Belgium.;Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium.
1081
10.1136/ijgc-2020-001617
Journal Article
en
European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32487685
1048-891X,1525-1438
2020-06-07 02:00:00+02:00
pubmed
International Journal of Gynecologic Cancer
Andrea Ciavattini;Giovanni Delli Carpini;Luca Giannella;Marc Arbyn;Maria Kyrgiou;Elmar A Joura;Jalid Sehouli;Xavier Carcopino;Charles W Redman;Pekka Nieminen;Maggie Cruickshank;Murat Gultekin
cervical cancer
2020-06-02 02:00:00+02:00
32487685
FR;FI;GB;US;IT;TR;DE;BE;AT
Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Faculty of Medicine, Università Politecnica delle Marche, Ancona, Italy.;Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.;Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College, London, W12 0NN, UK.;West London Gynaecological Cancer Centre, Queen Charlotte's and Chelsea, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK.;Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.;Department of Gynecology and Center for Oncological Surgery, Charité, University Medicine Berlin, Berlin, Germany.;Department of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE, UMR 7263, 13397, Marseille, France.;University Hospitals of North Midlands NHS Trust, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom.;Department of Obstetrics and Gynaecology, Helsinki University Hospital and Helsinki University, Helsinki, Finland.;Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.;Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ankara, Turkey mrtgultekin@yahoo.com.
1083
Letter
en
Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study.
https://www.ncbi.nlm.nih.gov/pubmed/32487122
2020-06-07 02:00:00+02:00
pubmed
Aged;Coronavirus Infections__epidemiology;Critical Illness;Female;France__epidemiology;Hemorrhage__epidemiology;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Retrospective Studies;Thrombosis__epidemiology;COVID-19
Service de réanimation polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France.;Service de réanimation polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France. damien.contou@ch-argenteuil.fr.
1085
Letter;Comment
en
Turning a surgical unit into a COVID-19 facility: Governance counts.
Michel Sfez;Alexandre Derichard;Marie-Laure Cittanova-Pansard
COVID-19;Governance;Surgery
2020-06-02 02:00:00+02:00
32502703
FR
Clinique Saint-Jean de Dieu, 2, Rue Rousselet, Paris, France. Electronic address: sfez_michel@yahoo.fr.;Clinique Saint-Jean de Dieu, 2, Rue Rousselet, Paris, France. Electronic address: alexandre.derichard@wanadoo.fr.;Clinique Saint-Jean de Dieu, 2, Rue Rousselet, Paris, France. Electronic address: mlcittanova@gmail.com.
1091
10.1016/j.afjem.2020.05.012
Editorial
en
Providing end-of-life care in the emergency department: Early experience from Médecins Sans Frontières during the Covid-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32837875
2211-419X
2020-06-07 02:00:00+02:00
pubmed
African Journal of Emergency Medicine
Anne-Marie Pegg;Miguel Palma;Cliff Roberson;Chibuzo Okonta;Marie-Hortense Nkokolo Massamba/Koudika;Natalie Roberts
2020-06-01 02:00:00+02:00
32837875
FR;CI;CA;US
Medical Department, Médecins Sans Frontières (MSF)-Operational Centre Paris (OCP), Paris, France.;Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada.;Medical Department, MSF-OCP, Paris, France.;School of Nursing, Columbia University, New York, NY, USA.;MSF-West and Central Africa, Abidjan, Cote d'Ivoire.;MSF-OCP, Paris, France.;Centre de réflexion sur l'action et les savoirs humanitaires (CRASH), MSF Foundation, Paris, France.
1095
10.3747/co.27.6685
Consensus Development Conference;Journal Article
en
Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32669938
The emergence of covid-19 has the potential to change the way in which the health care system can accommodate various patient populations and might affect patients with non-covid-19 problems. The Quebec Lung Cancer Network, which oversees thoracic oncology services in the province of Quebec under the direction of the Ministère de la Santé et des Services sociaux, convened to develop recommendations to deal with the potential disruption of services in thoracic oncology in the province of Quebec. The summary provided here has been adapted from the original document posted on the Programme québécois du cancer Web site at: https://www.msss.gouv.qc.ca/professionnels/documents/coronavirus-2019-ncov/PJ1_Recommandations_oncologie-thoracique-200415.pdf.
N Blais;M Bouchard;M Chinas;H Lizotte;M Morneau;J Spicer;S Martel
Thoracic cancer;covid-19;priorities
2020-06-01 02:00:00+02:00
32669938
FR;CA
Service d'hémato-oncologie, Département de médecine, Centre hospitalier de l'Université de Montréal, Montreal, QC.;Service de radio-oncologie, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC.;Programme québécois de cancérologie, Ministère de la Santé et des Services sociaux du Québec, Quebec City, QC.;Direction générale, Institut universitaire de cardiologie et pneumologie de Québec, Quebec City, QC.;Direction de l'offre de soins et services en cancérologie, Programme québécois de cancérologie, Ministère de la Santé et des Services sociaux du Québec, Quebec City, QC.;Division of Thoracic and Upper Gastrointestinal Surgery, Department of Surgery, McGill University, McGill University Health Centre, Montreal, QC.;Service de pneumologie, Institut universitaire de cardiologie et pneumologie de Québec, Quebec City, QC.
1100
Letter
en
Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.
Département d'anesthésie réanimation Brabois Adulte, CHRU Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France, Inserm UMR 1116, équipe 2, faculté de médecine, Université de Lorraine, 9, avenue de la Forêt de Haye - CS 50184, 54505 Vandœuvre-lès-Nancy cedex, France. Electronic address: mr.losser@chru-nancy.fr.;Département d'anesthésie réanimation Brabois Adulte, CHRU Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.;Pôle anesthésie réanimation, CHU de Grenoble-Alpes, 38000 Grenoble, France.;UMR Inserm 1160, UFR de médecine, Université Paris 7, Paris, France.
1114
10.1007/s11125-020-09475-0
Journal Article
en
COVID-19 causes unprecedented educational disruption: Is there a road towards a new normal?
https://www.ncbi.nlm.nih.gov/pubmed/32836420
COVID-19 confronts the education system with a new and massive crisis. What should a "new normal" look like for future generations? How can countries use the innovativeness of the recovery period to "build back better"? This Viewpoint highlights the UNESCO-led Global Coalition for Education initiative, which is seeking solutions to support learners and teachers, as well as governments throughout the recovery process, with a principal focus on inclusion, equity, and gender equality. The Viewpoint also argues that the current crisis is an opportunity for stronger international collaboration, which might provide a better focus and deliver solutions, including digital tools. Resilience and adaptability will be crucial for the next generations to navigate through the present-and any future-pandemic.
0033-1538,1573-9090
2020-06-07 02:00:00+02:00
pubmed
PROSPECTS
Hans d'Orville
Digital learning tools;International cooperation;Learning crisis;Pandemic;School closures
2020-06-03 02:00:00+02:00
32836420
FR
Paris, France.
1122
10.1111/ene.14373
Editorial
en
How to support the quality of life of people living with cognitive disorders: a (k)new challenge in the post-COVID-19 world.
https://www.ncbi.nlm.nih.gov/pubmed/32492256
1351-5101,1468-1331
2020-06-07 02:00:00+02:00
pubmed
European Journal of Neurology
Y Chen;C Chen
2020-06-03 02:00:00+02:00
32492256
FR;IE;SG
Global Brain Health Institute, TCD, Dublin, Ireland.;UMR-S1172, Degenerative and Vascular Cognitive Disorders, Inserm, CHU Lille, Lille Neurosciences and Cognition, Université de Lille, Lille, France.;Department of Pharmacology, Memory Aging and Cognition Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.
1124
10.1111/liv.14557
Journal Article
en
Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry?
https://www.ncbi.nlm.nih.gov/pubmed/32495496
While several studies from China have reported COVID-19-related liver injury, there are currently no data on liver dysfunction in hospitalized COVID-19 patients in Europe. The aim of this study was to describe the prevalence and predictive value of abnormal liver function in patients hospitalized with COVID-19. This was a retrospective cohort study of confirmed COVID-19 patients hospitalized in two referral hospitals in France. Clinical, biological and radiological data were collected and analysed. In all, 234 patients confirmed to have COVID-19 by RT-PCR were included. Liver function was abnormal in 66.6% of patients on admission. In multivariate logistic regression, abnormal liver test on admission were associated with in-hospital aggravation (OR = 4.1, 95% CI 1.5-10.8; P = .004) and mortality (OR 3.3; 95% CI = 1.04-10.5; P = .04). This study of liver tests in a European COVID-19 population confirms a high prevalence of abnormal liver tests on admission that are predictive of severe disease course and higher in-hospital mortality.
Department of Hepatology, Gastroenterology and Liver Transplantation, Montpellier University Hospital, University of Montpellier, Montpellier, France.;Department of Gastroenterology and Hepatology, Narbonne Hospital, Narbonne, France.;Department of Infectious Diseases, Montpellier University Hospital, University of Montpellier, Montpellier, France.;Department of Intensive Care Lapeyronie, Montpellier University Hospital, University of Montpellier, Montpellier, France.;Department of Internal Medicine Lapeyronie, Montpellier University Hospital, University of Montpellier, Montpellier, France.
1130
10.1007/s00259-020-04910-y
Editorial
en
Impact of the COVID-19 crisis on imaging in oncological trials.
https://www.ncbi.nlm.nih.gov/pubmed/32533240
1619-7070,1619-7089
2020-06-14 02:00:00+02:00
pubmed
Clinical Trials as Topic;Coronavirus Infections__complications;Humans;Incidental Findings;Neoplasms__diagnostic imaging;Pandemics;Patient Selection;Pneumonia__complications;Pneumonia, Viral__complications;Policy;COVID-19
European Journal of Nuclear Medicine and Molecular Imaging
Christophe M Deroose;Frédéric E Lecouvet;Laurence Collette;Daniela E Oprea-Lager;Wolfgang G Kunz;Luc Bidaut;Joost J C Verhoeff;Caroline Caramella;Egesta Lopci;Bertrand Tombal;Lioe-Fee de Geus-Oei;Laure Fournier;Marion Smits;Nandita M deSouza
2020-06-14 02:00:00+02:00
32533240
FR;GB;IT;NL;BE;DE
European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium. christophe.deroose@uzleuven.be.;Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.;Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.;European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium.;Department of Radiology, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.;European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.;Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers (VU University), Amsterdam, The Netherlands.;Department of Radiology, University Hospital, LMU Munich, Munich, Germany.;College of Science, University of Lincoln, Lincoln, UK.;Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.;Radiology Department, Hôpital Marie Lannelongue, Institut d'Oncologie Thoracique, Université Paris-Saclay, Le Plessis-Robinson, France.;Nuclear Medicine, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Milan, Italy.;Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.;Department of Radiology, AP-HP, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France.;Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, The Netherlands.;Cancer Research UK Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust-Sutton, Sutton, UK.
Nicholas Moore;Bruce Carleton;Patrick Blin;Pauline Bosco-Levy;Cecile Droz
2020-06-13 02:00:00+02:00
32529474
FR;CA;GB;US
Bordeaux PharmacoEpi, INSEMR CIC 1401, Universityd of Bordeaux, 146 rue Leo Saignat, 33076, Bordeaux, France. Nicholas.moore@u-bordeaux.fr.;Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.;Bordeaux PharmacoEpi, INSEMR CIC 1401, Universityd of Bordeaux, 146 rue Leo Saignat, 33076, Bordeaux, France.
1142
10.1093/cid/ciaa746
Journal Article
en
COVID-19 : Pacific Islands challenges.
https://www.ncbi.nlm.nih.gov/pubmed/32511697
1058-4838,1537-6591
2020-06-14 02:00:00+02:00
pubmed
Clinical Infectious Diseases
Simon Poignant;Laure Baudouin;Marc Vinclair;Sandrine Mons
2020-06-08 02:00:00+02:00
32511697
FR
Département d'Anesthésie et Réanimation. Hôpital du Taaone, Centre Hospitalier de Polynésie Française, Pirae, Tahiti, French Polynesia.
1144
10.5455/jpma.16
Journal Article
en
Endocrine vigilance in COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32515380
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for a pandemic that emerged in December 2019. Heterogeneous clinical forms are described from asymptomatic to severe hypoxaemic acute respiratory syndrome with multisystem organ failure. The impact of this coronavirus disease 2019 on the endocrine glands remains unknown. However, the results of previous studies on viruses from the same family allow us to write proposals for patients followed for chronic endocrine diseases. Currently, if these subjects are infected with SARS-CoV-2, they must not stop their treatment. In some cases, hormone replacement doses have to be increased. In case of worsening clinical signs, hormonal biological monitoring must be done. This article will be helpful for improving the management of chronic endocrine diseases that could affect thyroid, adrenals, gonads and pituitary gland functions. Proposals could be applied in COVID-19 infected subjects or in those who have been in contact with COVID-19 infected people.
Department of Diabetology-Endocrinology, University Hospital of Guadeloupe , Guadeloupe.;Diabetes and Endocrine Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.;Department of Endocrinology, National Hospital of Sri Lanka, Colombo, Sri Lanka.
1151
Journal Article;Review
en
Preparing for emerging respiratory pathogens such as SARS-CoV, MERS-CoV, and SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32532941
Preparing for emerging respiratory pathogens is a fundamental requirement for enhancements of the safeguard in healthcare settings. We are facing an increasing pressure to be prepared more than before. Healthcare organizations should be ready to deal with such emerging infectious disease. Here, we share some points that are essential to be considered while we prepare our institutions to prevent the transmission of emerging respiratory pathogens such as MERS-CoV and the recently emerging pandemic of SARS-CoV-2, the causative agent of COVID-19.
Jaffar A Al-Tawfiq;Mohammed A Garout;Philippe Gautret
2020-06-14 02:00:00+02:00
32532941
FR;US;SA
Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Department of Community Medicine and Public Health, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.;Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, IHU-Méditerranée Infection, Marseille, France.
1153
10.1007/s00134-020-06153-9
Journal Article;Review
en
Acute kidney injury in critically ill patients with COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32533197
Acute kidney injury (AKI) has been reported in up to 25% of critically-ill patients with SARS-CoV-2 infection, especially in those with underlying comorbidities. AKI is associated with high mortality rates in this setting, especially when renal replacement therapy is required. Several studies have highlighted changes in urinary sediment, including proteinuria and hematuria, and evidence of urinary SARS-CoV-2 excretion, suggesting the presence of a renal reservoir for the virus. The pathophysiology of COVID-19 associated AKI could be related to unspecific mechanisms but also to COVID-specific mechanisms such as direct cellular injury resulting from viral entry through the receptor (ACE2) which is highly expressed in the kidney, an imbalanced renin-angotensin-aldosteron system, pro-inflammatory cytokines elicited by the viral infection and thrombotic events. Non-specific mechanisms include haemodynamic alterations, right heart failure, high levels of PEEP in patients requiring mechanical ventilation, hypovolemia, administration of nephrotoxic drugs and nosocomial sepsis. To date, there is no specific treatment for COVID-19 induced AKI. A number of investigational agents are being explored for antiviral/immunomodulatory treatment of COVID-19 and their impact on AKI is still unknown. Indications, timing and modalities of renal replacement therapy currently rely on non-specific data focusing on patients with sepsis. Further studies focusing on AKI in COVID-19 patients are urgently warranted in order to predict the risk of AKI, to identify the exact mechanisms of renal injury and to suggest targeted interventions.
Paul Gabarre;Guillaume Dumas;Thibault Dupont;Michael Darmon;Elie Azoulay;Lara Zafrani
Acute kidney injury;COVID-19;Intensive care unit;Renin–angiotensin–aldosterone system
2020-06-12 02:00:00+02:00
32533197
FR
Medical Intensive Care Unit, Hopital Saint-Louis, Assistance Publique des Hôpitaux de Paris, University of Paris, Paris, France.;Medical Intensive Care Unit, Hopital Saint-Louis, Assistance Publique des Hôpitaux de Paris, University of Paris, Paris, France. lara.zafrani@aphp.fr.;UMR 976, INSERM, Paris, France. lara.zafrani@aphp.fr.
Yazine Mahjoub;Daniel Oscar Rodenstein;Vincent Jounieaux
2020-06-11 02:00:00+02:00
32527297
FR;BE
Cardiac Thoracic Vascular and Respiratory Intensive Care Unit, Amiens University Medical Centre, University Hospital Centre, Amiens, France. Mahjoub.Yazine@chu-amiens.fr.;Pneumology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Pneumology Department, Amiens University Medical Centre, Amiens, France.
1162
10.1016/j.amp.2020.06.005
English Abstract;Journal Article
fr
["Crown protection" or protective tendencies of the Corona Covid-19 and its improbable encounters].
https://www.ncbi.nlm.nih.gov/pubmed/32836304
The title of our paper could be receipted (intellectually receipted) like a paradox or like choking item. In real life of our hospital activity is not at all true because in both clinical situations the symptomatology of infectious disease was protected about a long psychotic or pseudo psychotic episode. The most important for the psychiatric stabilization was strictly observance and repetition of consultations who created a secure feel, necessarily for construction after psychodramatic real story Covid-19. Our clinical case shows the possibility of our patients to relativize the gravity of the pandemic and his impact. The modalities of psychotropic treatment are very important in this specific pathologic case and our presentation could give us new ideas in psychiatry and immunology about protection by ay antibiotherapy in pre- and post-operatory. Unlikely encounter with a disease that leads to an episode of madness and psychological care after a severe episode of Covid-19. Psychological support is upset by this disease, like the rest. The clinic returns to its original meaning: at the patient's bed to understand this new disease and its protective and/or revealing effects. Clinical presentation of an unlikely encounter in the context of the Covid-19 epidemic. Encounter with both a severe form of this new disease and psychopathological expression in intensive care and post-reanimation units. Psychological support in a patient suffering from a delusional episode and identity disorders related to Covid-19. Psychological support is disrupted by this disease, as is the rest. The clinic returns to its original meaning: in the patient's bed to understand this new disease and its protective and/or revealing effects. The singular and psychoanalytic listening allows the patient to understand the process of constructing his episode of delusional appearance, like dreamlike construction. Adaptation and creation of a clinic requiring to be as close as possible to the patient to allow the psychological restructuring having been disorganized in connection with the disease but also with the hospital and family environment, strongly impacted by anxiety.
Covid-19;Depression;Pandemic;Psychosis;Psychotherapy;Specific therapeutic protocol;Trouble of comportment
2020-06-11 02:00:00+02:00
32836304
FR
20, rue du Colonel-Dominé, 75013 Paris, France.;CHSF, Corbeil-Essonnes, France.
1163
10.1038/s41575-020-0328-2
Journal Article
en
COVID-19 and the liver-related deaths to come.
https://www.ncbi.nlm.nih.gov/pubmed/32528138
1759-5045,1759-5053
2020-06-14 02:00:00+02:00
pubmed
Nature Reviews Gastroenterology & Hepatology
Jean-Michel Pawlotsky
2020-06-11 02:00:00+02:00
32528138
FR
Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France. jean-michel.pawlotsky@aphp.fr.;Viruses, Hepatology, Cancer research team, INSERM U955, Créteil, France. jean-michel.pawlotsky@aphp.fr.
1173
10.1177/1090198120935067
Editorial
en
The COVID-19 Pandemic: Everything Old Is New Again in Public Health Education.
https://www.ncbi.nlm.nih.gov/pubmed/32517520
1090-1981,1552-6127
2020-06-14 02:00:00+02:00
pubmed
Betacoronavirus;Coronavirus Infections__epidemiology;Health Equity;Health Status Disparities;Healthcare Disparities__organization & administration;Humans;Pandemics;Pneumonia, Viral__epidemiology;Public Health__education;Social Determinants of Health__ethnology;Socioeconomic Factors;United States__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2
Health Education & Behavior
Jesus Ramirez-Valles;Eric Breton;David H Chae;Regine Haardörfer;Lisa M Kuhns
Health Equity Institute, San Francisco State University, San Francisco, CA, USA.;École des Hautes Études en Santé Publique, Rennes, France.;Auburn University, Auburn, AL, USA.;Emory University, Atlanta, GA, USA.;Northwestern University, Chicago, IL, USA.
1174
10.1002/jmv.26172
Journal Article
en
Dyspnea: The vanished warning symptom of COVID-19 pneumonia.
Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of Neurology, Division of Cognitive and Motor Aging, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York.;Division of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.;INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;AP-HP, Site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Groupe Hospitalier Universitaire APHP-Sorbonne Université, Paris, France.;Division of Pulmonary Diseases, Geneva University Hospitals and Faculty of Medicine and University of Geneva, Geneva, Switzerland.
1182
10.1093/ecco-jcc/jjaa120
Journal Article
en
Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.
https://www.ncbi.nlm.nih.gov/pubmed/32520312
The Coronavirus 2019 (COVID-19) pandemic has posed challenges in the routine care of patients with inflammatory bowel disease. One of the key challenges needing addressing is the quantification of the risks of immunosuppressive and biologic therapies in IBD patients during the pandemic. The similarities and differences between the previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with the previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.
1873-9946,1876-4479
2020-06-14 02:00:00+02:00
pubmed
Journal of Crohn's and Colitis
S Sebastian;H A Gonzalez;L Peyrin-Biroulet
2020-06-10 02:00:00+02:00
32520312
FR;GB
IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.;Hull York Medical School, Hull, UK.;Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.;Inserm U1256 NGERE, Lorraine University, Vandoeuvre-Les-Nancy, France.
1190
Letter
en
Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.
https://www.ncbi.nlm.nih.gov/pubmed/32540682
2020-06-14 02:00:00+02:00
pubmed
Jean-Marie Vaugeois
2020-06-10 02:00:00+02:00
32540682
FR
Normandie University, université de Rouen, université de Caen, ABTE, Rouen 76000, France, Département de Pharmacie, UFR Santé, 22, boulevard Gambetta, 76183 Rouen cedex 1, France. Electronic address: jean-marie.vaugeois@univ-rouen.fr.
1192
10.12890/2020_001769
Journal Article
en
Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32665938
We describe the case of a patient hospitalized for acute decompensated heart failure in a standard medical ward. During hospitalization, he was diagnosed with COVID-19 and transferred to a special unit. The clinical course was marked by worsening of the respiratory disease, the development of right parotiditis and thrombosis of the left internal jugular vein. Therapeutic anticoagulation was initiated and 2 days later, the minimal dermatoporosis lesions previously present in the upper extremities evolved to haemorrhagic bullae with intra-bullae blood clots and dissecting haematomas. Surgical management of the dissecting haematomas was difficult in the context of haemostasis abnormalities. The patient died 29 days after hospital admission.
Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasboug, Strasbourg, France.;Service de Dermatologie, Hôpitaux Universitaires de Strasboug, Strasbourg, France.
1199
10.1016/j.ijantimicag.2020.106054
Journal Article
en
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
https://www.ncbi.nlm.nih.gov/pubmed/32534188
The emergence and rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a potentially fatal disease, is swiftly leading to public health crises worldwide. The origin of SARS-CoV-2 infection was first reported in people exposed to a seafood market in Wuhan City, China in December 2019. It has been suggested that the infection is likely to be of zoonotic origin and transmitted to humans through a not-yet-known intermediary. As of 22 May 2020, the World Health Organization reported that there were approximately 4,995,996 confirmed cases and 327,821 deaths. SARS-CoV-2 is transmitted via inhalation or direct contact with droplets from infected people. It has an incubation period ranging from 2 to ≥14 days. The rate of spread of SARS-CoV-2 is greater than that for severe acute respiratory syndrome coronavirus and Middle East respiratory coronavirus. The symptoms are similar to influenza (i.e. breathlessness, sore throat and fatigue) and infected cases are isolated and treated. Infection is mild in most cases, but in elderly (>50 years) patients and those with cardiac and respiratory disorders, it may progress to pneumonia, acute respiratory distress syndrome and multi-organ failure. People with strong immunity or those who have developed herd immunity are asymptomatic. The fatality rate ranges from 3% to 4%. Recommended methods for diagnosis of COVID-19 are molecular tests (e.g. polymerase chain reaction) on respiratory secretions, chest scan and common laboratory diagnosis. Currently, treatment is essentially supportive, and the role of antiviral agents is yet to be established as a vaccine is not yet available. This review will focus on epidemiology, symptoms, transmission, pathogenesis, ongoing available treatments and future perspectives of SARS-CoV-2.
School of Chemistry, Monash University, Clayton, VIC-3800, Melbourne, Australia. Electronic address: a.sharmard@gmail.com.;School of Studies in Chemistry, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India.;Biocapteurs-Analyses-Environnement, Universite de Perpignan Via Domitia, 52 Avenue Paul Alduy, Perpignan CEDEX 66860, France, Sensbiotech, 21rue de Nogarede, 66400 Ceret, France.
Video as a public health knowledge transfer tool in Burkina Faso: A mixed evaluation comparing three narrative genres.
https://www.ncbi.nlm.nih.gov/pubmed/32520930
The dengue virus is endemic in many low- and middle-income countries. In Burkina Faso, the proportion of fevers that could be due to dengue is growing. In 2013, a dengue epidemic spread there, followed by other seasonal outbreaks. Dengue is often confused with malaria, and health workers are not trained to distinguish between them. Three training videos using different narrative genres were tested with nursing students from two institutions in Ouagadougou: journalistic, dramatic and animated video. The study aimed to determine if video is an effective knowledge transfer tool, if narrative genre plays a role in knowledge acquisition, and which narrative elements are the most appreciated.
Catherine Hébert;Christian Dagenais;Esther Mc Sween-Cadieux;Valéry Ridde
2020-06-10 02:00:00+02:00
32520930
FR;CA
Department of Psychology, University of Montreal, Montreal, Quebec, Canada.;French Institute For Research on sustainable Development (IRD), CEPED (IRD-Université Paris Descartes), Universités Paris Sorbonne Cités, ERL INSERM SAGESUD, Paris, France.
1210
10.1016/j.jemep.2020.100541
Editorial
fr
[COVID-19, human dignity and psychological trauma for caregivers: An open letter to health authorities].
https://www.ncbi.nlm.nih.gov/pubmed/32835058
2352-5525
2020-06-14 02:00:00+02:00
pubmed
Ethics, Medicine and Public Health
P Charlier
2020-06-12 02:00:00+02:00
32835058
FR
Laboratoire Anthropologie Archéologie Biologie (LAAB), université Paris-Saclay (UVSQ), 2, avenue de la Source-de-la-Bièvre, 78180 Montigny-Le-Bretonneux, France.;Musée du quai Branly-Jacques-Chirac, 222, rue de l'Université, 75007 Paris, France.
1215
10.1016/j.jaccas.2020.06.003
Case Reports
en
4 Cases of Aortic Thrombosis in Patients With COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32835285
Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications. This report describes 4 cases of aortic thrombosis in patients admitted for COVID-19 infection between March 26 and April 12, 2020, in Mulhouse, France. (Level of Difficulty: Intermediate.).
Service de médecine vasculaire, Hôpital Emile Muller de Mulhouse, Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace, Mulhouse, France.;Service de cardiologie, Hôpital Emile Muller de Mulhouse Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace, Mulhouse, France.;Service de chirurgie vasculaire, Hôpital Emile Muller de Mulhouse Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace, Mulhouse, France.
1218
Letter
en
Discrepancy in reports of COVID-19 onset of symptoms: are faulty data being collected?
Department of Infectious Diseases, Hotel Dieu de France, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.;Department of Infectious Diseases, Hotel Dieu de France, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. Electronic address: ramiwaked12@hotmail.com.;Department of Internal Medicine and Clinical Immunology, Hotel Dieu de France, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
1220
10.12890/2020_001751
Journal Article
en
Immune Thrombocytopenic Purpura in Patients with COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32665935
We described three COVID-19-infected patients with profound immune thrombocytopenia causing haemorrhagic mucocutaneous complications. We conclude that an immune mechanism was responsible as common causes were excluded. Since corticoids were considered harmful in the circumstances, the patients were successfully treated with intravenous immunoglobulins without later relapse.
Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult.
https://www.ncbi.nlm.nih.gov/pubmed/32835271
A 42-year-old man was admitted for an ST-segment elevation myocardial infarction revealing an acute thrombosis of the left anterior descending and right coronary arteries. Following this acute multivessel coronary occlusion in a young individual at low cardiovascular risk, he tested positive for severe acute respiratory syndrome-coronavirus-2 infection. (Level of Difficulty: Beginner.).
COVID-19, coronavirus-2019;SARS-CoV-2;SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2;STEMI, ST-segment elevation myocardial infarction;ULN, upper limit of normal value;acute coronary syndrome;arterial thrombosis;coronavirus disease-2019;myocardial infarction
2020-06-09 02:00:00+02:00
32835271
FR
ACTION (Allies in Cardiovascular Trials Initiatives and Organized Networks) Study Group, Sorbonne Université, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France.
1224
Letter
en
Neurological Involvement of COVID-19 Patients: Making the Most of MRI.
Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, 29 rue Manin, 75019, France.
1225
10.1002/anzf.1416
Journal Article
en
Family Therapy and COVID-19: International Reflections during the Pandemic from Systemic Therapists across the Globe.
https://www.ncbi.nlm.nih.gov/pubmed/32836731
The COVID-19 pandemic has convulsed human communities across the globe like no previous event in history. Family therapists, paradoxically, given the core of their work is with systems, are also experiencing upheaval in professional and personal lives, trying to work amidst a society in chaos. This paper offers a collection of reflections by systemic and family therapists from diverse cultures and contexts penned in the midst of the pandemic. The main intention in distilling these narratives is to preserve the 'cultural diversity' and 'ecological position' of the contributors, guided by phenomenology, cultural ecology, and systemic worldviews of 'experiencing.' The second intention is to 'unite' promoting solidarity in this isolating situation by bringing each story together, creating its own metaphor of a family: united, connected, stronger. As a cross-cultural family practitioner, with a strong mission for collaboration, the lead author acknowledges the importance of Context - the nation and location of the experience; Culture - the manner in which culture impacts on experience; Collaboration - enhancing partnership, enriching knowledge, and mapping the journey's direction; and Connectedness - combating isolation while enhancing unity. Since the key transmission of culture is through language, raw reflections were sought initially in the practitioners' own language, which were translated for an English-speaking readership. These narratives are honest and rich descriptions of the authors' lived experiences, diverse and distinctive. The contributors trust colleagues will find these reflections helpful, validating and acknowledging the challenges of this unique period in history.
0814-723X,1467-8438
2020-06-14 02:00:00+02:00
pubmed
Australian and New Zealand Journal of Family Therapy
Insight Counselling & Relationship Centre, Perth and Edith Cowan University Perth Australia.;Ackerman Institute for the Family New York USA.;Paduan Center of Family Therapy Padua Italy.;Center des Buttes-Chaumont Paris France.;Serbal Centro Desarrollos Sistémicos Santiago Chile.
1232
H2020 Research Infrastructures;H2020 Fast Track to Innovation;Agence Nationale de la Recherche;H2020 European Institute of Innovation and Technology
10.3390/v12060624
Journal Article;Research Support, Non-U.S. Gov't
en
Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples.
https://www.ncbi.nlm.nih.gov/pubmed/32521706
Clinical samples collected in coronavirus disease 19 (COVID-19), patients are commonly manipulated in biosafety level 2 laboratories for molecular diagnostic purposes. Here, we tested French norm NF-EN-14476+A2 derived from European standard EN-14885 to assess the risk of manipulating infectious viruses prior to RNA extraction. SARS-CoV-2 cell-culture supernatant and nasopharyngeal samples (virus-spiked samples and clinical samples collected in COVID-19 patients) were used to measure the reduction of infectivity after 10 minute contact with lysis buffer containing various detergents and chaotropic agents. A total of thirteen protocols were evaluated. Two commercially available formulations showed the ability to reduce infectivity by at least 6 log 10, whereas others proved less effective.
[{"country": "International", "agency": "H2020 Research Infrastructures", "grantid": "871029"}, {"country": "International", "agency": "H2020 Fast Track to Innovation", "grantid": "101003544"}, {"country": "International", "agency": "Agence Nationale de la Recherche", "grantid": "PREPMedVet"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "823666"}]
Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), 13005 Marseille, France.
1233
Letter
en
A plea for the pathogenic role of immune complexes in severe Covid-19.
EA 3181, Université Bourgogne Franche-Comté, Besançon, France. Electronic address: dvuitton@univ-fcomte.fr.;Department of Acute and Chronic Diseases, Education, and Transplantation, Gastroenterology unit, University Hospital, Besançon, France.;Immuno-biology Laboratory, Établissement Français du Sang (EFS) Bourgogne Franche-Comté, Besançon, France, U1098, Inserm-EFS-Université Bourgogne Franche-Comté, Besançon, France.;U996, Inflammation, Microbiome and Immunosurveillance, Inserm, Université Paris-Saclay, Clamart, France.
1235
Letter
en
Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.
https://www.ncbi.nlm.nih.gov/pubmed/32514592
2020-06-14 02:00:00+02:00
pubmed
Robin Jeannet;Thomas Daix;Rémy Formento;Jean Feuillard;Bruno François
2020-06-08 02:00:00+02:00
32514592
FR
UMR CNRS 7276, INSERM 1262, Faculty of Medicine, University of Limoges, 87000, Limoges, France.;Inserm CIC 1435 & UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France.;Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France.;Laboratory of Hematology, Dupuytren Teaching Hospital, 87000, Limoges, France.;Inserm CIC 1435 & UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France. b.francois@unilim.fr.;Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France. b.francois@unilim.fr.;Réanimation Polyvalente, CHU Dupuytren, 2 Avenue Martin-Luther King, 87042, Limoges, France. b.francois@unilim.fr.
Blood Transfusion service, Centre Hospitalier Universitaire, University of Liège, Liège, Belgium.;Department of Thrombosis-haemostasis and Transfusion, Centre Hospitalier Régional de la citadelle, Liège, Belgium.
1243
Letter
en
High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?
https://www.ncbi.nlm.nih.gov/pubmed/32529774
2020-06-14 02:00:00+02:00
pubmed
M Pineton de Chambrun;C Frere;M Miyara;Z Amoura;I Martin-Toutain;A Mathian;G Hekimian;A Combes
2020-06-12 02:00:00+02:00
32529774
FR
From the, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, Paris, France.;Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique Hôpitaux de Paris (APHP), Hôpital La Pitié- Salpêtrière, Paris, France.;Service de Médecine Interne 2, Centre de Référence de Maladie Rare Lupus Systémique et Syndrome des Anticorps Antiphospholipides, Institut E3M, APHP, Hôpital La Pitié- Salpêtrière, Paris, France.;Service d'Hématologie Biologique, APHP, Hôpital La Pitié-Salpêtrière, Paris, France.;Laboratoire d'Immunochimie, APHP, Hôpital La Pitié-Salpêtrière, Paris, France.
1247
Letter
en
Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32533322
2020-06-14 02:00:00+02:00
pubmed
H Chaumont;A San-Galli;F Martino;C Couratier;G Joguet;M Carles;E Roze;A Lannuzel
2020-06-12 02:00:00+02:00
32533322
FR;GP
Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, 97139, Pointe-à-Pitre/Abymes, France. hugo.chaumont@chu-guadeloupe.fr.;Faculté de Médecine, Université Des Antilles, Pointe-à-Pitre, France. hugo.chaumont@chu-guadeloupe.fr.;Institut National de La Santé Et de La Recherche Médicale, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau Et de La Moelle épinière, ICM, Faculté de Médecine de Sorbonne Université, U 1127, Paris, France. hugo.chaumont@chu-guadeloupe.fr.;Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, 97139, Pointe-à-Pitre/Abymes, France.;Faculté de Médecine, Université Des Antilles, Pointe-à-Pitre, France.;Centre Hospitalier Universitaire de La Guadeloupe, Service de Réanimation, Pointe-à-Pitre/Abymes, France.;Laboratoire de Biologie de La Reproduction, Centre Hospitalier Universitaire de La Guadeloupe, Pointe-à-Pitre/Abymes, France.;Institut National de La Santé Et de La Recherche Médicale, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau Et de La Moelle épinière, ICM, Faculté de Médecine de Sorbonne Université, U 1127, Paris, France.;AP-HP, Hôpital de La Pitié-Salpêtrière, Département de Neurologie, Paris, France.;Centre D'investigation Clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, France.
1248
Letter;Comment
en
Letter regarding "SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis".
Department of Nephrology, Saint Luc University Clinics, Institute of Experimental and Clinical Research, Catholic University of Louvain, Brussels, Belgium, Division of Nephrology, Amiens-Picardie University Hospital Center, Amiens, France. Electronic address: alexandre.candellier@gmail.com.;Department of Nephrology, Saint Luc University Clinics, Institute of Experimental and Clinical Research, Catholic University of Louvain, Brussels, Belgium.
1256
Letter
en
In-ICU COVID-19 patients' characteristics for an estimation in post-ICU rehabilitation care requirement.
https://www.ncbi.nlm.nih.gov/pubmed/32544435
2020-06-14 02:00:00+02:00
pubmed
Charlotte Poussardin;Walid Oulehri;Marie Eve Isner;Paul Michel Mertes;Olivier Collange
COVID-19;Post-resuscitation care;Rehabilitation
2020-06-13 02:00:00+02:00
32544435
FR
Pôle Anesthésie Réanimation Chirurgicale, service de Réanimation Chirurgicale, Hôpitaux Universitaires de Strasbourg NHC, 67000 Strasbourg, France, EA 3072, Institut de Physiologie, FMTS (Fédération de médecine translationnelle de Strasbourg), Faculté de Médecine de Strasbourg, Université de Strasbourg, Strasbourg, France.;Institut Universitaire de Réadaptation Clémenceau (IURC), Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.;Pôle Anesthésie Réanimation Chirurgicale, service de Réanimation Chirurgicale, Hôpitaux Universitaires de Strasbourg NHC, 67000 Strasbourg, France, EA 3072, Institut de Physiologie, FMTS (Fédération de médecine translationnelle de Strasbourg), Faculté de Médecine de Strasbourg, Université de Strasbourg, Strasbourg, France. Electronic address: olivier.collange@chru-strasbourg.fr.
1257
10.1007/s40620-020-00784-3
Editorial
en
The COVID-19 infection in dialysis: are home-based renal replacement therapies a way to improve patient management?
Mario Cozzolino;Giorgina Barbara Piccoli;Talat Alp Ikizler;Claudio Ronco
2020-06-17 02:00:00+02:00
32542561
FR;IT;US
Division of Nephrology and Dialysis, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. mario.cozzolino@unimi.it.;Centre Hospitalier Le Mans, France, Le Mans, France.;Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.;Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.;Department of Medicine, University of Padua, Padua, Italy.;Department of Nephrology, Dialysis and Kidney Transplant, International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy.
1277
10.1097/rlu.0000000000003135
Case Reports;Journal Article
en
Incidental Finding of COVID-19 Lung Infection in 18F-FDG PET/CT: What Should We Do?
https://www.ncbi.nlm.nih.gov/pubmed/32558722
We report the case of an asymptomatic (no fever, no cough, no dyspnea) 80-year-old woman who had an F-FDG PET/CT scan for initial staging of Lieberkühnian adenocarcinoma located on anal canal. Chest analysis incidentally revealed bilateral diffuse patchy ground-glass opacity with mild increasing F-FDG uptake, consistent with incidental COVID-19 infection finding during the March 2020 pandemic. The infection was confirmed by reverse transcription-polymerase chain reaction. It led us to improve patient flow and to undertake broader measures to avoid patient clinical issues and potential disease spreading.
Vincent Habouzit;Alicia Sanchez;Sabrina Dehbi;Nathalie Prevot;Pierre-Benoît Bonnefoy
2020-06-20 02:00:00+02:00
32558722
FR;UNK
From the Departments of Nuclear Medicine.;Radiology, CHU Saint-Etienne.;INSERM, U1059, Saint Etienne.;Université de Lyon, Lyon, France.
1281
British Heart Foundation;Wellcome Trust;Medical Research Council
10.1093/ehjci/jeaa178
Journal Article;Research Support, Non-U.S. Gov't
en
Global evaluation of echocardiography in patients with COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32556199
To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography.
2047-2404,2047-2412
2020-06-21 02:00:00+02:00
pubmed
European Heart Journal - Cardiovascular Imaging
Marc R Dweck;Anda Bularga;Rebecca T Hahn;Rong Bing;Kuan Ken Lee;Andrew R Chapman;Audrey White;Giovanni Di Salvo;Leyla Elif Sade;Keith Pearce;David E Newby;Bogdan A Popescu;Erwan Donal;Bernard Cosyns;Thor Edvardsen;Nicholas L Mills;Kristina Haugaa
Centre for Cardiovascular Science, University of Edinburgh, UK.;Columbia University Irving Medical Center, NY, USA.;University Hospital Padua, Paediatric Cardiology, Padua, Italy.;Department of Cardiology, University of Baskent, Ankara, Turkey.;University Hospital South Manchester, Cardiology, Wythenshawe, Manchester, UK.;Department of Cardiology, University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C. C. Iliescu', Bucharest, Romania.;University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France.;Centrum voor Hart en Vaatziekten, Universitair Ziekenhuis Brussel, Vrij Universiteit van Brussel, Brussels, Belgium.;Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.;Faculty of Medicine, University of Oslo, Oslo, Norway.;Usher Institute, University of Edinburgh, UK.
1282
10.1016/s2468-1253(20)30155-2
Journal Article
en
Converging pandemics: implications of COVID-19 for the viral hepatitis response in sub-Saharan Africa.
https://www.ncbi.nlm.nih.gov/pubmed/32553140
2468-1253
2020-06-21 02:00:00+02:00
pubmed
Africa South of the Sahara__epidemiology;Betacoronavirus;Clinical Laboratory Techniques;Coinfection__diagnosis;Coronavirus Infections__diagnosis;Hepatitis, Viral, Human__diagnosis;Humans;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2
The Lancet Gastroenterology & Hepatology
Neil Gupta;Hailemichael Desalegn;Ponsiano Ocama;Karine Lacombe;Richard Njouom;Mary Afihene;Lina Cunha;C Wendy Spearman;Mark W Sonderup;Fredrick Kateera
2020-06-20 02:00:00+02:00
32553140
FR;GH;UG;CM;US;MZ;ET;ZA;RW
Division of Global Health Equity, Brigham & Women's Hospital, Boston, MA 02115, USA, Partners In Health, Boston, MA, USA. Electronic address: ngupta5@bwh.harvard.edu.;Medicala Department, St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.;Makerere University College of Health Sciences, Kampala, Uganda.;Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France, Institut Pierre Louis d'Épidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France.;Virology Department, Centre Pasteur of Cameroon, Yaounde, Cameroon.;Department of Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Komfo Anokye Teaching Hospital, Kumasi, Ghana.;Hospital Privado de Maputo, Hepato-Gastroenterology Division, Department of Medicine, Maputo, Mozambique.;Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa, Faculty of Health Sciences and Groote Schuur Hospital, Observatory, Cape Town, South Africa.;Clinical Programs Department, Partners in Health/Inshuti Mu Buzima, Kigali, Rwanda.
1288
10.1684/abc.2020.1563
Historical Article;Journal Article
en
SFBC working group "Biochemical markers of COVID-19".
https://www.ncbi.nlm.nih.gov/pubmed/32540814
The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14th, the start of the planned containment exit from May 11th. Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions.
Service de biochimie, CHU de Bordeaux , RMSB, UMR5536 CNRS Université Bordeaux, France.;Service de biochimie, CHU de Bordeaux , Université Bordeaux, France.;Laboratoire de biochimie-biologie moléculaire-nutrition-métabolisme, CHU de Nancy , Université de Lorraine, Inserm UMR-S 1256, Faculté de médecine de Nancy, Vandoeuvre-lès-Nancy, France.;Laboratoire de biochimie-biologie moléculaire-nutrition-métabolisme, CHU de Nancy, France.;UF de biochimie-toxicologie, Centre hospitalier territorial de Nouméa, Nouvelle-Calédonie, France.;Service de biochimie et biologie moléculaire, Groupement hospitalier Sud, Hospices civils de Lyon, France.;Hôpital d'instruction des armées Bégin, Département des laboratoires, Saint-Mandé, France.;LBM Gen-Bio, Groupe Inovie, Clermont-Ferrand, France.;DMU BioPhyGen, Hôpital Necker-Enfants Malades, AP-HP Centre, Laboratoire de biochimie générale , UMRS1140, Faculté de pharmacie et Université de Paris, France.;HUPNVS, Hôpitaux Beaujon et Bichat, AP-HP Nord, Laboratoires de biochimie , Université de Paris, France.;Laboratoire de biologie médicale, Centre hospitalier de Gonesse, France.;Laboratoire de biologie médicale, Groupe hospitalier Bretagne Sud, Lorient, France.;Département de biochimie et hormonologie, CHU de Montpellier , DMU BioGeM, Hôpital Tenon, AP-HP Est, Département de biochimie, France.;Biochimie et génétique moléculaire, CHU Clermont-Ferrand , UMR CNRS 6293, Inserm 1103, Université Clermont Auvergne, France.
High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission.
https://www.ncbi.nlm.nih.gov/pubmed/32542464
We conducted two World Health Organization-commissioned reviews to inform use of high-flow nasal cannula (HFNC) in patients with coronavirus disease (COVID-19). We synthesized the evidence regarding efficacy and safety (review 1), as well as risks of droplet dispersion, aerosol generation, and associated transmission (review 2) of viral products.
0832-610X,1496-8975
2020-06-21 02:00:00+02:00
pubmed
Aerosols;Cannula;Coronavirus Infections__complications;Humans;Oxygen Inhalation Therapy__methods;Pandemics;Pneumonia, Viral__complications;Randomized Controlled Trials as Topic;Respiratory Insufficiency__physiopathology;COVID-19
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Arnav Agarwal;John Basmaji;Fiona Muttalib;David Granton;Dipayan Chaudhuri;Devin Chetan;Malini Hu;Shannon M Fernando;Kimia Honarmand;Layla Bakaa;Sonia Brar;Bram Rochwerg;Neill K Adhikari;Francois Lamontagne;Srinivas Murthy;David S C Hui;Charles Gomersall;Samira Mubareka;Janet V Diaz;Karen E A Burns;Rachel Couban;Quazi Ibrahim;Gordon H Guyatt;Per O Vandvik
Department of Medicine, University of Toronto, Toronto, ON, Canada.;Division of Critical Care, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.;Centre for Global Child Health, Hospital for Sick Children, Toronto, ON, Canada.;Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.;Department of Medicine, McMaster University, Hamilton, ON, Canada.;Department of Pediatrics, University of Toronto, Toronto, ON, Canada.;Division of Cardiology, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada.;Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.;Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada.;Schulich School of Medicine and Dentistry, Department of Medicine, Western University, London, ON, Canada.;Honours Life Sciences Program, Faculty of Science, McMaster University, Hamilton, ON, Canada.;School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA.;Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.;Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.;Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.;Université de Sherbrooke, Sherbrooke, Canada.;Centre de recherche du CHU de Sherbrooke, Sherbrooke, QC, Canada.;BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.;Stanley Ho, Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.;Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.;Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.;Pacific Medical Center, San Francisco, CA, USA.;World Health Organization, Geneva, Switzerland.;Unity Health Toronto - St. Michael's Hospital, Toronto, ON, Canada.;University of Toronto, Toronto, ON, Canada.;Li Ka Shing Knowledge Institute, Toronto, ON, Canada.;Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON, Canada.;MAGIC Evidence Ecosystem Foundation, Oslo, Norway. per.vandvik@gmail.com.
1294
Letter
en
Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy.
https://www.ncbi.nlm.nih.gov/pubmed/32557889
2020-06-21 02:00:00+02:00
pubmed
P Del Giudice;D Boudoumi;B Le Guen;M Reverte;J Gutnecht;J P Lacour;J P Kraemer;A Motard;M Roa
2020-06-18 02:00:00+02:00
32557889
FR
Infectiology-Dermatology Unit, Centre Hospitalier de Fréjus-Saint-Raphaël, Fréjus, France.;Pneumology Unit, Centre Hospitalier de Fréjus-Saint-Raphaël, Fréjus, France.;Dermatology Department, CHU Nice, Nice, France.;Biology Laboratory, Centre Hospitalier de Fréjus-Saint-Raphaël, Fréjus, France.
COVID-19 pandemic reveals the peril of ignoring metadata standards.
https://www.ncbi.nlm.nih.gov/pubmed/32561801
2052-4463
2020-06-21 02:00:00+02:00
pubmed
Betacoronavirus;Coronavirus Infections__epidemiology;Datasets as Topic;Genomics__standards;Humans;Metadata__standards;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2
Scientific Data
Lynn M Schriml;Maria Chuvochina;Neil Davies;Emiley A Eloe-Fadrosh;Robert D Finn;Philip Hugenholtz;Christopher I Hunter;Bonnie L Hurwitz;Nikos C Kyrpides;Folker Meyer;Ilene Karsch Mizrachi;Susanna-Assunta Sansone;Granger Sutton;Scott Tighe;Ramona Walls
2020-06-19 02:00:00+02:00
32561801
FR;GB;US;HK;AU
University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, MD, USA. lschriml@som.umaryland.edu.;Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Queensland, Australia.;Gump South Pacific Research Station, University of California Berkeley, Moorea, French Polynesia.;Department of Energy, Joint Genome Institute, Berkeley, California, 94598, USA.;European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, UK.;GigaScience, BGI-Hong Kong, NT, Hong Kong.;University of Arizona, Tucson, AZ, USA.;Argonne National Laboratory, Argonne, Illinois, USA.;National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA.;Oxford e-Research Centre, Department of Engineering Science, University of Oxford, Oxford, UK.;J. Craig Venter Institute, Rockville, Maryland, USA.;University of Vermont, Burlington, Vermont, USA.
The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32564017
The difference between the female and male immune response to COVID-19 infection, and infections in general, is multifactorial. The well-known determiners of the immune response, such as X and Y chromosomes, sex hormones, and microbiota, are functionally interconnected and influence each other in shaping the organism's immunity. We focus our commentary on the interplay between the genetic sex and mitochondria and how this may affect a sex-dependent immune response in COVID-19 infection. Realizing the existence of these interactions may help in designing novel methods or fine-tuning the existing and routine therapies to fight COVID-19 and other infections.
The Houston Methodist Research Institute, Houston, Texas, USA, mkloc@houstonmethodist.org.;Department of Surgery, The Houston Methodist Hospital, Houston, Texas, USA, mkloc@houstonmethodist.org.;Department of Genetics, M.D. Anderson Cancer Center, The University of Texas, Houston, Texas, USA, mkloc@houstonmethodist.org.;The Houston Methodist Research Institute, Houston, Texas, USA.;Department of Surgery, The Houston Methodist Hospital, Houston, Texas, USA.;Laboratory of Regenerative Medicine and Cell Biology, Military Institute of Hygiene and Epidemiology (WIHE), Warsaw, Poland.;UnivRennes, UMR 6290, CNRS, Institute of Genetics and Development of Rennes, Cell Cycle Group, Faculty of Medicine, Rennes, France.
1310
Clinical Trial Protocol;Letter;Multicenter Study
en
Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial.
https://www.ncbi.nlm.nih.gov/pubmed/32560746
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs.
Biological Resource Center, Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. jpdesilles@for.paris.;Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, Paris, France. jpdesilles@for.paris.;Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. jpdesilles@for.paris.;Intensive Care Department, Rothschild Foundation Hospital, Paris, France.;Clinical Research Unit, Rothschild Foundation Hospital, Paris, France.;CHRU Nancy, Pôle d'Anesthésie-Réanimation, 29 Avenue de Lattre de Tassigny, 54000, Nancy, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Valenciennes, Avenue Désandrouin, 59322, Valenciennes, France.;CHR Metz-Thionville-Site de Mercy, Service de Réanimation Polyvalente, 1 Allée du Château, 57350, Ars-Laquenexy, France.;Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Service d'Anesthésie-Réanimation Chirurgicale, 1 Avenue Molière, 67098, Strasbourg, France.;Université de Strasbourg, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), EA3072, Strasbourg, France.
1311
10.1007/s41885-020-00066-z
Journal Article
en
The Economic Cost of COVID Lockdowns: An Out-of-Equilibrium Analysis.
https://www.ncbi.nlm.nih.gov/pubmed/32838118
This paper estimates the cost of the lockdown of some sectors of the world economy in the wake of COVID-19. We develop a multi sector disequilibrium model with buyer-seller relations between agents located in different countries. The production network model allows us to study not only the direct cost of the lockdown but also indirect costs which emerge from the reductions in the availability of intermediate inputs. Agents determine the quantity of output and the proportions in which to combine inputs using prices that emerge from local interactions. The model is calibrated to the world economy using input-output data on 56 industries in 44 countries including all major economies. Within our model, the lockdowns are implemented as partial reductions in the output of some sectors using data on sectoral decomposition of capacity reductions. We use computational experiments to replicate the temporal sequence of the lockdowns implemented in different countries. World output falls by 7% at the early stage of the crisis when only China is under lockdown and by 23% at the peak of the crisis when many countries are under a lockdown. These direct impacts are amplified as the shock propagates through the world economy because of the buyer-seller relations. Supply-chain spillovers are capable of amplifying the direct impact by more than two folds. Naturally, the substitutability between intermediate inputs is a major determinant of the amplification. We also study the process of economic recovery following the end of the lockdowns. Price flexibility and minor technological adaptations help in reducing the time it takes for the economy to recover. The world economy takes about one quarter to move towards the new equilibrium in the optimistic and unlikely scenario of the end of all lockdowns. Recovery time is likely to be significantly greater if partial lockdowns persist.
Paris School of Economics, Université Panthéon-Sorbonne, Paris, France and Climate Finance Alpha, Paris, France.;Indian Instiute of Technology Madras, Chennai, India.
1313
10.1016/j.cjco.2020.06.008
Case Reports
en
Acute Myopericarditis in a Patient With Mild SARS-CoV-2 Respiratory Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32838254
Herein is presented a case of a 71-year-old woman with mild SARS-CoV-2 respiratory infection who experienced acute myopericarditis diagnosed using clinical, biological, and electrocardiogram data and cardiac magnetic resonance imaging. The presented case highlights the risk of cardiac involvement, even in the absence of severe respiratory COVID-19 infection. The mechanisms involved in acute myocardial injury in SARS-CoV-2 infection are not well known and requires further studies to determine whether it is related to direct myocardial damage by the virus or to a systemic condition.
2589-790X
2020-06-21 02:00:00+02:00
pubmed
CJC Open
Aissam Labani;Philippe Germain;Marie-Pierre Douchet;Mustapha Beghi;Jean Jacques Von Hunolstein;Floriane Zeyons;Catherine Roy;Soraya El Ghannudi
2020-06-20 02:00:00+02:00
32838254
FR
Radiology Cardiovascular Imaging, University Hospitals of Strasbourg, Strasbourg, France.;Cardiology, University Hospitals of Strasbourg, Strasbourg, France.;Biophysics and Nuclear Medicine, University Hospitals of Strasbourg, Strasbourg, France.;ICube, UMR 7357, University of Strasbourg/CNRS and FMTS, Faculty of Medicine, Strasbourg, France.
1319
10.1016/j.retram.2020.06.001
Journal Article;Review
en
COVID-19 paraclinical diagnostic tools: Updates and future trends.
https://www.ncbi.nlm.nih.gov/pubmed/32576508
COVID-19 is one of the most widely affecting pandemics. As for many respiratory viruses-caused diseases, diagnosis of COVID-19 relies on two main compartments: clinical and paraclinical diagnostic criteria. Rapid and accurate diagnosis is vital in such a pandemic. On one side, rapidity may enhance management effectiveness, while on the other, coupling efficiency and less costly procedures may permit more effective community-scale management.
Service d'hématologie, hôpital Saint-Antoine, AP-HP Sorbonne Université, 75012, Paris, France. Electronic address: Dr.tameemsoliman@gmail.com.;Department of Genetics, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russian Federation.;Department of Pathology, Faculty of Medicine, Tishreen University, Lattakia, Syria.;Service maladie du sang, centre hospitalier universitaire de Lille, 59000, Lille, France.;Department of Infectious Diseases, Faculty of Medicine, Damascus University, Damascus, Syria.
1320
10.1016/j.pharma.2020.05.004
Journal Article
fr
[Ethics and biomedical research during the COVID-19 epidemic: Let's not confuse speed and precipitation!]
https://www.ncbi.nlm.nih.gov/pubmed/32569622
0003-4509
2020-06-21 02:00:00+02:00
pubmed
Annales Pharmaceutiques Françaises
B Bertrand;B Bertrand;B Bertrand;P-M Bertrand
2020-06-20 02:00:00+02:00
32569622
FR
Service pharmacie, centre hospitalier de Grasse, chemin de Clavary, 06135 Grasse cedex, France, Comité de Protection des Personnes Sud Méditerranée V, Nice, France. Electronic address: ben.bertrand@ch-grasse.fr.;Pôle d'anesthésie réanimation, CHU Grenoble Alpes, Grenoble, France.;Service de chirurgie plastique et reconstructrice, hôpital de la Conception, Assistance publique-Hôpitaux de Marseille, Marseille, France, UMR1263, Inserm, Inra, AMU, laboratoire C2VN, France.;Service de médecine intensive et réanimation, centre hospitalier de Cannes, Cannes, France, Comité d'éthique du centre hospitalier de Cannes, Cannes, France.
1321
Letter
en
COVID-19 transmission among gastrointestinal endoscopists.
Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, France.;Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris.;Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, France. Electronic address: stanislas.chaussade@aphp.fr.
1324
10.1093/cid/ciaa790
Journal Article
en
Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32556265
Knowledge on the epidemiological features and transmission patterns of COVID-19 is accumulating. Detailed line-list data with household settings can advance the understanding of COVID-19 transmission dynamics.
1058-4838,1537-6591
2020-06-21 02:00:00+02:00
pubmed
Clinical Infectious Diseases
Xiao-Ke Xu;Xiao-Fan Liu;Ye Wu;Sheikh Taslim Ali;Zhanwei Du;Paolo Bosetti;Eric H Y Lau;Benjamin J Cowling;Lin Wang
COVID-19;hazard of infection;serial interval;super-spreading event;transmission
2020-06-18 02:00:00+02:00
32556265
FR;CN;GB;US;HK
College of Information and Communication Engineering, Dalian Minzu University, Dalian, China.;Web Mining Lab, Department of Media and Communication, City University of Hong Kong, Hong Kong Special Administrative Region, China.;Computational Communication Research Center, Beijing Normal University, Zhuhai, China.;School of Journalism and Communication, Beijing Normal University, Beijing, China.;WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.;Department of Integrative Biology, University of Texas at Austin, Austin, Texas, USA.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, CNRS, Paris, France.;Department of Genetics, University of Cambridge, Cambridge, UK.
1325
10.1016/j.jaci.2020.06.009
Journal Article
en
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.
https://www.ncbi.nlm.nih.gov/pubmed/32561389
The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.
0091-6749
2020-06-21 02:00:00+02:00
pubmed
Journal of Allergy and Clinical Immunology
Peter Valent;Cem Akin;Patrizia Bonadonna;Knut Brockow;Marek Niedoszytko;Boguslaw Nedoszytko;Joseph H Butterfield;Ivan Alvarez-Twose;Karl Sotlar;Juliana Schwaab;Mohamad Jawhar;Andreas Reiter;Mariana Castells;Wolfgang R Sperr;Hanneke C Kluin-Nelemans;Olivier Hermine;Jason Gotlib;Roberta Zanotti;Sigurd Broesby-Olsen;Hans-Peter Horny;Massimo Triggiani;Frank Siebenhaar;Alberto Orfao;Dean D Metcalfe;Michel Arock;Karin Hartmann
Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.;Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.;Allergy Unit, Verona University Hospital, Verona, Italy.;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.;Department of Dermatology, Medical University of Gdansk, Gdansk, Poland.;Mayo Clinic, Division of Allergic Diseases, Rochester, Minn.;Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.;Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.;Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.;Brigham and Women's Hospital, Mastocytosis Center, Harvard Medical School, Boston, Mass.;Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.;Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.;Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif.;Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.;Institute of Pathology, Ludwig-Maximilian-University, Munich, Germany.;Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.;Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.;Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC, CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.;Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.;Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.;Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland.
1328
Letter
en
Minimising COVID-19 exposure during tracheal intubation by using a transparent plastic box: A randomised prospective simulation study.
https://www.ncbi.nlm.nih.gov/pubmed/32562807
2020-06-21 02:00:00+02:00
pubmed
Simon Clariot;Guillaume Dumain;Elisabeth Gauci;Olivier Langeron;Éric Levesque
Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France. Electronic address: simon.clariot@aphp.fr.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France, Experimental Neuropathology Unit, Institut Pasteur, 75015 Paris, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France, EA DYNAMYC Université Paris-Est Créteil (UPEC), École Nationale Vétérinaire d'Alfort (ENVA), Faculté de Santé de Créteil, 8, rue du Général Sarrail, 94010 Créteil, France.
1333
10.1016/j.jbior.2020.100735
Journal Article;Research Support, Non-U.S. Gov't
en
Thromboembolic events and Covid-19.
https://www.ncbi.nlm.nih.gov/pubmed/32773098
The novel Corona virus infection (Covid-19) first identified in China in December 2019 has rapidly progressed in pandemic leading to significant mortality and unprecedented challenge for healthcare systems. Although the clinical spectrum of Covid-19 is variable, acute respiratory failure and systemic coagulopathy are common in severe Covid-19 patients. Lung is an important target of the SARS-CoV-2 virus causing eventually acute respiratory distress syndrome associated to a thromboinflammatory state. The cytokinic storm, thromboinflammation and pulmonary tropism are the bedrock of tissue lesions responsible for acute respiratory failure and for prolonged infection that may lead to multiple organ failure and death. The thrombogenicity of this infectious disease is illustrated by the high frequency of thromboembolic events observed even in Covid-19 patients treated with anticoagulation. Increased D-Dimers, a biomarker reflecting activation of hemostasis and fibrinolysis, and low platelet count (thrombocytopenia) are associated with higher mortality in Covid-19 patients. In this review, we will summarize our current knowledge on the thromboembolic manifestations, the disturbed hemostatic parameters, and the thromboinflammatory conditions associated to Covid-19 and we will discuss the modalities of anticoagulant treatment or other potential antithrombotic options.
Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France, Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France.;Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France, Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France.;Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France.;Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France.;Service de Médecine Vasculaire, CHU de Toulouse, 31059, Toulouse, France.;Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France, Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France. Electronic address: bernard.payrastre@inserm.fr.
1334
10.1016/j.etiqe.2020.06.001
English Abstract;Journal Article
fr
[COVID-19: On the verge of madness].
https://www.ncbi.nlm.nih.gov/pubmed/32837543
Disorganizations due to the current coronavirus SARS-CoV-2 pandemic that have required a national quarantine from the 17th of march to the 11 of May 2020, mangle and question. In view of the situation's extreme traumatic character and of the pathological consequences observed, we are going to try to give meaning to an almost chaotic situation. Our shared production, coming out of two psychologists - one being in quarantine and the other one not - crossed diary trying to put the theory in favor of the clinic, has for aim to build a support structuring thought. In fact, the breaking of COVID-19's death anxiety creates hysterical looking defense mechanisms within the entire society. When the extreme and sudden situation that we are describing can be understood as a paradoxical injunction as much as a denial of the split, we will focus our analyzes on both societal and hospital realities, that seems to jeopardize humanity, dignity, solidarity, equity, justice and autonomy principles. Describing, trying to put into words and analyzing all movements concerning the current situation, could lead to giving meaning to a situation which seems already deprived.
ATER, université Rouen-Normandie, 1, rue Thomas-Becket, 76130 Mont-Saint-Aignan, France.;Unité de soins palliatifs, centre des Massues, Croix-Rouge française, 92, rue Dr-Edmond-Locard, Lyon, France.
1340
10.3390/biology9060132
Journal Article
en
Unreported Cases for Age Dependent COVID-19 Outbreak in Japan.
https://www.ncbi.nlm.nih.gov/pubmed/32560572
We investigate the age structured data for the COVID-19 outbreak in Japan. We consider a mathematical model for the epidemic with unreported infectious patient with and without age structure. In particular, we build a new mathematical model and a new computational method to fit the data by using age classes dependent exponential growth at the early stage of the epidemic. This allows to take into account differences in the response of patients to the disease according to their age. This model also allows for a heterogeneous response of the population to the social distancing measures taken by the local government. We fit this model to the observed data and obtain a snapshot of the effective transmissions occurring inside the population at different times, which indicates where and among whom the disease propagates after the start of public mitigation measures.
2079-7737
2020-06-21 02:00:00+02:00
pubmed
Biology
Quentin Griette;Pierre Magal;Ousmane Seydi
age-structured data;coronavirus;epidemic mathematical model;isolation;public closings;quarantine;reported and unreported cases
2020-06-17 02:00:00+02:00
32560572
FR;SN
Institute of Mathematics of Bordeaux (UMR 5251), University of Bordeaux, F-33400 Talence, France.;Département Tronc Commun, École Polytechnique de Thiès, Thiès BP A10, Senegal.
1341
10.1111/bju.15149
Journal Article
en
The dramatic COVID-19 outbreak in italy is responsible of a huge drop in urological surgical activity: A multicenter observational study.
https://www.ncbi.nlm.nih.gov/pubmed/32558053
Italy is facing the COVID-19 outbreak with an abrupt reorganization of its national health-system, in order to augment care provision to symptomatic patients. The sudden shift of personnel and resources towards COVID-19 care has led to the reduction of surgery, with possible severe drawbacks. The aim of the study is to describe the trend in surgical volume in urology, in Italy.
COVID-19 outbreak;trend of variation;urologic surgery
2020-06-18 02:00:00+02:00
32558053
FR;IT;US;AT
University of Modena and Reggio Emilia, Modena, Italy.;Data Methods and Systems Statistical Laboratory, University of Brescia, Brescia, Italy.;Urology Unito, Humanitas Gavazzeni, Bergamo, Italy.;Chief of the Urology Unit, Azienda ULSS n.4 Veneto Orientale, Portogruaro, VE), Italy.;Urology Unit, Ospedale San Donato, Arezzo, Italy.;Chief of the Urology Unit, Ospedale Maggiore Borgo Trento, Verona, Italy.;AOU San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy.;Urology Unit, Ospedale San Carlo di Nancy, Roma, Italy.;ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.;Urology Unit, Ospedale San Martino, Genova, Italy.;Urology Unit, ASST Valle Olona, Busto Arsizio, Italy.;USC, Institute of Urology and Catherine and Joseph Aresty Department of Urology, Los Angeles, US.;Urology Unit, Villa Igea, Ancona, Italy.;Urology Unit, Ospedale San Bassiano, Bassano del Grappa, Italy.;Urology Unit, Azienda Ospedaliero Universitaria Careggi Firenze, Italy.;Urology Unit, AULSS 4, Portogruaro, Italy.;Urology Unit, AOU Citta della Salute e della Scienza, Torino, Italy.;Urology Unit, Villa Stuart, Roma, Italy.;Urology Unit, Azienda Ospedaliero-Universitaria di Udine, Italy.;Medical University of Graz, Graz, Steiermark, AT, Austria.;Urology Unit, Policlinico Abano Terme, Abano Terme, Italy.;Urology Unit, ASST Mantova, Italy.;Urology Unit, San Carlo di Potenza, Potenza, Italy.;ARNAS Garibaldi Hospital, Catania, Italy.;Urology Unit, ARNAS Garibaldi Hospital, Catania, Italy.;Chief of the Urology Unit, San Raffaele Turro, Milan, Italy.;Chief of Endourology Sub-Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.;Urology Unit, Ospedale San Paolo di Savona, Italy.;Urology Unit, Humanitas Gavazzeni, Bergamo, Italy.;Urology Unit, Policlinico Umberto I, Rome, Italy.;Urology Unit, Azienda USL Toscana, Grosseto, Italy.;Urology Unit, Città della Salute e della Scienza Hospital, Torino, Italy.;Chief of the Urology Unit, Ospedale Vito Fazzi, Lecce, Italy.;Urology Unit, Ospedale San Carlo Poma, Mantova, Italy.;Urology Unit, Sapienza University, Rome, Italy.;Urology Unit, San Raffaele Turro, Milan, Italy.;Chief of the Urology Unit, Policlinico Abano Terme, Abano, Padova, Italy.;Urology Unit, Azienda Ospedaliera A. Cardarelli, Naples, Italy.;Urology Unit, Ospedale San Paolo, Savona, Italy.;Urology Unit, AOU Policlinico Sant'Orsola Malpighi, Bologna, Italy.;Urology Unit, ASST Ospedale Manzoni, Lecco, Italy.;Urology Unit, ASST Manzoni, Lecco, Italy.;Urology Unit, Azienda Ospedaliera Universitaria Integrata di Verona - Ospedale Maggiore Borgo Trento, Verona, Italy.;Ospedale IRRCS Policlinico San Martino Genova, Italy.;Urology Unit, Maggiore della Carità Hospital, Novara, Italy.;ASAT Rhodense Ospedale Guido Salvini di Garbagnate, Garbagnate, Italy.;Urology Unit, AO Bianchi Melacrino Morelli, Calabria, Italy.;Urology Unit, AOU San Giovanni di Rio e Ruggi d'Aragona, Salerno, Italy.;Urology Unit, Ospedale Maggiore della Carita, Novara, Italy.;Urology Unit, Ospedale degli Infermi, Biella, Italy.;Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.
1353
10.1093/chemse/bjaa041
Journal Article
en
More than smell - COVID-19 is associated with severe impairment of smell, taste, and chemesthesis.
https://www.ncbi.nlm.nih.gov/pubmed/32564071
Recent anecdotal and scientific reports have provided evidence of a link between COVID-19 and chemosensory impairments such as anosmia. However, these reports have downplayed or failed to distinguish potential effects on taste, ignored chemesthesis, and generally lacked quantitative measurements. Here, we report the development, implementation and initial results of a multi-lingual, international questionnaire to assess self-reported quantity and quality of perception in three distinct chemosensory modalities (smell, taste, and chemesthesis) before and during COVID-19. In the first 11 days after questionnaire launch, 4039 participants (2913 women, 1118 men, 8 other, ages 19-79) reported a COVID-19 diagnosis either via laboratory tests or clinical assessment. Importantly, smell, taste and chemesthetic function were each significantly reduced compared to their status before the disease. Difference scores (maximum possible change ±100) revealed a mean reduction of smell (-79.7 ± 28.7, mean ± SD), taste (-69.0 ± 32.6), and chemesthetic (-37.3 ± 36.2) function during COVID-19. Qualitative changes in olfactory ability (parosmia and phantosmia) were relatively rare and correlated with smell loss. Importantly, perceived nasal obstruction did not account for smell loss. Furthermore, chemosensory impairments were similar between participants in the laboratory test and clinical assessment groups. These results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis. The multimodal impact of COVID-19 and lack of perceived nasal obstruction suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms.
0379-864X,1464-3553
2020-06-21 02:00:00+02:00
pubmed
Chemical Senses
Valentina Parma;Kathrin Ohla;Maria G Veldhuizen;Masha Y Niv;Christine E Kelly;Alyssa J Bakke;Keiland W Cooper;Cédric Bouysset;Nicola Pirastu;Michele Dibattista;Rishemjit Kaur;Marco Tullio Liuzza;Marta Y Pepino;Veronika Schöpf;Veronica Pereda-Loth;Shannon B Olsson;Richard C Gerkin;Paloma Rohlfs Domínguez;Javier Albayay;Michael C Farruggia;Surabhi Bhutani;Alexander W Fjaeldstad;Ritesh Kumar;Anna Menini;Moustafa Bensafi;Mari Sandell;Iordanis Konstantinidis;Antonella Di Pizio;Federica Genovese;Lina Öztürk;Thierry Thomas-Danguin;Johannes Frasnelli;Sanne Boesveldt;Özlem Saatci;Luis R Saraiva;Cailu Lin;Jérôme Golebiowski;Liang- Dar Hwang;Mehmet Hakan Ozdener;Maria Dolors Guàrdia;Christophe Laudamiel;Marina Ritchie;Jan Havlícek;Denis Pierron;Eugeni Roura;Marta Navarro;Alissa A Nolden;Juyun Lim;K L Whitcroft;Lauren R Colquitt;Camille Ferdenzi;Evelyn V Brindha;Aytug Altundag;Alberto Macchi;Alexia Nunez-Parra;Zara M Patel;Sébastien Fiorucci;Carl M Philpott;Barry C Smith;Johan N Lundström;Carla Mucignat;Jane K Parker;Mirjam van den Brink;Michael Schmuker;Florian Ph S Fischmeister;Thomas Heinbockel;Vonnie D C Shields;Farhoud Faraji;Enrique Santamaría;William E A Fredborg;Gabriella Morini;Jonas K Olofsson;Maryam Jalessi;Noam Karni;Anna D'Errico;Rafieh Alizadeh;Robert Pellegrino;Pablo Meyer;Caroline Huart;Ben Chen;Graciela M Soler;Mohammed K Alwashahi;Antje Welge-Lüssen;Jessica Freiherr;Jasper H B de Groot;Hadar Klein;Masako Okamoto;Preet Bano Singh;Julien W Hsieh;Danielle R Reed;Thomas Hummel;Steven D Munger;John E Hayes
Department of Psychology, Temple University.;Institute of Neuroscience and Medicine (INM-3), Research Center Jülich.;Department of Anatomy, School of Medicine, Mersin University.;Institute of Biochemistry, Food Science and Nutrition, The Hebrew University of Jerusalem.;AbScent.;Department of Food Science, The Pennsylvania State University.;Interdepartmental Neuroscience Program, University of California Irvine.;Institut de Chimie de Nice, Université Côte d'Azur.;Centre for Global Health Research, Usher Institute, The University of Edinburgh.;Department of Basic Medical Sciences, Neuroscience and Sensory Organs, Università degli Studi di Bari A. Moro.;V1-B, CSIR-Central Scientific Instruments Organisation.;Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro.;Food Science and Human Nutrition, University of Illinois at Urbana Champaign.;Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna.;GSBMS - Medecine Evolutive UMR5288, Université de Toulouse.;National Centre for Biological Sciences, National Centre for Biological Sciences, Tata Institute of Fundamental Research.;School of Life Sciences, Arizona State University.;Department of Psychology and Anthropology, University of Extremadura.;Department of General Psychology, University of Padova.;Psychiatry, Yale University School of Medicine.;Exercise and Nutritional Sciences, San Diego State University.;Department of Otolaryngology, Hospital Unit West, Aarhus University.;Biocomputation Group, University of Hertfordshire.;Neuroscience Area, SISSA, International School for Advanced Studies.;Neuropop Team, Lyon Neuroscience Research Center, CNRS UMR5292 - INSERM U1028 - University Lyon 1.;Department of Food and Nutrition, Functional Foods Forum, University of Helsinki, University of Turku.;Academic ORL Department, Aristotle University.;Section In-silico Biology and Machine Learning, Leibniz-Institute for Food Systems Biology at the Technical University of Munich.;Monell Chemical Senses Center.;Mersin University.;CSGA-Centre for Taste and Feeding Behavior, INRAE.;Anatomy, Université du Québec à Trois-Rivières.;Division of Human Nutrition and Health, Wageningen University.;Otorhinolaryngology, Medical Science University.;Translational Medicine Division, Sidra Medicine.;The University of Queensland Diamantina Institute, The University of Queensland.;Food Technology, IRTA.;DreamAir Llc.;Neurobiology and Behavior, University of California, Irvine.;Department of Zoology, Charles University.;Médecine Evolutive UMR5288, Université de Toulouse-CNRS.;Centre for Nutrition and Food Sciences, The University of Queensland.;Department of Food Science, University of Massachusetts.;Food Science and Technology, Oregon State University.;Ear Institute, UCL.;Lyon Neuroscience Research Center, Lyon Neuroscience Research Center, CNRS UMR5292 - INSERM U1028 - University Lyon 1.;EEE, Karunya University.;Otorhinolaryngology Department, Biruni University.;ENT Department, Italian Academy Of Rhinology - Assi Sette Llaghi Varese.;Department of Biology, Universidad de Chile.;Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine.;Institut de Chimie de Nice, UMR CNRS 7272, Université Côte d'Azur.;The Norfolk Smell & Taste Clinic, University of East Anglia.;Institute of Philosophy, University of London.;Department of Clinical Neuroscience, Karolinska Institutet.;Department of Molecular Medicine, University of Padova.;Department of Food and Nutritional Sciences, University of Reading.;Laboratory of Behavioural Gastronomy, Maastricht University.;Department of Computer Science, University of Hertfordshire.;Institute of Psychology, University of Graz.;Department of Anatomy, Howard University College of Medicine.;Biological Sciences Department, Fisher College of Science and Mathematics, Towson University.;Otolaryngology-Head and Neck Surgery, University of California San Diego Health.;Clinical Neuroproteomics Unit, Navarrabiomed-IDISNA.;Department of Psychology, Stockholm University.;University of Gastronomic Sciences.;Skull Base Research Center, The Five Senses Institute, Iran University of Medical Sciences.;Internal Medicine Department, Hadassah Medical Center.;Neurobiology, Goethe Universität Frankfurt.;ENT and Head and Neck Research Center and Department, Hazrat Rasoul Hospital, the Five Senses Institute, Iran University of Medical Sciences.;Food Science Department, University of Tennessee.;Health Care and Life Sciences, IBM T.J. Watson Research Center.;Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels University.;Psychiatry, Guangzhou Medical University.;Otorhinolaringology, Buenos Aires University and GEOG (Grupo de Estudio de Olfato y Gusto).;Surgery Department, ENT Division, Sultan Qaboos University.;Department of Otorhinolaryngology, University Hospital Basel, Basel.;Department of Psychiatry and Psychotherapy, FAU Erlangen.;Psychology, Utrecht University.;Department of Applied Biological Chemistry, The University of Tokyo.;Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo.;Rhinology- Olfactology Unit, ENT Department, Geneva University Hospitals.;Department of Otorhinolaryngology, TU Dresden.;Center for Smell and Taste, University of Florida.;Department of Pharmacology and Therapeutics, University of Florida.
1356
10.1016/j.micinf.2020.06.005
Journal Article
en
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
https://www.ncbi.nlm.nih.gov/pubmed/32574789
COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: "Death" and "Recovery". Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O2) requirements 10.4 l/min. At baseline, all patients had multiple biological abnormalities (lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer and liver enzymes). 24 patients (70.5%) recovered after TCZ therapy and 10 died (29.5%). Deceased subjects differed from patients in whom treatment was effective with regard to more pronounced lymphopenia (0.6 vs 1.0 G/l; p = 0.037), lower platelet number (156 vs 314 G/l; p = 0.0001), lower fibrinogen serum level (0.6 vs 1.0 G/l; p = 0.03), higher aspartate-amino-transferase (108 vs 57 UI/l; p = 0.05) and greater O2 requirements (11 vs 8 l/min; p = 0.003).
Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France.;Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.;Intensive Care Unit, Nord Franche-Comté Hospital, Belfort, France, Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.;Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.;Department of Pharmacology, Nord Franche-Comté Hospital, Belfort, France.;Department of Biology, Nord Franche-Comté Hospital, Belfort, France.;Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France, Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.;Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France. Electronic address: souhail.zayet@gmail.com.
1357
Letter
en
COVID-19 heath crisis: less colorectal resections and yet no more peritonitis or bowel obstruction as a collateral effect?
https://www.ncbi.nlm.nih.gov/pubmed/32542838
2020-06-21 02:00:00+02:00
pubmed
M K Collard;J H Lefèvre;F Batteux;Y Parc
2020-06-16 02:00:00+02:00
32542838
FR
Digestive Surgery Department, Saint-Antoine Hospital, APHP, Sorbonne University, Paris, France.;Department of Strategy and Transformation, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
1360
10.1016/j.ygyno.2020.06.486
Journal Article
en
Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations.
https://www.ncbi.nlm.nih.gov/pubmed/32563593
To develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic.
0090-8258
2020-06-21 02:00:00+02:00
pubmed
Gynecologic Oncology
Christen R Elledge;Sushil Beriwal;Cyrus Chargari;Supriya Chopra;Beth A Erickson;David K Gaffney;Anuja Jhingran;Ann H Klopp;William Small;Catheryn M Yashar;Akila N Viswanathan
2020-06-15 02:00:00+02:00
32563593
FR;IN;US
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Department of Radiation Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, India.;Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.;Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Department of Radiation Oncology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.;Department of Radiation Oncology, University of California San Diego, San Diego, CA, USA.;Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: anv@jhu.edu.
1365
10.1016/j.ajog.2020.06.022
Journal Article
en
Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth.
https://www.ncbi.nlm.nih.gov/pubmed/32553908
Despite the mainly reassuring outcomes for pregnant women with coronavirus disease 2019 reported by previous case series with small sample sizes, some recent reports of severe maternal morbidity requiring intubation and of maternal deaths show the need for additional data about the impact of coronavirus disease 2019 on pregnancy outcomes.
COVID-19 pneumonia;extracorporeal membrane oxygenation;intubation;maternal and neonatal outcomes;maternal morbidity;pregnancy;preterm birth;respiratory failure
2020-06-15 02:00:00+02:00
32553908
FR
Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France. Electronic address: loicsentilhes@hotmail.com.;Department of Obstetrics and Gynecology, Strasbourg University Hospitals, Strasbourg, France.;Department of Neonatology, Strasbourg University Hospital, Strasbourg, France.;Department of Anesthesiology, Strasbourg University Hospitals, Strasbourg, France.;Department of Infectious and Tropical Diseases, Strasbourg University Hospitals, Strasbourg, France.;Virology Laboratory, Strasbourg University Hospitals, Strasbourg, France.
1367
10.18176/jiaci.0625
Journal Article;Review
en
Upper and Lower Airways Functional Examination in Asthma and Respiratory Allergic Deseases. Considerations in the SARS-CoV-2 Post-Pandemic Situation.
https://www.ncbi.nlm.nih.gov/pubmed/32540791
Airway examination techniques are procedures that can potentially transmit infectious diseases to both patients and healthcare professionals who perform them, by various mechanisms. The pandemic situation due to the COVID-19 disease has practically halted most of the activity of the clinics and laboratories of pulmonary and nasal function, with clear recommendations in this regard. Being already in the early stages after the peak of the pandemic, we still do not know for sure what its consequences will be in the short or long term, since there are important gaps in the knowledge of aspects as fundamental as the transmission mechanisms of the virus, its pathophysiology and immune response or its diagnosis. In this review we will examine the different examination techniques available on the assessment of patients suffering from respiratory allergy, asthma and associated diseases, int the postpandemic momentum, highlighting their possible advantages and disadvantages. For this reason, we wanted to focus on exploring the entire upper and lower airways, from the perspective of the safety of both the healthcare professionals and patients and their specific characteristics. And at the same time we will approach the analysis of the intrinsic value that these interventions provide from the point of view of both diagnosis and management of these patients. The changing situation of this disease may cause some modifications of the assertions presented in this review in the future.While this guidance seeks to ensure a consistent wide approach, some differences in operational details may be applied due to local regulations.
1018-9068
2020-06-21 02:00:00+02:00
pubmed
Journal of Investigational Allergology and Clinical Immunology
Allergic rhinitis;Asthma;Bronchaill challenge;Inflammatory biomarkers;Lung function tests;Upper airways examination
2020-06-16 02:00:00+02:00
32540791
FR;ES;BO
Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain.;CIBER de Enfermedades Respiratorias (CIBERES), Spain.;Unidad Alergo-Rino, Centro Médico Teknon, Barcelona, Catalonia, Spain.;Unitat de Rinologia & Clínica de l'Olfacte, Servei d'Oto-rino-laringologia, Hospital Clinic Barcelona, Immunoalèrgia Respiratòria Clínica i Experimental, IDIBAPS, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain.;Department of Allergy, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.;Department of Respiratry Medicine, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.;Department of Allergy, Consorci Sanitari de Terrassa, Clínica Diagonal, Barcelona, Catalonia, Spain.;Department of Allergy, Fundación Jiménez Díaz, Madrid, Spain.
1368
10.1111/bjh.16943
Journal Article
en
Rapid screening of COVID-19 patients using white blood cell scattergrams, a study on 381 patients.
https://www.ncbi.nlm.nih.gov/pubmed/32542672
Complementary tools are warranted to increase the sensitivity of the initial testing for COVID-19. We identified a specific 'sandglass' aspect on the white blood cell scattergram of COVID-19 patients reflecting the presence of circulating plasmacytoid lymphocytes. Patients were dichotomized as COVID-19-positive or -negative based on reverse transcriptase polymerase chain reaction (RT-PCR) and chest computed tomography (CT) scan results. Sensitivity and specificity of the 'sandglass' aspect were 85·9% and 83·5% respectively. The positive predictive value was 94·3%. Our findings provide a non-invasive and simple tool to quickly categorize symptomatic patients as either COVID-19-probable or -improbable especially when RT-PCR and/or chest CT are not rapidly available.
Department of Hematobiology, CH Versailles, Le Chesnay, France.;Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.;INSERM UMR1153 ECSTRRA Team, Paris, France.;Department of Virology, CH de Versailles, Le Chesnay, France.;Department of Critical Care, CH de Versailles, Le Chesnay, France.;Department of Radiology, CH de Versailles, Le Chesnay, France.;Department of Pediatrics, Benioff Children's Hospital, Helen Diller Comprehensive cancer center, UCSF, San Francisco, CA, USA.;Department of Pediatrics, CH de Versailles, Le Chesnay, France.;Department of Internal Medecine and Infectious Diseases, CH de Versailles, Le Chesnay, France.;Department of Pneumology, CH de Versailles, Le Chesnay, France.;Emergency department, CH de Versailles, Le Chesnay, France.;Department of Hematology and Oncology, CH de Versailles, Le Chesnay, France.;UMR1184, University of Versailles Saint-Quentin-en-Yvelines and Paris Saclay, Versailles, France.;Department of Pharmacology, CH Versailles, Le Chesnay, France.
1374
10.1099/jgv.0.001452
Journal Article
en
Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
https://www.ncbi.nlm.nih.gov/pubmed/32538738
We constructed complex models of SARS-CoV-2 spike protein binding to pangolin or human ACE2, the receptor for virus transmission, and estimated the binding free energy changes using molecular dynamics simulation. SARS-CoV-2 can bind to both pangolin and human ACE2, but has a significantly lower binding affinity for pangolin ACE2 due to the increased binding free energy (9.5 kcal mol-1). Human ACE2 is among the most polymorphous genes, for which we identified 317 missense single-nucleotide variations (SNVs) from the dbSNP database. Three SNVs, E329G (rs143936283), M82I (rs267606406) and K26R (rs4646116), had a significant reduction in binding free energy, which indicated higher binding affinity than wild-type ACE2 and greater susceptibility to SARS-CoV-2 infection for people with them. Three other SNVs, D355N (rs961360700), E37K (rs146676783) and I21T (rs1244687367), had a significant increase in binding free energy, which indicated lower binding affinity and reduced susceptibility to SARS-CoV-2 infection.
Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200031, PR China.;University of Chinese Academy of Sciences, Beijing 100039, PR China.;National Engineering Research Center For the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, PR China.;The Joint Program in Infection and Immunity, a. Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China, and b. Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, PR China.;Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai 200032, PR China.
1381
10.1093/cid/ciaa768
Journal Article
en
Corticosteroids in patients with COVID-19: what about the control group?
Service de maladies infectieuses et tropicales, Centre Hospitalier Alpes Léman, France.;Service de médecine Interne, Centre Hospitalier Alpes Léman, France.;Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.;Department of Epidemiology and Public Health, University College London, London, United Kingdom.
1395
10.1186/s13054-020-03062-7
Journal Article;Review
en
The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32546188
In severe SARS-CoV-2 infections, emerging data including recent histopathological studies have emphasized the crucial role of endothelial cells (ECs) in vascular dysfunction, immunothrombosis, and inflammation.Histopathological studies have evidenced direct viral infection of ECs, endotheliitis with diffuse endothelial inflammation, and micro- and macrovascular thrombosis both in the venous and arterial circulations. Venous thrombotic events, particularly pulmonary embolism, with elevated D-dimer and coagulation activation are highly prevalent in COVID-19 patients. The pro-inflammatory cytokine storm, with elevated levels of interleukin-6 (IL-6), IL-2 receptor, and tumor necrosis factor-α, could also participate in endothelial dysfunction and leukocyte recruitment in the microvasculature. COVID-19-induced endotheliitis may explain the systemic impaired microcirculatory function in different organs in COVID-19 patients. Ongoing trials directly and indirectly target COVID-19-related endothelial dysfunctions: i.e., a virus-cell entry using recombinant angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS-2) blockade, coagulation activation, and immunomodulatory therapies, such as anti-IL-6 strategies. Studies focusing on endothelial dysfunction in COVID-19 patients are warranted as to decipher their precise role in severe SARS-CoV-2 infection and organ dysfunction and to identify targets for further interventions.
INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Saint-Louis Teaching Hospital, Paris University, Paris, France.;Anesthesia and Critical Care Department, Avicenne Teaching Hospital, Assistance Publique des Hôpitaux de Paris, Bobigny, France.;Department of Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Assistance Publique des Hôpitaux de Paris, 1, Avenue Claude Vellefaux, 75010, Paris, France.;INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Saint-Louis Teaching Hospital, Paris University, Paris, France. lara.zafrani@aphp.fr.;Department of Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Assistance Publique des Hôpitaux de Paris, 1, Avenue Claude Vellefaux, 75010, Paris, France. lara.zafrani@aphp.fr.
1399
Letter;Comment
en
Liver injury without liver failure in COVID-19 patients: how to explain, in some cases, elevated ammonia without hepatic decompensation.
Patrick M Honore;Leonel Barreto Gutierrez;Luc Kugener;Sebastien Redant;Rachid Attou;Andrea Gallerani;David De Bels
2020-06-16 02:00:00+02:00
32546201
FR;BE
ICU Department, Centre Hospitalier Universitaire Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. Patrick.Honore@CHU-Brugmann.be.;ICU Department, Centre Hospitalier Universitaire Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium.
1401
10.24875/ric.20000113
Journal Article
en
DISPERSION OF A NEW CORONAVIRUS SARS-COV-2 BY AIRLINES IN 2020: TEMPORAL ESTIMATES OF THE OUTBREAK IN MEXICO.
https://www.ncbi.nlm.nih.gov/pubmed/32584328
On January 23, 2020, China imposed a quarantine on the city of Wuhan to contain the SARS-CoV-2 outbreak. Regardless of this measure, the new infection has spread to several countries around the world.
Gustavo Cruz-Pacheco;José F Bustamante-Castañeda;Jean G Caputo;María E Jiménez-Corona;Samuel Ponce-de-León-Rosales
COVID-19;Coronavirus;Outbreak;SARS-CoV-2
2020-06-26 02:00:00+02:00
32584328
FR;MX
Department of Mathematics and Mechanics, Instituto de Investigaciones en Matemáticas Aplicadas y en Sistemas (IIMAS), National University of Mexico (UNAM), Mexico City, Mexico.;Graduate Program in Mathematical Sciences, UNAM, Mexico City, Mexico.;Laboratory of Mathematics, Institut National des Sciences Appliquées de Rouen Normandie, Saint-Etienne du Rouvray, France.;Department of Epidemiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.;Division of Graduate Studies and Research, Facultad de Odontología, UNAM, Mexico City, Mexico.;Programa Universitario de Investigación en Salud, UNAM, Mexico City, Mexico.
COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. Jerome.Lechien@umons.ac.be.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. Jerome.Lechien@umons.ac.be.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.;Rhinology-Olfactology Unit, Department of Otorhinolaryngology, Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.;Department of Otolaryngology-Head and Neck Surgery, CHU de Montreal, Montreal, Canada.;Department of Otolaryngology-Head and Neck Surgery, APHM, Aix-Marseille Univ, Hopital La Conception, Marseille, France.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.
1427
Journal Article
en
Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
https://www.ncbi.nlm.nih.gov/pubmed/32573419
Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 is likely due to a cytokine storm characterised by a major release of pro-inflammatory cytokines, including interleukin-6 (IL-6). Blocking excessive IL-6 production might be the key to the COVID-19-ARDS treatment. Beneficial effects of IL-6 blockade using a humanised anti-IL-6 receptor antibody, tocilizumab (TCZ) were previously reported in patients with COVID-19 related ARDS. The aim of the study was to study the variation over time of several biomarkers, demonstrated to be predictors of poor prognostic, in subjects successfully treated with TCZ for severe COVID-19.
Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France. thierry.conrozier@hnfc.fr.;Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France.;Department of Biology, Nord Franche-Comté Hospital, Belfort, France.;Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.;Intensive Care Unit, Nord Franche-Comté Hospital, Belfort, France.;Pharmacy, Nord Franche-Comté Hospital, Belfort, France.
1428
10.1128/aac.00819-20
Journal Article;Research Support, Non-U.S. Gov't
en
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
https://www.ncbi.nlm.nih.gov/pubmed/32366720
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.
Université de Paris, NeuroDiderot, Inserm, F-75019 Paris, France, Neurophysiologie clinique, Service de Physiologie - Explorations Fonctionnelles, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France. Electronic address: geoffroy.vellieux@aphp.fr.;Université de Paris, NeuroDiderot, Inserm, F-75019 Paris, France, Neurophysiologie clinique, Service de Physiologie - Explorations Fonctionnelles, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France.;Médecine intensive-réanimation, AP-HP, Bichat-Claude Bernard Hospital, F-75018 Paris, France.;Médecine intensive-réanimation, AP-HP, Bichat-Claude Bernard Hospital, F-75018 Paris, France, Université de Paris, INSERM UMR1148, Team 6, F-75018 Paris, France.
1430
10.1007/s15010-020-01467-8
Journal Article
en
Utility of CT scan in patients with initial negative PCR for SARS-CoV2: a report of three cases.
https://www.ncbi.nlm.nih.gov/pubmed/32583171
PCR-based viral RNA to confirm the diagnosis of SARS-CoV-2 infection has a sensitivity of around 70%. We report three cases of patients with negative initial PCR and CT scan lesions that led us to suspect COVID-19, but which one(s) are really COVID-19?
0300-8126,1439-0973
2020-06-28 02:00:00+02:00
pubmed
Infection
Kevin Bouiller;Sébastien Humbert;Camille Payet-Revest;Anne-Sophie Brunel;Adrien Mareshal;Quentin Lepiller;Franck Grillet;Catherine Chirouze
Infectious and Tropical Disease Department, University Hospital Besancon (CHRU Besancon), 3 Boulevard Alexandre Fleming, 25030, Besançon, France. kbouiller@chu-besancon.fr.;UMR CNRS 6249, Chrono Environnement, University of Burgundy Franche-Comté, Besançon, France. kbouiller@chu-besancon.fr.;Internal Medicine Department, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Infectious and Tropical Disease Department, University Hospital Besancon (CHRU Besancon), 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Dermatology Department, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Laboratory of Virology, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Radiology Department, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Infectious and Tropical Disease Department, University Hospital Besancon (CHRU Besancon), 3 Boulevard Alexandre Fleming, 25030, Besançon, France. cchirouze@chu-besancon.fr.;UMR CNRS 6249, Chrono Environnement, University of Burgundy Franche-Comté, Besançon, France. cchirouze@chu-besancon.fr.
1433
Letter
en
Implementation of a non-invasive oxygenation support strategy during the COVID-19 pandemic in an ephemeral Respiratory Intermediate Care Unit.
https://www.ncbi.nlm.nih.gov/pubmed/32651097
2020-06-28 02:00:00+02:00
pubmed
Tsipora N Guenancia;Anne Rosa;Charles Damoisel;Frédéric J Mercier;Bénédicte Jeannin
2020-06-24 02:00:00+02:00
32651097
FR
Département d'anesthésie-réanimation, hôpital Antoine-Béclère, université Paris-Saclay, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France. Electronic address: tguenancia@gmail.com.;Département d'anesthésie-réanimation, hôpital Antoine-Béclère, université Paris-Saclay, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France.;Réanimation polyvalente, hôpital Antoine-Béclère, université Paris-Saclay, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France.
1440
10.3390/biology9060135
Journal Article
en
On a Coupled Time-Dependent SIR Models Fitting with New York and New-Jersey States COVID-19 Data.
https://www.ncbi.nlm.nih.gov/pubmed/32599867
This article describes a simple Susceptible Infected Recovered (SIR) model fitting with COVID-19 data for the month of March 2020 in New York (NY) state. The model is a classical SIR, but is non-autonomous; the rate of susceptible people becoming infected is adjusted over time in order to fit the available data. The death rate is also secondarily adjusted. Our fitting is made under the assumption that due to limiting number of tests, a large part of the infected population has not been tested positive. In the last part, we extend the model to take into account the daily fluxes between New Jersey (NJ) and NY states and fit the data for both states. Our simple model fits the available data, and illustrates typical dynamics of the disease: exponential increase, apex and decrease. The model highlights a decrease in the transmission rate over the period which gives a quantitative illustration about how lockdown policies reduce the spread of the pandemic. The coupled model with NY and NJ states shows a wave in NJ following the NY wave, illustrating the mechanism of spread from one attractive hot spot to its neighbor.
2079-7737
2020-06-28 02:00:00+02:00
pubmed
Biology
Benjamin Ambrosio;M A Aziz-Alaoui
COVID-19;Network;New Jersey;New York;SIR models
2020-06-24 02:00:00+02:00
32599867
FR
UNIHAVRE, LMAH, FR-CNRS-3335, ISCN, Normandie University, 76600 Le Havre, France.
1447
10.1038/s41559-020-1237-z
Journal Article
en
COVID-19 lockdown allows researchers to quantify the effects of human activity on wildlife.
https://www.ncbi.nlm.nih.gov/pubmed/32572222
2397-334X
2020-06-28 02:00:00+02:00
pubmed
Nature Ecology & Evolution
Christian Rutz;Matthias-Claudio Loretto;Amanda E Bates;Sarah C Davidson;Carlos M Duarte;Walter Jetz;Mark Johnson;Akiko Kato;Roland Kays;Thomas Mueller;Richard B Primack;Yan Ropert-Coudert;Marlee A Tucker;Martin Wikelski;Francesca Cagnacci
2020-06-22 02:00:00+02:00
32572222
FR;CA;SA;GB;US;IT;NL;DK;DE
Centre for Biological Diversity, School of Biology, University of St Andrews, St Andrews, UK. christian.rutz@st-andrews.ac.uk.;Radcliffe Institute for Advanced Study, Harvard University, Cambridge, MA, USA. christian.rutz@st-andrews.ac.uk.;Department of Migration, Max Planck Institute of Animal Behavior, Radolfzell, Germany.;Department of Biology, University of Konstanz, Konstanz, Germany.;Department of Ocean Sciences, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.;Centre for the Advanced Study of Collective Behaviour, University of Konstanz, Konstanz, Germany.;Red Sea Research Center and Computational Biosciences Research Center, King Abdullah University of Science and Technology, Thuwal, Kingdom of Saudi Arabia.;Ecology and Evolutionary Biology Department, Yale University, New Haven, CT, USA.;Center for Biodiversity and Global Change, Yale University, New Haven, CT, USA.;Sea Mammal Research Unit, University of St Andrews, St Andrews, UK.;Department of Biology, Aarhus University, Aarhus, Denmark.;Centre d'Etudes Biologiques de Chizé, La Rochelle Université - CNRS, UMR 7372, Villiers en Bois, France.;North Carolina Museum of Natural Sciences, Biodiversity Lab, Raleigh, NC, USA.;Fisheries, Wildlife, and Conservation Biology Program, College of Natural Resources, North Carolina State University, Raleigh, NC, USA.;Senckenberg Biodiversity and Climate Research Centre, Senckenberg Gesellschaft für Naturforschung, Frankfurt (Main), Germany.;Department of Biological Sciences, Goethe University, Frankfurt (Main), Germany.;Biology Department, Boston University, Boston, MA, USA.;Department of Environmental Science, Institute for Water and Wetland Research, Radboud University, Nijmegen, The Netherlands.;Department of Biodiversity and Molecular Ecology, Research and Innovation Centre, Fondazione Edmund Mach, Trento, Italy.
Recherches Translationnelles sur le VIH et Maladies Infectieuses/INSERM U1175, Institut de Recherche pour le Développement et Université de Montpellier, France. Electronic address: ahidjo.ayouba@ird.fr.;Recherches Translationnelles sur le VIH et Maladies Infectieuses/INSERM U1175, Institut de Recherche pour le Développement et Université de Montpellier, France.;Recherches Translationnelles sur le VIH et Maladies Infectieuses/INSERM U1175, Institut de Recherche pour le Développement et Université de Montpellier, France, Département de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.;Département de bacteriologie-virologie, CHU de Montpellier, 34295 Montpellier, France.
1454
Letter
en
SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pubmed/32572527
2020-06-28 02:00:00+02:00
pubmed
Slim Fourati;Sophie Hue;Jean-Michel Pawlotsky;Armand Mekontso-Dessap;Nicolas de Prost
2020-06-22 02:00:00+02:00
32572527
FR
Virology Unit, Département de prévention, diagnostic et traitement des infections, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France.;INSERM U955, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.;INSERM U955 Team « Virus Hepatology Cancer », Créteil, France.;Département Immunologie-Hématologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France.;INSERM U955 Team 16, Créteil, France.;Vaccine Research Institute (VRI), Faculté de Médecine, Université Paris Est Créteil, 94010, Créteil, France.;Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France.;Groupe de Recherche Clinique CARMAS, Université Paris Est-Créteil, Créteil, France.;INSERM U955, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France. nicolas.de-prost@aphp.fr.;Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France. nicolas.de-prost@aphp.fr.;Groupe de Recherche Clinique CARMAS, Université Paris Est-Créteil, Créteil, France. nicolas.de-prost@aphp.fr.;Service de Médecine Intensive Réanimation, Hôpital Henri Mondor, Créteil, France. nicolas.de-prost@aphp.fr.
1455
Letter
en
Impact of COVID-19 pandemic on emergency department services acuity and possible collateral damage.
Department of Emergency Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.;Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan, College of Medicine, National Taiwan University, Taipei, Taiwan.;Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: chulintsai@ntu.edu.tw.
1462
10.1016/j.scitotenv.2020.140426
Journal Article
en
Impact of lockdown measures to combat Covid-19 on air quality over western Europe.
https://www.ncbi.nlm.nih.gov/pubmed/32593893
Recent studies based on observations have shown the impact of lockdown measures taken in various European countries to contain the Covid-19 pandemic on air quality. However, these studies are often limited to compare situations without and with lockdown measures, which correspond to different time periods and then under different meteorological conditions. We propose a modelling study with the WRF-CHIMERE modelling suite for March 2020, an approach allowing to compare atmospheric composition with and without lockdown measures without the biases of meteorological conditions. This study shows that the lockdown effect on atmospheric composition, in particular through massive traffic reductions, has been important for several short-lived atmospheric trace species, with a large reduction in NO2 concentrations, a lower reduction in Particulate Matter (PM) concentrations and a mitigated effect on ozone concentrations due to non-linear chemical effects.
Laboratoire de Météorologie Dynamique (LMD), Ecole Polytechnique, IPSL Research University, Ecole Normale Supérieure, Université Paris-Saclay, Sorbonne Universités, UPMC Univ Paris 06, CNRS, Route de Saclay, 91128 Palaiseau, France. Electronic address: menut@lmd.polytechnique.fr.;Laboratoire de Météorologie Dynamique (LMD), Ecole Polytechnique, IPSL Research University, Ecole Normale Supérieure, Université Paris-Saclay, Sorbonne Universités, UPMC Univ Paris 06, CNRS, Route de Saclay, 91128 Palaiseau, France, Now at Citepa, Technical Reference Center for Air Pollution and Climate Change, 42, rue de Paradis, 75010 Paris, France.;Laboratoire Interuniversitaire des Systèmes Atmosphériques (LISA), UMR CNRS 7583, Université Paris Est Créteil et Université de Paris, Institut Pierre Simon Laplace, Créteil, France.;Laboratoire de Météorologie Dynamique (LMD), Ecole Polytechnique, IPSL Research University, Ecole Normale Supérieure, Université Paris-Saclay, Sorbonne Universités, UPMC Univ Paris 06, CNRS, Route de Saclay, 91128 Palaiseau, France.
1469
10.1016/j.ctrv.2020.102063
Journal Article;Review
en
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
https://www.ncbi.nlm.nih.gov/pubmed/32623296
The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.
Department of Pharmacy, CHU Reims, France, Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr.;Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com.;Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France, UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com.;Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr.;Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr.;Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr.;Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr.;Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com.;Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France, EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr.;Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France, Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr.;Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France, EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr.
1475
10.1016/j.retram.2020.06.003
Journal Article;Review
en
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
https://www.ncbi.nlm.nih.gov/pubmed/32620465
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: huyongxian2000@aliyun.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: elainetansuyin@outlook.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: yangyingying15@zju.edu.cn.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: 457166156@qq.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: weiguoqing2000@sina.com.;State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: zjusujunwei@zju.edu.cn.;Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: cncuiqu@hotmail.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: ayjin2007@aliyun.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: yanglizju@163.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: fushan0817@163.com.;Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: jfzhou@tjh.tjmu.edu.cn.;State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China. Electronic address: qiulg@ihcams.ac.cn.;Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China. Electronic address: zhangxxi@sina.com.;Department of Hematology, Shanghai Tongji Hospital, Shanghai, China. Electronic address: lab7182@tongji.edu.cn.;Department of Hematology, Peking University Third Hospital, Beijing, China. Electronic address: drjinghm@163.com.;Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. Electronic address: liyuhua2011gz@163.com.;Transplant and Cellular Immunotherapy Programs, Department of Hematology, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France. Electronic address: BLAISED@ipc.unicancer.fr.;Sorbonne University, Department of Hematology, Hôpital Saint Antoine, Paris, France, INSERM UMRs 938, EBMT Paris Study Office/CEREST-TC, Paris, France. Electronic address: mohamad.mohty@inserm.fr.;Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel. Electronic address: Arnon.Nagler@sheba.health.gov.il.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: huanghe@zju.edu.cn.
1479
10.1212/nxi.0000000000000823
Case Reports;Journal Article
en
COVID-19-associated ophthalmoparesis and hypothalamic involvement.
From the Department of Neurology (E.P.-G., J.F., A.M.-D., L.Q.), Neuroradiology Unit (M.T., B.G.-A.), Radiology Department, Microbiology Department (N.R.), and Gastroenterology Department (C.G.-O.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain.;From the Department of Neurology (E.P.-G., J.F., A.M.-D., L.Q.), Neuroradiology Unit (M.T., B.G.-A.), Radiology Department, Microbiology Department (N.R.), and Gastroenterology Department (C.G.-O.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain. lquerol@santpau.cat.
1496
Letter
en
Short-term acceptability by patients and psychiatrists of the turn to psychiatric teleconsultation in the context of the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32511825
2020-06-28 02:00:00+02:00
pubmed
Adult;Attitude of Health Personnel;Coronavirus Infections;France;Humans;Mental Disorders__therapy;Mentally Ill Persons;Pandemics;Patient Acceptance of Health Care__statistics & numerical data;Pneumonia, Viral;Psychiatry__statistics & numerical data;Remote Consultation__organization & administration;COVID-19
Romain Colle;Abd El Kader Ait Tayeb;Delphine de Larminat;Line Commery;Bruno Boniface;Pierre-Alexandre Lasica;Florence Gressier;Rima Mecifi;Samuel Rotenberg;Adrien Rigal;Sarah Zitoun;Antonia Mezzacappa;Cerasella Nicolicea;Edouard Chaneac;Severine Martin;Walid Choucha;Patrick Hardy;Elisabeth Schouman-Claeys;Emmanuelle Corruble
2020-06-28 02:00:00+02:00
32511825
FR
Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.;Faculté de Médecine Paris-Saclay, Equipe MOODS, INSERM, CESP, Université Paris-Saclay, Le Kremlin Bicêtre, France.;Direction de l'Organisation Médicale et des Relations avec les Universités, Assistance Publique-Hôpitaux de Paris, Paris, France.
1505
10.1016/j.amp.2020.06.014
Journal Article
fr
[The Covid-19 pandemic: Media overdose, fear and soon antonomasia? A squared pandemic].
Health Service Executive (HSE) Summerhill Community Mental Health Service, W35 KC58 Summerhill, Wexford, Ireland.;Faculty of Medicine, Université catholique de Louvain, avenue Emmanuel Mounier 50, B-1200 Woluwé-Saint-Lambert, Belgique.;Université catholique de Louvain , CHU UCL Namur, avenue Dr. G. Thérasse, B. 5530 Yvoir, Belgique.;Faculty of Psychology, Université catholique de Louvain, place Cardinal Mercier 10, 1348 Ottignies-Louvain-la-Neuve, Belgique.
1507
10.1016/j.therap.2020.06.013
Journal Article
en
Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review.
https://www.ncbi.nlm.nih.gov/pubmed/32665090
Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of pro-inflammatory cytokines (Il1, IL6, TNFα) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19.
University Saint-Étienne, 42000 Saint-Étienne, France.;Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France, Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France, IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier, France.;Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux, France.;Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble, France. Electronic address: Jean-Luc.Cracowski@univ-grenoble-alpes.fr.
1518
Case Reports;Letter
en
SARS-CoV-2-associated cold agglutinin disease: a report of two cases.
Department of Internal Medicine, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, 2 rue Ambroise Paré, 75010, Paris, France.;Department of Intensive Care, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, Paris, France.;Department of Internal Medicine, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, 2 rue Ambroise Paré, 75010, Paris, France. damin.sene@aphp.fr.
1522
10.1016/j.acvd.2020.06.001
Comparative Study;Journal Article;Multicenter Study
en
Worrying decrease in hospital admissions for myocardial infarction during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32636131
How coronavirus 2019 (COVID-19) is affecting management of myocardial infarction is a matter of concern, as medical resources have been massively reorientated and the population has been in lockdown since 17 March 2020 in France.
Pierre Lantelme;Sandrine Couray Targe;Pierre Metral;Thomas Bochaton;Sylvain Ranc;Maggie Le Bourhis Zaimi;Andre Le Coanet;Pierre-Yves Courand;Brahim Harbaoui
Acute coronary syndrome;COVID-19;Infarctus du myocarde;Myocardial infarction
2020-06-25 02:00:00+02:00
32636131
FR
University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15 Lyon, France, Cardiology Department, Hôpital Croix-Rousse and Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. Electronic address: pierre.lantelme@chu-lyon.fr.;Department of Medical Information, Hospices Civils de Lyon, Lyon, France.;Department of Medical Information, Saint-Joseph Hospital, Lyon, France.;Cardiology Department, Hôpital Louis-Pradel, Lyon, France.;Cardiology Department, Saint-Joseph Hospital, Lyon, France.;University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15 Lyon, France, Cardiology Department, Hôpital Croix-Rousse and Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.
1526
10.1136/bjophthalmol-2020-316776
Journal Article
en
Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32586933
Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged.
0007-1161,1468-2079
2020-06-28 02:00:00+02:00
pubmed
British Journal of Ophthalmology
Rupesh Agrawal;Ilaria Testi;Cecilia S Lee;Edmund Tsui;Marian Blazes;Jennifer E Thorne;Annabelle A Okada;Justine R Smith;Peter J McCluskey;John H Kempen;Christoph Tappeiner;Manisha Agarwal;Bahram Bodaghi;Quan Dong Nguyen;Vishali Gupta;Marc D De Smet;Manfred Zierhut;Carlos Pavesio
National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore rupesh_agrawal@ttsh.com.sg c.pavesio@nhs.net ndquan@stanford.edu.;Singapore Eye Research Institute, Singapore, Singapore.;School of Material Science and Engineering, Nanyang Technological University, Singapore, Singapore.;Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.;Department of Ophthalmology, University of Washington, Seattle, USA.;UCLA Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA.;Wilmer Eye Institute, Johns Hopkins University School of Medicine, USA, Baltimore.;Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, New South Wales, Japan.;Flinders University College of Medicine and Public Health, Adelaide, Australia.;Department of Ophthalmology, Director Save Sight Institute, The University of Sydney, Sydney, Pennsylvania, Australia.;Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, USA.;Eye Unit, MyungSung Christian Medical Center, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia.;Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Shroff Eye Centre, New Delhi, India.;Department of Ophthalmology,, Sorbonne University, Paris, France.;Byers Eye Institute, Stanford Medical School, Stanford, USA.;Advanced Eye Centre, Postgraduate Institute of Medical Education (PGIMER), Chandigarh, India.;Department of Ophthalmology ZNA Middelheim, Antwerp, Belgium.;Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.
1527
10.1016/j.jhin.2020.06.028
Journal Article
en
Dynamic of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk health care workers and hospital staff.
https://www.ncbi.nlm.nih.gov/pubmed/32593608
Staff members from Covid-19 highly exposed units were invited to participate in a six month study of SARS-CoV-2 carriage and seroprevalence. The results of Day 1 and Day 15 visits show that 41 SARS-CoV-2 infections were confirmed by RT-PCR and/or serology in 326 participants (overall infection rate=12.6%). Having co-morbidity or symptoms at the time of collection was a risk factor for infection but not working as a physician/nurse. This universal screening in high-risk units irrespective of symptoms allowed asymptomatic and potentially contagious infected workers to be self-isolated during 7 days.
0195-6701
2020-06-28 02:00:00+02:00
pubmed
Journal of Hospital Infection
Charlotte Martin;Isabel Montesinos;Nicolas Dauby;Christine Gilles;Hafid Dahma;Sigi Van Den Wijngaert;Stéphane De Wit;Marc Delforge;Nathan Clumeck;Olivier Vandenberg
2020-06-25 02:00:00+02:00
32593608
FR;BE;GB
Department of Infectious Diseases, CHU Saint-Pierre - Université Libre de Bruxelles (ULB), Brussels, Belgium.;LHUB-ULB, Microbiology, Brussels, Belgium.;Department of Infectious Diseases, CHU Saint-Pierre - Université Libre de Bruxelles (ULB), Brussels, Belgium, Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium, Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles (ULB), Brussels, Belgium.;Gynecology-Obstetric Department, CHU Saint-Pierre - Université Libre de Bruxelles (ULB), Brussels, Belgium.;LHUB-ULB, Microbiology, Brussels, Belgium, University College London.
1530
Letter
en
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
https://www.ncbi.nlm.nih.gov/pubmed/32629139
2020-07-05 02:00:00+02:00
pubmed
David Lebeaux;Matthieu Revest
2020-07-03 02:00:00+02:00
32629139
FR
Service de Microbiologie, Unité Mobile d'Infectiologie, AP-HP, Hôpital Européen Georges Pompidou, Université de Paris, France. 20 rue Leblanc, 75015, PARIS, France. Electronic address: david.lebeaux@aphp.fr.;Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 2 rue Henri Le Guilloux, 35033, Rennes Cedex, France.
1534
10.1002/lary.28957
Journal Article
en
Evolution of Olfactory Disorders in COVID-19 Patients.
https://www.ncbi.nlm.nih.gov/pubmed/32617990
A high frequency and a strong association of olfactory/gustatory impairment with COVID-19 were reported. Its spontaneous evolution remains unknown. The aim of this study was to investigate the spontaneous evolution of olfactory disorders in COVID-19 patients.
0023-852X,1531-4995
2020-07-05 02:00:00+02:00
pubmed
The Laryngoscope
Victor Gorzkowski;Sibylle Bevilacqua;Alexandre Charmillon;Roger Jankowski;Patrice Gallet;Cécile Rumeau;Duc Trung Nguyen
ENT - Head and Neck Surgery Department, Université de Lorraine, CHRU-Nancy, Nancy, France.;Infectious Disease Department, Université de Lorraine, CHRU-Nancy, Nancy, France.;Université de Lorraine, Inserm, NGERE, Nancy, France.;Université de Lorraine, DevAH, Nancy, France.;Université de Lorraine, Inserm, IADI, Nancy, France.
1542
10.1093/cid/ciaa677
Journal Article
en
Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.
https://www.ncbi.nlm.nih.gov/pubmed/32623470
In patients with severe COVID-19, data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.
Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, Nancy, France.;University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, Nancy, France.;Department of Methodology, Promotion, and Investigation, University Hospital of Nancy, University of Lorraine, Nancy, France.;Department of Virology, University Hospital of Nancy, Nancy, France, Laboratory of Physical Chemistry and Microbiology for the Environment, LCPME UMR 7564 CNRS-UL, Villers-les-Nancy, France.;Department of Nephrology, University Hospital of Nancy, Nancy, France.;Department of Infectious Diseases, University Hospital of Nancy, Nancy, France.;Department of Anesthesiology and Intensive Care Medicine, University Hospital of Nancy, Vandoeuvre-Lès-Nancy, France.;Medical Intensive Care Unit, University Hospital of Nancy, Brabois Hospital, Nancy, France.
1544
10.1016/j.ejogrb.2020.06.049
Journal Article
en
Fetal heart rate changes on the cardiotocograph trace secondary to maternal COVID-19 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32645644
To determine the cardiotocograph (CTG) changes in women with symptomatic COVID-19 infection.
0301-2115
2020-07-05 02:00:00+02:00
pubmed
European Journal of Obstetrics & Gynecology and Reproductive Biology
Anna Gracia-Perez-Bonfils;Oscar Martinez-Perez;Elisa Llurba;Edwin Chandraharan
Hospital General de l'Hospitalet, Barcelona, Spain, Autonomous University of Barcelona, Spain. Electronic address: gracia.anna@gmail.com.;Obs Simulation Unit, Spain, Puerta de Hierro-Majadahonda University Hospital, Universidad Autónoma de Madrid, Spain, Universidad Católica de Murcia, Spain.;Sant Pau University Hospital, Barcelona, Spain.;Global Academy of Medical Education & Training, London, United Kingdom.
1557
10.1007/s00330-020-07035-w
Journal Article
en
COVID-19 impact assessment on the French radiological centers: a nationwide survey.
https://www.ncbi.nlm.nih.gov/pubmed/32621241
To determine the impact of the COVID-19 on the CT activities in French radiological centers during the epidemic peak.
COVID-19;Prospective;Radiology;Surveys and questionnaires;Tomography;X-Ray computed
2020-07-03 02:00:00+02:00
32621241
FR
University Hospital Centre Poitiers, Radiology, 2 rue de la milétrie, 86000, Poitiers, Vienne, France. guillaume.herpe@chu-poitiers.fr.;Université de Poitiers Laboratoire de Mathématiques et Applications, Dactim Mis Team, 86073, Chasseneuil, Nouvelle-Aquitaine, France. guillaume.herpe@chu-poitiers.fr.;Université de Poitiers Laboratoire de Mathématiques et Applications, Dactim Mis Team, 86073, Chasseneuil, Nouvelle-Aquitaine, France.;University Hospital of Rennes, Radiology, Rennes, Ille-et-Vilaine, France.;TELEDIAG, 69009, Lyon, France.;CHU Clermont-Ferrand, Service de Radiologie B, 63003, Clermont-Ferrand, France.;CTM groupe, 34967, Montpellier, Occitanie, France.;APHM, Radiology, 13015, Marseille, PACA, France.;Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Radiology, 68051, Mulhouse, Grand Est, France.;European Hospital Group Georges-Pompidou, Radiology, 75908, Paris, Ile-de-France, France.;Centre Hospitalier Universitaire de Nice Hôpital Pasteur, Radiology, 06189, Nice, Alpes Maritimes, France.;CHU Nimes, 30029, Nimes, Gard, France.;CHU Timone, Radiology, 13385, Marseille, BDR, France.;APHP Hopital Beaujon, Paris, France.;Imadis téléradiologie, 69002, Lyon, Rhône, France.;Nouvel Hôpital Civil, Radiology, 67000, Strasbourg, Alsace, France.;CHRU de Nancy, RADIOLOGY, 54500, Nancy, Grand Est, France.;CHU Purpan, Service central d'imagerie médicale, 31059, Toulouse, Haute-Garonne, France.;Sorbonne Université, Radiology, 75013, Paris, Île-de-France, France.;University Hospital Poitiers, Radiology, Poitiers, France.;CHU Poitiers, Clinical Investigation Center CIC1402, 86021, Poitiers, Vienne, France.;La Timone Hospital, Radiology, Marseille, BDR, France.;CHU de Poitiers, Service de Radiologie, Poitiers, France.;University Hospital Center of Nîmes, Radiology, Nîmes, Gard, France.
1559
10.3389/fimmu.2020.01409
Journal Article;Review
en
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.
https://www.ncbi.nlm.nih.gov/pubmed/32714335
As the world is severely affected by COVID-19 pandemic, the use of chloroquine and hydroxychloroquine in prevention or for the treatment of patients is allowed in multiple countries but remained at the center of much controversy in recent days. This review describes the properties of chloroquine and hydroxychloroquine, and highlights not only their anti-viral effects but also their important immune-modulatory properties and their well-known use in autoimmune diseases, including systemic lupus and arthritis. Chloroquine appears to inhibit in vitro SARS virus' replication and to interfere with SARS-CoV2 receptor (ACE2). Chloroquine and hydroxychloroquine impede lysosomal activity and autophagy, leading to a decrease of antigen processing and presentation. They are also known to interfere with endosomal Toll-like receptors signaling and cytosolic sensors of nucleic acids, which result in a decreased cellular activation and thereby a lower type I interferons and inflammatory cytokine secretion. Given the antiviral and anti-inflammatory properties of chloroquine and hydroxychloroquine, there is a rational to use them against SARS-CoV2 infection. However, the anti-interferon properties of these molecules might be detrimental, and impaired host immune responses against the virus. This duality could explain the discrepancy with the recently published studies on CQ/HCQ treatment efficacy in COVID-19 patients. Moreover, although these treatments could be an interesting potential strategy to limit progression toward uncontrolled inflammation, they do not appear per se sufficiently potent to control the whole inflammatory process in COVID-19, and more targeted and/or potent therapies should be required at least in add-on.
Université de Strasbourg, INSERM UMR - S1109, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiencies, Strasbourg, France.;Université de Strasbourg, Faculty of Pharmacy, Illkirch, France.;Université de Paris, CNRS UMR-8601, Paris, France.;Team Chemistry & Biology, Modeling & Immunology for Therapy, CBMIT, Paris, France.;Université de Strasbourg, Faculty of Medicine, Strasbourg, France.;Université de Strasbourg, Faculty of Life Sciences, Strasbourg, France.
1561
Letter
en
Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals?
DMU ESPRIT, pharmacy, Pitié-Salpêtrière hospital, AP-HP, Paris, France.;Sorbonne University, GRC 29, AP-HP, DMU DREAM, Department of Anaesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France.;Sorbonne University, GRC 29, AP-HP, DMU DREAM, Department of Anaesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France. Electronic address: jean-michel.constantin@aphp.fr.;DMU ESPRIT, pharmacy, faculté de pharmacie de Paris, Pitié-Salpêtrière hospital, AP-HP, Paris, France.
1565
Letter
en
Letter to the Editor: COVID-19-Related Liver Injury and Clinical Outcomes: Does It Really Exist?
https://www.ncbi.nlm.nih.gov/pubmed/32619043
We read with interest the study by Lei and colleagues on the association between markers of liver injury and mortality in coronavirus disease 2019 (COVID-19) in China. The authors have painstakingly collated data from a large number of COVID-19 patients from multiple centers across Wuhan. They found that an increase in aspartate aminotransferase (AST) and its dynamicity correlated with COVID-19-related liver injury and patient outcomes. They concluded that the dynamic patterns of liver injury indicators, represented by AST, correspond with COVID-19-related liver injury.
The Liver Unit and Monarch Liver Lab, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India.;Gastroenterology and Advanced GI Endoscopy, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India.
1574
10.1016/j.chaos.2020.110077
Journal Article
en
Spreading of infections on random graphs: A percolation-type model for COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32834619
We introduce an epidemic spreading model on a network using concepts from percolation theory. The model is motivated by discussing the standard SIR model, with extensions to describe effects of lockdowns within a population. The underlying ideas and behaviour of the lattice model, implemented using the same lockdown scheme as for the SIR scheme, are discussed in detail and illustrated with extensive simulations. A comparison between both models is presented for the case of COVID-19 data from the USA. Both fits to the empirical data are very good, but some differences emerge between the two approaches which indicate the usefulness of having an alternative approach to the widespread SIR model.
0960-0779
2020-07-05 02:00:00+02:00
pubmed
Chaos, Solitons & Fractals
Fabrizio Croccolo;H Eduardo Roman
Critical percolation;Monte Carlo simulations;Random graphs;SIR Model
2020-07-03 02:00:00+02:00
32834619
FR;IT
Universite de Pau et des Pays de l'Adour, E2S UPPA, CNRS, TOTAL, LFCR UMR5150, Anglet, France.;Department of Physics, University of Milano-Bicocca, Piazza delle Scienze 3, Milan 20126, Italy.
1578
10.1016/j.accpm.2020.05.016
Journal Article
en
Ultrasound findings in patients with COVID-19 pneumonia in early and late stages: Two case-reports.
Department of Anaesthesia and Intensive Care Medicine, University Hospital of Marseille, Aix-Marseille University, Marseille, France, C2VN Inra Inserm, Faculty of medicine, Aix- Marseille University, Marseille, France.;Department of Anaesthesia and Intensive Care Medicine, University Hospital of Marseille, Aix-Marseille University, Marseille, France.;Department of Anaesthesiology and Intensive Care, University Hospital of Dijon, Dijon, France.;Department of Anaesthesiology and Intensive Care, University Hospital of Dijon, Dijon, France, Lipness Team, Inserm Research Centre LNC-UMR1231 and LabEx LipSTIC, Université Bourgogne Franche-Comté, Dijon, France. Electronic address: belaid_bouhemad@hotmail.com.
1584
10.1016/j.biocon.2020.108693
Journal Article;Review
en
The Fox and the Crow. A need to update pest control strategies.
https://www.ncbi.nlm.nih.gov/pubmed/32834058
The recent discovery that cats and mustelids can be infected by SARS-CoV-2 may raise the question of monitoring domestic, feral and wild populations of such animals, as an adjunct to the elimination of COVID-19 in humans. Emergency solutions might consider large scale control of these animals in the wild. However, looking at science recently published on native vertebrate pest control reveals first that usual controls do not succeed in reducing animal numbers and associated damages, second that controlling can be counter-productive in increasing the infectious risks for humans and livestock. The examples of red fox and corvids are detailed in a European context, illustrating the urgent need for an ethical evaluation of ecological and economic costs and benefits of pest control strategies. A complete scientific evaluation process must be implemented and up-dated regularly, to be organized in four major steps, once the aim of the control strategy has been defined: (1) evaluating damages/risks caused by the animals, to be balanced with the ecosystem services they may provide, also in terms of economic costs; (2) unravelling spatial and temporal population dynamics of target animals to identify, if any, optimal control scenarios - which could be done within an adaptive management framework; (3) estimating the economic costs of implementing those optimal control scenarios, to be compared to the economic costs of damages/diseases; (4) finally evaluating how the control strategy reached its aims. A modern fable of the Fox and the Crow should deliver a timely moral for an ethical, ecological and economical appraisal of pest control strategies in Europe.
0006-3207
2020-07-05 02:00:00+02:00
pubmed
Biological Conservation
Frédéric Jiguet
2020-07-03 02:00:00+02:00
32834058
FR
UMR7204 Centre d'Ecologie et des Sciences de la Conservation, MNHN-CNRS-SU, CP135, 43 Rue Buffon, 75005 Paris, France.
1586
10.1017/s0033291720002500
Journal Article
en
COVID-19 lockdown and mental health: why we must look into oncology units.
Service thérapie cellulaire et hématologie clinique, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.;CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Emergency Medicine, Clermont Auvergne University, Clermont-Ferrand, France.;CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, Clermont Auvergne University, Clermont-Ferrand, Auvergne-Rhône-Alpes, France.
1587
Letter
en
COVID-19 on cruise ships: preventive quarantine or abandonment of patients?
Richard Pougnet;Laurence Pougnet;Jean-Dominique Dewitte;David Lucas;Brice Loddé
COVID-19;pandemics;quarantine
2020-07-01 02:00:00+02:00
32604459
FR
French Society for Maritime Medicine, Faculty of Medicine and Health Sciences, University of Western Brittany, Brest, France. richard.pougnet@live.fr.;Centre for Professional and Environmental Pathologies, Morvan Teaching Hospital (CHRU), Brest, France. richard.pougnet@live.fr.;Laboratory for Studies and Research in Sociology (LABERS), EA 3149, University of Western Brittany, Brest, France. richard.pougnet@live.fr.;French Society for Maritime Medicine, Faculty of Medicine and Health Sciences, University of Western Brittany, Brest, France.;Clermont-Tonnerre Military Teaching Hospital, rue du Colonel Fontferrier, 29200 Brest, France.;Centre for Professional and Environmental Pathologies, Morvan Teaching Hospital (CHRU), Brest, France.;Laboratory for Studies and Research in Sociology (LABERS), EA 3149, University of Western Brittany, Brest, France.
1592
Letter
en
Investigation of a family outbreak of COVID-19 using systematic rapid diagnostic tests raises new questions about transmission.
Department of Infectious Diseases, Centre Hospitalier Régional d'Orléans, Orléans, France.;Department of Infectious Diseases, Hôpital Tenon, Sorbonne University, Paris, France.;Department of Infectious Diseases, Centre Hospitalier Régional d'Orléans, Orléans, France. Electronic address: laurent.hocqueloux@chr-orleans.fr.
1604
10.1111/jth.14980
Journal Article
en
Lupus anticoagulant is frequent in patients with Covid-19: Response to Reply.
https://www.ncbi.nlm.nih.gov/pubmed/32608109
We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (1). Different authors had confirmed these results (2). Connell and colleagues had discussed, in the Journal, technical points concerning LAC as well as anti-phospholipids (aPL) auto-antibodies detection (3).
1538-7933,1538-7836
2020-07-05 02:00:00+02:00
pubmed
Journal of Thrombosis and Haemostasis
Inès Harzallah;Agathe Debliquis;Bernard Drénou
2020-06-30 02:00:00+02:00
32608109
FR
Groupe Hospitalier de la région Mulhouse Sud Alsace, Laboratoire d'Hématologie, 20 rue Dr Laënnec, 68070, Mulhouse, cedex, France.
1615
10.1016/j.ejvs.2020.07.003
Journal Article
en
Acute Aortic Thrombosis Revealing a COVID-19 Infection.
https://www.ncbi.nlm.nih.gov/pubmed/32800476
1078-5884
2020-07-12 02:00:00+02:00
pubmed
European Journal of Vascular and Endovascular Surgery
Raphaël Coscas;Marc Coggia
2020-07-07 02:00:00+02:00
32800476
FR
Department of Vascular Surgery, Ambroise Paré University Hospital, Boulogne-Billancourt, France, UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, Villejuif, France. Electronic address: rcoscas@gmail.com.;Department of Vascular Surgery, Ambroise Paré University Hospital, Boulogne-Billancourt, France.
1624
10.1684/abc.2020.1576
Journal Article
en
Interactive pedagogical tools could be helpful for medical education continuity during COVID-19 outbreak.
https://www.ncbi.nlm.nih.gov/pubmed/32627731
Training and education are essential for medical students. During the COVID-19 outbreak, numerous schools and universities have had to close. Ensuring pedagogical continuity requires alternatives to the traditional classroom, especially in medical education. Usual distance learning tools such as videos and downloadable handouts are not sufficient to promote efficient teaching. Distance learning requires self-motivation and does not give you direct access to your instructor. Some students fear the loss of human contact with an instructor - like asking questions during and after class - which promotes learning, understanding and communication. Moreover, classical distance learning methods do not offer immediate feedback that can help students in their understanding of the lecture. In this context, interactive pedagogic tools (IPT) could be useful for medical education continuity and for maintaining human contact necessary in pedagogy. We briefly evaluated interactive pedagogic tool compared to traditionnal distancial tools on medical students. This study showed the importance to have direct contact with a teacher and feedback during a lecture and to not exclusively perform distance learning without direct interaction and feedback. Hence, in the present context, we encourage teacher to use this type of tools to maintain direct interaction with students - which is essential in pedagogy - and ensure a qualitative pedagogical continuity.
active distance learning;audience response system;medical education continuity;online interactive pedagogy tools
2020-07-07 02:00:00+02:00
32627731
FR
University of Lille, Faculty of pharmaceutical and biological sciences, Lille, France, CHU Lille, Laboratory of biochemistry, biology and pathology center, Lille, France, Inserm, UMR-1011-European genomic institute for diabetes, Institut Pasteur de Lille, Université de Lille, France.;CHU Lille, Laboratory of biochemistry, biology and pathology center, Lille, France, University of Lille, Faculty of medicine, Lille, France, Inserm, UMR 1172, JPArc, Faculté de médecine, Université de Lille, France.
1627
10.1136/bcr-2020-236815
Case Reports;Journal Article
en
Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis.
https://www.ncbi.nlm.nih.gov/pubmed/32641442
We report on a patient with coronavirus disease 2019 (COVID-19) and decompensated cirrhosis who experienced a favourable outcome of severe immune thrombocytopaenic purpura (ITP) after administration of intravenous immunoglobulin and high-dose dexamethasone. The present case suggests that it is reasonable to evoke ITP in case of profound thrombocytopaenia in a patient with COVID-19.
Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland gregoire.stalder@chuv.ch.
1628
H2020 Research Infrastructures;H2020 European Institute of Innovation and Technology;Agence Nationale de la Recherche;H2020 European Institute of Innovation and Technology;Institut National de la Santé et de la Recherche Médicale
10.3390/v12070735
Journal Article;Research Support, Non-U.S. Gov't
en
Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?
https://www.ncbi.nlm.nih.gov/pubmed/32646015
Standard precautions to minimize the risk of SARS-CoV-2 transmission implies that infected cell cultures and clinical specimens may undergo some sort of inactivation to reduce or abolish infectivity. We evaluated three heat inactivation protocols (56 °C-30 min, 60 °C-60 min and 92 °C-15 min) on SARS-CoV-2 using (i) infected cell culture supernatant, (ii) virus-spiked human sera (iii) and nasopharyngeal samples according to the recommendations of the European norm NF EN 14476-A2. Regardless of the protocol and the type of samples, a 4 Log10 TCID50 reduction was observed. However, samples containing viral loads > 6 Log10 TCID50 were still infectious after 56 °C-30 min and 60 °C-60 min, although infectivity was < 10 TCID50. The protocols 56 °C-30 min and 60 °C-60 min had little influence on the RNA copies detection, whereas 92 °C-15 min drastically reduced the limit of detection, which suggests that this protocol should be avoided for inactivation ahead of molecular diagnostics. Lastly, 56 °C-30 min treatment of serum specimens had a negligible influence on the results of IgG detection using a commercial ELISA test, whereas a drastic decrease in neutralizing titers was observed.
Boris Pastorino;Franck Touret;Magali Gilles;Xavier de Lamballerie;Remi N Charrel
COVID-19;ELISA;SARS-CoV-2;coronavirus;heat inactivation;neutralization;serology;virus neutralization test
2020-07-07 02:00:00+02:00
32646015
FR
[{"country": "International", "agency": "H2020 Research Infrastructures", "grantid": "871029"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "101003544"}, {"country": "International", "agency": "Agence Nationale de la Recherche", "grantid": "PREPMedVet"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "IMI2 VHFMODRAD 823666"}, {"country": "International", "agency": "Institut National de la Santé et de la Recherche Médicale", "grantid": "REACTing"}]
Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Aix-Marseille University, 13005 Marseille, France.
1631
10.1111/jdv.16593
Journal Article
en
Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.
Journal of the European Academy of Dermatology and Venereology
E Papadavid;J Scaribrick;P Ortiz Romero;P Guaglino;M Vermeer;R Knobler;R Stadler;M Bagot
2020-07-07 02:00:00+02:00
32416629
FR;GR;GB;US;IT;NL;ES;DE;AT
2nd Dermatology Department, National and Kapodistrian University of Athens, Athens, Greece.;University Hospital Birmingham, Birmingham, UK.;Dermatology Department, University 12 of Octubre, Madrid, Spain.;Department of Dermatology, University of Turin, Turin, Italy.;University of Leiden, Leiden, Netherlands.;Department of Dermatology, Medical University of Vienna, Vienna, Austria.;Department of Dermatology, Venerology, Allergology und Phlebology, Johannes Wesling Klinikum Minden, Minden, Germany.;University of Paris, Hospital Saint-Louis, Paris, France.
1632
Letter;Research Support, Non-U.S. Gov't;Comment
en
Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19.
Research Institute of Cancerology of Montpellier, National Institute of Health and Medical Research, INSERM U1194, IRCM, ICM, Montpellier University, Montpellier, France.
1634
10.1016/s0140-6736(20)31528-2
Journal Article;Retraction of Publication
en
Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32653079
0140-6736
2020-07-12 02:00:00+02:00
pubmed
The Lancet
Christian Funck-Brentano;Lee S Nguyen;Joe-Elie Salem
2020-07-09 02:00:00+02:00
32653079
FR
AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France. Electronic address: christian.funck-brentano@aphp.fr.;AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France.
1635
Letter
en
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France, INSERM UMRS 1140, Paris University, Paris, France. Electronic address: virginie.siguret@aphp.fr.;Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris University, Paris, France, INSERM UMRS 1144, Paris University, Paris, France.;Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France, INSERM UMRS 1140, Paris University, Paris, France.;Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France, EA 3518, Paris University, Paris, France.;Department of Anesthesiology and Critical Care, Lariboisière Hospital, Paris University, Paris, France.
1647
10.1111/bju.15164
Journal Article
en
Urology surgical activity and COVID-19: risk assessment at the epidemic peak: a Parisian multicentre experience.
https://www.ncbi.nlm.nih.gov/pubmed/32640121
1464-4096
2020-07-12 02:00:00+02:00
pubmed
BJU International
Alexandre Ingels;Steeven Bibas;Maher Abdessater;Thomas Tabourin;Morgan Roupret;Emmanuel Chartier-Kastler;Gwendolyn Barker;Nouha Tobbal;Steeve Doizi;Olivier Cussenot;Doriane Prost;Francois Desgrandchamps;Idir Ouzaid;Paul Rollin;Jean-Francois Hermieu;Francois Audenet;Mickael Userovici;Arnaud Mejean;Julien Anract;Sabine Roux;Michael Peyromaure;Nicolas Couteau;Cédric Lebacle;Jacques Irani;Dimitri Vordos;René Yiou;Andras Hoznek;Cecile M Champy;Jose Batista Da Costa;Alexandre de la Taille
2020-07-08 02:00:00+02:00
32640121
FR
Department of Urology, UPEC - Henri Mondor Hospital, AP-HP, Creteil, France.;Department of Urology, AP-HP, Pitié-Salpétrière Hospital, Sorbonne Université, Paris.;Department of Urology, AP-HP, Tenon Hospital, Sorbonne Université, Paris, France.;Department of Urology, AP-HP, Saint-Louis Hospital, Paris, France.;Department of Urology, AP-HP, Bichat Hospital, Paris, France.;Department of Urology, AP-HP, HEGP Hospital, Paris, France.;Department of Urology, AP-HP, Cochin Hospital, Paris, France.;Department of Urology, AP-HP, Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France.
1648
10.1371/journal.pone.0235597
Journal Article
en
Exploring the future of land use and food security: A new set of global scenarios.
https://www.ncbi.nlm.nih.gov/pubmed/32639991
Facing a growing and more affluent world population, changing climate and finite natural resources, world food systems will have to change in the future. The aim of the Agrimonde-Terra foresight study was to build global scenarios linking land use and food security, with special attention paid to overlooked aspects such as nutrition and health, in order to help explore the possible future of the global food system. In this article, we seek to highlight how the resulting set of scenarios contributes to the debate on land use and food security and enlarges the range of possible futures for the global food system. We highlight four main contributions. Combining a scenario building method based on morphological analysis and quantitative simulations with a tractable and simple biomass balance model, the proposed approach improves transparency and coherence between scenario narratives and quantitative assessment. Agrimonde-Terra's scenarios comprise a wide range of alternative diets, with contrasting underlying nutritional and health issues, which accompany contrasting urbanization and rural transformation processes, both dimensions that are lacking in other sets of global scenarios. Agrimonde-Terra's scenarios share some similarities with existing sets of global scenarios, notably the SSPs, but are usually less optimistic regarding agricultural land expansion up to 2050. Results suggest that changing global diets toward healthier patterns could also help to limit the expansion in agricultural land area. Agrimonde-Terra's scenarios enlarge the scope of possible futures by proposing two pathways that are uncommon in other sets of global scenarios. The first proposes to explore possible reconnection of the food industry and regional production within supranational regional blocs. The second means that we should consider that a 'perfect storm', induced by climate change and an ecological crisis combined with social and economic crises, is still possible. Both scenarios should be part of the debate as the current context of the COVID-19 pandemic shows.
1932-6203
2020-07-12 02:00:00+02:00
pubmed
Agriculture;Computer Simulation;Conservation of Natural Resources;Coronavirus Infections__economics;Diet;Food Quality;Food Supply;Global Health;Humans;Pandemics__economics;Pneumonia, Viral__economics;Urbanization;COVID-19
PLOS ONE
Olivier Mora;Chantal Le Mouël;Marie de Lattre-Gasquet;Catherine Donnars;Patrice Dumas;Olivier Réchauchère;Thierry Brunelle;Stéphane Manceron;Elodie Marajo-Petitzon;Clémence Moreau;Marc Barzman;Agneta Forslund;Pauline Marty
2020-07-08 02:00:00+02:00
32639991
FR
DEPE, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Paris, France.;Agrocampus-Ouest, SMART-LERECO, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Rennes, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), ART-DEV, Montpellier, France.;ART-DEV, Université de Montpellier, CIRAD, CNRS, Université de Montpellier 3, Montpellier, France.;Université de Perpignan Via Domitia, Montpellier, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), CIRED, Montpellier, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), CIRED, Nogent-sur-Marne, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), Paris, France.;Département EcoSocio, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Rennes, France.
1654
10.1111/tesg.12451
Journal Article
en
Discourse and Strategic Use of the Military in France and Europe in the COVID-19 Crisis.
https://www.ncbi.nlm.nih.gov/pubmed/32834143
In March 2020, the French President called to war against the COVID-19 which was followed by the launch of a military operation called Operation Resilience. This use of martial rhetoric initiated an effective mobilisation consisting in logistical assistance to the health sector. While armies are increasingly used to deal with environmental disasters, aside from their traditional role, this paper postulates that the geography of the French and international military engagement can be used to analyse both the institutional strategy of crisis management and the message governments send to their population. Military involvement differs in terms of missions given and of the amount of troops mobilised. It first questions the use of the military in the name of national resilience in the political discourse and the way it displays a symbolic message to the population, before analysing the role of armies in the crisis through the spatiality of their interventions.
0040-747X,1467-9663
2020-07-12 02:00:00+02:00
pubmed
Tijdschrift voor economische en sociale geografie
Florian Opillard;Angélique Palle;Léa Michelis
COVID‐19;Europe;France;military;resilience
2020-07-09 02:00:00+02:00
32834143
FR
Institute for Strategic Research (IRSEM, Paris) / IHEAL-CREDA Paris France.;Institute for Strategic Research (IRSEM, Paris) / UMR Prodig Paris France.;Rennes 1 University / IRSEM Paris France.
1655
10.1016/j.banm.2020.07.004
Journal Article
en
COVID-19 epidemic phases: Criteria, challenges and issues for the future.
Académie nationale de médecine, 16, rue Bonaparte, 75006 Paris, France.
1660
10.1016/j.frl.2020.101690
Journal Article
en
COVID-19 and the march 2020 stock market crash. Evidence from S&P1500.
https://www.ncbi.nlm.nih.gov/pubmed/32837377
This paper investigates the US stock market performance during the crash of March 2020 triggered by COVID-19. We find that natural gas, food, healthcare, and software stocks earn high positive returns, whereas equity values in petroleum, real estate, entertainment, and hospitality sectors fall dramatically. Moreover, loser stocks exhibit extreme asymmetric volatility that correlates negatively with stock returns. Firms react in a variety of different ways to the COVID-19 revenue shock. The analysis of the 8K and DEF14A filings of poorest performers reveals departures of senior executives, remuneration cuts, and (most surprisingly) newly approved cash bonuses and salary increases.
1544-6123
2020-07-12 02:00:00+02:00
pubmed
Finance Research Letters
Mieszko Mazur;Man Dang;Miguel Vega
2020-07-09 02:00:00+02:00
32837377
FR;VN
IESEG School of Management (LEM-CNRS 9221), Parvis de la Défense, 92800 Puteaux, France.;The University of Da Nang, University of Economics, 71 Ngu Hanh Son Street, Danang City 550000, Vietnam.
1662
10.1259/bjr.20200515
Journal Article
en
Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32584604
During the first two decades of the 21st century, there have been three coronavirus infection outbreaks raising global health concerns by severe acute respiratory syndrome coronavirus (SARS-CoV), the Middle East respiratory syndrome coronavirus (MERS-CoV), and the SARS-CoV-2. Although the reported imaging findings of coronavirus infection are variable and non-specific, the most common initial chest radiograph (CXR) and CT findings are ground-glass opacities and consolidation with peripheral predominance and eventually spread to involve both lungs as the disease progresses. These findings can be explained by the immune pathogenesis of coronavirus infection causing diffuse alveolar damage. Although it is insensitive in mild or early coronavirus infection, the CXR remains as the first-line and the most commonly used imaging modality. That is because it is rapid and easily accessible and helpful for monitoring patient progress during treatment. CT is more sensitive to detect early parenchymal lung abnormalities and disease progression, and can provide an alternative diagnosis. In this pictorial review, various coronavirus infection cases are presented to provide imaging spectrums of coronavirus infection and present differences in imaging among them or from other viral infections, and to discuss the role of imaging in viral infection outbreaks.
Tomas Franquet;Yeon Joo Jeong;Hiu Yin Sonia Lam;Ho Yuen Frank Wong;Yeun-Chung Chang;Myung Jin Chung;Kyung Soo Lee
2020-07-06 02:00:00+02:00
32584604
FR;CN;GB;TW;HK;ES;KR
Department of Radiology, Hospital de Sant Pau. Universidad Autónoma de Barcelona, Barcelona, Spain.;Department of Radiology and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.;Department of Radiology, Queen Mary Hospital, Hong Kong, China.;Department of Medical Imaging, National Taiwan University Hospital and Department of Radiology, National Taiwan University College of Medicine, Taipei, Taiwan.;Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine (SKKU-SOM), Seoul, Korea.
1663
10.1002/hpm.3015
Journal Article
en
Principalism in public health decision making in the context of the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32648280
The COVID-19 pandemic lead scientists and governmental authorities to issue clinical and public health recommendations based on progressively emerging evidence and expert opinions and many of these fast-tracked to peer-reviewed publications. Concerns were raised on scientific quality and generalizability of this emerging evidence.
0749-6753,1099-1751
2020-07-12 02:00:00+02:00
pubmed
The International Journal of Health Planning and Management
Paulo Ferrinho;Mohsin Sidat;Gisela Leiras;Fernando Passos Cupertino de Barros;Horácio Arruda
COVID-19;principalism;public health decision making
2020-07-10 02:00:00+02:00
32648280
FR;CA;PT;MZ;BR
Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal.;Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique.;European Network of Medical Residents in Public Health (EuroNet MRPH), Paris, France.;Conselho Nacional dos Secretários de Saude-CONASS, Faculdade de Medicina da Universidade Federal de Goiás, Núcleo de Estudos em Saúde Pública da Universidade de Brasília, Brasilia, Brazil.;Directeur national de santé publique et sous-ministre adjoint, Ministère de la Santé et des Services sociaux, Quebec, Canada.
1671
10.1038/s41433-020-1080-0
Journal Article
en
Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective.
https://www.ncbi.nlm.nih.gov/pubmed/32651545
The coronavirus disease 2019 (COVID-19) pandemic has imposed measures of social distancing and barriers in delivery of "in person" education. Institutions, involved in training the next generation of ophthalmologists, are using alternative teaching methods to maintain the standard of education.
2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece. eirchat@yahoo.gr.;Department of Ophthalmology, Altino Ventura Foundation, Recife, Brazil.;Department of Ophthalmology, HOPE Eye Hospital, Recife, Brazil.;Department of Ophthalmology, Reference Center in Rare diseases, DHU Sight Restore, Hôpital Pitié Salpêtrière, Sorbonne Université, Paris, France.;Department of Ophthalmology, Aneurin Bevan University Health Board, Wales, UK.;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.;Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France.;Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel.;Hadassah School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.;Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.;Department of Retina and Vitreous, Clínica de Oftalmología de Cali, Cali, Colombia.;Department of Ophthalmology, National University of Malaysia, Kuala Lumpur, Malaysia.;Westmead and Central (Save Sight Institute) Clinical Schools, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, NSW, Australia.;State Key Laboratory of Ophthalmology, Retina Division, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.;Division of Ophthalmology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.;Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
1678
Letter;Comment
en
Delayed acute bronchiolitis in infants hospitalized for COVID-19.
Department of general pediatrics, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;INSERM, IMRB, Univ Paris Est Creteil, Team GEIC2O, Creteil, France.;Centre of Rare Lung Diseasees (RESPIRARE®), Créteil, France.
1679
10.1590/0034-7167-2020-0247
Journal Article
po
In defense of the Unified Health System in the context of SARS-CoV-2 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32667577
To discuss the political and structural conditions for establishing the Unified Health System (UHS - Sistema Único de Saúde, SUS) in coping with the SARS-CoV-2 pandemic.
Janieiry Lima de Araújo;Kalyane Kelly Duarte de Oliveira;Rodrigo Jácob Moreira de Freitas
2020-07-10 02:00:00+02:00
32667577
FR;BR
Universidade do Estado do Rio Grande do Norte, Pau dos Ferros, Rio Grande do Norte, Brazil.
1684
10.1007/s00428-020-02886-6
Journal Article;Review
en
Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists.
https://www.ncbi.nlm.nih.gov/pubmed/32642842
Since its initial recognition in December 2019, Coronavirus disease 19 (COVID-19) has quickly spread to a pandemic infectious disease. The causative agent has been recognized as a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily affecting the respiratory tract. To date, no vaccines are available nor any specific treatment. To limit the number of infections, strict directives have been issued by governments that have been translated into equally rigorous guidelines notably for post-mortem examinations by international and national scientific societies. The recommendations for biosafety control required during specimen collection and handling have strongly limited the practice of autopsies of the COVID-19 patients to a few adequate laboratories. A full pathological examination has always been considered an important tool to better understand the pathophysiology of diseases, especially when the knowledge of an emerging disorder is limited and the impact on the healthcare system is significant. The first evidence of diffuse alveolar damage in the context of an acute respiratory distress syndrome has now been joined by the latest findings that report a more complex scenario in COVID-19, including a vascular involvement and a wide spectrum of associated pathologies. Ancillary tools such as electron microscopy and molecular biology used on autoptic tissue samples from autopsy are also significantly contributing to confirm and/or identify new aspects useful for a deeper knowledge of the pathogenetic mechanisms. This article will review and summarize the pathological findings described in COVID-19 until now, chiefly focusing on the respiratory tract, highlighting the importance of autopsy towards a better knowledge of this disease.
0945-6317,1432-2307
2020-07-12 02:00:00+02:00
pubmed
Virchows Archiv
Fiorella Calabrese;Federica Pezzuto;Francesco Fortarezza;Paul Hofman;Izidor Kern;Angel Panizo;Jan von der Thüsen;Sergei Timofeev;Gregor Gorkiewicz;Francesca Lunardi
Autopsy;COVID-19;Lung;Pandemic;SARS-CoV-2
2020-07-09 02:00:00+02:00
32642842
FR;RU;SI;IT;NL;ES;AT
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Via A. Gabelli 61, 35121, Padova, Italy. fiorella.calabrese@unipd.it.;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Via A. Gabelli 61, 35121, Padova, Italy.;Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank BB-0033-00025, University Côte d'Azur, Nice, France.;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.;Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.;Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.;Moscow City Hospital #40, Moscow, Russia.;Institute of Pathology, Medical University of Graz, Graz, Austria.
1687
10.1183/23120541.00182-2020
Journal Article
en
COVID-19 necrotising pneumonia and extracorporeal membrane oxygenation: a challenge for anticoagulation.
https://www.ncbi.nlm.nih.gov/pubmed/32665949
ECMO and curative anticoagulation may be associated with severe bleeding events in #COVID19 pneumonia. ECMO and high levels of anticoagulation must be considered with caution in the most severe patients with #SARS-CoV-2 necrotising pneumonia. https://bit.ly/3clhu31.
2312-0541
2020-07-12 02:00:00+02:00
pubmed
ERJ Open Research
Suzanne Goursaud;Martin Mombrun;Damien du Cheyron
2020-07-06 02:00:00+02:00
32665949
FR
Dept of Medical Intensive Care, Caen University Hospital, Caen, France.;Normandie Univ., UNICAEN, INSERM, U1237, PhIND "Physiopathology and imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.
1697
10.1016/j.yebeh.2020.107262
Journal Article;Review
en
Bridging the healthcare gap: Building the case for epilepsy virtual clinics in the current healthcare environment.
https://www.ncbi.nlm.nih.gov/pubmed/32645620
Access to quality healthcare remains a challenge that is complicated by mounting pressures to control costs, and now, as we witness, the unprecedented strain placed on our healthcare delivery systems due to the COVID-19 pandemic. Challenges in healthcare access have driven a need for innovative approaches ensuring connectivity to health providers. Telehealth services and virtual clinics offer accessible disease management pathways for patients living in health resource limited areas or, as in the case of the COVID-19 pandemic, where there may be potential barriers to existing healthcare resources. Those suffering with serious chronic disorders often cannot be seen by a healthcare specialist due to their limited availability, or the lack of a specialist within a reasonable proximity. Epilepsy represents such a disorder where most of the world's population lacks the availability of necessary specialists. Virtual clinics allow for specialist care and an ability to perform necessary ambulatory electroencephalogram (EEG) monitoring by placing the technologies directly in patients' homes or at local clinics near the patients' homes. By moving the diagnostic process out of the hospital or epilepsy center, it becomes possible to overcome growing gaps in neurology services. Virtual clinics have the potential to expand access to high-quality, cost-effective care for the patient. The virtual clinic remotely connects those in need of medical support with specialists anywhere in the world, at any time of the day.
1525-5050
2020-07-12 02:00:00+02:00
pubmed
Epilepsy & Behavior
Bruce Lavin;Cassie Dormond;Morris H Scantlebury;Pierre-Yves Frouin;Martin J Brodie
Epilepsy;Telemedicine;Virtual clinic
2020-07-06 02:00:00+02:00
32645620
FR;CA;GE;CH;US;GB
BioSerenity, Inc, Atlanta Georgia, Serenity Medical Services, Paris, France. Electronic address: Bruce.lavin@bioserenity.com.;High Lantern Group, Geneva, Switzerland.;Departments of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, University of Calgary, Canada.;BioSerenity, Inc, Atlanta Georgia, Serenity Medical Services, Paris, France.;Epilepsy Unit, University of Glasgow, Glasgow, Scotland, UK.
1701
10.1089/lap.2020.0535
Journal Article
en
Image-Guided Surgical e-Learning in the Post-COVID-19 Pandemic Era: What Is Next?
https://www.ncbi.nlm.nih.gov/pubmed/32628558
The current unprecedented coronavirus 2019 (COVID-19) crisis has accelerated and enhanced e-learning solutions. During the so-called transition phase, efforts were made to reorganize surgical services, reschedule elective surgical procedures, surgical research, academic education, and careers to optimize results. The intention to switch to e-learning medical education is not a new concern. However, the current crisis triggered an alarm to accelerate the transition. Efforts to consider e-learning as a teaching and training method for medical education have proven to be efficient. For image-guided therapies, the challenge requires more effort since surgical skills training is combined with image interpretation training, thus the challenge is to cover quality educational content with a balanced combination of blended courses (online/onsite). Several e-resources are currently available in the surgical scenario; however, further efforts to enhance the current system are required by accelerating the creation of new learning solutions to optimize complex surgical education needs in the current disrupted environment.
1092-6429,1557-9034
2020-07-12 02:00:00+02:00
pubmed
Journal of Laparoendoscopic & Advanced Surgical Techniques
Alain García Vazquez;Juan M Verde;Francesca Dal Mas;Mariano Palermo;Lorenzo Cobianchi;Jacques Marescaux;Benoit Gallix;Bernard Dallemagne;Silvana Perretta;Mariano E Gimenez
Department of Image-Guided Liver Interventions, IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France.;Department of Minimally-Invasive Surgery, IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France.;Department of Strategy and Enterprise, Lincoln International Business School, University of Lincoln, Lincoln, United Kingdom.;Department of Percutaneous Surgery, DAICIM Foundation, Teaching, Research, Assistance in Minimally Invasive Surgery, Buenos Aires, Argentina.;Department of Clinic, Diagnostic, and Pediatric Science, University of Pavia, Pavia, Italy.
1704
10.1136/esmoopen-2020-000852
Journal Article
en
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
https://www.ncbi.nlm.nih.gov/pubmed/32669298
The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of care in the majority of metastatic clear cell renal cell carcinoma (mccRCC) patients. It remains unclear whether therapies should be modified in response to the COVID-19 pandemic.
Medical Oncology and Haematology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.;Coordinating Center, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.;Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK.;Department Medical Oncology, Gustave Roussy, Villejuif, Île-de-France, France.;Medical Oncology, Royal Marsden Hospital NHS Trust, London, London, UK.;Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany.;Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Division of Medicine an Laboratory Sciences, Akershus University Hospital, Lorenskog, Norway.;Biomedical Sciences and Human Oncology, Università degli Studi di Bari Aldo Moro, Bari, Italy.;Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Medicine I, Clinical Division of Oncology, Vienna, Austria.;Medical Oncology, Weill Cornell Medicine, New York, New York, USA.;Medical Oncology and Haematology, Kantonsspital St Gallen, Sankt Gallen, Switzerland christian.rothermundt@kssg.ch.
1723
10.1186/s13613-020-00716-1
Journal Article
en
Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study.
https://www.ncbi.nlm.nih.gov/pubmed/32676824
COVID-19 ARDS could differ from typical forms of the syndrome.
2110-5820
2020-07-19 02:00:00+02:00
pubmed
Annals of Intensive Care
J-L Diehl;N Peron;R Chocron;B Debuc;E Guerot;C Hauw-Berlemont;B Hermann;J L Augy;R Younan;A Novara;J Langlais;L Khider;N Gendron;G Goudot;J-F Fagon;T Mirault;D M Smadja
ARDS;COVID-19;Physiological dead-space;Ventilatory ratio
2020-07-16 02:00:00+02:00
32676824
FR
Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France. jean-luc.diehl@aphp.fr.;Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, 20 Rue Leblanc, 75015, Paris, France. jean-luc.diehl@aphp.fr.;Intensive Care Unit, AH-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.;Université de Paris, PARCC, INSERM, 75015, Paris, France.;Emergency Department, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.;Plastic Surgery Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.;Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.;Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, 75015, Paris, France.;Vascular Medicine Department, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.
1736
10.1016/j.jaad.2020.07.048
Journal Article
en
Lack of association between chilblains outbreak and SARS-CoV-2: histological and serological findings from a new immunoassay.
https://www.ncbi.nlm.nih.gov/pubmed/32682889
0190-9622
2020-07-19 02:00:00+02:00
pubmed
Journal of the American Academy of Dermatology
Vivien Hébert;Anne-Bénédicte Duval-Modeste;Pascal Joly;Véronique Lemée;Lucie Cellier;Fabienne Jouen;Benoit Veber;Laurent Drouot;Olivier Boyer
2020-07-16 02:00:00+02:00
32682889
FR
Normandie Univ, UNIROUEN, Inserm, U1234, FOCIS Center of Excellence PAn'THER, Rouen University Hospital, Department of Dermatology, Rouen, France. Electronic address: Vivien.Hebert@chu-rouen.fr.;Normandie Univ, UNIROUEN, Inserm, U1234, FOCIS Center of Excellence PAn'THER, Rouen University Hospital, Department of Dermatology, Rouen, France.;Department of Virology, Rouen University Hospital, Rouen, France.;Department of Patholohy, Rouen University Hospital, Rouen, France.;Normandie Univ, UNIROUEN, Inserm, U1234, FOCIS Center of Excellence PAn'THER, Rouen University Hospital, Département of Immunology and Biotherapy, Rouen, France.;Department of Reanimation, Rouen University Hospital, Rouen, France.
1740
Letter
en
Necrotic acral lesions and lung failure in a fatal case of COVID-19.
NESMOS Department, Department of Dermatology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.;Queensland University, Brisbane, Australia.;Dermatology Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani'-IRCCS, Rome, Italy.;Cardiovascular-Respiratory Science Department, Sant'Andrea Hospital-Sapienza University of Rome, Rome, Italy.;Critical Care Unit, Clìnica Corachan, Barcelona, Spain.;Clinical Research/Epidemiology in Pneumonia & Sepsis (CRIPS), Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.;Centro de Investigaciòn Biomedica en Red de Enfermedades Respirorias (CIBERES), Instituto Salud Carlos III, Madrid, Spain.;Clinical Research, CHU, Université Montepellier-Nimes, Nimes, France.
1741
10.1111/ene.14440
Journal Article
en
Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak.
https://www.ncbi.nlm.nih.gov/pubmed/32677329
Post-viral olfactory dysfunction is well established and has been shown to be a key symptom of COVID-19 with more than 66% of European and US patients reporting some degree of loss of smell. Persistent olfactory dysfunction appears to be commonplace and will drive the demand for general practitioner, otolaryngology or neurology consultation in the next few months - evidence regarding recovery will be essential in counselling our patients.
1351-5101,1468-1331
2020-07-19 02:00:00+02:00
pubmed
European Journal of Neurology
C M Chiesa-Estomba;J R Lechien;T Radulesco;J Michel;L J Sowerby;C Hopkins;S Saussez
COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Otorhinolaryngology - Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otolaryngology - Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Oto-Rhino-Laryngology Head and Neck Surgery, Aix Marseille Univ, APHM, IUSTI, La Conception University Hospital, Marseille, France.;Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.;King's College, London, UK.;Department of Head and Neck Surgery, EpiCURA Hospital, Hornu, Belgium.
University Hospital of Nice, Nice, France burel-vandenbos.f@chu-nice.fr.
1747
Letter
en
Response to letter: COVID-19 and macular edema-a necessary blindness?
https://www.ncbi.nlm.nih.gov/pubmed/32683486
2020-07-19 02:00:00+02:00
pubmed
Jean-François Korobelnik
2020-07-18 02:00:00+02:00
32683486
FR
Service d'ophtalmologie, CHU Bordeaux, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.;Inserm, Bordeaux Population Health Research Center, team LEHA, Université de Bordeaux, UMR 1219, F-33000, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.
1748
Letter
en
COVID-19: What type of cytokine storm are we dealing with?
https://www.ncbi.nlm.nih.gov/pubmed/32681651
2020-07-19 02:00:00+02:00
pubmed
Guillaume Monneret;Ihsane Benlyamani;Morgane Gossez;Jesus F Bermejo-Martin;Marta Martín-Fernandez;Pierre Sesques;Florent Wallet;Fabienne Venet
2020-07-18 02:00:00+02:00
32681651
FR;ES
EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France.;Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.;Biomedical research Department, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.;Biomedical research Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, Spain.;Medical Intensive Care Unit, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, France.;Department of Hematology, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, France.
1769
10.1038/s41591-020-1001-6
Journal Article
en
A stochastic agent-based model of the SARS-CoV-2 epidemic in France.
https://www.ncbi.nlm.nih.gov/pubmed/32665655
Many European countries have responded to the COVID-19 pandemic by implementing nationwide protection measures and lockdowns1. However, the epidemic could rebound when such measures are relaxed, possibly leading to a requirement for a second or more, repeated lockdowns2. Here, we present results of a stochastic agent-based microsimulation model of the COVID-19 epidemic in France. We examined the potential impact of post-lockdown measures, including physical distancing, mask-wearing and shielding individuals who are the most vulnerable to severe COVID-19 infection, on cumulative disease incidence and mortality, and on intensive care unit (ICU)-bed occupancy. While lockdown is effective in containing the viral spread, once lifted, regardless of duration, it would be unlikely to prevent a rebound. Both physical distancing and mask-wearing, although effective in slowing the epidemic and in reducing mortality, would also be ineffective in ultimately preventing ICUs from becoming overwhelmed and a subsequent second lockdown. However, these measures coupled with the shielding of vulnerable people would be associated with better outcomes, including lower mortality and maintaining an adequate ICU capacity to prevent a second lockdown. Benefits would nonetheless be markedly reduced if most people do not adhere to these measures, or if they are not maintained for a sufficiently long period.
1078-8956,1546-170X
2020-07-19 02:00:00+02:00
pubmed
Nature Medicine
Nicolas Hoertel;Martin Blachier;Carlos Blanco;Mark Olfson;Marc Massetti;Marina Sánchez Rico;Frédéric Limosin;Henri Leleu
2020-07-14 02:00:00+02:00
32665655
FR;ES;US
AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France. nico.hoertel@yahoo.fr.;INSERM U1266, Paris, France. nico.hoertel@yahoo.fr.;Paris University, Paris, France. nico.hoertel@yahoo.fr.;Public Health Expertise, Paris, France.;National Institute on Drug Abuse, Bethesda, MD, USA.;Columbia University/New York State Psychiatric Institute, New York, NY, USA.;AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.;Universidad Complutense de Madrid, Campus de Somosaguas, Pozuelo de Alarcon, Spain.;INSERM U1266, Paris, France.;Paris University, Paris, France.
1773
10.1093/jtm/taaa114
Journal Article
en
COVID-19 and dengue co-infection in a returning traveller.
https://www.ncbi.nlm.nih.gov/pubmed/32657339
In march 2020, a pandemic of respiratory infection due to the SARS-CoV2 is underway, dengue fever epidemics are at the same time present in many regions of the inter-equatorial zone. We report the first cases of covid19-dengue co-infection, which occurred in Mayotte, a French island in the Indian Ocean.
Unité de Maladies Infectieuses et Tropicales, Centre Hospitalier Andrée Rosemon, F-97300 Cayenne, French Guiana.;Ecosystèmes Amazoniens et Pathologie Tropicale, EA3593, Université de Guyane, F97300-Cayenne, French Guiana.;Intensive Care Unit, Centre Hospitalier de Mayotte, F-97600 Mamoudzou, Mayotte, France.;Centre d'Investigation Clinique, CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 Cayenne, French Guiana.;Medical Biology Laboratory, Centre Hospitalier de Mayotte, F-97600 Mamoudzou, Mayotte, France.
1791
10.1017/dmp.2020.234
Journal Article
en
Adaptation of Coronavirus Disease (COVID-19) Protocols to a Parisian Maternity Unit During the 2020 Pandemic: A Managerial Perspective.
https://www.ncbi.nlm.nih.gov/pubmed/32660662
The coronavirus disease (COVID-19) pandemic overwhelmed health services in France during March 2020 and, to cope, service delivery was reduced in most disciplines. However, as this was impossible for Obstetrics, the COVID-19 infection had to be added to existing clinical care pathways at the children's hospital, Hôpital Necker-Enfants Malades. This was further complicated by an increasing number of pregnancies affected by infection, in addition to scientific uncertainty about the virus. Procedures based on scientific recommendations from French and international authorities were adapted to maternity care and regularly updated as the situation progressed. Weekly medical manager team meetings covered the evolving clinical situation, and an initial evaluation revealed that our procedures worked well. However, it was necessary to adapt the policy as the epidemic progressed rapidly. Shortly after March 16, traffic control bundling was implemented in anticipation of a dramatic increase in pregnant women affected by infection and to better protect the staff. By April 18, with the peak of the COVID-19 epidemic receding, protocols were again readjusted to meet new service delivery requirements. Although a full debrief is yet to occur, from an operational level perspective, staff response was more than satisfactory. While preventing another epidemic may be impossible, this experience will improve our resilience in the future.
1935-7893,1938-744X
2020-07-19 02:00:00+02:00
pubmed
Disaster Medicine and Public Health Preparedness
Ali Ghanchi
COVID-19 pandemic;Paris;infection prevention and control policies;midwifery unit management;traffic control bundling
2020-07-14 02:00:00+02:00
32660662
FR
Université de Paris, CRESS, INSERM, INRA, Paris, and Service d'Obstétrique, Maternité, chirurgie médecine et imagerie fœtales, APHP, Hôpital Necker Enfants Malades, Paris.
1805
10.1016/j.jhin.2020.07.005
Journal Article
en
Nosocomial transmission prevention of SARS-Cov-2 using a preoperative chest CT: a monocentric study during the outbreak.
Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France. Electronic address: Julian.TOUATI@ap-hm.fr.;Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France.;Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France, Aix-Marseille University, LIIE, 27 boulevard Jean Moulin, 13005 Marseille, France.;Dept. of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 54-317, Cambridge, MA 02139-4307.;Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France, Aix-Marseille University, CRMBM-CEMEREM (UMR73-39) 27 boulevard Jean Moulin 13005 Marseille, France.
1806
10.1136/annrheumdis-2020-218146
Journal Article
en
Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal et al.
Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
1809
the French Agricultural Research Centre for International Development (CIRAD);the French General Directorate for Food (DGAL);French National Research Agency under the Investments for the Future Program;H2020 "Monitoring outbreak events for disease surveillance in a data science context" (MOOD);SONGES Project FEDER and Occitanie
10.1111/tbed.13738
Journal Article
en
Monitoring online media reports for early detection of unknown diseases: Insight from a retrospective study of COVID-19 emergence.
https://www.ncbi.nlm.nih.gov/pubmed/32683774
Event-based surveillance (EBS) systems monitor a broad range of information sources to detect early signals of disease emergence, including new and unknown diseases. In December 2019, a newly identified coronavirus emerged in Wuhan (China), causing a global coronavirus disease (COVID-19) pandemic. A retrospective study was conducted to evaluate the capacity of three event-based surveillance (EBS) systems (ProMED, HealthMap and PADI-web) to detect early COVID-19 emergence signals. We focused on changes in online news vocabulary over the period before/after the identification of COVID-19, while also assessing its contagiousness and pandemic potential. ProMED was the timeliest EBS, detecting signals one day before the official notification. At this early stage, the specific vocabulary used was related to 'pneumonia symptoms' and 'mystery illness'. Once COVID-19 was identified, the vocabulary changed to virus family and specific COVID-19 acronyms. Our results suggest that the three EBS systems are complementary regarding data sources, and all require timeliness improvements. EBS methods should be adapted to the different stages of disease emergence to enhance early detection of future unknown disease outbreaks.
1865-1674,1865-1682
2020-07-19 02:00:00+02:00
pubmed
Transboundary and Emerging Diseases
Sarah Valentin;Alizé Mercier;Renaud Lancelot;Mathieu Roche;Elena Arsevska
[{"country": "", "agency": "the French Agricultural Research Centre for International Development (CIRAD)"}, {"country": "", "agency": "the French General Directorate for Food (DGAL)"}, {"country": "", "agency": "French National Research Agency under the Investments for the Future Program", "grantid": "ANR-16-CONV-0004"}, {"country": "", "agency": "H2020 "Monitoring outbreak events for disease surveillance in a data science context" (MOOD)", "grantid": "874850"}, {"country": "", "agency": "SONGES Project FEDER and Occitanie"}]
Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes.
https://www.ncbi.nlm.nih.gov/pubmed/32683744
Coronavirus disease 2019 (COVID-19) is a rapidly progressing pandemic, with four million confirmed cases and 280 000 deaths at the time of writing. Some studies have suggested that diabetes is associated with a greater risk of developing severe forms of COVID-19. The primary objective of the present study was to compare the clinical features and outcomes in hospitalized COVID-19 patients with vs without diabetes.
Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, Amiens, France.;PériTox = UMR_I 01, University of Picardy Jules Verne, Amiens, France.;Department of Infectious Diseases, Amiens University Hospital, Amiens, France.;Laboratory of Clinical Pharmacology, Amiens University Hospital, Amiens, France.;Department of Pulmonary diseases, Amiens University Hospital, Amiens, France.;Laboratory of Virology, Amiens University Hospital, Amiens, France.;Department of Geriatrics, Amiens University Hospital, Amiens, France.;Surgical Intensive Care Unit, Amiens University Hospital, Amiens, France.;Department of Rheumatology, Amiens University Hospital, Amiens, France.;Department of Nephrology, Amiens University Hospital, Amiens, France.;Department of Orthopaedics and Traumatology, Amiens University Hospital, Amiens, France.;Medical Intensive Care Unit, Amiens University Hospital, Amiens, France.;Department of Medical Informatics, Amiens University Hospital, Amiens, France.;Department of Epidemiology, Amiens University Hospital, Amiens, France.
1823
10.1016/j.cmi.2020.07.028
Journal Article
en
Post-COVID-19 chronic symptoms: a postinfectious entity?
https://www.ncbi.nlm.nih.gov/pubmed/32712242
1198-743X
2020-07-26 02:00:00+02:00
pubmed
Clinical Microbiology and Infection
Benjamin Davido;Sophie Seang;Roland Tubiana;Pierre de Truchis
COVID-19 and the brain: impact on nuclear medicine in neurology.
https://www.ncbi.nlm.nih.gov/pubmed/32700058
1619-7070,1619-7089
2020-07-26 02:00:00+02:00
pubmed
European Journal of Nuclear Medicine and Molecular Imaging
Silvia Morbelli;Ozgul Ekmekcioglu;Henryk Barthel;Nathalie L Albert;Ronald Boellaard;Diego Cecchin;Eric Guedj;Adriaan A Lammertsma;Ian Law;Ivan Penuelas;Franck Semah;Tatjana Traub-Weidinger;Elsmarieke van de Giessen;Andrea Varrone;Valentina Garibotto
2020-07-23 02:00:00+02:00
32700058
FR;SE;CH;AT;IT;NL;TR;ES;DK;DE
IRCCS Ospedale Policlinico San Martino, Genoa, Italy. silviadaniela.morbelli@hsanmartino.it.;Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Department of Health Sciences(DISSAL), University of Genoa, Genoa, Italy. silviadaniela.morbelli@hsanmartino.it.;Department of Nuclear Medicine, Sisli Etfal Education and Research Hospital, Istanbul, Turkey.;Department of Nuclear Medicine, Leipzig University, Leipzig, Germany.;Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany.;Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, De Boelelaan, 1117, Amsterdam, Netherlands.;Nuclear Medicine Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy.;APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille Univ, Marseille, France.;Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.;Department of Nuclear Medicine, Clinica Universidad de Navarra, IdiSNA, University of Navarra, Pamplona, Spain.;Nuclear Medicine Department, University Hospital, Lille, France.;Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.;Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, Meibergdreef 9, Amsterdam, The Netherlands.;Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.;NIMTLab, Faculty of Medicine, Geneva University, Geneva, Switzerland.;Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.
1843
10.1016/j.jaip.2020.07.016
Journal Article
en
Managing Food Allergy in Schools During the COVID-19 Pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32711118
In the wake of the COVID-19 pandemic and massive disruptions to daily life in the spring of 2020, in May 2020, the Centers for Disease Control (CDC) released guidance recommendations for schools regarding how to have students attend while adhering to principles of how to reduce the risk of contracting SARS-CoV-2. As part of physical distancing measures, the CDC is recommending that schools who traditionally have had students eat in a cafeteria or common large space instead have children eat their lunch or other meals in the classroom at already physically distanced desks. This has sparked concern for the safety of food-allergic children attending school, and some question of how the new CDC recommendations can coexist with recommendations in the 2013 CDC Voluntary Guidelines on Managing Food Allergy in Schools as well as accommodations that students may be afforded through disability law that may have previously prohibited eating in the classroom. This expert consensus explores the issues related to evidence-based management of food allergy at school, the issues of managing the health of children attending school that are acutely posed by the constraints of an infectious pandemic, and how to harmonize these needs so that all children can attend school with minimal risk from both an infectious and allergic standpoint.
2213-2198
2020-07-26 02:00:00+02:00
pubmed
The Journal of Allergy and Clinical Immunology: In Practice
Matthew Greenhawt;Marcus Shaker;David R Stukus;David M Fleischer;Jonathan Hourihane;Mimi L K Tang;Elissa M Abrams;Julie Wang;Theresa A Bingemann;Edmond S Chan;Jay Lieberman;Hugh A Sampson;S Allan Bock;Michael C Young;Susan Waserman;Douglas P Mack
Allergen bans;Americans with Disabilities Act;Anaphylaxis;CDC;COVID-19;Epinephrine;Food allergy;Hand washing;Rehabilitation Act of 1973;SARS-CoV-2;Schools;Social distancing;Stock epinephrine
2020-07-23 02:00:00+02:00
32711118
IE;FR;CA;LB;GB;US;AU
Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo. Electronic address: Matthew.Greenhawt@childrenscolorado.org.;Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, NH, Department of Pediatrics, Dartmouth Children's Hospital, Dartmouth Geisel School of Medicine, Hanover, NH.;Department of Pediatrics, Division of Allergy and Immunology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.;Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.;Department of Paediatrics, Royal College of Surgeons, Dublin, Ireland.;Department of Allergy and Immunology, The Royal Children's Hospital Melbourne, Murdoch Children's Research Institute, University of Melbourne, Parkville, Victoria, Australia.;Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, The University of Manitoba, Winnipeg, Manitoba, Canada.;Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.;University of Rochester Division of Allergy, Immunology and Rheumatology, Rochester, NY.;BC Children's Hospital, Division of Allergy & Immunology, The University of British Columbia, Vancouver, British Columbia, Canada.;Division of Allergy and Immunology, The University of Tennessee, Memphis, TN.;Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, DBV Technologies, Montrouge, France.;Deptartment of Pediatrics, University of Colorado School of Medicine (Emeritus), Aurora, Colo.;Division of Allergy & Immunology, Children's Hospital Boston, Harvard Medical School, Boston, Mass.;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada, Halton Pediatric Allergy, Burlington, Ontario, Canada.
1845
10.1177/2054358120944298
Journal Article
en
COVID-19 Outbreak in a Hemodialysis Center: A Retrospective Monocentric Case Series.
https://www.ncbi.nlm.nih.gov/pubmed/32782814
The rapid worldwide spread of COVID-19 has posed a serious threat to patients treated with kidney replacement therapy (KRT). Moreover, the impact of the disease on hemodialysis centers, the patients, and the health care workers is still not completely understood.
Department of Nephrology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.;Department of Cardiology, Université de Mons, Belgium.;Department of Endocrinology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.;Department of Cardiology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.;Department of Infectious Disease, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.
1848
10.1093/eurheartj/ehaa588
Journal Article
en
Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pubmed/32710612
0195-668X,1522-9645
2020-07-26 02:00:00+02:00
pubmed
European Heart Journal
Marc Bonnet;Anne Champagnac;Pierre Lantelme;Brahim Harbaoui
2020-07-25 02:00:00+02:00
32710612
FR
Cardiology Department, Hôpital Croix-Rousse and Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Histopathology Department, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
1861
10.1016/j.ejogrb.2020.07.025
Journal Article;Review
en
Sars-CoV-2 in pregnancy: Why is it better than expected?
https://www.ncbi.nlm.nih.gov/pubmed/32739606
Since the outbreak of Coronavirus disease in December 2019, information specific to pregnancy remains limited and controversial. Based on data from previous reports, it has been noticed that contrary to prior pandemics such as SARS, MERS and H1N1 and although pregnancy is usually considered as a condition of high susceptibility to viral infections, new SARS-CoV2 infection seems to have a more benign clinical course when affecting pregnant women. We speculate that during pregnancy the physiological "silencing" of the Th1 pro-inflammatory response may blunt the cytokines storm which is thought to play a key-role in the pathogenesis of the severe complications of Covid-19.
0301-2115
2020-07-26 02:00:00+02:00
pubmed
European Journal of Obstetrics & Gynecology and Reproductive Biology
Tullio Ghi;Elvira di Pasquo;Arsene Mekinian;Leonardo Calza;Tiziana Frusca
Immunology;Inflammation;Pregnancy;Sars-CoV-2
2020-07-24 02:00:00+02:00
32739606
FR;IT
Department of Obstetrics and Gynecology, University of Parma, Parma, Italy. Electronic address: tullio.ghi@unipr.it.;Department of Obstetrics and Gynecology, University of Parma, Parma, Italy.;Department of Internal Medicine, Referral Center for Autoimmune Diseases, Saint Antoine Hospital, Sorbonne University, Paris, France.;Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy.
1862
Letter
en
Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?
https://www.ncbi.nlm.nih.gov/pubmed/32773341
2020-07-26 02:00:00+02:00
pubmed
B Nobile;M Durand;P Courtet;P Van de Perre;N Nagot;J P Molès;E Olié
Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France, PSNREC, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France. Electronic address: benedicte.nobile@gmail.com.;Pathogenesis and Control of Chronic Infection, INSERM, EFS, Université de Montpellier, Montpellier, France.;Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France, PSNREC, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France, FondaMental Foundation, France.;Pathogenesis and Control of Chronic Infection, INSERM, EFS, Université de Montpellier, Montpellier, France, Department of Medical Information, CHU Montpellier, France.
1867
10.1001/jamapediatrics.2020.2141
Journal Article
en
Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From the Mother to the Infant.
https://www.ncbi.nlm.nih.gov/pubmed/32687548
2168-6203
2020-07-26 02:00:00+02:00
pubmed
JAMA Pediatrics
Sergio Verd;Jaume Ponce-Taylor;Gemma Ginovart
2020-07-20 02:00:00+02:00
32687548
FR;ES
Pediatric Division, Department of Primary Care, Balearic Health Authority, La Vileta Surgery, Palma de Mallorca, Spain.;Balearic Institute of Medical Research (IdISBa), Palma de Mallorca, Spain.;Division of Accidents & Emergency, Department of Primary Care, Balearic Health Authority, La Vileta Surgery, Palma de Mallorca, Spain.;Neonatal Unit, Department of Pediatrics. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
1879
10.1080/1744666x.2020.1791086
Journal Article
en
Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak.
https://www.ncbi.nlm.nih.gov/pubmed/32615046
Routine medical and ophthalmic care is being drastically curtailed in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Uveitis patients require particular attention because of their theoretical risk of viral infection, in the context of therapeutic immunosuppression.
1744-666X,1744-8409
2020-07-26 02:00:00+02:00
pubmed
Expert Review of Clinical Immunology
Dinu Stanescu-Segall;Thomas Sales de Gauzy;Rhianon Reynolds;Livia Faes;Dominika Pohlmann;Kaivon Pakzad-Vaezi;Daniel Ting;David Saadoun;Jayakrishna Ambati;Anat Loewenstein;Bahram Bodaghi;Marc D de Smet;Sara Touhami
Department of Ophthalmology, IHU FOReSIGHT, Sorbonne University-APHP , Paris, France.;Department of Ophthalmology, Aneurin Bevan University Health Board , Newport, UK.;Department of Ophthalmology, Cantonal Hospital Lucerne , Lucerne, Switzerland.;Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health , Berlin, Germany.;Department of Ophthalmology and Visual Sciences, University of British Columbia , Vancouver, Canada.;Singapore National Eye Center , Singapore, Singapore.;Department of Internal Medicine, Pitié Salpétrière University Hospital, Sorbonne University-APHP , Paris, France.;Center for Advanced Vision Science, Department of Ophthalmology, Department of Pathology, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine , Charlottesville, VA, USA.;Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel.;Department of Ophthalmology, University of Leiden, the Netherlands, MIOS - Retina and Ocular Inflammation Center , Lausanne, Switzerland.
1891
10.3324/haematol.2020.265066
Journal Article
en
ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults.
Department of Oncology and Haematology, HIA Sainte-Anne, Toulon, France, laurys84@hotmail.com.;Biology Unit, HIA Sainte-Anne, Toulon, France.;Respiratory Disease Unit, HIA Sainte-Anne, Toulon, France.;Department of Internal Medicine, HIA Sainte-Anne, Toulon, France.
1892
10.1038/s41586-020-2558-4
Journal Article
en
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
https://www.ncbi.nlm.nih.gov/pubmed/32698191
COVID-19 has rapidly become a pandemic for which no antiviral drug or vaccine is yet available2-4. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals worldwide but definitive evidence for HCQ efficacy in treatment of COVID-19 is still missing6,7,17,18. We evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (VeroE6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to placebo, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor HCQ+AZTH showed a significant effect on the viral load levels in any of the tested compartments. When the drug was used as a pre-exposure prophylaxis (PrEP), HCQ did not confer protection against acquisition of infection. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral treatment for COVID-19 in humans.
0028-0836,1476-4687
2020-07-26 02:00:00+02:00
pubmed
Nature
Pauline Maisonnasse;Jérémie Guedj;Vanessa Contreras;Sylvie Behillil;Caroline Solas;Romain Marlin;Thibaut Naninck;Andres Pizzorno;Julien Lemaitre;Antonio Gonçalves;Nidhal Kahlaoui;Olivier Terrier;Raphael Ho Tsong Fang;Vincent Enouf;Nathalie Dereuddre-Bosquet;Angela Brisebarre;Franck Touret;Catherine Chapon;Bruno Hoen;Bruno Lina;Manuel Rosa Calatrava;Sylvie van der Werf;Xavier de Lamballerie;Roger Le Grand
2020-07-22 02:00:00+02:00
32698191
FR
Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.;Université de Paris, INSERM, IAME, F-75018, Paris, France.;Unité de Génétique Moléculaire des Virus à ARN, GMVR: Institut Pasteur, UMR CNRS 3569, Université de Paris, Paris, France.;Centre National de Référence des Virus des infections respiratoires (dont la grippe), Institut Pasteur, Paris, France.;Aix-Marseille Univ, APHM, Unité des Virus Emergents (UVE) IRD 190, INSERM 1207, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, 13005, Marseille, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.;Plate-forme de microbiologie mutualisée (P2M), Pasteur International Bioresources Network (PIBnet), Institut Pasteur, Paris, France.;Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Laboratoire de Virologie, Centre National de Référence des Virus des infections respiratoires (dont la grippe), Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69004, Lyon, France.;Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France. roger.le-grand@cea.fr.
1905
10.1007/s00264-020-04712-9
Journal Article
en
Evaluation of containment measures' effect on orthopaedic trauma surgery during the COVID-19 pandemic: a retrospective comparison between 2019 and 2020.
https://www.ncbi.nlm.nih.gov/pubmed/32696333
There is no available information about the effect of containment measures on trauma surgery activity. The aim of this study was to analyse and report the containment measures' impact on trauma surgery activity during the COVID-19 pandemic in order to quickly react and adjust in case of a new sanitary crisis and containment.
Department of Orthopaedic and Traumatology, Edouard Herriot Hospital, 5 place d'Arsonval, 69003, Lyon, France.;Claude Bernard University, Lyon, France.;Department of Orthopaedic and Traumatology, Desgenettes Military Hospital, Lyon, France.;Department of Orthopaedic and Traumatology, Edouard Herriot Hospital, 5 place d'Arsonval, 69003, Lyon, France. agathe.alvernhe@chu-lyon.fr.;Claude Bernard University, Lyon, France. agathe.alvernhe@chu-lyon.fr.;Department of Orthopaedic and Traumatology, Desgenettes Military Hospital, Lyon, France. agathe.alvernhe@chu-lyon.fr.
1909
10.1136/annrheumdis-2020-218173
Journal Article
en
Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al.
Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
1917
10.1183/13993003.01875-2020
Journal Article
en
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation.
https://www.ncbi.nlm.nih.gov/pubmed/32732333
Viral respiratory infections are the main causes of asthma exacerbation. The susceptibility of asthmatics to develop an exacerbation when they present with severe pneumonia due to SARS-CoV-2 infection is unknown. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who required hospitalisation during the spring 2020 outbreak in Paris, France.
Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Le Kremlin-Bicêtre, France.;AP-HP, Service de physiologie et d'explorations fonctionnelles respiratoires (CRISALIS/F-CRIN network), Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Département d'information médicale, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de médecine intensive-réanimation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Département d'anesthésie et réanimation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de pharmacie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service d'imagerie médicale, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de médecine interne, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
1919
10.1007/s00415-020-10108-x
Journal Article
en
Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.
https://www.ncbi.nlm.nih.gov/pubmed/32734353
Evidence of immune-mediated neurological syndromes associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is limited. We therefore investigated clinical, serological and CSF features of coronavirus disease 2019 (COVID-19) patients with neurological manifestations.
0340-5354,1432-1459
2020-08-02 02:00:00+02:00
pubmed
Journal of Neurology
Antoine Guilmot;Sofia Maldonado Slootjes;Amina Sellimi;Maroussia Bronchain;Bernard Hanseeuw;Leila Belkhir;Jean Cyr Yombi;Julien De Greef;Lucie Pothen;Halil Yildiz;Thierry Duprez;Catherine Fillée;Ahalieyah Anantharajah;Antoine Capes;Philippe Hantson;Philippe Jacquerye;Jean-Marc Raymackers;Frederic London;Souraya El Sankari;Adrian Ivanoiu;Pietro Maggi;Vincent van Pesch
Department of Neurology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Hippocrate 10, 1200, Brussels, Belgium.;Department of Internal Medicine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Radiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Biology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Intensive Care, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Neurology, Clinique Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium.;Department of Neurology, CHU UCL Namur Site Godinne, Yvoir, Belgium.;Department of Neurology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Hippocrate 10, 1200, Brussels, Belgium. vincent.vanpesch@uclouvain.be.
1923
10.1002/alr.22677
Journal Article
en
International registry of otolaryngologist-head and neck surgeons with COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32735062
It has become clear that healthcare workers are at high risk, and otolaryngology has been theorized to be among the highest risk specialties for coronavirus disease 2019 (COVID-19). The purpose of this study was to detail the international impact of COVID-19 among otolaryngologists, and to identify instructional cases.
2042-6976,2042-6984
2020-08-02 02:00:00+02:00
pubmed
International Forum of Allergy & Rhinology
Leigh J Sowerby;Kate Stephenson;Alexander Dickie;Federico A Di Lella;Niall Jefferson;Hannah North;R Daniele De Siati;Rebecca Maunsell;Michael Herzog;Raghu Nandhan;Marilena Trozzi;Puya Dehgani-Mobaraki;Antoine Melkane;Claudio Callejas;Harald Miljeteig;Diane Smit;Daniel Dibildox Reynoso;Joao Eloi Moura;Ann Hermansson;Shazia Peer;Lisa Burnell;Nicolas Fakhry;Carlos Chiesa-Estomba;Özlem Önerci Çelebi;Sergei Karpischenko;Steven Sobol;Zoukaa Sargi;Zara M Patel
Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.;Department of Paediatric Otolaryngology, Birmingham Children's Hospital, Birmingham, UK.;Department of Otorhinolaryngology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.;Department of Otolaryngology-Head and Neck Surgery, John Hunter Adult and Children's' Hospitals, Newcastle, NSW, Australia.;Department of Otolaryngology-Head and Neck Surgery, Children's Hospital Westmead and Westmead Hospital, Sydney, NSW, Australia.;Department of Otorhinolaryngology, Saint-Luc University Hospital, University of Louvain, Brussels, Belgium.;Department of Otorhinolaryngology, State University of Campinas (UNICAMP), Campinas, Brazil.;Department of Otorhinolaryngology-Head and Neck Surgery, Carl-Thiem-Klinikum, Cottbus, Germany.;Department of Otorhinolaryngology - Head and Neck Surgery, Madras ENT Research Foundation, Chennai, India.;Airway Surgery Unit, Pediatric Surgery Department, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.;Association "Naso Sano" Onlus, Umbria Regional Registry of Volunteer Activities, Department of Otorhinolaryngology and Head and Neck Surgery, Gubbio-Gualdo Tadino Hospital, Perugia, Italy.;Department of Otolaryngology-Head and Neck Surgery, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.;Department of Otolaryngology, Pontificia Universidad Católica de Chile, Santiago, Chile.;Norwegian Society of Otorhinolaryngology-Head and Neck Surgery, Nesttun, Norway.;University Medical Center Utrecht, Utrecht, Netherlands.;Department of Otolaryngology Hospital Medica Sur, Mexico, Mexico.;Department of Otorhinolaryngology, Coimbra Hospital and University Centre, Coimbra, Portugal.;Department of Otolaryngology, Lund University, Lund, Sweden.;Division of Otorhinolaryngology, University of Cape Town, Cape Town, South Africa.;ENT Morningside, Morningside Mediclinic, Sandton, Johannesburg, South Africa.;Department of Otolaryngology-Head and Neck Surgery, Hôpitaux Universitaires de Marseille Conception, Assistance Publique-Hôpitaux de Marseille (APHM), Aix-Marseille University, Marseille, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario de Donostia, San Sebastian, Spain.;Department of Otolaryngology-Head and Neck Surgery, Istanbul Training and Research Hospital, Istanbul, Turkey.;Department of Otolaryngology, Saint Petersburg Research Institute of Ear, Throat, Nose and Speech, First Pavlov State Medical University, Saint Petersburg, Russia.;Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA.;Department of Otolaryngology, University of Miami, Miami, FL.;Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA.
1941
10.5001/omj.2020.81
Editorial
en
Lessons to Learn from COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32802418
1999-768X,2070-5204
2020-08-02 02:00:00+02:00
pubmed
Oman Medical Journal
Khaled Moustafa
2020-07-31 02:00:00+02:00
32802418
FR
Editor of Arabic Science Archive, Paris, France.
1952
10.2340/00015555-3610
Journal Article
en
Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns.
Department of Dermatology, Military Teaching Hospital Bégin, 69 avenue de Paris, FR-94160 Saint Mandé, France. E-mail: ac.fougerousse@gmail.com.
1957
Instituto de Salud Carlos III
10.1186/s12916-020-01693-9
Journal Article;Research Support, Non-U.S. Gov't
en
"The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32731868
Citizens affected by substance use disorders are high-risk populations for both SARS-CoV-2 infection and COVID-19-related mortality. Relevant vulnerabilities to COVID-19 in people who suffer substance use disorders are described in previous communications. The COVID-19 pandemic offers a unique opportunity to reshape and update addiction treatment networks.
Hugo López-Pelayo;Henri-Jean Aubin;Colin Drummond;Geert Dom;Francisco Pascual;Jürgen Rehm;Richard Saitz;Emanuele Scafato;Antoni Gual
Addictions;COVID-19;Harm-reduction;Stigma;Substance use disorder;Telemedicine
2020-07-31 02:00:00+02:00
32731868
FR;RU;CA;GB;US;IT;ES;BE;DE
[{"country": "International", "agency": "Instituto de Salud Carlos III", "grantid": "JR19/00025"}]
Grup Recerca Addiccions Clínic (GRAC-GRE), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic Barcelona, Rosselló 149, 08036, Barcelona, Spain. hlopez@clinic.cat.;Socidrogalcohol (Spanish Society of Drug and Alcohol Specialists), Barcelona, Spain. hlopez@clinic.cat.;Département de psychiatrie et d'addictologie, Université Paris-Saclay, Route de l'Orme aux Merisiers - RD 128 91190 Saint-Aubin, Paris, France.;Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM 1018, Paris, France.;Groupe Hospitalo-Universitaire AP-HP, Paris, France.;Addiction Psychiatry, Addictions Department, National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College, 16 De Crespigny Park, Camberwell, London, SE5 8AF, UK.;European Federation of Addiction Societies (EUFAS), 16 De Crespigny Park, Camberwell, London, SE5 8AF, UK.;Antwerp University (UA, CAPRI), Antwerp, Belgium.;Belgian Professional Psychiatry Association, Antwerp, Belgium.;European Federation of Addiction Societies (EUFAS), Antwerp, Belgium.;European Psychiatric Association (EPA), Prinsstraat 13, 2000, Antwerp, Belgium.;SOCIDROGALCOHOL, Barcelona, Spain.;CAARFE, Valencia, Spain.;Departamento de Biología Aplicada, Alicante, Spain.;UCA, Alcoy, Alicante, Spain.;Institute for Mental Health Policy Research & Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.;Dalla Lana School of Public Health and Department of Psychiatry, University of Toronto (UofT), 155 College St., Toronto, Canada.;Epidemiological Research Unit, Technische Universität Dresden, Klinische Psychologie and Psychotherapie, Dresden, Germany.;Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.;Department of Community Health Sciences (CHS), Boston University School of Public Health, 715 Albany St, Boston, MA, 02118, USA.;Medicine, Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA, 02118, USA.;Grayken Center on Addiction, Boston Medical Center, Boston, MA, 02118, USA.;WHO Collaborating Centre on Research and Health-Osservatorio Nazionale Alcol, Promotion on Alcohol and Alcohol-related Health, Problems (ITA-79), Istituto Superiore di Sanità, Rome, Italy.;Società Italiana di Alcologia - SIA, EUFAS Istituto Superiore di Sanità, Rome, Italy.;Grup Recerca Addiccions Clínic (GRAC-GRE), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic Barcelona, Rosselló 149, 08036, Barcelona, Spain.;International Network on Brief Interventions for Alcohol and Other Drugs (INEBRIA), Barcelona, Spain.
1959
10.1136/bmj.m2924
Journal Article;Practice Guideline
en
Remdesivir for severe covid-19: a clinical practice guideline.
https://www.ncbi.nlm.nih.gov/pubmed/32732352
What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.
1756-1833
2020-08-02 02:00:00+02:00
pubmed
Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antiviral Agents__therapeutic use;Betacoronavirus__isolation & purification;Coronavirus Infections__diagnosis;Guideline Adherence;Humans;Length of Stay__statistics & numerical data;Network Meta-Analysis;Pandemics;Pneumonia, Viral__diagnosis;Randomized Controlled Trials as Topic;Respiration, Artificial__statistics & numerical data;Severity of Illness Index;Time Factors;Treatment Outcome;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada rochwerg@mcmaster.ca.;Department of Medicine, McMaster University, Hamilton, Ontario Canada.;Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.;Department of Medicine, University of Toronto, Toronto, Ontario, Canada.;Pharmacy Department-Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.;National Center for Infectious Diseases, Singapore.;Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.;Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.;Not panel member, systematic review team and resource for guideline panel.;Department of Pulmonary and Critical Care, Dokuz Eylul University, School of Medicine, Izmir, Turkey.;Evidence Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.;Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.;Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.;Division of Pulmonary, Critical Care and Sleep Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.;Division of Critical Care Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.;Emergency Medical Services, Faculty of Medicine, Tunis, Tunisia.;Guangdong Kuaiwen Information Technology Co. LTD, Guangzhou, Guangdong, China.;Department of Medicine, Centre de recherche du CHU de Sherbrooke, Sherbrooke, Quebec, Canada.;McMaster University (alumnus).;Pulmonary Division, Heart Institute (InCor)- HCFMUSP, Medical School, University of Sao Paulo, São Paulo, Brazil.;Research Institute, Hospital do Coração (HCor), São Paulo, Brazil.;Division of Hospital Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.;Department of Anaesthesia and Critical Care, College of Health Sciences, Makerere University, Kampala, Uganda.;Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.;Not panel member, resource for methodology and content support.;Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.;Kalusugan ng Mag-Ina (Health of Mother and Child), Inc., Quezon City, Philippines.;Asia-Pacific Center for Evidence-Based Healthcare, Manila, Philippines.;Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo, Norway.
Interplay between SARS-CoV-2 and the type I interferon response.
https://www.ncbi.nlm.nih.gov/pubmed/32726355
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current COVID-19 pandemic. An unbalanced immune response, characterized by a weak production of type I interferons (IFN-Is) and an exacerbated release of proinflammatory cytokines, contributes to the severe forms of the disease. SARS-CoV-2 is genetically related to SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV), which caused outbreaks in 2003 and 2013, respectively. Although IFN treatment gave some encouraging results against SARS-CoV and MERS-CoV in animal models, its potential as a therapeutic against COVID-19 awaits validation. Here, we describe our current knowledge of the complex interplay between SARS-CoV-2 infection and the IFN system, highlighting some of the gaps that need to be filled for a better understanding of the underlying molecular mechanisms. In addition to the conserved IFN evasion strategies that are likely shared with SARS-CoV and MERS-CoV, novel counteraction mechanisms are being discovered in SARS-CoV-2-infected cells. Since the last coronavirus epidemic, we have made considerable progress in understanding the IFN-I response, including its spatiotemporal regulation and the prominent role of plasmacytoid dendritic cells (pDCs), which are the main IFN-I-producing cells. While awaiting the results of the many clinical trials that are evaluating the efficacy of IFN-I alone or in combination with antiviral molecules, we discuss the potential benefits of a well-timed IFN-I treatment and propose strategies to boost pDC-mediated IFN responses during the early stages of viral infection.
Margarida Sa Ribero;Nolwenn Jouvenet;Marlène Dreux;Sébastien Nisole
2020-07-29 02:00:00+02:00
32726355
FR
CIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, École Normale Supérieure de Lyon, Univ Lyon, Lyon, France.;Institut Pasteur, CNRS UMR3569, Paris, France.;IRIM, CNRS UMR9004, Université de Montpellier, Montpellier, France.
1966
10.3390/ma13153339
Journal Article;Review
en
3D Printing to Support the Shortage in Personal Protective Equipment Caused by COVID-19 Pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32727050
Currently, the emergence of a novel human coronavirus disease, named COVID-19, has become a great global public health concern causing severe respiratory tract infections in humans. Yet, there is no specific vaccine or treatment for this COVID-19 where anti-disease measures rely on preventing or slowing the transmission of infection from one person to another. In particularly, there is a growing effort to prevent or reduce transmission to frontline healthcare professionals. However, it is becoming an increasingly international concern respecting the shortage in the supply chain of critical single-use personal protective equipment (PPE). To that scope, we aim in the present work to provide a comprehensive overview of the latest 3D printing efforts against COVID-19, including professional additive manufacturing (AM) providers, makers and designers in the 3D printing community. Through this review paper, the response to several questions and inquiries regarding the following issues are addressed: technical factors connected with AM processes; recommendations for testing and characterizing medical devices that additively manufactured; AM materials that can be used for medical devices; biological concerns of final 3D printed medical parts, comprising biocompatibility, cleaning and sterility; and limitations of AM technology.
ENSTA Bretagne, IRDL-UMR CNRS 6027, F-29200 Brest, France.;Arts et Metiers Institute of Technology, University of Bordeaux, CNRS, Bordeaux INP, INRAE, I2M Bordeaux, F-33400 Talence, France.
1973
Letter
en
Are clinical outcomes worse for pregnant women ≥ 20 weeks' gestation infected with COVID-19? A multicenter case-control study with propensity score matching.
https://www.ncbi.nlm.nih.gov/pubmed/32730899
2020-08-02 02:00:00+02:00
pubmed
Dominique A Badr;Jérémie Mattern;Andrew Carlin;Anne-Gaël Cordier;Evelyne Maillart;Larissa El Hachem;Hanane El Kenz;Marc Andronikof;David De Bels;Charles Damoisel;Thierry Preseau;Dorothée Vignes;Mieke M Cannie;Christelle Vauloup-Fellous;Jean-François Fils;Alexandra Benachi;Jacques C Jani;Alexandre J Vivanti
COVID-19;Diabetes;Endotracheal intubation;High-risk pregnancy;Hypertension;Intensive care unit;Pregnancy;Propensity score matching;Respiratory failure;SARS-CoV-2
2020-07-27 02:00:00+02:00
32730899
FR;BE
Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Division of Obstetrics and Gynecology, Bicêtre Hospital, Paris Saclay University, AP-HP, Le Kremlin-Bicêtre, France.;Department of Infectious Diseases, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Obstetrics and Gynecology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France.;Department of Transfusion and Blood Bank, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Emergency, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Department of Intensive Care, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Critical Care, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Department of Emergency, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Internal Medicine and Immunology, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Department of Radiology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Virology, Paul Brousse Hospital, Paris Saclay University, AP-HP, Villejuif, France.;Ars Statistica, Nivelles, Belgium.;Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: jackjani@hotmail.com.
1977
10.1016/j.ohx.2020.e00129
Journal Article
en
Conversion of self-contained breathing apparatus mask to open source powered air-purifying particulate respirator for fire fighter COVID-19 response.
https://www.ncbi.nlm.nih.gov/pubmed/32835140
To assist firefighters and other first responders to use their existing equipment for respiration during the COVID-19 pandemic without using single-use, low-supply, masks, this study outlines an open source kit to convert a 3M-manufactured Scott Safety self-contained breathing apparatus (SCBA) into a powered air-purifying particulate respirator (PAPR). The open source PAPR can be fabricated with a low-cost 3-D printer and widely available components for less than $150, replacing commercial conversion kits saving 85% or full-fledged proprietary PAPRs saving over 90%. The parametric designs allow for adaptation to other core components and can be custom fit specifically to fire-fighter equipment, including their suspenders. The open source PAPR has controllable air flow and its design enables breathing even if the fan is disconnected or if the battery dies. The open source PAPR was tested for air flow as a function of battery life and was found to meet NIOSH air flow requirements for 4 h, which is 300% over expected regular use.
Department of Mechanical Engineering-Engineering Mechanics, Michigan Technological University, Houghton, MI 49931, USA.;Department of Materials Science & Engineering, Michigan Technological University, USA.;Department of Electrical & Computer Engineering, Michigan Technological University, USA.;Équipe de Recherche sur les Processus Innovatifs (ERPI), Université de Lorraine, France.;School of Electrical Engineering, Aalto University, Finland.
1984
10.1016/j.ejps.2020.105495
Journal Article
en
Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages.
https://www.ncbi.nlm.nih.gov/pubmed/32730844
In December 2019, a new coronavirus was identified in the Hubei province of central china and named SARS-CoV-2. This new virus induces COVID-19, a severe respiratory disease with high death rate. A putative target to interfere with the virus is the host transmembrane serine protease family member II (TMPRSS2). This enzyme is critical for the entry of coronaviruses into human cells by cleaving and activating the spike protein (S) of SARS-CoV-2. Repositioning approved, investigational and experimental drugs on the serine protease domain of TMPRSS2 could thus be valuable. There is no experimental structure for TMPRSS2 but it is possible to develop quality structural models for the serine protease domain using comparative modeling strategies as such domains are highly structurally conserved. Beside the TMPRSS2 catalytic site, we predicted on our structural models a main exosite that could be important for the binding of protein partners and/or substrates. To block the catalytic site or the exosite of TMPRSS2 we used structure-based virtual screening computations and two different collections of approved, investigational and experimental drugs. We propose a list of 156 molecules that could bind to the catalytic site and 100 compounds that may interact with the exosite. These small molecules should now be tested in vitro to gain novel insights over the roles of TMPRSS2 or as starting point for the development of second generation analogs.
0928-0987
2020-08-02 02:00:00+02:00
pubmed
European Journal of Pharmaceutical Sciences
Natesh Singh;Etienne Decroly;Abdel-Majid Khatib;Bruno O Villoutreix
Univ. Lille, INSERM, Institut Pasteur de Lille, U1177, F-59000 Lille, France.;Aix Marseille Univ. CNRS, AFMB UMR 7257, Marseille, France.;Univ. Bordeaux, Allée Geoffroy St Hilaire, 33615 Pessac, France, INSERM, LAMC, UMR 1029, Allée Geoffroy St Hilaire, 33615 Pessac, France.;Univ. Lille, INSERM, Institut Pasteur de Lille, U1177, F-59000 Lille, France. Electronic address: bruno.villoutreix@inserm.fr.
1989
10.1093/ecco-jcc/jjaa150
Journal Article
en
Care of the Patient with IBD Requiring Hospitalization During the COVID-19 Pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32722757
The management of IBD has been highly impacted in the context of the COVID-19 pandemic, with restriction of hospitalizations and unprecedented redeployment of healthcare resources. Hospital admissions of IBD patients should be limited to reduce the risks of coronavirus transmission. However, delaying hospitalization of IBD patients with severe or complicated disease may increase the risk of poor outcomes. Delaying surgery in some cases may increase the risk of disease progression, post-operative morbidity and disease complications. IBD patients who are infected with SARS-CoV-2 may have a higher risk of poor outcomes than the general population, potentially related to concomitant medications, especially corticosteroids. There is no evidence today that IBD patients with COVID-19 have worse outcomes if they receive immunosuppressant medications including thiopurines, biologics and novel small molecules. This article summarizes recommendations by the international membership of IOIBD regarding hospitalizations of IBD patients, either for active or complicated IBD or severe COVID-19, and for management of IBD patients according to SARS-CoV-2 infectious status.
1873-9946,1876-4479
2020-08-02 02:00:00+02:00
pubmed
Journal of Crohn's and Colitis
Matthieu Allez;Phillip Fleshner;Richard Gearry;Peter L Lakatos;David T Rubin
2020-07-29 02:00:00+02:00
32722757
FR;CA;NZ;US;HU
Hôpital Saint-Louis, Department of Gastroenterology, APHP, Université de Paris, France.;Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.;Department of Medicine, University of Otago, Christchurch, New Zealand.;McGill University, Division of Gastroenterology Department of Medicine, Montreal, Canada and Semmelweis University, 1st Department of Medicine, Budapest, Hungary.;University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
1993
Letter
en
Surgery and COVID-19: Balancing the nosocomial risk a french academic center experience during the epidemic peak.
https://www.ncbi.nlm.nih.gov/pubmed/32725815
2020-08-02 02:00:00+02:00
pubmed
A Ingels;S Bibas;J B Da Costa;A Attias;F Brunetti;N De Angelis;P Desgranges;C-H Flouzat-Lachaniette;T Folliguet;T Ivanov;O Langeron;L Lelde;E Levesque;P L Corvoisier;C Marmorat;F Melendugno;J-P Meningaud;F Mesli;W Paillusson;S Palfi;L Pedre;D Somacale;C M Champy;A de la Taille
2020-07-29 02:00:00+02:00
32725815
FR
Department of Urology, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Anesthesiology and Intensive Care, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Visceral surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Vascular surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Orthopedic surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Cardiac surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;INSERM, CIC 1430 - Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Reconstructive surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Gastroenterology, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Neurosurgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.
1994
10.1038/s41577-020-0407-1
Journal Article
en
Tissue damage from neutrophil-induced oxidative stress in COVID-19.
CNRS, INSERM UMRS 1124, Faculté des sciences fondamentales et biomédicales, Université de Paris, Paris, France.;Centre de Recherche Saint-Antoine, INSERM UMRS 938, Sorbonne Université, Paris, France.;Institute of Cardiometabolism and Nutrition (ICAN), GRC 27 GRECO, INSERM 1166, Sorbonne Université, Paris, France.;Université de Paris, CNRS-UMR 7086, Interfaces, Traitements, Organisation et DYnamique des Systèmes (ITODYS), Paris, France.;Service de psychiatrie et de psychologie médicale, Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Paris, France.;Service de biochimie endocrinienne et oncologie, Hôpital Pitié-Salpêtrière AP-HP, Sorbonne Université, Paris, France.;CNRS, INSERM UMRS 1124, Faculté des sciences fondamentales et biomédicales, Université de Paris, Paris, France. christel.becker@parisdescartes.fr.
2003
10.1002/ddr.21732
Journal Article;Review
en
Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?
https://www.ncbi.nlm.nih.gov/pubmed/32761647
The severe acute respiratory syndrome coronavirus-2 (SARS-COV-2), a novel coronavirus responsible for the recent infectious pandemic, is known to downregulate angiotensin-converting enzyme-2 (ACE2). Most current investigations focused on SARS-COV-2-related effects on the renin-angiotensin system and especially the resultant increase in angiotensin II, neglecting its effects on the kinin-kallikrein system. SARS-COV-2-induced ACE2 inhibition leads to the augmentation of bradykinin 1-receptor effects, as ACE2 inactivates des-Arg9-bradykinin, a bradykinin metabolite. SARS-COV-2 also decreases bradykinin 2-receptor effects as it affects bradykinin synthesis by inhibiting cathepsin L, a kininogenase present at the site of infection and involved in bradykinin production. The physiologies of both the renin-angiotensin and kinin-kallikrein system are functionally related suggesting that any intervention aiming to treat SARS-COV-2-infected patients by triggering one system but ignoring the other may not be adequately effective. Interestingly, the snake-derived bradykinin-potentiating peptide (BPP-10c) acts on both systems. BPP-10c strongly decreases angiotensin II by inhibiting ACE, increasing bradykinin-related effects on the bradykinin 2-receptor and increasing nitric oxide-mediated effects. Based on a narrative review of the literature, we suggest that BPP-10c could be an optimally effective option to consider when aiming at developing an anti-SARS-COV-2 drug.
National Egyptian Center for Toxicological Researches, Faculty of Medicine, University of Cairo, Cairo, Egypt.;Department of Medical and Toxicological Critical Care, Lariboisière Hospital, University of Paris, INSERM UMRS-1144, Paris, France.
2014
10.1021/acs.jproteome.0c00535
Journal Article
en
Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window.
https://www.ncbi.nlm.nih.gov/pubmed/32697082
Rapid but yet sensitive, specific, and high-throughput detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples is key to diagnose infected people and to better control the spread of the virus. Alternative methodologies to PCR and immunodiagnostics that would not require specific reagents are worthy to investigate not only for fighting the COVID-19 pandemic but also to detect other emergent pathogenic threats. Here, we propose the use of tandem mass spectrometry to detect SARS-CoV-2 marker peptides in nasopharyngeal swabs. We documented that the signal from the microbiota present in such samples is low and can be overlooked when interpreting shotgun proteomic data acquired on a restricted window of the peptidome landscape. In this proof-of-concept study, simili nasopharyngeal swabs spiked with different quantities of purified SARS-CoV-2 viral material were used to develop a nanoLC-MS/MS acquisition method, which was then successfully applied on COVID-19 clinical samples. We argue that peptides ADETQALPQR and GFYAQGSR from the nucleocapsid protein are of utmost interest as their signal is intense and their elution can be obtained within a 3 min window in the tested conditions. These results pave the way for the development of time-efficient viral diagnostic tests based on mass spectrometry.
COVID-19;SARS-CoV-2;mass spectrometry;peptides;proteomics;viral protein detection, nasopharyngeal swab
2020-08-05 02:00:00+02:00
32697082
FR
INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris Saclay, CEA, 30200 Bagnols-sur-Cèze, France.;U1047, Institut National de la Santé et de la Recherche Médicale, Université Montpellier, Montpellier, France.;VBMI, INSERM U1047, Université de Montpellier, Service de Microbiologie et Hygiène Hospitalière, CHU Nîmes, Nîmes, France.;VBMI, INSERM U1047, Université de Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France.
2016
Letter
en
COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans.
https://www.ncbi.nlm.nih.gov/pubmed/32768565
The emergence of COVID-19 has triggered many works aiming at identifying the animal intermediate potentially involved in the transmission of SARS-CoV-2 to humans. The presence of SARS-CoV-2-related viruses in Malayan pangolins, in silico analysis of the ACE2 receptor polymorphism and sequence similarities between the Receptor Binding Domain (RBD) of the spike proteins of pangolin and human Sarbecoviruses led to the proposal of pangolin as intermediary. However, the binding affinity of the pangolin ACE2 receptor for SARS-CoV-2 RBD was later on reported to be low. Here, we provide evidence that the pangolin is not the intermediate animal at the origin of the human pandemic. Moreover, data available do not fit with the spillover model currently proposed for zoonotic emergence which is thus unlikely to account for this outbreak. We propose a different model to explain how SARS-CoV-2 related coronaviruses could have circulated in different species, including humans, before the emergence of COVID-19.
2020-08-09 02:00:00+02:00
pubmed
Roger Frutos;Jordi Serra-Cobo;Tianmu Chen;Christian A Devaux
COVID-19;Coronavirus;Pangolin;SARS-CoV-2;Zoonosis;Zoonotic model
2020-08-05 02:00:00+02:00
32768565
FR;CN;ES
Cirad, UMR 17, Intertryp, Montpellier, France, IES, UMR 5214 Univ. Montpellier-CNRS, Montpellier, France. Electronic address: roger.frutos@cirad.fr.;Department of Evolutionary Biology, Ecology and Environmental Sciences, University of Barcelona, Biodiversity Research Institute, Barcelona, Spain.;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, PR China.;IHU-Méditerranée Infection and CNRS, Marseille, France.
2019
Letter
en
EMS dispatch center activity during the COVID-19 containment.
https://www.ncbi.nlm.nih.gov/pubmed/32826107
2020-08-09 02:00:00+02:00
pubmed
Yann Penverne;Joel Jenvrin;Emmanuel Montassier
Activity;COVID-19;Calls;EMS dispatch center
2020-08-05 02:00:00+02:00
32826107
FR
Department of Emergency Medicine & SAMU44, CHU de Nantes, 44000 Nantes, France.;Department of Emergency Medicine & SAMU44, CHU de Nantes, 44000 Nantes, France, MiHAR lab, University of Nantes, France. Electronic address: emmanuel.montassier@chu-nantes.fr.
2023
10.1111/all.14549
Journal Article;Review
en
Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32762135
Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage were associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin converting enzyme 2 (ACE2). As a result of SARS-Cov-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistanceas well as lung and endothelial damage, two severe outcomes of COVID-19. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is the most potent antioxidant in humans and can block the AT1 R axis. Cabbage contains precursors of sulforaphane, the most active natural activator of Nrf2. Fermented vegetables contain many lactobacilli, which are also potent Nrf2 activators. Three examples are given: Kimchi in Korea, westernized foods and the slum paradox. It is proposed that fermented cabbage is a proof-of-concept of dietary manipulations that may enhance Nrf2-associated antioxidant effects helpful in mitigating COVID-19 severity.
0105-4538,1398-9995
2020-08-09 02:00:00+02:00
pubmed
Allergy
Jean Bousquet;Josep M Anto;Wienczyslawa Czarlewski;Tari Haahtela;Susana C Fonseca;Guido Iaccarino;Hubert Blain;Alain Vidal;Aziz Sheikh;Cezmi A Akdis;Torsten Zuberbier
Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.;MACVIA-France and CHU, Montpellier, France.;ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.;Universitat Pompeu Fabra (UPF), Barcelona, Spain.;CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;MASK-air, Montpellier, France.;Medical Consulting Czarlewski, Levallois, France.;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Finland.;GreenUPorto - Sustainable Agrifood Production Research Centre, DGAOT, Faculty of Sciences, University of Porto, Campus de Vairão, Porto, Portugal.;Federico II University, Department of Advanced Biomedical Sciences, Napoli, Italy.;Department of Geriatrics, Montpellier University hospital and MUSE, Montpellier, France.;World Business Council for Sustainable Development (WBCSD), Maison de la Paix, Geneva, Switzerland & AgroParisTech - Paris Institute of Technology for Life, Food and Environmental Sciences, Paris, France.;Usher Institute, University of Edinburgh, Scotland, UK.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
2027
10.1016/j.ijid.2020.08.012
Journal Article
en
New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France.
https://www.ncbi.nlm.nih.gov/pubmed/32771635
New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients.
Physiologie-Explorations Fonctionnelles, FHU APOLLO, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France justine.frija@aphp.fr.;Université de Paris, Inserm U 1141, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service de radiologie, Paris, France.;Université de Paris, Inserm U 1152, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service de maladies infectieuses et tropicales, Paris, France.;Université de Paris, Inserm U 1137, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service d'endocrinologie, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service de pneumologie, Paris, France.;Physiologie-Explorations Fonctionnelles, FHU APOLLO, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.
2041
10.1016/j.clinre.2020.07.012
Journal Article
en
Drastic decrease of urgent endoscopies outside regular working hours during the Covid-19 pandemic in the paris area.
https://www.ncbi.nlm.nih.gov/pubmed/32788129
The coronavirus 2019 (COVID-19) pandemic has significantly affected medical care. We surmise that the number of urgent endoscopies outside regular working hours in the Paris area decreased as a result. The objective of this study was to describe the observed number of acts during the 2020 mandatory period of home isolation, compared to the values in prior years and the expected value for 2020.
2210-7401
2020-08-09 02:00:00+02:00
pubmed
Clinics and Research in Hepatology and Gastroenterology
COVID-19 pandemic;Endoscopy outside regular working hours;Urgent endoscopy
2020-08-04 02:00:00+02:00
32788129
FR
Sorbonne Université, Endoscopy Unit, AP-HP, Hôpital Saint-Antoine, 75012 Paris, France. Electronic address: aymeric.becq@aphp.fr.;Endoscopy Unit, AP-HP, Hôpital Beaujon, 92110 Clichy, France.;Sorbonne Université, Endoscopy Unit, AP-HP, Hôpital Pitié Salpêtrière, 75013 Paris, France.;Paris 12 Université, APH-HP, Hôpital Henri Mondor, 94010 Créteil, France.;Gastroenterology Department, AP-HP, Hôpital Européen Georges Pompidou, Assistance, 75015 Paris, France.;Sorbonne Université, Endoscopy Unit, AP-HP, Hôpital Saint-Antoine, 75012 Paris, France.
2050
10.1515/jpm-2020-0280
Journal Article;Review
en
COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice.
https://www.ncbi.nlm.nih.gov/pubmed/32739908
An issue of the novel coronavirus infection spreading is currently in the first place among others in the list of the international medical community. Due to lack of information, conflicting research findings, multicomponent effect of the virus on the body host, as well as various consequences that the virus triggers in the body, now every medical specialty does study the viral attack pathogenesis. Recent months showed that vascular complications are the most severe in the Coronavirus Disease 2019 (COVID-19) and are the main cause of death in the patients. The mechanisms of vascular complications are complex and affect both the hemostatic system and immune responses, "inflammatory storm", disorders of the renin-angiotensin-aldosterone system, endotheliopathy, etc. Due to the leading role of vascular complications in the viral infection pathogenesis, several groups of patients are at extra risk, including pregnant women, patients with a burdened obstetric history, with hereditary thrombophilia and antiphospholipid syndrome, and patients after in vitro fertilization (IVF). In this category of pregnant women, use of low-molecular-weight heparins (LMWH) is particularly important for both prevention of vascular and obstetric complications, and for pathogenetic therapy of COVID-19.
1619-3997,0300-5577
2020-08-09 02:00:00+02:00
pubmed
Journal of Perinatal Medicine
Alexander Makatsariya;Ekaterina Slukhanchuk;Viktoriya Bitsadze;Jamilya Khizroeva;Maria Tretyakova;Valentina Tsibizova;Andrey Dobryakov;Ismail Elalamy;Jean C Gris
Department of Obstetrics and Gynecology, I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.;Gynecological Unit of Petrovsky National Research Center of Surgery, Moscow, Russia.;Department of Gynecology, «Medical Center» LLC, Moscow, Russia.;Department of Functional and Ultrasound Diagnostics, Almazov National Medical Research Centre, Saint Petersburg, Russia.;Pathologo-Anatomical Department of City Clinical Hospital, Bakhrushin Brothers Hospital, Moscow, Russia.;Hematology Department of Thrombosis Center, Tenon University Hospital, Medicine Sorbonne University, Paris, France.;Hematology Department of Montpellier University, Montpellier, France.
2051
10.1111/ene.14466
Journal Article
en
Large vessel stroke in six patients following SARS-CoV-2 infection: a retrospective case study series of acute thrombotic complications on stable underlying atherosclerotic disease.
https://www.ncbi.nlm.nih.gov/pubmed/32761999
Ischemic stroke has been described in association with COVID-19. Several pathophysiological mechanisms have been suggested i.e prothrombotic state, cardiac injury etc. We sought to assess the potential association between ischemic stroke associated with SARS-CoV-2 infection and underlying atherosclerotic lesions.
Neurovascular Unit Interventional Neuroradiology Department, Foch Hospital, Suresnes, France.;Neurovascular Unit, Saint Denis Hospital, France.;Neurovascular Unit, Bichat University Hospital, Paris, France.;Neurovascular Unit, Interventional Neuroradiology Department, Kremlin-Bicetre University Hospital, France.;Neurovascular Unit, Interventional Neuroradiology Department, Lariboisiere University Hospital Paris, France.;Interventional Neuroradiology Department Rothschild Fundation, Paris, France.
2058
10.1007/s12603-020-1416-2
Journal Article;Review
en
COVID-19, Virology and Geroscience: A Perspective.
https://www.ncbi.nlm.nih.gov/pubmed/32744561
A new coronavirus, called SARS-CoV-2, was identified in Wuhan, China, in December 2019. The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease 2019 (COVID-19). Older adults have higher peak of viral load and, especially those with comorbidities, had higher COVID-19-related fatality rates than younger adults. In this Perspective paper, we summarize current knowledge about SARS-CoV-2 and aging, in order to understand why older people are more affected by COVID-19. We discuss about the possibility that the so-called "immunosenescence" and "inflammaging" processes, already present in a fraction of frail older adults, could allow the immune escape of SARS-CoV-2 leading to COVID-19 serious complications. Finally, we propose to use geroscience approaches to the field of COVID-19.
Camille Vellas, INSERM UMR1043 - CNRS UMR5282 Centre de Physiopathologie Toulouse-Purpan (CPTP), Toulouse, France, vellas.camille@gmail.com.
2062
10.1080/21645515.2020.1787068
Journal Article
en
Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development.
https://www.ncbi.nlm.nih.gov/pubmed/32755425
The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, physicians and researchers have begun to publish relevant findings, and much evidence is available on coronaviruses previously circulating in human and animal populations. In this review, we situate COVID-19 in its context as a transboundary viral disease, and provide a comprehensive discussion focused on the discovery, spread, virology, pathogenesis, and clinical features of this disease, its causative coronaviral pathogen, and approaches to combating the disease through immunotherapies and other treatments and vaccine development. An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-2 carriers within the population, which may hamper efforts against COVID-19. Finally, we emphasize that vaccines against SARS-CoV-2, which may be developed by 2021, will be essential for prevention of COVID-19.
Human coronavirus;origin;pathogenesis;public health;respiratory viruses;sars-CoV-2
2020-08-05 02:00:00+02:00
32755425
FR;JP;MA
Virology Unit¸ Viral Hepatitis Laboratory, Institut Pasteur Du Maroc , Casablanca, Morocco.;Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University , Kagoshima, Japan.;Medical Virology and BSL3 Laboratory, Institut Pasteur Du Maroc , Casablanca, Morocco.;Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science , Tokyo, Japan.
2065
10.1007/s00464-020-07835-7
Journal Article
en
Surgical challenges and research priorities in the era of the COVID-19 pandemic: EAES membership survey.
https://www.ncbi.nlm.nih.gov/pubmed/32749615
Healthcare systems and general surgeons are being challenged by the current pandemic. The European Association for Endoscopic Surgery (EAES) aimed to evaluate surgeons' experiences and perspectives, to identify gaps in knowledge, to record shortcomings in resources and to register research priorities.
0930-2794,1432-2218
2020-08-09 02:00:00+02:00
pubmed
Surgical Endoscopy
Marco Milone;Francesco Maria Carrano;Emina Letić;Andreas Shamiyeh;Antonello Forgione;Bang Wool Eom;Beat P Müller-Stich;Carmen Balagué Ponz;Christos Kontovounisios;Daniel Preda;Dejan Ignjatovic;Elisa Cassinotti;Eugenia Yiannakopoulou;George Theodoropoulos;Gil Faria;Luca Morelli;Marguerite Gorter-Stam;Sheraz Markar;Thanjakumar Arulampalam;Therese Velthoven;Stavros A Antoniou;Nader K Francis
COVID-19;Laparoscopy;Pandemic;Surgical challenges
2020-08-04 02:00:00+02:00
32749615
FR;CY;NO;PT;BA;GR;GB;US;RO;IT;NL;ES;DE;KR;AT
Department of Clinical Medicine and Surgery, University of Naples "Federico II", via pansini 5, Naples, Italy.;Department of Applied Medical-Surgical Sciences, University of Rome "Tor Vergata", Rome, Italy.;Humanitas Clinical and Research Center - IRCCS, via Manzoni 56, Rozzano, Milan, Italy.;Department of General Surgery, Faculty of Medicine, University of Sarajevo, Čekaluša 90, 71000, Sarajevo, Bosnia and Herzegovina.;Ludwig Boltzmann Institute for Operative Laparoscopy and 2nd Surgical Department, Academic Teaching Hospital of Linz, Krankenhausstrasse 9, 4020, Linz, Austria.;Department of Surgical Oncology and Minimally Invasive Surgery, AIMS Academy, Niguarda Hospital, Milan, Italy.;Center for Gastric Cancer, National Cancer Center, Research Institute and Hospital, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, Republic of Korea.;Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.;Service of General & Digestive Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK.;1st Clinic of Surgery, Craiova Emergency Clinical County Hospital, Craiova, Romania.;Department of Digestive Surgery, Akershus University Hospital, Oslo, Norway.;Maggiore Policlinico Hospital, Fondazione IRCCS Cà Granda, Milan, Italy.;Department of Biomedical Sciences, Faculty of Health Sciences, University of West Attica, Athens, Greece.;First Department of Propaedeutic Surgery, Hippocration Hospital, Medical School of Athens University, 11527, Athens, Greece.;CINTESIS-Center for Research in Health Technologies and Information Systems, 4200-450, Porto, Portugal.;General Surgery, Hospital de Pedro Hispano, Unidade Local de Saúde de Matosinhos, 4464-513, Senhora da Hora, Portugal.;Department of Traslational Research and of New Surgical and Medical Technologies, Azienda Ospedaliero-Universitaria Pisana/University of Pisa, Pisa, Italy.;Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands.;Division of Surgery, Department of Surgery & Cancer, St Mary's Hospital - Imperial College Healthcare NHS Trust, London, UK.;Department of General Surgery, Colchester General Hospital, Colchester, UK.;European Association for Endoscopic Surgery, Rome, Italy.;Department of Surgery, European University of Cyprus, Nicosia, Cyprus.;Griffin Institute (Northwick Park Institute of Medical Research), Northwick Park Hospital, Harrow, HA1 3UJ, UK. nader.francis@ydh.nhs.uk.;Yeovil District Hospital, Somerset, BA21 4AT, UK. nader.francis@ydh.nhs.uk.
2066
10.1007/s10640-020-00478-1
Journal Article
en
Suggestions for a Covid-19 Post-Pandemic Research Agenda in Environmental Economics.
https://www.ncbi.nlm.nih.gov/pubmed/32836846
In this article we draw upon early lessons from the 2020 Covid-19 crisis and discuss how these may relate to a future research agenda in environmental economics. In particular, we describe how the events surrounding the Covid-19 crisis may inform environmental research related to globalization and cooperation, the green transition, pricing carbon externalities, as well as the role of uncertainty and timing of policy inventions. We also discuss the implications for future empirical research in this area.
0924-6460,1573-1502
2020-08-09 02:00:00+02:00
pubmed
Environmental and Resource Economics
Robert J R Elliott;Ingmar Schumacher;Cees Withagen
Department of Economics, Birmingham University, Birmingham, United Kingdom.;IPAG Business School, 183 Bvd St Germain, 75006 Paris, France.;Department of Spatial Economics Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
2072
Editorial;Comment
en
To immunosuppress: whom, when and how? That is the question with COVID-19.
Divisions of Infectious Diseases and Public Health, Oregon Health and Sciences University, Portland, Oregon, USA winthrop@ohsu.edu.;Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, Le Kremlin Bicêtre, France.;Université Paris-Sud, Center for Immunology of Viral Infections and Autoimmune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le Kremlin Bicêtre, France.
2076
10.1007/s10640-020-00473-6
Journal Article
en
Impacts of the COVID-19 Pandemic on the Global Agricultural Markets.
https://www.ncbi.nlm.nih.gov/pubmed/32836856
This paper analyses the impacts on global agricultural markets of the demand shock caused by the COVID-19 pandemic and the first wave of lockdown measures imposed by the governments in the first semester of 2020 to contain it. Specifically, we perform a scenario-based analysis on the IMF economic growth forecasts for 2020 and 2021 using a global multi-commodity agricultural market model. According to our results, the sharp decline in economic growth causes a decrease in international meat prices by 7-18% in 2020 and dairy products by 4-7% compared to a business as usual situation. Following the slowdown of the economy, biofuel prices fall strongly in 2020, followed by their main feedstocks, maize and oilseeds. Although the income losses and local supply chain disruptions associated with the pandemic undoubtedly has led to an increase in food insecurity in many developing countries, global food consumption is largely unaffected due to the inelastic demand of most agricultural commodities and the short duration of the shock. From an environmental viewpoint, the COVID-19 impacts point to a modest reduction of direct greenhouse gases from agriculture of about 1% or 50 million tonnes of carbon dioxide equivalents in 2020 and 2021.
0924-6460,1573-1502
2020-08-09 02:00:00+02:00
pubmed
Environmental and Resource Economics
Christian Elleby;Ignacio Pérez Domínguez;Marcel Adenauer;Giampiero Genovese
European Commission, Joint Research Centre, Seville, Spain.;Agro-Food Trade and Markets Division, OECD, Paris, France.
2077
10.1007/s10640-020-00488-z
Journal Article
en
Assessing Short-Term and Long-Term Economic and Environmental Effects of the COVID-19 Crisis in France.
https://www.ncbi.nlm.nih.gov/pubmed/32836852
In response to the COVID-19 health crisis, the French government has imposed drastic lockdown measures for a period of 55 days. This paper provides a quantitative assessment of the economic and environmental impacts of these measures in the short and long term. We use a Computable General Equilibrium model designed to assess environmental and energy policies impacts at the macroeconomic and sectoral levels. We find that the lockdown has led to a significant decrease in economic output of 5% of GDP, but a positive environmental impact with a 6.6% reduction in CO2 emissions in 2020. Both decreases are temporary: economic and environmental indicators return to their baseline trajectory after a few years. CO2 emissions even end up significantly higher after the COVID-19 crisis when we account for persistently low oil prices. We then investigate whether implementing carbon pricing can still yield positive macroeconomic dividends in the post-COVID recovery. We find that implementing ambitious carbon pricing speeds up economic recovery while significantly reducing CO2 emissions. By maintaining high fossil fuel prices, carbon taxation reduces the imports of fossil energy and stimulates energy efficiency investments while the full redistribution of tax proceeds does not hamper the recovery.
0924-6460,1573-1502
2020-08-09 02:00:00+02:00
pubmed
Environmental and Resource Economics
Paul Malliet;Frédéric Reynès;Gissela Landa;Meriem Hamdi-Cherif;Aurélien Saussay
CO2 emissions;Carbon tax;Macroeconomic modeling;Neo-Keynesian CGE model;Post-COVID economy
2020-08-04 02:00:00+02:00
32836852
GB;FR;NL
OFCE - French Economic Observatory, Paris, France.;NEO - Netherlands Economic Observatory, Rotterdam, The Netherlands.;TNO - Netherlands Organization for Applied Scientific Research, The Hague, The Netherlands.;LSE - London School of Economics, London, UK.
2082
10.1139/cjm-2020-0373
Journal Article
en
Keeping the Microbiology Lab Alive: Essential Microbiology Lab Skill Development in the Wake of COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32758098
NA.
0008-4166,1480-3275
2020-08-09 02:00:00+02:00
pubmed
Canadian Journal of Microbiology
Tanya C Noel;Joseph E Rubin;Yanelis Acebo Guerrero;Maria C Davis;Heather Dietz;Josie Libertucci;Nicole Sukdeo
2020-08-06 02:00:00+02:00
32758098
FR;CA;GB;US
University of Windsor, 8637, Integrative Biology, Windsor, Ontario, Canada , Tanya.Noel@uwindsor.ca.;University of Saskatchewan College of Veterinary Medicine, 70399, Veterinary Microbiology, Saskatoon, Saskatchewan, Canada , jer298@mail.usask.ca.;Integrated DNA Technologies Inc, 10865, Coralville, Iowa, United States , yaceboguerrero@idtdna.com.;University of Regina Department of Biology, 98642, Regina, Saskatchewan, Canada , maria.davis@uregina.ca.;University of Regina Department of Biology, 98642, Regina, Saskatchewan, Canada , Heather.Dietz@uregina.ca.;McMaster University, 3710, Hamilton, Ontario, Canada , libertj@mcmaster.ca.;College of New Caledonia, 6726, Biology, Prince George, British Columbia, Canada , sukdeon1@cnc.bc.ca.
2085
10.1684/epd.2020.1175
Journal Article
en
Did the COVID-19 pandemic silence the needs of people with epilepsy?
https://www.ncbi.nlm.nih.gov/pubmed/32759092
The COVID-19 pandemic shook European healthcare systems, with unavoidable gaps in the management of patients with chronic diseases. We describe the impact of the pandemic on epilepsy care in three tertiary epilepsy centres from Spain and Italy, the most affected European countries. The three epilepsy centres, members of the European EpiCARE network, manage more than 5,700 people with epilepsy. In Bologna and Barcelona, the hospitals housing the epilepsy centres were fully converted into COVID-19 units. We describe the reorganization of the clinics and report on the frequency of SARS-CoV-2 in people with epilepsy as well as the frequency of seizures in patients admitted to the COVID units. Finally, we elaborate on critical issues regarding the second phase of the pandemic. The activities related to epilepsy care were reduced to less than 10% and were deprioritized. Discharges were expedited and elective epilepsy surgeries, including vagal nerve stimulator implantations, cancelled. Hospitalizations and EEG examinations were limited to emergencies. The outpatient visits for new patients were postponed, and follow-up visits mostly managed by telehealth. Antiseizure medication weaning plans and changes in vagal nerve stimulator settings were halted. Among the 5,700 people with epilepsy managed in our centres, only 14 tested positive for SARS-CoV-2, without obvious impact on their epilepsy. None of the 2,122 patients admitted to COVID units experienced seizures among the early symptoms. Epilepsy care was negatively impacted by the pandemic, irrespective of COVID-19 epidemiology or conversion of the hospital into a COVID-19 centre. The pandemic did not silence the needs of people with epilepsy, and this must be considered in the planning of the second phase.
Epilepsy Unit, Department of Pediatric Neuroscience. Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy. Member of ERN EpiCARE.;IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. Member of ERN EpiCARE, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology in Children, University Hospitals of Lyon (HCL), Coordinator of the ERN EpiCARE and of the Brain Dynamics and Cognition Team (DYCOG),INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Lyon, France, Research Coordinator, Epilepsy Unit, San Juan de Dios Children's Hospital, Member of the ERN EpiCARE and Universitat de Barcelona, Barcelona, Spain.;Epilepsy Monitoring Unit, Department of Neurology, Hospital del Mar, Barcelona, Spain. Member of ERN EpiCARE, Hospital del Mar Medical Research Institute (IMIM) Barcelona, Spain.
2087
Letter
en
Letter to the Editors: Statins and COVID-19: Efficacy Still to Be Proven.
https://www.ncbi.nlm.nih.gov/pubmed/32767854
We read with interest the article by Bloom et al reporting liver biochemistry-associated trends, etiologies, and outcomes in 60 patients with coronavirus disease 2019 (COVID-19). The authors reported that 69% of the patients had abnormal liver function tests (LFTs) on admission and 93% during their hospital stay, with an aspartate aminotransferase (AST) predominance. These results are similar to our own experience of 234 patients admitted with COVID-19 according to World Health Organization (WHO) diagnostic guidelines.
Department of Hepatology and Liver Transplantation, Centre Hospitalier Universitaire Montpellier, Montpellier, France.
2089
10.1093/geront/gnaa104
Journal Article
en
Changes in Subjective Age During COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32766780
To examine change in subjective age with the emergence of coronavirus disease 2019 (COVID-19). Two competing hypotheses were tested: (a) people felt increasingly older due to the stress generated by the pandemic; (b) people felt increasingly younger due to psychological distancing from older age, a vulnerability to COVID-19.
0016-9013,1758-5341
2020-08-09 02:00:00+02:00
pubmed
The Gerontologist
Antonio Terracciano;Yannick Stephan;Damaris Aschwanden;Ji Hyun Lee;Amanda A Sesker;Jason E Strickhouser;Martina Luchetti;Angelina R Sutin
Age identity;Coronavirus;Longitudinal;Multilevel Modeling;SARS-CoV-2
2020-08-07 02:00:00+02:00
32766780
FR;US
Department of Geriatrics, Florida State University College of Medicine, Tallahassee, Florida.;Euromov, University of Montpellier, Montpellier, France.;Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine, Tallahassee, Florida.
2090
National Research Foundation of Korea;National Research Foundation of Korea
10.1002/jmv.26397
Journal Article
en
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
https://www.ncbi.nlm.nih.gov/pubmed/32767684
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).
0146-6615,1096-9071
2020-08-09 02:00:00+02:00
pubmed
Journal of Medical Virology
Meehyun Ko;Sangeun Jeon;Wang-Shick Ryu;Seungtaek Kim
[{"country": "", "agency": "National Research Foundation of Korea", "grantid": "NRF-2017M3A9G6068245"}, {"country": "", "agency": "National Research Foundation of Korea", "grantid": "NRF-2020M3E9A1041756"}]
Value of electrocardiography in coronavirus disease 2019 (COVID-19).
https://www.ncbi.nlm.nih.gov/pubmed/32805546
In December 2019, reports of an unknown pneumonia not responsive to traditional treatments arose in Wuhan, China. The pathogen was subsequently identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known to be responsible for the coronavirus disease-2019 (COVID-19) illness, and public health emergency of international concern was declared by the World Health Organization. There is increasing awareness of the cardiovascular manifestations of COVID-19 disease, and the adverse impact of cardiovascular involvement on its prognosis. In this setting, the electrocardiogram (ECG) is one of the leading tools to assess the extent of cardiac involvement in COVID-19 patients, due to its wide disponibility, low cost, and the possibility of remote evaluation. In this article, we review the role of the ECG in the identification of cardiac involvement in COVID-19, highlighting relevant clinical implications.
College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.;Division of Cardiac Electrophysiology, Madinah Cardiac Centre, Madinah, Saudi Arabia.;Department of Cardiology, Dr Siyami Ersek Hospital Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.;Second Department of Cardiology, Evangelismos General Hospital of Athens, Athens, Greece.;Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, USA, Cardiology Department, Hospital de la Santa Creu i Sant Pau, CIBERCV, Barcelona, Spain.;South American Center of Excellence for Cardiovascular Health (CESCAS), Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.;Laboratory of Cardiovascular Physiology, Chinese University Shenzhen Research Institute, PR China.;Heart Rhythm Service, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada.;Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, PR China.;Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, PR China. Electronic address: gary.tse@doctors.org.uk.;Heart Rhythm Service, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada. Electronic address: Adrian.Baranchuk@kingstonhsc.ca.
2110
10.1016/j.jhep.2020.07.042
Journal Article
en
Impact of COVID-19 on global hepatitis C elimination efforts.
https://www.ncbi.nlm.nih.gov/pubmed/32777322
COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress.
0168-8278
2020-08-09 02:00:00+02:00
pubmed
Journal of Hepatology
Sarah Blach;Loreta A Kondili;Alessio Aghemo;Zongzhen Cai;Ellen Dugan;Chris Estes;Ivane Gamkrelidze;Siya Ma;Jean Michel Pawlotsky;Devin Razavi-Shearer;Homie Razavi;Imam Waked;Stefan Zeuzem;Antonio Craxi
Center for Disease Analysis Foundation, Lafayette, Colorado, United States. Electronic address: sblach@cdafound.org.;National Center for Global Health- Istituto Superiore di Sanità Rome Italy.;Internal Medicine and Hepatology Division, Humanitas Clinical and Research Center - IRCCS, Rozzano (Mi) - Italy, Humanitas University, Department of Biomedical Sciences, Milan, Italy.;Center for Disease Analysis Foundation, Lafayette, Colorado, United States.;National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, 94010 Créteil, France, INSERM U955, 94010 Créteil, France.;National Liver Institute, Menoufia University, Egypt.;Internal Medicine Department, Goethe University Hospital, Frankfurt, Germany.;Gastroenterology and Hepatology Unit, Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
2115
10.1016/j.amcp.2020.08.003
Journal Article;Review
fr
[Arterial and venous thrombosis in patients with COVID-19].
https://www.ncbi.nlm.nih.gov/pubmed/32837203
1261-694X
2020-08-09 02:00:00+02:00
pubmed
Archives des Maladies du Coeur et des Vaisseaux - Pratique
S Zuily;V Dufrost;D Wahl
2020-08-07 02:00:00+02:00
32837203
FR
Université de Lorraine, Inserm DCAC UMR_S 1116 et Service de médecine vasculaire et centre de compétences régional maladies rares vasculaires, maladies autoimmunes et systémiques, syndrome de Marfan et apparentés, CHRU de Nancy, Institut Lorrain Louis-Mathieu, rue du Morvan, 54511 Vandoeuvre-lès-Nancy Cedex, France.
2116
10.1016/s2665-9913(20)30272-1
Journal Article
en
Anakinra for severe forms of COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32838318
2665-9913
2020-08-09 02:00:00+02:00
pubmed
The Lancet Rheumatology
Laine Marc;Bonello Laurent
2020-08-07 02:00:00+02:00
32838318
FR
Department of Cardiology, Assistance Publique des Hôpitaux de Marseille, Hôpital Nord, Marseille 13015, France.;Centre for CardioVascular and Nutrition research and Faculté de Médecine de Marseille, Aix-Marseille University, Marseille, France.
2117
10.1016/j.ijantimicag.2020.106136
Journal Article
en
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.
https://www.ncbi.nlm.nih.gov/pubmed/32777263
During the Covid-19 pandemic, a large number of intensive care unit (ICU) patients received hydroxychloroquine. The primary objective of our study was to assess the effects of hydroxychloroquine according to its plasma concentration in ICU patients. To this purpose, a single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to our ICU with a confirmed Covid-19 pneumonia and treated by hydroxychloroquine were included. We compared 17 patients in whom the hydroxychloroquine plasma concentration was in the therapeutic target (on-target) and 12 patients in whom the plasma concentration was below the target (off-target). The follow-up of patients was 15 days. No association was found between hydroxychloroquine plasma concentration and viral load evolution (p = 0.77). There was no significant difference between the two groups for the duration of mechanical ventilation, length of ICU stay, in-hospital mortality, and 15-days mortality. This finding suggests that hydroxychloroquine administration for Covid-19 patients hospitalized in ICU is not associated with improved outcomes. These results need confirmation by larger multicenter studies.
Covid-19 pneumonia;Hydroxychloroquine;Intensive care unit
2020-08-07 02:00:00+02:00
32777263
FR
Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France. Electronic address: alexandre.lopez@ap-hm.fr.;Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France.;Service de Pharmacologie Clinique et Pharmacovigilance, APHM, Institut de neurosciences des systèmes, Inserm UMR 1106, Université d'Aix-Marseille, France.;Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, 13005 Marseille, France.;Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France, Center for Cardiovascular and Nutrition Research (C2VN) Aix Marseille Université, INSERM, INRA, Marseille, 13005, France.
2118
Letter
en
Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic.
giant cell arteritis;glucocorticoids;health services research
2020-08-07 02:00:00+02:00
32769152
FR
Neuroradiology, The Fondation Adolphe de Rothschild Hospital, Paris, France alecler@for.paris.;Internal Medicine, The Fondation Adolphe de Rothschild Hospital, Paris, France.;Ophthalmology, The Fondation Adolphe de Rothschild Hospital, Paris, France.
2124
10.1016/j.jhin.2020.08.009
Journal Article
en
Wearing of face masks by healthcare workers during covid-19 lockdown: what did the public observe through the French media?
https://www.ncbi.nlm.nih.gov/pubmed/32798641
Wearing a face mask is a major issue in the fight against Covid-19 pandemic spreading. The French general population widely started to wear this individual protection equipment usually dedicated to healthcare workers, without being educated to its correct use. People base their behavior on what they see in the media. However, we observed that masks wearing of healthcare workers published in the media during the pandemic was only conform on 70.8% of the photographs collected on some of the main French information websites. Health authorities should communicate widely about the good practices for mask wearing in general population.
COVID-19 pandemic;filtering face piece (FFP) mask;media;surgical mask
2020-08-13 02:00:00+02:00
32798641
FR
Infection control unit, Brest Teaching Hospital, F-29200 Brest, France.;Infection control unit, Brest Teaching Hospital, F-29200 Brest, France, University of Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France. Electronic address: philippe.saliou@chu-brest.fr.
2133
10.1016/s2213-2600(20)30328-3
Journal Article
en
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.
https://www.ncbi.nlm.nih.gov/pubmed/32798468
Patients with COVID-19 who develop severe acute respiratory distress syndrome (ARDS) can have symptoms that rapidly evolve to profound hypoxaemia and death. The efficacy of extracorporeal membrane oxygenation (ECMO) for patients with severe ARDS in the context of COVID-19 is unclear. We aimed to establish the clinical characteristics and outcomes of patients with respiratory failure and COVID-19 treated with ECMO.
Sorbonne University, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France, Service de médecine intensive-réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Département de Santé Publique, Centre de Pharmacoépidémiologie, Paris, France.;Sorbonne University, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France, Service de chirurgie cardiaque, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Biotherapy and Inflammation-Immunopathology-Biotherapy Department, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Sorbonne University, INSERM, UMR-S 959, Immunology-Immunopathology-Immunotherapy, Paris, France.;Assistance Publique-Hôpitaux de Paris Sorbonne University, Hôpital Tenon, Service de Médecine intensive Réanimation, Paris, France, INSERM Institut Mondor de Recherche Biomédicale, Team GEIC20, Créteil, France.;Service de médecine intensive-réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Sorbonne University, INSERM, UMR-S 959, Immunology-Immunopathology-Immunotherapy, Paris, France.;Service de Pneumologie, Médecine intensive, Réanimation, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Assistance Publique-Hôpitaux de Paris Sorbonne University, Hôpital Tenon, Service de Médecine intensive Réanimation, Paris, France.;Service de Pneumologie, Médecine intensive, Réanimation, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Sorbonne University, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France.;Assistance Publique-Hôpitaux de Paris Sorbonne University Saint Antoine Hospital, Service de médecine intensive-réanimation, Paris, France.;GRC 29, DMU DREAM, Department of Anaesthesiology and Critical Care, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Sorbonne University, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France, Service de médecine intensive-réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France. Electronic address: alain.combes@aphp.fr.
2135
Letter
en
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.
https://www.ncbi.nlm.nih.gov/pubmed/32790951
We read with much interest the recent observational study of Nougier et al., which aimed at studying thrombin generation (TG) and fibrinolysis profiles of COVID-19 patients admitted to an intensive care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic heparin.[1] They reported that thrombin potential remained within normal range despite heparin and that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL tPA (referred to as 'TEM-tPA'), they reported decreased clot lysis in COVID-19 patients, which was more pronounced in patients who presented a thrombotic event, compared to event-free patients.
2020-08-16 02:00:00+02:00
pubmed
Michael Hardy;Jonathan Douxfils;Marion Bareille;Sarah Lessire;Isabelle Gouin-Thibault;Pierre Fontana;Thomas Lecompte;François Mullier
Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS, Hematology Laboratory, Yvoir, Belgium.;Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS, Anesthesiology Department, Yvoir, Belgium.;Université de Namur, Département Pharmacie, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS, Namur, Belgium.;Qualiblood s.a, Namur, Belgium.;INSERM, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, CHU de Rennes, Département d'Hématologie Biologique, Rennes, France.;Département de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland.
2137
10.1164/rccm.202007-2670le
Journal Article
en
Reply to : Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19 Related Acute Respiratory Distress Syndrome: Worth the Effort!
https://www.ncbi.nlm.nih.gov/pubmed/32795240
1073-449X,1535-4970
2020-08-16 02:00:00+02:00
pubmed
American Journal of Respiratory and Critical Care Medicine
Alexandra Monnier;Pierre-Emmanuel Falcoz;Julie Helms;Ferhat Meziani
2020-08-14 02:00:00+02:00
32795240
FR
Hôpitaux universitaires de Strasbourg, 36604, Médecine Intensive-Réanimation, Strasbourg, France.;Hopitaux universitaires de Strasbourg, 36604, Department of Thoracic Surgery, Strasbourg, France.;Hôpitaux universitaires de Strasbourg, 36604, intensive care, Strasbourg, France.;Hôpitaux universitaires de Strabourg, réanimation médicale, Strasbourg, France, ferhat.Meziani@chru-strasbourg.fr.
2143
10.1080/07853890.2020.1803499
Journal Article
en
A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area.
https://www.ncbi.nlm.nih.gov/pubmed/32723107
To identify predictive factors of unfavourable outcome among patients hospitalized for COVID-19.
Departement of Internal Medicine, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Centre for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France.;Emergency Department, AP-HP.Nord, Beaujon Hospital, Clichy, France.;Department of Anaesthesiology and Intensive Care, AP-HP.Nord, Beaujon Hospital, DMU PARABOL, University of Paris, Clichy, France.;Department of Radiology, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Laboratory of Microbiology, AP-HP.Nord, Beaujon Hospital, Clichy, France.;Laboratory of Hematology and Hemostasis, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Laboratory of Biochemistry, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Departement of Pancreatology, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.
2148
10.1002/uog.22178
Journal Article
en
Anatomical and timely assessment of protein expression of angiotensin-converting enzyme 2, SARS-CoV-2 specific receptor, in fetal and placental tissues: new insight for perinatal counseling.
https://www.ncbi.nlm.nih.gov/pubmed/32798244
Infection with SARS-CoV2 does not spare pregnant women and the possibility of vertical transmission which might lead to fetal damages is pending.
0960-7692,1469-0705
2020-08-16 02:00:00+02:00
pubmed
Ultrasound in Obstetrics & Gynecology
V Faure-Bardon;P Isnard;N Roux;M Leruez-Ville;T Molina;B Bessieres;Y Ville
EA 73-28, Université de Paris, Paris, France.;AP-HP, Department of Obstetrics and Fetal Medicine, Hospital Necker-Enfants Malades, Paris, France.;AP-HP, Department of Histology, Embryology and Cytogenetics, Hospital Necker-E.M, Paris, France.;Institut National de la Santé et de la Recherche Médicale (INSERM), U1151, CNRS UMR 8253, Hospital Necker-E.M, Department of Growth and Signaling, Université de Paris, Paris, France.;AP- HP, Virology Laboratory, Hospital Necker-E.M, Paris, France.
2153
Letter
en
Fatal Covid-19 vasoplegic shock in a recipient few hours before double lung transplantation in high emergency.
https://www.ncbi.nlm.nih.gov/pubmed/32785961
SARS-Cov2 outbreak has deeply impacted French lung transplant programs by the decreased number of lung donors, the scarcity of intensive care unit (ICU) beds and most importantly, the assumed worse prognosis of Covid-19 in recipients during perioperative period. Despite no evidence has been published to suggest that lung transplant recipients were at high-risk of acquiring the virus or developing severe Covid-19, immunosuppression may worsen the prognosis of such infection in patient transplanted for end-staged lung diseases.
Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, France, INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, France.;Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Bichat-Claude Bernard, Service de Pneumologie B et Transplantation Pulmonaire, Paris, France.;Intensive care Unit, CHU Lille, Lille, France.;Department of Respirology, CHU Lille, Lille, France.;Department of Cardiac Surgery, CHU Lille, Lille, France.
2158
10.1136/bcr-2020-237511
Case Reports;Journal Article
en
Successful continuation of pregnancy in a patient with COVID-19-related ARDS.
https://www.ncbi.nlm.nih.gov/pubmed/32788159
A 33-year-old pregnant woman was hospitalised with fever, cough, myalgia and dyspnoea at 23.5 weeks of gestation (WG). Development of acute respiratory distress syndrome (ARDS) mandated invasive mechanical ventilation. A nasopharyngeal swab proved positive for severe acute respiratory syndrome coronavirus 2 by reverse transcription-PCR. The patient developed hypertension and biological disorders suggesting pre-eclampsia and HELLP (haemolysis, elevated liver enzyme levels and low platelet levels) syndrome. Pre-eclampsia was subsequently ruled out by a low ratio of serum soluble fms-like tyrosine kinase-1 to placental growth factor. Given the severity of ARDS, delivery by caesarean section was contemplated. Because the ratio was normal and the patient's respiratory condition stabilised, delivery was postponed. She recovered after 10 days of mechanical ventilation. She spontaneously delivered a healthy boy at 33.4 WG. Clinical and laboratory manifestations of COVID-19 infection can mimic HELLP syndrome. Fetal extraction should not be systematic in the absence of fetal distress or intractable maternal disease. Successful evolution was the result of a multidisciplinary teamwork.
Laura Federici;Olivier Picone;Didier Dreyfuss;Jeanne Sibiude
adult intensive care;mechanical ventilation;obstetrics and gynaecology;pneumonia (infectious disease)
2020-08-11 02:00:00+02:00
32788159
FR
Service de médecine intensive reanimation, Hôpital Louis-Mourier, Colombes, France laura.federici85@gmail.com.;Service de gynécologie-obstétrique, Hôpital Louis-Mourier, Colombes, Île-de-France, France.;IAME-U11337, INSERM, Paris, Île-de-France, France.;Service de médecine intensive reanimation, Hôpital Louis-Mourier, Colombes, France.;Unit UMR S-1155 Common and Rare Kidney Disease, INSERM, Paris, Île-de-France, France.
2165
10.1136/bmjsrh-2020-200709
Editorial
en
The impact of COVID-19 on contraception and abortion care policy and practice: experiences from selected countries.
https://www.ncbi.nlm.nih.gov/pubmed/32788180
2515-1991,2515-2009
2020-08-16 02:00:00+02:00
pubmed
BMJ Sexual & Reproductive Health
Deborah J Bateson;Patricia A Lohr;Wendy V Norman;Caroline Moreau;Kristina Gemzell-Danielsson;Paul D Blumenthal;Lesley Hoggart;Hang-Wun Raymond Li;Abigail R A Aiken;Kirsten I Black
abortion;family planning services;health services accessibility;induced;long-acting reversible contraception;reproductive health services
2020-08-11 02:00:00+02:00
32788180
FR;SE;CA;GB;US;HK;AU
Family Planning New South Wales, Sydney, New South Wales, Australia deborahb@fpnsw.org.au.;Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.;British Pregnancy Advisory Service (BPAS), Stratford upon Avon, UK.;Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada.;Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.;Population Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.;CESP Centre for Research in Epidemiology and Population Health, INSERM (Institut National de la Santé et de la Recherche Medicale), Villejuif, France.;Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.;Karolinska University Hospital, Stockholm, Sweden.;Stanford University School of Medicine, Stanford, California, USA.;Faculty of Wellbeing, Education and Language Studies, The Open University, Milton Keynes, UK.;Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong.;LBJ School of Public Affairs, The University of Texas at Austin, Austin, Texas, USA.;Women's Health, Neonatology and Paediatrics, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32620062
Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testing a wide array of possible medications. In particular, the off-label use of hydroxychloroquine for COVID-19 prophylaxis and treatment has created many unprecedented challenges for the scientific community and the public.
1744-666X,1744-8409
2020-08-16 02:00:00+02:00
pubmed
Expert Review of Clinical Immunology
Sebastian E Sattui;Jean W Liew;Elizabeth R Graef;Ariella Coler-Reilly;Francis Berenbaum;Alí Duarte-García;Carly Harrison;Maximilian F Konig;Peter Korsten;Michael S Putman;Philip C Robinson;Emily Sirotich;Manuel F Ugarte-Gil;Kate Webb;Kristen J Young;Alfred H J Kim;Jeffrey A Sparks
Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY, USA.;Division of Rheumatology, Department of Medicine, University of Washington , Seattle, WA, USA.;Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, USA.;Division of Rheumatology, Department of Medicine, Washington University School of Medicine , St. Louis, MO, USA.;Department of Rheumatology, Sorbonne University, INSERM CRSA, AP-HP , Paris, France.;Division of Rheumatology, Mayo Clinic , Rochester, MN, USA.;LupusChat , New York, NY, USA.;Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine , Baltimore, MD, USA.;Department of Nephrology and Rheumatology, University Medical Center Göttingen , Göttingen, Germany.;Department of Medicine, Northwestern University , Chicago, IL, USA.;University of Queensland Faculty of Medicine , Brisbane, Australia.;Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada.;Canadian Arthritis Patient Alliance , Toronto, ON, Canada.;School of Medicine, Universidad Científica Del Sur and Hospital Nacional Guillermo Almenara Irigoyen , EsSalud, Lima, Peru.;Department of Paediatric Rheumatology, University of Cape Town , Cape Town, South Africa.;Francis Crick Institute , London, UK.;Division of Rheumatic Diseases, UT Southwestern Medical Center , Dallas, TX, USA.;Division of Rheumatology, Department of Medicine, Washington University School of Medicine , Saint Louis, MO, USA.;Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School , Boston, MA, USA.
2168
10.1093/trstmh/traa066
Journal Article
en
Testing wastewater to detect severe acute respiratory syndrome coronavirus 2 in communities.
https://www.ncbi.nlm.nih.gov/pubmed/32780856
Research groups around the world are starting to analyse whether wastewater surveillance is a useful tool to monitor the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in communities. Reported studies from the Netherlands, USA, Australia and France have demonstrated that SARS-CoV-2 can be detected and quantified in wastewater, allowing the total number of community infections to be estimated as well as monitoring whether the virus has returned to a community after elimination. Further work is required to improve the quantification of virus, to better detect the virus at low levels and to ensure wastewater samples are representative of the community under surveillance.
0035-9203,1878-3503
2020-08-16 02:00:00+02:00
pubmed
Transactions of the Royal Society of Tropical Medicine and Hygiene
Anthony D Harries;Selma Dar Berger;Srinath Satyanarayana;Pruthu Thekkur;Ajay M V Kumar
International Union Against Tuberculosis and Lung Disease, Paris, France.;London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.;International Union Against Tuberculosis and Lung Disease, South-east Asia Office, C-6 Qutub Institutional Area, New Delhi 110016, India.;Yenepoya Medical College, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangalore 575018, India.
2170
10.1021/acs.jcim.0c00545
Journal Article
en
Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein-Protein Interfaces.
https://www.ncbi.nlm.nih.gov/pubmed/32786511
Protein-protein interactions (PPIs) are attractive targets for drug design because of their essential role in numerous cellular processes and disease pathways. However, in general, PPIs display exposed binding pockets at the interface, and as such, have been largely unexploited for therapeutic interventions with low-molecular weight compounds. Here, we used docking and various rescoring strategies in an attempt to recover PPI inhibitors from a set of active and inactive molecules for 11 targets collected in ChEMBL and PubChem. Our focus is on the screening power of the various developed protocols and on using fast approaches so as to be able to apply such a strategy to the screening of ultralarge libraries in the future. First, we docked compounds into each target using the fast "pscreen" mode of the structure-based virtual screening (VS) package Surflex. Subsequently, the docking poses were postprocessed to derive a set of 3D topological descriptors: (i) shape similarity and (ii) interaction fingerprint similarity with a co-crystallized inhibitor, (iii) solvent-accessible surface area, and (iv) extent of deviation from the geometric center of a reference inhibitor. The derivatized descriptors, together with descriptor-scaled scoring functions, were utilized to investigate possible impacts on VS performance metrics. Moreover, four standalone scoring functions, RF-Score-VS (machine-learning), DLIGAND2 (knowledge-based), Vinardo (empirical), and X-SCORE (empirical), were employed to rescore the PPI compounds. Collectively, the results indicate that the topological scoring algorithms could be valuable both at a global level, with up to 79% increase in areas under the receiver operating characteristic curve for some targets, and in early stages, with up to a 4-fold increase in enrichment factors at 1% of the screened collections. Outstandingly, DLIGAND2 emerged as the best scoring function on this data set, outperforming all rescoring techniques in terms of VS metrics. The described methodology could help in the rational design of small-molecule PPI inhibitors and has direct applications in many therapeutic areas, including cancer, CNS, and infectious diseases such as COVID-19.
1549-9596,1549-960X
2020-08-16 02:00:00+02:00
pubmed
Journal of Chemical Information and Modeling
Natesh Singh;Ludovic Chaput;Bruno O Villoutreix
2020-08-11 02:00:00+02:00
32786511
FR
Université de Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France.
2171
10.1007/s00345-020-03402-w
Journal Article
en
Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pubmed/32776243
The current COVID-19 pandemic is transforming our urologic practice and most urologic societies recommend to defer any surgical treatment for prostate cancer (PCa) patients. It is unclear whether a delay between diagnosis and surgical management (i.e., surgical delay) may have a detrimental effect on oncologic outcomes of PCa patients. The aim of the study was to assess the impact of surgical delay on oncologic outcomes.
Biochemical recurrence;COVID-19;Delay;Oncologic outcomes;Prostate cancer
2020-08-10 02:00:00+02:00
32776243
FR;IT;BE;CH
Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. romain.diamand@erasme.ulb.ac.be.;Urology Department, La Croix du Sud Hospital, Quint Fonsegrives, France.;Urology Department, CHU Toulouse, Toulouse, France.;Urology Department, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.;Urology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland.;Urology Department, CHU de Grenoble, Grenoble, France.;Grenoble Alpes University, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.;Urology Department, Jules Bordet Institute, Brussels, Belgium.;Urology Department, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.;Urology Department, University Clinics Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Urology Department, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;Urology Department, Clinique Saint-Augustin, Bordeaux, France.;Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.
2194
10.1051/medsci/2020123
English Abstract;Journal Article
fr
[Tracing the origins of SARS-COV-2 in coronavirus phylogenies].
https://www.ncbi.nlm.nih.gov/pubmed/32773024
SARS-CoV-2 is a new human coronavirus (CoV), which emerged in People's Republic of China at the end of 2019 and is responsible for the global Covid-19 pandemic that caused more than 540 000 deaths in six months. Understanding the origin of this virus is an important issue and it is necessary to determine the mechanisms of its dissemination in order to be able to contain new epidemics. Based on phylogenetic inferences, sequence analysis and structure-function relationships of coronavirus proteins, informed by the knowledge currently available, we discuss the different scenarios evoked to account for the origin - natural or synthetic - of the virus. On the basis of currently available data, it is impossible to determine whether SARS-CoV-2 is the result of a natural zoonotic emergence or an accidental escape from experimental strains. Regardless of its origin, the study of the evolution of the molecular mechanisms involved in the emergence of this pandemic virus is essential to develop therapeutic and vaccine strategies.
0767-0974,1958-5381
2020-08-16 02:00:00+02:00
pubmed
médecine/sciences
Erwan Sallard;José Halloy;Didier Casane;Jacques van Helden;Étienne Decroly
2020-08-10 02:00:00+02:00
32773024
FR
École Normale Supérieure de Paris, 45 rue d'Ulm, 75005 Paris, France.;Université de Paris, CNRS, LIED UMR 8236, 85 bd Saint-Germain, 75006 Paris, France.;Université Paris-Saclay, CNRS, IRD, UMR Évolution, Génomes, Comportement et Écologie, 91198, Gif-sur-Yvette, France - Université de Paris, UFR Sciences du Vivant, F-75013 Paris, France.;CNRS, Institut Français de Bioinformatique, IFB-core, UMS 3601, Évry, France - Aix-Marseille Univ, Inserm, laboratoire Theory and approaches of genome complexity (TAGC), Marseille, France.;AFMB, CNRS, Aix-Marseille Univ, UMR 7257, Case 925, 163 avenue de Luminy, 13288 Marseille Cedex 09, France.
2199
10.15252/emmm.202013038
Journal Article
en
Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes.
https://www.ncbi.nlm.nih.gov/pubmed/32816392
Early in the COVID-19 pandemic, type 2 diabetes (T2D) was marked as a risk-factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at-risk groups based on immuno-inflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated with COVID-19 severity in T2D. Broad-spectrum immunophenotyping quantified 15 leukocyte populations in peripheral circulation from a cohort of 45 hospitalised COVID-19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxic CD8+ lymphocytes was associated with severe COVID-19 and requirement for intensive care in both non-diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classical CD14Hi CD16- monocytes were specifically associated with severe COVID-19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type-1 interferon pathway (IL6, IL8, CCL2, INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity of COVID-19 in T2D. These findings allow precise identification of T2D patients with severe COVID-19 as well as provide evidence that the type-1 interferon pathway may be an actionable therapeutic target for future studies.
Cordeliers Research Centre, INSERM, IMMEDIAB Laboratory, Sorbonne Université, Université de Paris, F-75006, Paris, France.;Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.;Department of diabetology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.;Department of Diabetology, Endocrinology and Nutrition, Bichat Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.;Aix Marseille University, INSERM, INRA, C2VN, Marseille, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France. Endocrinology, France.;Centre de Ressources Biologique « biobank Lariboisière », BB-0033-00064. APHP. Nord, Université de Paris, Paris Diderot. Hôpital Lariboisière, Paris 10, France.;Center for Interdisciplinary Research in Biology (CIRB), College de France - Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Sciences et Lettres (PSL) Research University, Paris, France.
2202
10.1002/oby.23014
Journal Article
en
Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795 patients.
https://www.ncbi.nlm.nih.gov/pubmed/32815621
Preliminary data from different cohorts of small sample size or with short follow-up indicate poorer prognosis in people with obesity compared to other patients. This study aims to precisely describe the strength of association between obesity in patients hospitalised with Covid-19 and mortality and clarify the risk according to usual cardiometabolic risk factors in a large cohort.
Metabolically Benign;Obesity;SARS-CoV-2;body mass index;mortality determinants;obesity
2020-08-20 02:00:00+02:00
32815621
FR
Université de Paris, F-75015, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Nutrition, Centre Spécialisé Obésité, Hôpital Européen Georges Pompidou, Paris, France.;INSERM, UMR1153, Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Unité de Recherche clinique, Hôpital Cochin, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Intensive Réanimation, Hôpital Européen Georges Pompidou, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service d'informatique médicale, biostatistiques et santé publique, Hôpital Européen Georges Pompidou, Paris, France.;INSERM, Cordeliers Research Center, Information sciences to support personalized medicine, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges-Pompidou, CIC1418 and DMU CARTE, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Chirurgie Digestive, Oncologique et Bariatrique, Hôpital Européen Georges Pompidou, Paris, France.
2206
10.1183/13993003.01104-2020
Journal Article;Research Support, Non-U.S. Gov't
en
Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study.
https://www.ncbi.nlm.nih.gov/pubmed/32616597
The outbreak of coronavirus disease 2019 (COVID-19) has globally strained medical resources and caused significant mortality.
The D-Lab, Dept of Precision Medicine, GROW - School for Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands g.wu@maastrichtuniversity.nl.;Guangyao Wu and Pei Yang are joint first authors.;Guangyao Wu and Xiang Wang are co-corresponding authors.;Dept of Radiology, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, China.;The D-Lab, Dept of Precision Medicine, GROW - School for Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands.;Dept of Radiology and Nuclear Medicine, GROW- School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.;Dept of Ultrasound, The Central Hospital of Huangshi, Huangshi, China.;Dept of Respiratory Medicine, CHU of Liège, Liège, Belgium.;Dept of Infectiology, CHU of Liège, Liège, Belgium.;Dept of Radiology, China Resources Wuhan Iron and Steel Hospital, Wuhan, China.;Dept of Radiology, The Central Hospital of Shaoyang, Shaoyang, China.;Dept of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.;Dept of Intensive Care Unit, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, China.;National Institute for Infectious Diseases - IRCCS, Rome, Italy.;Dept of Biomedical, Clinical and Experimental Sciences "Mario Serio", University of Florence, Florence, Italy.;Unit of Respiratory Pathophysiology, Respiratory Diseases and Allergy Clinic, Dept of Internal Medicine and Medical Specialties, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.;Unit of Interventional Pulmonology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.;Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liège, Liège, Belgium.;Dept of Radiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
2208
10.2214/ajr.20.23546
Journal Article
en
Could Spectral CT Have a Potential Benefit in Coronavirus Disease (COVID-19)?
https://www.ncbi.nlm.nih.gov/pubmed/32822225
OBJECTIVE. The purpose of this study is to evaluate the potential benefit of spectral imaging, notably electron density imaging, in patients with suspected or confirmed coronavirus disease (COVID-19), by retrospectively reviewing the cases of four patients who each underwent two chest CT scans for confirmed COVID-19. CONCLUSION. The use of spectral CT with electron density imaging could improve the assessment of lung lesion extent in patients with early-stage COVID-19.
Department of Radiology, Antony's Private Hospital, 25 Ave de la Providence, 92160 Antony, France.
2217
Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (HMRF)
10.1038/s41590-020-0773-7
Journal Article
en
ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32807944
The SARS-CoV-2 virus emerged in December 2019 and has caused a worldwide pandemic due to the lack of any pre-existing immunity. Accurate serology testing is urgently needed to help diagnose infection, determine past exposure of populations and assess the response to a future vaccine. The landscape of antibody responses to SARS-CoV-2 is unknown. In this study, we utilized the luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19. We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses. ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificity. Our findings could be used to develop second-generation diagnostic tests to improve serological assays for COVID-19 and are important in understanding pathogenicity.
1529-2908,1529-2916
2020-08-23 02:00:00+02:00
pubmed
Nature Immunology
Asmaa Hachim;Niloufar Kavian;Carolyn A Cohen;Alex W H Chin;Daniel K W Chu;Chris K P Mok;Owen T Y Tsang;Yiu Cheong Yeung;Ranawaka A P M Perera;Leo L M Poon;J S Malik Peiris;Sophie A Valkenburg
2020-08-17 02:00:00+02:00
32807944
FR;CN;GB;HK
[{"country": "", "agency": "Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (HMRF)", "grantid": "COVID190115"}]
HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.;HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. niloufar@hku.hk.;Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d'Immunologie Biologique, Paris, France. niloufar@hku.hk.;Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. niloufar@hku.hk.;Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.;Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China.;HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. sophiev@hku.hk.
2231
Letter
en
COVID-19 and its psychological consequences: Beware of the respiratory subtype of panic disorder.
https://www.ncbi.nlm.nih.gov/pubmed/32818605
2020-08-23 02:00:00+02:00
pubmed
Hervé Javelot;Luisa Weiner;Coraline Hingray;Rafael C Freire;Antonio E Nardi
2020-08-18 02:00:00+02:00
32818605
FR;CA;BR
Établissement Public De Santé Alsace Nord, Brumath, France, Laboratoire De Toxicologie Et Pharmacologie Neuro Cardiovasculaire, Université De Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.;Clinique De Psychiatrie, CHU De Strasbourg, France, Laboratoire De Psychologie Des Cognitions, Université De Strasbourg, Strasbourg, France.;Pôle Hospitalo-Universitaire De Psychiatrie d'Adultes Du Grand Nancy, Centre Psychothérapique De Nancy, Laxou, France, CHU De Nancy, Département De Neurologie, Nancy, France.;Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio De Janeiro, Rio De Janeiro, Brazil.;Department of Psychiatry and Centre for Neuroscience Studies, Queen's University, Kingston, Canada.
2236
10.1111/ijlh.13312
Journal Article
en
Interest of the cellular population data analysis as an aid in the early diagnosis of SARS-CoV-2 infection.
https://www.ncbi.nlm.nih.gov/pubmed/32812365
Coronavirus disease 2019 (COVID-19) is characterized by a high contagiousness requiring isolation measures. At this time, diagnosis is based on the positivity of specific RT-PCR and/or chest computed tomography scan, which are time-consuming and may delay diagnosis. Complete blood count (CBC) can potentially contribute to the diagnosis of COVID-19. We studied whether the analysis of cellular population data (CPD), provided as part of CBC-Diff analysis by the DxH 800 analyzers (Beckman Coulter), can help to identify SARS-CoV-2 infection.
Fonds De La Recherche Scientifique - FNRS;Fonds De La Recherche Scientifique - FNRS
10.3390/mps3030059
Journal Article
en
SARS-CoV-2 Detection for Diagnosis Purposes in the Setting of a Molecular Biology Research Lab.
https://www.ncbi.nlm.nih.gov/pubmed/32824827
The emergence of the SARS-CoV-2 virus and the exponential growth of COVID-19 cases have created a major crisis for public health systems. The critical identification of contagious asymptomatic carriers requires the isolation of viral nucleic acids, reverse transcription, and amplification by PCR. However, the shortage of specific proprietary reagents or the lack of automated platforms have seriously hampered diagnostic throughput in many countries. Here, we provide a procedure for SARS-CoV-2 detection for diagnostic purposes from clinical samples in the setting of a basic research molecular biology lab. The procedure details the necessary steps for daily analysis of up to 500 clinical samples with a team composed of 12 experienced researchers. The protocol has been designed to rely on widely available reagents and devices, to cope with heterogeneous clinical specimens, to guarantee nucleic acid extraction from very scarce biological material, and to minimize the rate of false-negative results.
[{"country": "", "agency": "Fonds De La Recherche Scientifique - FNRS", "grantid": "34972507"}, {"country": "", "agency": "Fonds De La Recherche Scientifique - FNRS", "grantid": "31454280"}]
Namur Research Institute for Life Sciences (NARILIS), Integrated Veterinary Research Unit (URVI), University of Namur, 61 rue de Bruxelles, 5000 Namur, Belgium.;KU Leuven, Laboratory of Clinical Bacteriology and Mycology, campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.;Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.;CHU UCL NAMUR, Laboratory of microbiology and molecular biology, Site Godinne, 5530 Yvoir, Belgium.
2251
10.1164/rccm.202006-2521le
Journal Article
en
On Happy Hypoxia and on Sadly Ignored "Acute Vascular Distress Syndrome" in COVID-19 Patients.
https://www.ncbi.nlm.nih.gov/pubmed/32813543
1073-449X,1535-4970
2020-08-23 02:00:00+02:00
pubmed
American Journal of Respiratory and Critical Care Medicine
Vincent Jounieaux;Daniel Oscar Rodenstein;Yazine Mahjoub
University Hospital Centre Amiens-Picardie, 36673, PNEUMOLOGY, Amiens, France, jounieaux.vincent@chu-amiens.fr.;Cliniques universitaires Saint-Luc, 70492, Pneumology Department, Bruxelles, Belgium.;University Hospital Centre Amiens-Picardie, 36673, Department of Anesthesia and Critical Care., Amiens, France.
2253
10.1101/2020.03.02.968818
Preprint
en
Rapid metagenomic characterization of a case of imported COVID-19 in Cambodia.
https://www.ncbi.nlm.nih.gov/pubmed/32511296
Rapid production and publication of pathogen genome sequences during emerging disease outbreaks provide crucial public health information. In resource-limited settings, especially near an outbreak epicenter, conventional deep sequencing or bioinformatics are often challenging. Here we successfully used metagenomic next generation sequencing on an iSeq100 Illumina platform paired with an open-source bioinformatics pipeline to quickly characterize Cambodia's first case of COVID-2019.
2020-03-08 01:00:00+01:00
pubmed
Jessica E Manning;Jennifer A Bohl;Sreyngim Lay;Sophana Chea;Ly Sovann;Yi Sengdoeurn;Seng Heng;Chan Vuthy;Katrina Kalantar;Vida Ahyong;Michelle Tan;Jonathan Sheu;Cristina M Tato;Joseph L DeRisi;Laurence Baril;Veasna Duong;Philippe Dussart;Erik A Karlsson
Laboratory of Malaria and Vector Research, US National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.;Cambodian Center for Disease Control, Ministry of Health, Phnom Penh, Cambodia.;Chan Zuckerberg Initiative, Redwood City, California, USA.;Chan Zuckerberg Biohub, San Francisco, California, USA.;Institut Pasteur du Cambodge, Phnom Penh, Cambodia.;Virology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
25
World Health Organization
10.2807/1560-7917.es.2020.25.9.2000178
Journal Article
en
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.
https://www.ncbi.nlm.nih.gov/pubmed/32156327
In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020. We detail the first European cases. As at 21 February, nine European countries reported 47 cases. Among 38 cases studied, 21 were linked to two clusters in Germany and France, 14 were infected in China. Median case age was 42 years; 25 were male. Late detection of the clusters' index cases delayed isolation of further local cases. As at 5 March, there were 4,250 cases.
[{"country": "International", "agency": "World Health Organization", "grantid": "001"}]
European Centre for Disease Prevention and Control, Stockholm, Sweden.;World Health Organisation Regional Office for Europe, Copenhagen, Denmark.;Robert Koch Institute, Berlin, Germany.;Santé Publique France - Direction des maladies infectieuses, Saint-Maurice, France.;Centre national de référence Virus des infections respiratoires, dont la grippe, Institut Pasteur, Paris, France.;Centre national de référence Virus des infections respiratoires, dont la grippe, Hospices civils de Lyon, Lyon, France.;Istituto Superiore di Sanita, Rome, Italy.;Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy.;Coordination Centre for Health Alerts and Emergencies. Spanish Ministry of Health, Madrid, Spain.;Servicio de Epidemiología, Dirección General de Salut Pública, Islas Baleares, Spain.;Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (Rospotrebnadzor), Moscow, Russia.;Department of Infectious Disease Prevention and Control, Common Community Commission, Brussels-Capital Region, Brussels, Belgium.;Chief Physician, Infection control unit, Lapland Hospital District, Rovaniemi, Finland.;County Medical Officer, Jönköping Region, Jönköping, Sweden.;Santé publique France - Direction des régions, Cellule régionale Nouvelle Aquitaine, Bordeaux, France.;Santé publique France - Direction des régions, Cellule régionale Ile-de-France, Paris, France.;Santé publique France - Direction des régions, Cellule régionale Auvergne-Rhône-Alpes, Lyon, France.;National Centre for Microbiology, WHO-National Influenza Centre, Institute of Health Carlos III. Madrid, Spain.;National Centre of Epidemiology, CIBERESP, Institute of Health Carlos III. Madrid, Spain.;Dirección General de Salut Pública, Islas Baleares, Spain.;State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Moscow, Russia.;St. Pierre Hospital, Brussels, Belgium.;Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute, KU Leuven - University of Leuven, Leuven, Belgium.;Epidemiology of infectious diseases, Sciensano, Brussels, Belgium.;Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.;Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.;Public Health Agency of Sweden, Solna, Sweden.;Jönköping Region, Jönköping, Sweden.;These authors have contributed equally to the manuscript.
31
10.1016/j.tmaid.2020.101624
Journal Article
en
Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine?
https://www.ncbi.nlm.nih.gov/pubmed/32179125
An ongoing epidemic of respiratory diseases caused by a novel coronavirus (COVID 2019, SARS-CoV2) started in Wuhan, Hubei, in China at the end of December 2019. The French government decided to repatriate the 337 French nationals living in Wuhan and place them in quarantine in their home country. We decided to test them all for SARS-Cov2 twice in order to reduce anxiety among the population and decision-makers.
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
https://www.ncbi.nlm.nih.gov/pubmed/32155444
The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.
Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.;Department of Biochemistry, University of Washington, Seattle, WA 98195, USA, Institute Pasteur & CNRS UMR 3569, Unité de Virologie Structurale, Paris 75015, France.;Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA.;Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA, Department of Global Health, University of Washington, Seattle, WA 98195, USA.;Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu.
34
10.1016/j.ijantimicag.2020.105938
Journal Article
en
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
https://www.ncbi.nlm.nih.gov/pubmed/32171740
Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
Christian A Devaux;Jean-Marc Rolain;Philippe Colson;Didier Raoult
COVID-19;Chloroquine;Coronavirus;SARS-CoV-2
2020-03-12 01:00:00+01:00
32171740
FR
Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France, CNRS, Marseille, France, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: christian.devaux@mediterranee-infection.com.;Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
39
Preprint
en
SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways.
https://www.ncbi.nlm.nih.gov/pubmed/32550242
The SARS-CoV-2 coronavirus, the etiologic agent responsible for COVID-19 coronavirus disease, is a global threat. To better understand viral tropism, we assessed the RNA expression of the coronavirus receptor, ACE2, as well as the viral S protein priming protease TMPRSS2 thought to govern viral entry in single-cell RNA-sequencing (scRNA-seq) datasets from healthy individuals generated by the Human Cell Atlas consortium. We found that ACE2, as well as the protease TMPRSS2, are differentially expressed in respiratory and gut epithelial cells. In-depth analysis of epithelial cells in the respiratory tree reveals that nasal epithelial cells, specifically goblet/secretory cells and ciliated cells, display the highest ACE2 expression of all the epithelial cells analyzed. The skewed expression of viral receptors/entry-associated proteins towards the upper airway may be correlated with enhanced transmissivity. Finally, we showed that many of the top genes associated with ACE2 airway epithelial expression are innate immune-associated, antiviral genes, highly enriched in the nasal epithelial cells. This association with immune pathways might have clinical implications for the course of infection and viral pathology, and highlights the specific significance of nasal epithelia in viral infection. Our findings underscore the importance of the availability of the Human Cell Atlas as a reference dataset. In this instance, analysis of the compendium of data points to a particularly relevant role for nasal goblet and ciliated cells as early viral targets and potential reservoirs of SARS-CoV-2 infection. This, in turn, serves as a biological framework for dissecting viral transmission and developing clinical strategies for prevention and therapy.
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.;Université Côte d'Azur, CNRS, IPMC, Sophia-Antipolis 06560, France.;Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, Netherlands.;Groningen Research Institute for Asthma and COPD, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, Netherlands.
40
10.1101/2020.02.19.20025452
Preprint
en
The serial interval of COVID-19 from publicly reported confirmed cases.
https://www.ncbi.nlm.nih.gov/pubmed/32511454
We estimate the distribution of serial intervals for 468 confirmed cases of COVID-19 reported in 93 Chinese cities by February 8, 2020. The mean and standard deviation are 3.96 (95% CI 3.53-4.39) and 4.75 (95% CI 4.46-5.07) days, respectively, with 12.6% of reports indicating pre-symptomatic transmission.
The University of Texas at Austin, Austin, Texas 78712, The United States of America.;Dalian Minzu University, Dalian 116600, China.;Computational Communication Research Center, Beijing Normal University, Zhuhai, 519087, China.;School of Journalism and Communication, Beijing Normal University, Beijing, 100875, China.;Institut Pasteur, 28 rue du Dr Roux, Paris 75015, France.;The University of Hong Kong, Hong Kong SAR, China.;Santa Fe Institute, Santa Fe, New Mexico, The United States of America.
David Baud;Eric Giannoni;Léo Pomar;Xiaolong Qi;Karin Nielsen-Saines;Didier Musso;Guillaume Favre
2020-03-17 01:00:00+01:00
32197096
FR;CN;CH;US
Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: david.baud@chuv.ch.;Clinic of Neonatology, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.;Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland.;CHESS Center, The First Hospital of Lanzhou University, Lanzhou, China.;Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.;Aix Marseille Université, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée infection, Marseille, France, Laboratoire Eurofins Labazur Guyane, French Guiana, France.
52
10.1016/j.tmaid.2020.101632
Journal Article
en
Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot.
https://www.ncbi.nlm.nih.gov/pubmed/32205269
Rapid virological diagnosis is needed to limit the length of isolation for suspected COVID-19 cases.
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
https://www.ncbi.nlm.nih.gov/pubmed/32224310
On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020.
Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Department of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux, France, INSERM U1219, University of Bordeaux, Bordeaux, France.;Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.;National Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France.;National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France, Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.;Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;National Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France, Mutualized Platform of Microbiology, Pasteur International Bioresources Network, The Institut Pasteur, Paris, France.;Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.;Santé Publique France, Saint Maurice, France.;Infection Control Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Department of Epidemiology, Biostatistics and Clinical Research, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Center for Clinical Investigation, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France. Electronic address: yazdan.yazdanpanah@aphp.fr.
74
10.1111/jsr.13052
Journal Article;Review
en
Dealing with sleep problems during home confinement due to the COVID-19 outbreak: Practical recommendations from a task force of the European CBT-I Academy.
https://www.ncbi.nlm.nih.gov/pubmed/32246787
In the current global home confinement situation due to the COVID-19 outbreak, most individuals are exposed to an unprecedented stressful situation of unknown duration. This may not only increase daytime stress, anxiety and depression levels, but also disrupt sleep. Importantly, because of the fundamental role that sleep plays in emotion regulation, sleep disturbance can have direct consequences upon next day emotional functioning. In this paper, we summarize what is known about the stress-sleep link and confinement as well as effective insomnia treatment. We discuss those effects of the current home confinement situation that can disrupt sleep but also those that could benefit sleep quality. We suggest adaptions of cognitive behavioural therapy elements that are feasible to implement for those facing changed work schedules and requirements, those with health anxiety and those handling childcare and home-schooling, whilst also recognizing the general limitations imposed on physical exercise and social interaction. Managing sleep problems as best as possible during home confinement can limit stress and possibly prevent disruptions of social relationships.
UMR 5287, Institut de Neurosciences Intégratives et Cognitives d'Aquitaine, Neuroimagerie et Cognition Humaine, CNRS, Université de Bordeaux, Bordeaux, France.;Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.;Department of Human Sciences, University of Rome 'G. Marconi' - Telematic, Italy.;Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.;Northumbria Centre for Sleep Research, Northumbria University, Newcastle, UK.;Institut für Bewusstseins- und Traumforschung, Vienna, Austria.;Department of Psychology, University of Bielefeld, Bielefeld, Germany.;Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.;Stockholm Health Care Services, Stockholm County Council, Huddinge Hospital, Stockholm, Sweden.;Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
77
Letter
fr
[Clozapine prescription in the wake of the coronavirus (SARS CoV-2) outbreak: What measures? Why?]
Pôle 93G04 de Psychiatrie d'Adultes, EPS Ville Evrard. 5 rue du Dr Delafontaine 93200, Saint Denis, France.;Pôle 93G04 de Psychiatrie d'Adultes, EPS Ville Evrard. 5 rue du Dr Delafontaine 93200, Saint Denis, France. Electronic address: f.mouaffak@epsve.fr.
81
Letter
en
An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19.
https://www.ncbi.nlm.nih.gov/pubmed/32246784
2020-04-05 02:00:00+02:00
pubmed
Serge Nataf
2020-04-04 02:00:00+02:00
32246784
FR
Bank of Tissues and Cells, Hôpital Edouard Herriot, Lyon University Hospital, Lyon, France.;CarMeN Laboratory, INSERM 1060, INRA 1397, INSA, Oullins, France.;Department of Cytology/Histology, Lyon-Est School of Medicine, University Claude Bernard Lyon-1, Lyon, France.
84
Letter;Review
en
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis.
A Wollenberg;C Flohr;D Simon;M J Cork;J P Thyssen;T Bieber;M S de Bruin-Weller;S Weidinger;M Deleuran;A Taieb;C Paul;M Trzeciak;T Werfel;J Seneschal;S Barbarot;U Darsow;A Torrelo;J-F Stalder;Å Svensson;D Hijnen;C Gelmetti;Z Szalai;U Gieler;L De Raeve;B Kunz;P Spuls;L B von Kobyletzki;R Fölster-Holst;P V Chernyshov;S Christen-Zaech;A Heratizadeh;J Ring;C Vestergaard
2020-03-31 02:00:00+02:00
32223003
FR;SE;BE;UA;CH;GB;US;PL;IT;NL;ES;HU;DK;DE
Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany.;Department of Dermatology I, München Klinik Thalkirchner Strasse, Munich, Germany.;St John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Sheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.;Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.;Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark.;Department of Dermatology and Allergy, Christine Kühne-Center for Allergy Research and Education, University Hospital of Bonn, Bonn, Germany.;National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.;Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.;University of Bordeaux, Bordeaux, France.;Department of Dermatology, Toulouse University, Toulouse, France.;Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.;Department of Adult and Pediatric Dermatology, CHU Bordeaux, University of Bordeaux, Bordeaux, France.;Department of Dermatology, CHU, Nantes, France.;Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.;Department of Dermatology, Hospital Infantil Niño Jesús, Madrid, Spain.;Department of Dermatology, Nantes Université, CHU Nantes, UMR 1280 PhAN, INRAE, F-4400, Nantes, France.;Department of Dermatology, Skane University Hospital, Malmö, Sweden.;Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Pathophysiology and Transplantation, Foundation IRCCS, Cà Granda Ospedale Maggiore Policlinico, Foundation IRCCS, Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.;Department of Dermatology, Heim Pál National Children's Institute, Budapest, Hungary.;Department of Dermatology, University of Gießen and Marburg GmbH, Gießen, Germany.;Department of Dermatology, Universitair Ziekenhuis Brussel (UZB), Free University of Brussels (VUB), Brussels, Belgium.;Dermatologicum, Hamburg, Germany.;Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.;University Healthcare Research Center, Faculty of Medicine, Lund University, Lund, Sweden.;Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.;Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine.;Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.;Christine-Kühne Center for Allergy Research and Education (CK-Care), Davos, Switzerland.
85
10.1213/ane.0000000000004844
Journal Article;Review
en
Essential Role of Patient Blood Management in a Pandemic: A Call for Action.
https://www.ncbi.nlm.nih.gov/pubmed/32243296
The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic. Global health care now faces unprecedented challenges with widespread and rapid human-to-human transmission of SARS-CoV-2 and high morbidity and mortality with COVID-19 worldwide. Across the world, medical care is hampered by a critical shortage of not only hand sanitizers, personal protective equipment, ventilators, and hospital beds, but also impediments to the blood supply. Blood donation centers in many areas around the globe have mostly closed. Donors, practicing social distancing, some either with illness or undergoing self-quarantine, are quickly diminishing. Drastic public health initiatives have focused on containment and "flattening the curve" while invaluable resources are being depleted. In some countries, the point has been reached at which the demand for such resources, including donor blood, outstrips the supply. Questions as to the safety of blood persist. Although it does not appear very likely that the virus can be transmitted through allogeneic blood transfusion, this still remains to be fully determined. As options dwindle, we must enact regional and national shortage plans worldwide and more vitally disseminate the knowledge of and immediately implement patient blood management (PBM). PBM is an evidence-based bundle of care to optimize medical and surgical patient outcomes by clinically managing and preserving a patient's own blood. This multinational and diverse group of authors issue this "Call to Action" underscoring "The Essential Role of Patient Blood Management in the Management of Pandemics" and urging all stakeholders and providers to implement the practical and commonsense principles of PBM and its multiprofessional and multimodality approaches.
Aryeh Shander;Susan M Goobie;Matthew A Warner;Matti Aapro;Elvira Bisbe;Angel A Perez-Calatayud;Jeannie Callum;Melissa M Cushing;Wayne B Dyer;Jochen Erhard;David Faraoni;Shannon Farmer;Tatyana Fedorova;Steven M Frank;Bernd Froessler;Hans Gombotz;Irwin Gross;Nicole R Guinn;Thorsten Haas;Jeffrey Hamdorf;James P Isbister;Mazyar Javidroozi;Hongwen Ji;Young-Woo Kim;Daryl J Kor;Johann Kurz;Sigismond Lasocki;Michael F Leahy;Cheuk-Kwong Lee;Jeong Jae Lee;Vernon Louw;Jens Meier;Anna Mezzacasa;Manuel Munoz;Sherri Ozawa;Marco Pavesi;Nina Shander;Donat R Spahn;Bruce D Spiess;Jackie Thomson;Kevin Trentino;Christoph Zenger;Axel Hofmann
2020-04-04 02:00:00+02:00
32243296
FR;JE;RU;CA;CN;CH;US;AT;HK;IT;AU;ZA;ES;MX;KR;DE
From the Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Health, Englewood, New Jersey.;Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.;Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.;Cancer Center Clinique Genolier, Genolier, Switzerland.;Department of Anesthesiology, Perioperative Medicine Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.;Department of Critical Care, Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico.;Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.;Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, New York.;Australian Red Cross Lifeblood and Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.;Department of Surgery, Evangelisches Klinikum Niederrhein, Duisburg, Germany.;Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.;Medical School, Division of Surgery, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia.;School of Health Sciences and Graduate Studies, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.;Institute of Anesthesiology, Resuscitation and Transfusiology of the National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Acad. V. I. Kulakov, Ministry of Health of the Russian Federation, Moscow, Russia.;Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.;Department of Anesthesia, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia.;Discipline of Acute Care Medicine, University of Adelaide, Adelaide, South Australia, Australia.;Department of Anesthesiology and Intensive Care, General Hospital Linz, Linz, Austria.;Northern Light Health, Brewer, Maine.;Accumen, Inc, San Diego, California.;Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.;Department of Anesthesiology, University Children's Hospital Zurich, Zurich, Switzerland.;Medical School, The University of Western Australia, Western Australia Patient Blood Management Group, Perth, Western Australia, Australia.;Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.;Department of Anesthesiology and Transfusion Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy and Center for Gastric Cancer, National Cancer Center, Ilsandong-gu, Goyang, Korea.;Austrian Federal Ministry of Health, Vienna, Austria.;Department Applied Sciences, University of Applied Sciences, Vienna, Austria.;Département Anesthésie-Réanimation, Anesthésie Samu Urgences Réanimation, CHU Angers, Angers, France.;Department of Haematology, PathWest Laboratory Medicine, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Australia.;Hong Kong Red Cross Blood Transfusion Service, Hong Kong Special Administrative Region, China.;Department of Obstetrics and Gynecology, Soonchunhyang University Hospital, Seoul, Korea.;Division Clinical Haematology, Department of Medicine, University of Cape Town, Cape Town, South Africa.;Clinic of Anesthesiology and Intensive Care Medicine, Johannes Kepler University Linz, Linz, Austria.;Vifor Pharma, Glattbrugg, Switzerland.;Department of Surgical Sciences, Biochemistry and Immunology, School of Medicine, University of Málaga, Málaga, Spain.;Patient Blood Management, Englewood Health, Englewood, New Jersey.;Department of Anesthesiology and Intensive Care, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, San Donato Milanese, Milan, Italy.;Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, North Carolina.;Institute of Anesthesiology, University of Zurich, University Hospital of Zurich, Zurich, Switzerland.;Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida.;South African National Blood Service, Johannesburg, South Africa.;Medical School, The University of Western Australia, Perth, Western Australia, Australia.;Data and Digital Innovation, East Metropolitan Health Service, Perth, Western Australia, Australia.;Center for Health Law and Management, University of Bern, Bern, Switzerland.;Institute of Anesthesiology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.;Medical School, The University of Western Australia, Crawley, Western Australia, Australia.;School of Health Sciences and Graduate Studies, Curtin University, Perth, Western Australia, Australia.
90
10.1016/j.jfo.2020.03.001
Editorial
fr
[Hand hygiene and facemasks against COVID-19: Should we consider alternate strategies?]
Hôpital Fondation Rothschild, 29, rue Manin, 75019, Paris, France, Hôpital Bichat-Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France. Electronic address: icochereau@for.paris.;Hôpital Fondation Rothschild, 29, rue Manin, 75019, Paris, France.
98
Clinical Trial;Letter
en
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Université de Paris, Inserm, PARCC, 75015 Paris, France, CIC1418 and DMU CARTE, hôpital européen Georges-Pompidou, AP-HP, 56, rue Leblanc, 75015 Paris, France. Electronic address: jean-sebastien.hulot@aphp.fr.
113
10.1111/vox.12926
Journal Article;Review
en
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
https://www.ncbi.nlm.nih.gov/pubmed/32240545
Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.
0042-9007,1423-0410
2020-04-05 02:00:00+02:00
pubmed
Vox Sanguinis
Pierre Tiberghien;Xavier de Lamballerie;Pascal Morel;Pierre Gallian;Karine Lacombe;Yazdan Yazdanpanah
Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong, 226006, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China.;Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou, 225300, China.;College of Life Sciences, Henan Normal University, Xinxiang, 453007, China.;Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China. zhangcy1999@ips.ac.cn.
124
Case Reports;Letter
en
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
Department of Therapeutic Innovation and Early Testing. Electronic address: jean-marie.michot@gustaveroussy.fr.;Medical Oncology, University Paris Saclay, Gustave Roussy.;Molecular Analysis, modélisation et imagerie de la Maladie cancéreuse, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, INSERM, CNRS.;Department of Biology, University Paris Saclay, Gustave Roussy.;Department of Medical Imaging.;Department of Therapeutic Innovation and Early Testing.;Department of Pharmacy, Villejuif, France.;Intensive Care Department, Université Paris-Saclay, Gustave Roussy Villejuif, France.
125
10.1016/j.ijantimicag.2020.105980
Editorial
en
Chloroquine as a prophylactic agent against COVID-19?
Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France.;Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France, Service des Maladies Infectieuses, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Service des Maladies Infectieuses, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, Service des Maladies Infectieuses, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France, Centre National de Référence du Paludisme, Marseille, France. Electronic address: bruno.pradines@gmail.com.
142
Letter;Comment
en
Surgery and the COVID-19 epidemic: Some additional precautions. Re: "Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic".
Department of Gynecologic Surgery, CHU d'Estaing, 1, place Lucie et Raymond-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr.;Department of Gynecologic Surgery, CHU d'Estaing, 1, place Lucie et Raymond-Aubrac, 63000 Clermont-Ferrand, France.
160
10.1007/s12204-020-2167-2
Journal Article
en
Prediction of COVID-19 Outbreak in China and Optimal Return Date for University Students Based on Propagation Dynamics.
https://www.ncbi.nlm.nih.gov/pubmed/32288415
On 12 December 2019, a novel coronavirus disease, named COVID-19, began to spread around the world from Wuhan, China. It is useful and urgent to consider the future trend of this outbreak. We establish the 4+1 penta-group model to predict the development of the COVID-19 outbreak. In this model, we use the collected data to calibrate the parameters, and let the recovery rate and mortality change according to the actual situation. Furthermore, we propose the BAT model, which is composed of three parts: simulation of the return rush (Back), analytic hierarchy process (AHP) method, and technique for order preference by similarity to an ideal solution (TOPSIS) method, to figure out the best return date for university students. We also discuss the impacts of some factors that may occur in the future, such as secondary infection, emergence of effective drugs, and population flow from Korea to China.
analytic hierarchy process (AHP);epidemic dynamics model, nonlinear least squares;technique for order preference by similarity to an ideal solution (TOPSIS)
2020-04-07 02:00:00+02:00
32288415
FR;CN
1SJTU-ParisTech Elite Institute of Technology, Shanghai Jiao Tong University, Shanghai, 200240 China.;2School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai, 200240 China.;3School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240 China.
161
10.1093/eurheartj/ehaa278
Journal Article
en
Strategies to control COVID-19 and future pandemics in Africa and around the globe.
https://www.ncbi.nlm.nih.gov/pubmed/32255477
0195-668X,1522-9645
2020-04-12 02:00:00+02:00
pubmed
European Heart Journal
Anouar Fanidi;Xavier Jouven;Bamba Gaye
2020-04-07 02:00:00+02:00
32255477
FR;GB;UNK
The African Research Network.;MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.;Université de Paris, PARCC, INSERM, F-75015 Paris, France.;Cardiology Department, Georges-Pompidou European Hospital, Paris, France.
162
10.1016/j.ancard.2020.04.001
Journal Article;Review
fr
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1st April 2020].
https://www.ncbi.nlm.nih.gov/pubmed/32303363
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection.
B El Boussadani;C Benajiba;A Aajal;A Ait Brik;O Ammour;J El Hangouch;O Oussama;B Oussama;N Tahiri;Z Raissuni
COVID-19;Cardiac impact;Gestion des thérapeutiques;Impact cardiaque;Therapeutics management
2020-04-07 02:00:00+02:00
32303363
FR;MA
Service de cardiologie, centre hospitalier universitaire Tanger Tétouan Al Hoceima, faculté de médecine et de pharmacie de Tanger, université Abdelmalek Essadi, Tanger, Maroc.;Service de cardiologie, centre hospitalier universitaire Tanger Tétouan Al Hoceima, faculté de médecine et de pharmacie de Tanger, université Abdelmalek Essadi, Tanger, Maroc. Electronic address: zainab.raissouni@hotmail.com.
165
10.1148/radiol.2020201365
Journal Article;Practice Guideline
en
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society.
https://www.ncbi.nlm.nih.gov/pubmed/32255413
With more than 900 000 confirmed cases worldwide and nearly 50 000 deaths during the first 3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as an unprecedented health care crisis. The spread of COVID-19 has been heterogeneous, resulting in some regions having sporadic transmission and relatively few hospitalized patients with COVID-19 and others having community transmission that has led to overwhelming numbers of severe cases. For these regions, health care delivery has been disrupted and compromised by critical resource constraints in diagnostic testing, hospital beds, ventilators, and health care workers who have fallen ill to the virus exacerbated by shortages of personal protective equipment. Although mild cases mimic common upper respiratory viral infections, respiratory dysfunction becomes the principal source of morbidity and mortality as the disease advances. Thoracic imaging with chest radiography and CT are key tools for pulmonary disease diagnosis and management, but their role in the management of COVID-19 has not been considered within the multivariable context of the severity of respiratory disease, pretest probability, risk factors for disease progression, and critical resource constraints. To address this deficit, a multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing patients with COVID-19 across a spectrum of health care environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints. Fourteen key questions, corresponding to 11 decision points within the three scenarios and three additional clinical situations, were rated by the panel based on the anticipated value of the information that thoracic imaging would be expected to provide. The results were aggregated, resulting in five main and three additional recommendations intended to guide medical practitioners in the use of chest radiography and CT in the management of COVID-19.
Geoffrey D Rubin;Christopher J Ryerson;Linda B Haramati;Nicola Sverzellati;Jeffrey P Kanne;Suhail Raoof;Neil W Schluger;Annalisa Volpi;Jae-Joon Yim;Ian B K Martin;Deverick J Anderson;Christina Kong;Talissa Altes;Andrew Bush;Sujal R Desai;Onathan Goldin;Jin Mo Goo;Marc Humbert;Yoshikazu Inoue;Hans-Ulrich Kauczor;Fengming Luo;Peter J Mazzone;Mathias Prokop;Martine Remy-Jardin;Luca Richeldi;Cornelia M Schaefer-Prokop;Noriyuki Tomiyama;Athol U Wells;Ann N Leung
2020-04-07 02:00:00+02:00
32255413
FR;CA;CN;JP;GB;US;IT;NL;KR;DE
From the Department of Radiology, Duke University School of Medicine, Box 3808, Durham, NC 27705 (G.D.R.), Department of Medicine, University of British Columbia, Vancouver, Canada (C.J.R.), Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (L.B.H.), Department of Scienze Radiologiche, Department of Medicine and Surgery, University of Parma, Parma, Italy (N.S.), Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wis (J.P.K.), Division of Pulmonary, Critical Care & Sleep Medicine, Lenox Hill Hospital, New York, NY (S.R.), Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University